00012807842025Q112-31falseonehttp://fasb.org/us-gaap/2024#OtherAssetshttp://fasb.org/us-gaap/2024#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrenthttp://www.htgc.com/20250331#OneMonthSecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember0.0465631March 28, 2025.3333.3333.3333xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureiso4217:GBPiso4217:EURhtgc:firmhtgc:segmenthtgc:portfolioCompanyhtgc:equityInvestmenthtgc:creditFacilityhtgc:votePerShare00012807842025-01-012025-03-310001280784htgc:CommonStockParValueZeroPointZeroZeroOnePerShareMember2025-01-012025-03-310001280784htgc:SixPointTwoFiveNotesDueTwoThousandThirtyThreeMember2025-01-012025-03-3100012807842025-04-240001280784us-gaap:InvestmentUnaffiliatedIssuerMember2025-03-310001280784us-gaap:InvestmentUnaffiliatedIssuerMember2024-12-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMember2025-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMember2024-12-3100012807842025-03-3100012807842024-12-310001280784us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2025-03-310001280784us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-12-3100012807842024-01-012024-12-310001280784us-gaap:InvestmentUnaffiliatedIssuerMember2025-01-012025-03-310001280784us-gaap:InvestmentUnaffiliatedIssuerMember2024-01-012024-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMember2025-01-012025-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMember2024-01-012024-03-3100012807842024-01-012024-03-310001280784us-gaap:CommonStockMember2024-12-310001280784us-gaap:AdditionalPaidInCapitalMember2024-12-310001280784us-gaap:RetainedEarningsMember2024-12-310001280784us-gaap:RetainedEarningsMember2025-01-012025-03-310001280784us-gaap:CommonStockMember2025-01-012025-03-310001280784us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001280784us-gaap:CommonStockMember2025-03-310001280784us-gaap:AdditionalPaidInCapitalMember2025-03-310001280784us-gaap:RetainedEarningsMember2025-03-310001280784us-gaap:CommonStockMember2023-12-310001280784us-gaap:AdditionalPaidInCapitalMember2023-12-310001280784us-gaap:RetainedEarningsMember2023-12-3100012807842023-12-310001280784us-gaap:RetainedEarningsMember2024-01-012024-03-310001280784us-gaap:CommonStockMember2024-01-012024-03-310001280784us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001280784us-gaap:CommonStockMember2024-03-310001280784us-gaap:AdditionalPaidInCapitalMember2024-03-310001280784us-gaap:RetainedEarningsMember2024-03-3100012807842024-03-310001280784htgc:AdvisorFundsMember2025-01-012025-03-310001280784Debt Investments Biotechnology Tools and PathAI, Inc., Senior Secured, Maturity Date January 2027, Prime + 2.15%, Floor rate 9.15%, 7.85% Exit Fee2025-03-310001280784Debt Investments Biotechnology Tools (1.69%)2025-03-310001280784Debt Investments Communications & Networking and Aryaka Networks, Inc. Senior Secured, Maturity Date December 2028, Prime + 1.80%, Floor rate 9.30%, PIK Interest 1.25%, 6.73% Exit Fee2025-03-310001280784Debt Investments Communications & Networking (1.37%)2025-03-310001280784Debt Investments Consumer & Business Services and Altumint, Inc. Senior Secured, Maturity Date December 2027, Prime + 3.65%, Floor rate 12.15%, 2.50% Exit Fee2025-03-310001280784Debt Investments Consumer & Business Services and Carwow LTD Senior Secured, Maturity Date December 2027, Prime + 4.70%, Floor rate 11.45%, PIK Interest 1.45%, 4.95% Exit Fee2025-03-310001280784Debt Investments Consumer & Business Services and GoEuro Travel GmbH. Senior Secured, Maturity Date November 2029, Prime + 3.45%, Floor rate 10.45%, 4.50% Exit Fee2025-03-310001280784Debt Investments Consumer & Business Services and Houzz, Inc. Convertible Debt, Maturity Date May 2028, PIK Interest 11.50%2025-03-310001280784Debt Investments Consumer & Business Services and Jobandtalent USA, Inc. Senior Secured, Maturity Date October 2028, 1-month SOFR + 0.00%, Floor rate 1.00%, PIK Interest 7.00%, 5.33% Exit Fee2025-03-310001280784Debt Investments Consumer & Business Services and Plentific Ltd. Senior Secured, Maturity Date October 2026, Prime + 2.55%, Floor rate 11.05%, 2.95% Exit Fee2025-03-310001280784Debt Investments Consumer & Business Services and Provi, Senior Secured, Maturity Date December 2026, Prime + 4.40%, Floor rate 10.65%, 2.95% Exit Fee2025-03-310001280784Debt Investments Consumer & Business Services and Riviera Partners LLC. Senior Secured, Maturity Date March 2028, 3-month SOFR + 8.27%, Floor rate 9.27%2025-03-310001280784Debt Investments Consumer & Business Services and RVShare, LLC, Senior Secured, Maturity Date December 2026, 3-month SOFR + 5.50%, Floor rate 6.50%, PIK Interest 4.00%2025-03-310001280784Debt Investments Consumer & Business Services and SeatGeek, Inc., Senior Secured, Maturity Date May 2026, Prime + 7.00%, Floor rate 10.50%, PIK Interest 0.50%, 4.00% Exit Fee2025-03-310001280784Debt Investments Consumer & Business Services, Senior Secured, Maturity Date July 2026, Prime + 2.50%, Floor rate 10.75%, PIK Interest 0.50%, 3.00% Exit Fee2025-03-310001280784Debt Investments Consumer & Business Services and Total SeatGeek, Inc.2025-03-310001280784Debt Investments Consumer & Business Services and Skyword, Inc. Senior Secured, Maturity Date November 2027, Prime + 2.75%, Floor rate 9.25%, PIK Interest 1.75%, 3.00% Exit Fee2025-03-310001280784Debt Investments Consumer & Business Services and Tectura Corporation, Senior Secured, Maturity Date January 2027, FIXED 8.25%2025-03-310001280784Debt Investments Consumer & Business Services and Thumbtack, Inc. Senior Secured, Maturity Date March 2028, Prime + 2.45%, Floor rate 10.95%, PIK Interest 1.50%2025-03-310001280784Debt Investments Consumer & Business Services and Veem, Inc., Senior Secured, Maturity Date March 2027, Prime + 4.00%, Floor rate 12.00%, PIK Interest 1.25%2025-03-310001280784Debt Investments Consumer & Business Services and Veem, Inc., Senior Secured, Maturity Date March 2027, Prime + 4.70%, Floor rate 12.70%, PIK Interest 1.50%.2025-03-310001280784Debt Investments Consumer & Business Services, and Total Veem, Inc.2025-03-310001280784Debt Investments Consumer & Business Services (18.03%)2025-03-310001280784Debt Investments Diversified Financial Services and Gibraltar Acquisition, LLC, Unsecured, Maturity Date September 2026, FIXED 3.45%, PIK Interest 8.05%2025-03-310001280784Debt Investments Diversified Financial Services, Unsecured, Maturity Date September 2026, Fixed 11.95%2025-03-310001280784Debt Investments Diversified Financial Services and Total Gibraltar Acquisition, LLC,.2025-03-310001280784Debt Investments Diversified Financial Services and Next Insurance, Inc, Senior Secured, Maturity Date February 2028, Prime -(1.50%), Floor rate 4.75%, PIK Interest 5.50%2025-03-310001280784Debt Investments Diversified Financial Services (2.42%)2025-03-310001280784Debt Investments Drug Discovery & Development and Adaptimmune Therapeutics plc. Senior Secured, Maturity Date June 2029, Prime + 1.15%, Floor rate 9.65%, PIK Interest 2.00%, 5.85% Exit Fee2025-03-310001280784Debt Investments Drug Discovery & Development and Akero Therapeutics, Inc. Senior Secured, Maturity Date March 2027, Prime + 3.65%, Floor rate 7.65%, 5.85% Exit Fee2025-03-310001280784Debt Investments Drug Discovery & Development and Aldeyra Therapeutics, Inc. Senior Secured, Maturity Date April 2026, Prime + 3.10%, Floor rate 11.10%, 8.90% Exit Fee2025-03-310001280784Debt Investments Drug Discovery & Development and Alector, Inc.. Senior Secured, Maturity Date December 2028, Prime + 1.05%, Floor rate 8.05%, 4.75% Exit Fee2025-03-310001280784Debt Investments Drug Discovery & Development and AmplifyBio, LLC, Senior Secured, Maturity Date January 2027, Prime + 2.50%, Floor rate 9.50%, Cap rate 10.75%, 5.85% Exit Fee2025-03-310001280784Debt Investments Drug Discovery & Development and Arcus Biosciences, Inc., Senior Secured, Maturity Date September 2029, Prime + 1.95%, Floor rate 10.45%, 7.75% Exit Fee2025-03-310001280784Debt Investments Drug Discovery & Development and ATAI Life Sciences N.V., Senior Secured, Maturity Date August 2026, Prime + 4.30%, Floor rate 9.05%, 6.95% Exit Fee2025-03-310001280784Debt Investments Drug Discovery & Development and Axsome Therapeutics, Inc. Senior Secured, Maturity Date January 2028 Prime + 2.20%, Floor rate 9.95%, Cap rate 10.70%, 5.78% Exit Fee2025-03-310001280784Debt Investments Drug Discovery & Development and bluebird bio, Inc. Senior Secured, Maturity Date April 2029, Prime + 1.45%, Floor rate 9.95%, PIK Interest 2.45%, 6.45% Exit Fee2025-03-310001280784Debt Investments Drug Discovery & Development and Braeburn, Inc., Senior Secured, Maturity Date October 2028, Prime + 2.45%, Floor rate 10.95%, PIK Interest 1.10%, 5.45% Exit Fee2025-03-310001280784Debt Investments Drug Discovery & Development and COMPASS Pathways plc, Senior Secured, Maturity Date July 2027, Prime + 1.50%, Floor rate 9.75%, PIK Interest 1.40%, 4.75% Exit Fee2025-03-310001280784Debt Investments Drug Discovery & Development and Corium, Inc. Senior Secured, Maturity Date September 2026, Prime + 5.70%, Floor rate 8.95%, 7.75% Exit Fee2025-03-310001280784Debt Investments Drug Discovery & Development and Disc Medicine, Inc., Senior Secured, Maturity Date December 2029, Prime + 1.75%, Floor rate 8.25%, 6.75% Exit Fee2025-03-310001280784Debt Investments Drug Discovery & Development and enGene, Inc. Senior Secured, Maturity Date January 2028, Prime + 0.75%, Floor rate 9.25%, Cap rate 9.75%, PIK Interest 1.15%, 5.50% Exit Fee2025-03-310001280784Debt Investments Drug Discovery & Development and Heron Therapeutics, Inc.. Senior Secured, Maturity Date May 2026, Prime + 1.70%, Floor rate 9.95%, PIK Interest 1.50%, 3.00% Exit Fee2025-03-310001280784Debt Investments Drug Discovery & Development and Hibercell, Inc. Senior Secured, Maturity Date May 2025, Prime + 5.40%, Floor rate 8.65%, 4.95% Exit Fee2025-03-310001280784Debt Investments Drug Discovery & Development and Kura Oncology, Inc. Senior Secured, Maturity Date November 2027, Prime + 2.40%, Floor rate 8.65%, 6.05% Exit Fee2025-03-310001280784Debt Investments Drug Discovery & Development and Madrigal Pharmaceutical, Inc. Senior Secured, Maturity Date May 2027, Prime + 2.45%, Floor rate 8.25%, 5.35% Exit Fee2025-03-310001280784Debt Investments Drug Discovery & Development and MoonLake Immunotherapeutics, Senior Secured, Maturity Date April 2030, Prime + 1.45%, Floor rate 8.45%, 6.95% Exit Fee2025-03-310001280784Debt Investments Drug Discovery & Development and NorthSea Therapeutics, Convertible Debt, Maturity Date December 2025, FIXED 6.00%2025-03-310001280784Debt Investments Drug Discovery & Development and Phathom Pharmaceuticals, Inc., Senior Secured, Maturity Date December 2027, Prime + 1.35%, Floor rate 9.85%, Cap rate 10.35%, PIK Interest 2.15%, 7.06% Exit Fee2025-03-310001280784Debt Investments Drug Discovery & Development and Phathom Pharmaceuticals, Inc., Senior Secured, Maturity Date December 2027, Prime + 1.35%, Floor rate 9.85%, Cap rate 10.35%, PIK Interest 2.15%, 3.00% Exit Fee2025-03-310001280784Debt Investments Drug Discovery & Development and Total Phathom Pharmaceuticals, Inc.2025-03-310001280784Debt Investments Drug Discovery & Development and Replimune Group, Inc. Senior Secured, Maturity Date October 2027, Prime + 1.75%, Floor rate 7.25%, Cap rate 9.00%, PIK Interest 1.50%, 4.95% Exit Fee2025-03-310001280784Debt Investments Drug Discovery & Development and Savara, Inc.. Senior Secured, Maturity Date April 2030, Prime + 1.45%, Floor rate 7.45%, 6.95% Exit Fee2025-03-310001280784Debt Investments Drug Discovery & Development and SynOx Therapeutics Limited, Senior Secured, Maturity Date May 2027, Prime + 1.40%, Floor rate 9.90%, 7.25% Exit Fee2025-03-310001280784Debt Investments Drug Discovery & Development and uniQure B.V., Senior Secured, Maturity Date January 2027, Prime + 4.70%, Floor rate 7.95%, 6.10% Exit Fee2025-03-310001280784Debt Investments Drug Discovery & Development and Viridian Therapeutics, Inc., Senior Secured, Maturity Date October 2026, Prime + 4.20%, Floor rate 7.45%, Cap rate 8.95%, 6.00% Exit Fee2025-03-310001280784Debt Investments Drug Discovery & Development and X4 Pharmaceuticals, Inc. Senior Secured, Maturity Date July 2027, Prime + 3.15%, Floor rate 10.15%, 3.72% Exit Fee2025-03-310001280784Debt Investments Drug Discovery & Development (53.38%)2025-03-310001280784Debt Investments Electronics & Computer Hardware and Locus Robotics Corp., Senior Secured, Maturity Date December 2028, Prime + 3.00%, Floor rate 9.50%, 4.00% Exit Fee2025-03-310001280784Debt Investments Electronics & Computer Hardware and Shield AI, Inc., Senior Secured, Maturity Date February 2029, Prime + 0.85%, Floor rate 6.85%, Cap rate 9.60%, PIK Interest 2.50%, 2.50% Exit Fee2025-03-310001280784Debt Investments Electronics & Computer Hardware (8.20%)2025-03-310001280784Debt Investments Healthcare Services, Other and Blue Sprig Pediatrics, Inc. Senior Secured, Maturity Date November 2026, 3-month SOFR + 5.26%, Floor rate 6.00%, PIK Interest 4.45%2025-03-310001280784Debt Investments Healthcare Services, Other and Carbon Health Technologies, Inc., Senior Secured, Maturity Date February 2028, Prime + 3.10%, Floor rate 8.10%, 3.78% Exit Fee2025-03-310001280784Debt Investments Healthcare Services, Other and Curana Health Holdings, LLC, Senior Secured, Maturity Date January 2028, Prime + 1.45%, Floor rate 9.20%, 4.95% Exit Fee2025-03-310001280784Debt Investments Healthcare Services, Other and Ennoble Care LLC, Senior Secured, Maturity Date February 2030, Prime + 2.60%, Floor rate 10.35%, 7.95% Exit Fee2025-03-310001280784Debt Investments Healthcare Services, Other and Equality Health, LLC, Senior Secured, Maturity Date February 2026, Prime + 4.25%, Floor rate 9.50%, PIK Interest 1.55%2025-03-310001280784Debt Investments Healthcare Services, Other and Main Street Rural, Inc. Senior Secured, Maturity Date July 2027, Prime + 1.95%, Floor rate 9.95%, 6.85% Exit Fee2025-03-310001280784Debt Investments Healthcare Services, Other and Marathon Health, LLC, Senior Secured, Maturity Date February 2029, Prime + 0.75%, Floor rate 8.75%, PIK Interest 2.25%, 3.00% Exit Fee2025-03-310001280784Debt Investments Healthcare Services, Other and Marathon Health, LLC, Senior Secured, Maturity Date February 2029, Prime + 3.00%, Floor rate 11.00%2025-03-310001280784Debt Investments Total Marathon Health, LLC2025-03-310001280784Debt Investments Healthcare Services, Other and Modern Life, Inc. Senior Secured, Maturity Date February 2027, Prime + 2.75%, Floor rate 8.75%, 5.00% Exit Fee2025-03-310001280784Debt Investments Healthcare Services, Other and NeueHealth, Inc. Senior Secured, Maturity Date June 2028, Prime + 1.15%, Floor rate 9.65%, PIK Interest 2.50%, 2.50% Exit Fee2025-03-310001280784Debt Investments Healthcare Services, Other and Recover Together, Inc. Senior Secured, Maturity Date July 2027, Prime + 1.90%, Floor rate 10.15%, 7.50% Exit Fee2025-03-310001280784Debt Investments Healthcare Services, Other and Strive Health Holdings, LLC, Senior Secured, Maturity Date September 2027, Prime + 0.70%, Floor rate 9.20%, 5.95% Exit Fee2025-03-310001280784Debt Investments Healthcare Services, Other and Vida Health, Inc. Senior Secured, Maturity Date July 2026, Prime - 2.75% Floor rate 5.75%, PIK Interest 5.35%, 4.95% Exit Fee2025-03-310001280784Debt Investments Healthcare Services, Other and WellBe Senior Medical, LLC, Senior Secured, Maturity Date May 2029, Prime + 0.75%, Floor rate 7.75%, PIK Interest 2.65%, 6.75% Exit Fee2025-03-310001280784Debt Investments Healthcare Services, Other (30.79%)2025-03-310001280784Debt Investments Information Services and Saama Technologies, LLC, Senior Secured, Maturity Date July 2027, Prime + 0.70%, Floor rate 8.95%, PIK Interest 2.00%, 2.95% Exit Fee2025-03-310001280784Debt Investments Information Services (1.02%)2025-03-310001280784Debt Investments Manufacturing Technology and VulcanForms Inc. Secured, Maturity Date January 2028, Prime + 4.25%, Floor rate 11.25%, 4.25% Exit Fee2025-03-310001280784Debt Investments Manufacturing Technology (0.99%)2025-03-310001280784Debt Investments Medical Devices & Equipment and Orchestra BioMed Holdings, Inc., Secured, Maturity Date November 2028, Prime + 2.00%, Floor rate 9.50%, 6.35% Exit Fee2025-03-310001280784Debt Investments Medical Devices & Equipment and Senseonics Holdings, Inc., Senior Secured, Maturity Date September 2027 Prime + 1.40%, Floor rate 9.90%, 6.95% Exit Fee2025-03-310001280784Debt Investments Medical Devices & Equipment and Sight Sciences, Inc., Senior Secured, Maturity Date July 2028, Prime + 2.35%, Floor rate 10.35%, 5.95% Exit Fee2025-03-310001280784Debt Investments Medical Devices & Equipment (3.73%) 2025-03-310001280784Debt Investments Software and Alchemer LLC, Senior Secured, Maturity Date May 2028, 1-month SOFR + 8.14%, Floor rate 9.14%2025-03-310001280784Debt Investments Software and Allvue Systems, LLC, Senior Secured, Maturity Date September 2029, 3-month SOFR + 6.50%, Floor rate 7.50%2025-03-310001280784Debt Investments Software and AlphaSense, Inc., Senior Secured, Maturity Date June 2029, 3-month SOFR + 6.25%, Floor rate 8.25%2025-03-310001280784Debt Investments Software and Annex Cloud, Senior Secured, Maturity Date February 2027, 3-month SOFR + 10.00%, Floor rate 11.00%2025-03-310001280784Debt Investments Software and Armis, Inc., Senior Secured, Maturity Date March 2028, Prime + 0.00%, Floor rate 7.50%, PIK Interest 2.00%, 2.25% Exit Fee2025-03-310001280784Debt Investments Software and Armis, Inc., Senior Secured, Maturity Date March 2028, Prime + 1.25%, Floor rate 7.50%, PIK Interest 2.00%, 2.25% Exit Fee2025-03-310001280784Debt Investments Software and Total Armis, Inc.2025-03-310001280784Debt Investments Software and Babel Street, Senior Secured, Maturity Date December 2027, 3-month SOFR + 8.00%, Floor rate 9.00%2025-03-310001280784Debt Investments Software and Behavox Limited, Senior Secured, Maturity Date September 2027, Prime - 0.55%, Floor rate 7.45%, PIK Interest 3.00%, 4.95% Exit Fee2025-03-310001280784Debt Investments Software and Brain Corporation, Senior Secured, Maturity Date September 2028, Prime + 1.35%, Floor rate 9.85%, PIK Interest 2.50%, 3.95% Exit Fee2025-03-310001280784Debt Investments Software and Carbyne, Inc., Senior Secured, Maturity Date February 2029, Prime + 3.50%, Floor rate 10.00%, 3.50% Exit Fee2025-03-310001280784Debt Investments Software and Ceros, Inc., Senior Secured, Maturity Date September 2026, 3-month SOFR + 8.99%, Floor rate 9.89%2025-03-310001280784Debt Investments Software and CoreView USA, Inc., Senior Secured, Maturity Date January 2029, Prime +2.75%, Floor rate 9.25%, 4.95% Exit Fee2025-03-310001280784Debt Investments Software and Coronet Cyber Security Ltd., Senior Secured, Maturity Date October 2028, Prime - 2.95%, Floor rate 3.55%, PIK Interest 5.85%2025-03-310001280784Debt Investments Software and Dashlane, Inc., Senior Secured, Maturity Date December 2027, Prime + 3.05%, Floor rate 11.55%, PIK Interest 1.10%, 6.28% Exit Fee2025-03-310001280784Debt Investments Software and Dispatch Technologies, Inc., Senior Secured, Maturity Date April 2028, 3-month SOFR + 8.01%, Floor rate 8.76%2025-03-310001280784Debt Investments Software and DocPlanner, Senior Secured, Maturity Date January 2030, Prime + 2.75%, Floor rate 9.75%, 4.25% Exit Fee2025-03-310001280784Debt Investments Software and Dragos, Inc., Senior Secured, Maturity Date July 2027, Prime + 2.00%, Floor rate 8.75%, PIK Interest 2.00%, 2.00% Exit Fee2025-03-310001280784Debt Investments Software and DroneDeploy, Inc., Senior Secured, Maturity Date November 2028, Prime + 2.45%, Floor rate 9.95%, 5.00% Exit Fee2025-03-310001280784Debt Investments Software and Earnix, Inc., Senior Secured, Maturity Date June 2029, Prime - 1.15%, Floor rate 5.35%, PIK Interest 4.45%2025-03-310001280784Debt Investments Software and Elation Health, Inc., Senior Secured, Maturity Date April 2029, Prime + 1.75%, Floor rate 9.25%, PIK Interest 1.30%, 3.95% Exit Fee2025-03-310001280784Debt Investments Software and Fortified Health Security, Senior Secured, Maturity Date December 2027, 1-month SOFR + 7.64%, Floor rate 8.54%2025-03-310001280784Debt Investments Software and Harness, Inc., Senior Secured, Maturity Date March 2029, Prime - 2.25%, Floor rate 5.25%, Cap rate 6.50%, PIK Interest 6.25%, 1.00% Exit Fee2025-03-310001280784Debt Investments Software and iGrafx, LLC, Senior Secured, Maturity Date May 2027, 1-month SOFR + 8.61%, Floor rate 9.51%, 0.47% Exit Fee2025-03-310001280784Debt Investments Software and iSpot.tv, Inc., Senior Secured, Maturity Date January 2029, Prime + 2.25%, Floor rate 8.75%, PIK Interest 1.00%, 5.70% Exit Fee2025-03-310001280784Debt Investments Software and Khoros, Senior Secured, Maturity Date January 2025, 3-month SOFR + 4.50%, Floor rate 5.50%, PIK Interest 4.50%2025-03-310001280784Debt Investments Software and Leapwork ApS., Senior Secured, Maturity Date February 2026, Prime + 0.25%, Floor rate 7.00%, PIK Interest 1.95%, 2.70% Exit Fee2025-03-310001280784Debt Investments Software and LinenMaster, LLC., Senior Secured, Maturity Date August 2028, 1-month SOFR + 6.25%, Floor rate 7.25%, PIK Interest 2.15%2025-03-310001280784Debt Investments Software and Loftware, Inc., Senior Secured, Maturity Date March 2028, 3-month SOFR + 7.88%, Floor rate 8.88%2025-03-310001280784Debt Investments Software and LogicSource, Senior Secured, Maturity Date July 2027, 1-month SOFR + 8.93%, Floor rate 9.93%2025-03-310001280784Debt Investments Software and LogRhythm, Inc., Senior Secured, Maturity Date July 2029, 3-month SOFR + 7.50%, Floor rate 8.50%2025-03-310001280784Debt Investments Software and Marigold Group, Inc., Senior Secured, Maturity Date November 2026, PIK Interest 6-month SOFR + 10.55%, Floor rate 11.55%2025-03-310001280784Debt Investments Software and Mobile Solutions Services, Senior Secured, Maturity Date December 2025, 6-month SOFR + 9.31%, Floor rate 10.06%2025-03-310001280784Debt Investments Software and Morphisec Information Security 2014 Ltd., Senior Secured, Maturity Date October 2027, Prime + 3.45%, Floor rate 11.70%, 5.95% Exit Fee2025-03-310001280784Debt Investments Software and New Relic, Inc., Senior Secured, Maturity Date November 2030, 3-month SOFR + 6.75%, Floor rate 7.75%2025-03-310001280784Debt Investments Software and Omeda Holdings, LLC, Senior Secured, Maturity Date July 2027, 3-month SOFR + 8.05%, Floor rate 9.05%2025-03-310001280784Debt Investments Software and PayIt, LLC, Senior Secured, Maturity Date December 2028, Prime + 1.45%, Floor rate 7.95%, PIK Interest 1.50%, 5.00% Exit Fee2025-03-310001280784Debt Investments Software and Pindrop Security, Inc., Senior Secured, Maturity Date June 2029, Prime + 3.50%, Floor rate 10.00%, 2.00% Exit Fee2025-03-310001280784Debt Investments Software and Remodel Health Holdco, LLC., Senior Secured, Maturity Date December 2028 ,Prime + 2.35%, Floor rate 10.35%, 6.50% Exit Fee2025-03-310001280784Debt Investments Software and Reveleer, Senior Secured, Maturity Date February 2027, Prime + 0.65%, Floor rate 9.15%, PIK Interest 2.00%, 5.05% Exit Fee2025-03-310001280784Debt Investments Software and Semperis Technologies Inc., Senior Secured, Maturity Date April 2028, Prime - 1.75%, Floor rate 6.75%, PIK Interest 3.25%2025-03-310001280784Debt Investments Software and ShadowDragon, LLC, Senior Secured, Maturity Date December 2026, 3-month SOFR + 8.88%, Floor rate 9.78%2025-03-310001280784Debt Investments Software and Simon Data, Inc., Senior Secured, Maturity Date March 2027, Prime + 1.00%, Floor rate 8.75%, PIK Interest 1.95%, 2.95% Exit Fee2025-03-310001280784Debt Investments Software and Sisense Ltd., Senior Secured, Maturity Date July 2027, Prime + 1.50%, Floor rate 9.50%, PIK Interest 1.95%, 5.95% Exit Fee2025-03-310001280784Debt Investments Smartsheet Inc.., Senior Secured, Maturity Date January 2031 , 3-month SOFR + 6.50%, Floor rate 7.25%2025-03-310001280784Debt Investments Snappt, Inc., Senior Secured, Maturity Date April 2029, Prime + 2.35%, Floor rate 8.85%, PIK Interest 1.00%, 4.25% Exit Fee2025-03-310001280784Debt Investments Software and Streamline Healthcare Solutions, Senior Secured, Maturity Date March 2028, 3-month SOFR + 7.25%, Floor rate 8.25%2025-03-310001280784Debt Investments Software and Sumo Logic, Inc., Senior Secured, Maturity Date May 2030, 6-month SOFR + 6.50%, Floor rate 7.50%2025-03-310001280784Debt Investments Software and Suzy, Inc.., Senior Secured, Maturity Date August 2027, Prime + 1.75%, Floor rate 10.00%, PIK Interest 1.95%, 3.45% Exit Fee2025-03-310001280784Debt Investments Software and TaxCalc., Senior Secured, Maturity Date November 2029, Daily SONIA + 8.17%, Floor rate 8.67%2025-03-310001280784Debt Investments Software and ThreatConnect, Inc., Senior Secured, Maturity Date May 2026, 3-month SOFR + 9.15%, Floor rate 10.00%2025-03-310001280784Debt Investments Software and Tipalti Solutions Ltd., Senior Secured, Maturity Date April 2029, Prime + 0.45%, Floor rate 6.45%, PIK Interest 2.30%2025-03-310001280784Debt Investments Software and Tipalti Solutions Ltd., Senior Secured, Maturity Date April 2029, Prime + 0.45%, Floor rate 6.45%, PIK Interest 2.30%, 3.75% Exit Fee2025-03-310001280784Debt Investments Software and Total Tipalti Solutions Ltd.2025-03-310001280784Debt Investments Software and Zappi, Inc., Senior Secured, Maturity Date December 2027, 3-month SOFR + 8.03%, Floor rate 9.03%2025-03-310001280784Debt Investments Software and Zimperium, Inc., Senior Secured, Maturity Date May 2027, 3-month SOFR + 8.31%, Floor rate 9.31%2025-03-310001280784Debt Investments Software (61.81%)2025-03-310001280784Debt Investments Space Technologies and Voyager Space Holdings, Inc., Senior Secured, Maturity Date July 2028, Prime + 1.25%, Floor rate 9.75%, PIK Interest 2.50%, 5.50% Exit Fee2025-03-310001280784Debt Investments Space Technologies (2.47%)2025-03-310001280784Debt Investments Sustainable and Renewable Technology and Electric Hydrogen Co., Senior Secured, May 2028, Prime + 2.25%, Floor rate 10.75%, PIK Interest 1.25%, 4.89% Exit Fee2025-03-310001280784Debt Investments Sustainable and Renewable Technology (0.99%)2025-03-310001280784Debt Investments (186.90%)2025-03-310001280784Equity Investments Biotechnology Tools and Alamar Biosciences, Inc., Equity, Acquisition Date 2/21/2024, Series Preferred Series C2025-01-012025-03-310001280784Equity Investments Biotechnology Tools and Alamar Biosciences, Inc., Equity, Acquisition Date 2/21/2024, Series Preferred Series C2025-03-310001280784Equity Investments Biotechnology Tools (0.05%)2025-03-310001280784Equity Investments Consumer & Business Products and Fabletics, Inc., Equity, Acquisition Date 4/30/2010, Series Common Stock2025-01-012025-03-310001280784Equity Investments Consumer & Business Products and Fabletics, Inc., Equity, Acquisition Date 4/30/2010, Series Common Stock2025-03-310001280784Equity Investments Consumer & Business Products and Fabletics, Inc., Equity, Acquisition Date 7/16/2013, Series Preferred Series B2025-01-012025-03-310001280784Equity Investments Consumer & Business Products and Fabletics, Inc., Equity, Acquisition Date 7/16/2013, Series Preferred Series B2025-03-310001280784Equity Investments Consumer & Business Products and Total Fabletics, Inc.2025-03-310001280784Equity Investments Consumer & Business Products and Grove Collaborative, Inc., Equity, Acquisition Date 4/30/2021, Series Common Stock2025-01-012025-03-310001280784Equity Investments Consumer & Business Products and Grove Collaborative, Inc., Equity, Acquisition Date 4/30/2021, Series Common Stock2025-03-310001280784Equity Investments Consumer & Business Products and Savage X Holding, LLC, Equity, Acquisition Date 4/30/2010, Series Class A Units2025-01-012025-03-310001280784Equity Investments Consumer & Business Products and Savage X Holding, LLC, Equity, Acquisition Date 4/30/2010, Series Class A Units2025-03-310001280784Equity Investments Consumer & Business Products (0.02%)2025-03-310001280784Equity Investments Consumer & Business Services and Carwow LTD, Equity, Acquisition Date 12/15/2021, Series Preferred Series D-42025-01-012025-03-310001280784Equity Investments Consumer & Business Services and Carwow LTD, Equity, Acquisition Date 12/15/2021, Series Preferred Series D-42025-03-310001280784Equity Investments Consumer & Business Services and Jobandtalent USA, Inc., Equity, Acquisition Date 2/11/2025, Series Preferred Series F2025-01-012025-03-310001280784Equity Investments Consumer & Business Services and Jobandtalent USA, Inc., Equity, Acquisition Date 2/11/2025, Series Preferred Series F2025-03-310001280784Equity Investments Consumer & Business Services and Lyft, Inc., Equity, Acquisition Date 12/26/2018, Series Common Stock2025-01-012025-03-310001280784Equity Investments Consumer & Business Services and Lyft, Inc., Equity, Acquisition Date 12/26/2018, Series Common Stock2025-03-310001280784Equity Investments Consumer & Business Services and Nerdy Inc., Equity, Acquisition Date 9/17/2021, Series Common Stock2025-01-012025-03-310001280784Equity Investments Consumer & Business Services and Nerdy Inc., Equity, Acquisition Date 9/17/2021, Series Common Stock2025-03-310001280784Equity Investments Consumer & Business Services and OfferUp, Inc., Equity, Acquisition Date 10/25/2016, Series Preferred Series A2025-01-012025-03-310001280784Equity Investments Consumer & Business Services and OfferUp, Inc., Equity, Acquisition Date 10/25/2016, Series Preferred Series A2025-03-310001280784Equity Investments Consumer & Business Services and OfferUp, Inc., Equity, Acquisition Date 10/25/2016, Series Preferred Series A-12025-01-012025-03-310001280784Equity Investments Consumer & Business Services and OfferUp, Inc., Equity, Acquisition Date 10/25/2016, Series Preferred Series A-12025-03-310001280784Equity Investments Consumer & Business Services and Total OfferUp, Inc.2025-03-310001280784Equity Investments Consumer & Business Services and Oportun, Equity, Acquisition Date 6/28/2013, Series Common Stock2025-01-012025-03-310001280784Equity Investments Consumer & Business Services and Oportun, Equity, Acquisition Date 6/28/2013, Series Common Stock2025-03-310001280784Equity Investments Consumer & Business Services and Reischling Press, Inc., Equity, Acquisition Date 7/31/2020, Series Common Stock2025-01-012025-03-310001280784Equity Investments Consumer & Business Services and Reischling Press, Inc., Equity, Acquisition Date 7/31/2020, Series Common Stock2025-03-310001280784Equity Investments Consumer & Business Services and Rhino Labs, Inc., Equity, Acquisition Date 1/24/2022, Series Common Stock2025-01-012025-03-310001280784Equity Investments Consumer & Business Services and Rhino Labs, Inc., Equity, Acquisition Date 1/24/2022, Series Common Stock2025-03-310001280784Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 5/23/2018, Series Common Stock2025-01-012025-03-310001280784Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 5/23/2018, Series Common Stock2025-03-310001280784Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 6/6/2016, Series Preferred Series BB2025-01-012025-03-310001280784Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 6/6/2016, Series Preferred Series BB2025-03-310001280784Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 12/29/2023, Series Preferred Series C2025-01-012025-03-310001280784Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 12/29/2023, Series Preferred Series C2025-03-310001280784Equity Investments Consumer & Business Services and Total Tectura Corporation2025-03-310001280784Equity Investments Consumer & Business Services and Worldremit Group Limited, Equity, Acquisition Date 6/24/2024, Series Preferred Series X2025-01-012025-03-310001280784Equity Investments Consumer & Business Services and Worldremit Group Limited, Equity, Acquisition Date 6/24/2024, Series Preferred Series X2025-03-310001280784Equity Investments Consumer & Business Services (0.40%)2025-03-310001280784Equity Investments Diversified Financial Services and Gibraltar Acquisition, LLC, Equity, Acquisition Date 3/1/2018, Series Member Units2025-01-012025-03-310001280784Equity Investments Diversified Financial Services and Gibraltar Acquisition, LLC, Equity, Acquisition Date 3/1/2018, Series Member Units2025-03-310001280784Equity Investments Diversified Financial Services and Hercules Adviser LLC, Equity, Acquisition Date 3/26/2021, Series Member Units2025-01-012025-03-310001280784Equity Investments Diversified Financial Services and Hercules Adviser LLC, Equity, Acquisition Date 3/26/2021, Series Member Units2025-03-310001280784Equity Investments Diversified Financial Services and Newfront Insurance Holdings, Inc., Equity, Acquisition Date 9/30/2021, Series Preferred Series D-22025-01-012025-03-310001280784Equity Investments Diversified Financial Services and Newfront Insurance Holdings, Inc., Equity, Acquisition Date 9/30/2021, Series Preferred Series D-22025-03-310001280784Equity Investments Diversified Financial Services (3.38%)2025-03-310001280784Equity Investments Drug Delivery and Aytu BioScience, Inc., Equity, Acquisition Date 3/28/2014, Series Common Stock2025-01-012025-03-310001280784Equity Investments Drug Delivery and Aytu BioScience, Inc., Equity, Acquisition Date 3/28/2014, Series Common Stock2025-03-310001280784Equity Investments Drug Delivery and BioQ Pharma Incorporated, Equity, Acquisition Date 12/8/2015, Series Preferred Series D2025-01-012025-03-310001280784Equity Investments Drug Delivery and BioQ Pharma Incorporated, Equity, Acquisition Date 12/8/2015, Series Preferred Series D2025-03-310001280784Equity Investments Drug Delivery and PDS Biotechnology Corporation, Equity, Acquisition Date 4/6/2015, Series Common Stock2025-01-012025-03-310001280784Equity Investments Drug Delivery and PDS Biotechnology Corporation, Equity, Acquisition Date 4/6/2015, Series Common Stock2025-03-310001280784Equity Investments Drug Delivery and Talphera, Inc, Equity, Acquisition Date 12/10/2018, Series Common Stock2025-01-012025-03-310001280784Equity Investments Drug Delivery and Talphera, Inc, Equity, Acquisition Date 12/10/2018, Series Common Stock2025-03-310001280784Equity Investments Drug Delivery (0.00%)2025-03-310001280784Equity Investments Drug Discovery & Development and Akero Therapeutics, Inc., Equity, Acquisition Date 3/8/2024, Series Common Stock2025-01-012025-03-310001280784Equity Investments Drug Discovery & Development and Akero Therapeutics, Inc., Equity, Acquisition Date 3/8/2024, Series Common Stock2025-03-310001280784Equity Investments Drug Discovery & Development and Arcus Biosciences, Inc., Equity, Acquisition Date 2/19/2025, Series Common Stock2025-01-012025-03-310001280784Equity Investments Drug Discovery & Development and Arcus Biosciences, Inc., Equity, Acquisition Date 2/19/2025, Series Common Stock2025-03-310001280784Equity Investments Drug Discovery & Development and Avalo Therapeutics, Inc., Equity, Acquisition Date 8/19/2014, Series Common Stock2025-01-012025-03-310001280784Equity Investments Drug Discovery & Development and Avalo Therapeutics, Inc., Equity, Acquisition Date 8/19/2014, Series Common Stock2025-03-310001280784Equity Investments Drug Discovery & Development and Axsome Therapeutics, Inc., Equity, Acquisition Date 5/9/2022, Series Common Stock2025-01-012025-03-310001280784Equity Investments Drug Discovery & Development and Axsome Therapeutics, Inc., Equity, Acquisition Date 5/9/2022, Series Common Stock2025-03-310001280784Equity Investments Drug Discovery & Development and Bicycle Therapeutics PLC, Equity, Acquisition Date 10/5/2020, Series Common Stock2025-01-012025-03-310001280784Equity Investments Drug Discovery & Development and Bicycle Therapeutics PLC, Equity, Acquisition Date 10/5/2020, Series Common Stock2025-03-310001280784Equity Investments Drug Discovery & Development and BridgeBio Pharma, Inc., Equity, Acquisition Date 6/21/2018, Series Common Stock2025-01-012025-03-310001280784Equity Investments Drug Discovery & Development and BridgeBio Pharma, Inc., Equity, Acquisition Date 6/21/2018, Series Common Stock2025-03-310001280784Equity Investments Drug Discovery & Development and Dare Biosciences, Inc., Equity, Acquisition Date 1/8/2015, Series Common Stock2025-01-012025-03-310001280784Equity Investments Drug Discovery & Development and Dare Biosciences, Inc., Equity, Acquisition Date 1/8/2015, Series Common Stock2025-03-310001280784Equity Investments Drug Discovery & Development and Dynavax Technologies, Equity, Acquisition Date 7/22/2015, Series Common Stock2025-01-012025-03-310001280784Equity Investments Drug Discovery & Development and Dynavax Technologies, Equity, Acquisition Date 7/22/2015, Series Common Stock2025-03-310001280784Equity Investments Drug Discovery & Development and Heron Therapeutics, Inc., Equity, Acquisition Date 7/25/2023, Series Common Stock2025-01-012025-03-310001280784Equity Investments Drug Discovery & Development and Heron Therapeutics, Inc., Equity, Acquisition Date 7/25/2023, Series Common Stock2025-03-310001280784Equity Investments Drug Discovery & Development and Hibercell, Inc., Equity, Acquisition Date 5/7/2021, Series Preferred Series B2025-01-012025-03-310001280784Equity Investments Drug Discovery & Development and Hibercell, Inc., Equity, Acquisition Date 5/7/2021, Series Preferred Series B2025-03-310001280784Equity Investments Drug Discovery & Development and HilleVax, Inc, Equity, Acquisition Date 5/3/2022, Series Common Stock2025-01-012025-03-310001280784Equity Investments Drug Discovery & Development and HilleVax, Inc, Equity, Acquisition Date 5/3/2022, Series Common Stock2025-03-310001280784Equity Investments Drug Discovery & Development and Kura Oncology, Inc., Equity, Acquisition Date 6/16/2023, Series Common Stock2025-01-012025-03-310001280784Equity Investments Drug Discovery & Development and Kura Oncology, Inc., Equity, Acquisition Date 6/16/2023, Series Common Stock2025-03-310001280784Equity Investments Drug Discovery & Development and Madrigal Pharmaceutical, Inc., Equity, Acquisition Date 9/29/2023, Series Common Stock2025-01-012025-03-310001280784Equity Investments Drug Discovery & Development and Madrigal Pharmaceutical, Inc., Equity, Acquisition Date 9/29/2023, Series Common Stock2025-03-310001280784Equity Investments Drug Discovery & Development and NorthSea Therapeutics, Equity, Acquisition Date 12/15/2021, Series Preferred Series C2025-01-012025-03-310001280784Equity Investments Drug Discovery & Development and NorthSea Therapeutics, Equity, Acquisition Date 12/15/2021, Series Preferred Series C2025-03-310001280784Equity Investments Drug Discovery & Development and Phathom Pharmaceuticals, Inc., Equity, Acquisition Date 6/9/2023, Series Common Stock2025-01-012025-03-310001280784Equity Investments Drug Discovery & Development and Phathom Pharmaceuticals, Inc., Equity, Acquisition Date 6/9/2023, Series Common Stock2025-03-310001280784Equity Investments Drug Discovery & Development and Rafael Holdings, Inc. (p.k.a. Cyclo Therapeutics, Inc.), Equity, Acquisition Date 4/6/2021, Series Common Stock2025-01-012025-03-310001280784Equity Investments Drug Discovery & Development and Rafael Holdings, Inc. (p.k.a. Cyclo Therapeutics, Inc.), Equity, Acquisition Date 4/6/2021, Series Common Stock2025-03-310001280784Equity Investments Drug Discovery & Development and Rocket Pharmaceuticals, Ltd., Equity, Acquisition Date 8/22/2007, Series Common Stock2025-01-012025-03-310001280784Equity Investments Drug Discovery & Development and Rocket Pharmaceuticals, Ltd., Equity, Acquisition Date 8/22/2007, Series Common Stock2025-03-310001280784Equity Investments Drug Discovery & Development and Savara, Inc., Equity, Acquisition Date 8/11/2015, Series Common Stock2025-01-012025-03-310001280784Equity Investments Drug Discovery & Development and Savara, Inc., Equity, Acquisition Date 8/11/2015, Series Common Stock2025-03-310001280784Equity Investments Drug Discovery & Development and uniQure B.V., Equity, Acquisition Date 1/31/2019, Series Common Stock2025-01-012025-03-310001280784Equity Investments Drug Discovery & Development and uniQure B.V., Equity, Acquisition Date 1/31/2019, Series Common Stock2025-03-310001280784Equity Investments Drug Discovery & Development and Valo Health, LLC, Equity, Acquisition Date 12/11/2020, Series Preferred Series B2025-01-012025-03-310001280784Equity Investments Drug Discovery & Development and Valo Health, LLC, Equity, Acquisition Date 12/11/2020, Series Preferred Series B2025-03-310001280784Equity Investments Drug Discovery & Development and Valo Health, LLC, Equity, Acquisition Date 10/31/2022, Series Preferred Series C2025-01-012025-03-310001280784Equity Investments Drug Discovery & Development and Valo Health, LLC, Equity, Acquisition Date 10/31/2022, Series Preferred Series C2025-03-310001280784Equity Investments Drug Discovery & Development and Total Valo Health LLC2025-03-310001280784Equity Investments Drug Discovery & Development and Verge Analytics, Inc., Equity, Acquisition Date 9/6/2023, Series Preferred Series C2025-01-012025-03-310001280784Equity Investments Drug Discovery & Development and Verge Analytics, Inc., Equity, Acquisition Date 9/6/2023, Series Preferred Series C2025-03-310001280784Equity Investments Drug Discovery & Development and Viridian Therapeutics, Inc., Equity, Acquisition Date 11/6/2023, Series Common Stock2025-01-012025-03-310001280784Equity Investments Drug Discovery & Development and Viridian Therapeutics, Inc., Equity, Acquisition Date 11/6/2023, Series Common Stock2025-03-310001280784Equity Investments Drug Discovery & Development and X4 Pharmaceuticals, Inc., Equity, Acquisition Date 11/26/2019, Series Common Stock2025-01-012025-03-310001280784Equity Investments Drug Discovery & Development and X4 Pharmaceuticals, Inc., Equity, Acquisition Date 11/26/2019, Series Common Stock2025-03-310001280784Equity Investments Drug Discovery & Development (1.81%)2025-03-310001280784Equity Investments Electronics & Computer Hardware and Locus Robotics Corp., Equity, Acquisition Date 11/17/2022, Series Preferred Series F2025-01-012025-03-310001280784Equity Investments Electronics & Computer Hardware and Locus Robotics Corp., Equity, Acquisition Date 11/17/2022, Series Preferred Series F2025-03-310001280784Equity Investments Electronics & Computer Hardware and Shield AI, Inc., Equity, Acquisition Date 2/7/2025, Series Preferred Series F12025-01-012025-03-310001280784Equity Investments Electronics & Computer Hardware and Shield AI, Inc., Equity, Acquisition Date 2/7/2025, Series Preferred Series F12025-03-310001280784Equity Investments Electronics & Computer Hardware and Skydio, Inc., Equity, Acquisition Date 3/8/2022, Series Preferred Series E2025-01-012025-03-310001280784Equity Investments Electronics & Computer Hardware and Skydio, Inc., Equity, Acquisition Date 3/8/2022, Series Preferred Series E2025-03-310001280784Equity Investments Electronics & Computer Hardware (0.15%)2025-03-310001280784Equity Investments Healthcare Services, Other and 23andMe, Inc., Equity, Acquisition Date 3/11/2019, Series Common Stock2025-01-012025-03-310001280784Equity Investments Healthcare Services, Other and 23andMe, Inc., Equity, Acquisition Date 3/11/2019, Series Common Stock2025-03-310001280784Equity Investments Healthcare Services, Other and Carbon Health Technologies, Inc., Equity, Acquisition Date 3/30/2021, Series Common Stock2025-01-012025-03-310001280784Equity Investments Healthcare Services, Other and Carbon Health Technologies, Inc., Equity, Acquisition Date 3/30/2021, Series Common Stock2025-03-310001280784Equity Investments Healthcare Services, Other and Click Therapeutics, Inc., Equity, Acquisition Date 5/20/2024, Series Common Stock2025-01-012025-03-310001280784Equity Investments Healthcare Services, Other and Click Therapeutics, Inc., Equity, Acquisition Date 5/20/2024, Series Common Stock2025-03-310001280784Equity Investments Healthcare Services, Other and Curana Health Holdings, LLC, Equity, Acquisition Date 5/13/2024, Series Common Units2025-01-012025-03-310001280784Equity Investments Healthcare Services, Other and Curana Health Holdings, LLC, Equity, Acquisition Date 5/13/2024, Series Common Units2025-03-310001280784Equity Investments Healthcare Services, Other and Main Street Rural, Inc., Equity, Acquisition Date 10/28/2024, Series Preferred Series D2025-01-012025-03-310001280784Equity Investments Healthcare Services, Other and Main Street Rural, Inc., Equity, Acquisition Date 10/28/2024, Series Preferred Series D2025-03-310001280784Equity Investments Healthcare Services, Other and WellBe Senior Medical, LLC, Equity, Acquisition Date 6/10/2024, Series Common Units2025-01-012025-03-310001280784Equity Investments Healthcare Services, Other and WellBe Senior Medical, LLC, Equity, Acquisition Date 6/10/2024, Series Common Units2025-03-310001280784Equity Investments Healthcare Services, Other (0.37%)2025-03-310001280784Equity Investments Information Services and Yipit, LLC, Equity, Acquisition Date 12/30/2021, Series Preferred Series E2025-01-012025-03-310001280784Equity Investments Information Services and Yipit, LLC, Equity, Acquisition Date 12/30/2021, Series Preferred Series E2025-03-310001280784Equity Investments Information Services (0.23%)2025-03-310001280784Equity Investments Medical Devices & Equipment and Coronado Aesthetics, LLC, Equity, Acquisition Date 10/15/2021, Series Common Units2025-01-012025-03-310001280784Equity Investments Medical Devices & Equipment and Coronado Aesthetics, LLC, Equity, Acquisition Date 10/15/2021, Series Common Units2025-03-310001280784Equity Investments Medical Devices & Equipment and Coronado Aesthetics, LLC, Equity, Acquisition Date 10/15/2021, Series Preferred Series A-22025-01-012025-03-310001280784Equity Investments Medical Devices & Equipment and Coronado Aesthetics, LLC, Equity, Acquisition Date 10/15/2021, Series Preferred Series A-22025-03-310001280784Equity Investments Medical Devices & Equipment and Total Coronado Aesthetics, LLC2025-03-310001280784Equity Investments Medical Devices & Equipment (0.00%)2025-03-310001280784Equity Investments Semiconductors and Achronix Semiconductor Corporation, Equity, Acquisition Date 7/1/2011, Series Preferred Series C2025-01-012025-03-310001280784Equity Investments Semiconductors and Achronix Semiconductor Corporation, Equity, Acquisition Date 7/1/2011, Series Preferred Series C2025-03-310001280784Equity Investments Semiconductors (0.00%)2025-03-310001280784Equity Investments Software and Armis, Inc., Equity, Acquisition Date 10/18/2024, Series Preferred Series D2025-01-012025-03-310001280784Equity Investments Software and Armis, Inc., Equity, Acquisition Date 10/18/2024, Series Preferred Series D2025-03-310001280784Equity Investments Software and Black Crow AI, Inc. affiliates, Equity, Acquisition Date 3/24/2021, Series Preferred Note2025-01-012025-03-310001280784Equity Investments Software and Black Crow AI, Inc. affiliates, Equity, Acquisition Date 3/24/2021, Series Preferred Note2025-03-310001280784Equity Investments Software and CapLinked, Inc., Equity, Acquisition Date 10/26/2012, Series Preferred Series A-32025-01-012025-03-310001280784Equity Investments Software and CapLinked, Inc., Equity, Acquisition Date 10/26/2012, Series Preferred Series A-32025-03-310001280784Equity Investments Software and Contentful Global, Inc., Equity, Acquisition Date 12/22/2020, Series Preferred Series C2025-01-012025-03-310001280784Equity Investments Software and Contentful Global, Inc., Equity, Acquisition Date 12/22/2020, Series Preferred Series C2025-03-310001280784Equity Investments Software and Contentful Global, Inc., Equity, Acquisition Date 11/20/2018, Series Preferred Series D2025-01-012025-03-310001280784Equity Investments Software and Contentful Global, Inc., Equity, Acquisition Date 11/20/2018, Series Preferred Series D2025-03-310001280784Equity Investments Software and Total Contentful Global, Inc.2025-03-310001280784Equity Investments Software and DNAnexus, Inc, Equity, Acquisition Date 3/21/2014, Series Preferred Series C2025-01-012025-03-310001280784Equity Investments Software and DNAnexus, Inc, Equity, Acquisition Date 3/21/2014, Series Preferred Series C2025-03-310001280784Equity Investments Software and Docker, Inc., Equity, Acquisition Date 11/29/2018, Series Common Stock2025-01-012025-03-310001280784Equity Investments Software and Docker, Inc., Equity, Acquisition Date 11/29/2018, Series Common Stock2025-03-310001280784Equity Investments Software and Druva Holdings, Inc., Equity, Acquisition Date 10/22/2015, Series Preferred Series 22025-01-012025-03-310001280784Equity Investments Software and Druva Holdings, Inc., Equity, Acquisition Date 10/22/2015, Series Preferred Series 22025-03-310001280784Equity Investments Software and Druva Holdings, Inc., Equity, Acquisition Date 8/24/2017, Series Preferred Series 32025-01-012025-03-310001280784Equity Investments Software and Druva Holdings, Inc., Equity, Acquisition Date 8/24/2017, Series Preferred Series 32025-03-310001280784Equity Investments Software and Total Druva Holdings, Inc.2025-03-310001280784Equity Investments Software and HighRoads, Inc., Equity, Acquisition Date 1/18/2013, Series Common Stock2025-01-012025-03-310001280784Equity Investments Software and HighRoads, Inc., Equity, Acquisition Date 1/18/2013, Series Common Stock2025-03-310001280784Equity Investments Software and Leapwork ApS., Equity, Acquisition Date 8/25/2023, Series Preferred Series B22025-01-012025-03-310001280784Equity Investments Software and Leapwork ApS., Equity, Acquisition Date 8/25/2023, Series Preferred Series B22025-03-310001280784Equity Investments Software and Lightbend, Inc., Equity, Acquisition Date 12/4/2020, Series Common Stock2025-01-012025-03-310001280784Equity Investments Software and Lightbend, Inc., Equity, Acquisition Date 12/4/2020, Series Common Stock2025-03-310001280784Equity Investments Software and Nextdoor.com, Inc., Equity, Acquisition Date 8/1/2018, Series Common Stock2025-01-012025-03-310001280784Equity Investments Software and Nextdoor.com, Inc., Equity, Acquisition Date 8/1/2018, Series Common Stock2025-03-310001280784Equity Investments Software and SingleStore, Inc., Equity, Acquisition Date 11/25/2020, Series Preferred Series E2025-01-012025-03-310001280784Equity Investments Software and SingleStore, Inc., Equity, Acquisition Date 11/25/2020, Series Preferred Series E2025-03-310001280784Equity Investments Software and SingleStore, Inc., Equity, Acquisition Date 8/12/2021, Series Preferred Series F2025-01-012025-03-310001280784Equity Investments Software and SingleStore, Inc., Equity, Acquisition Date 8/12/2021, Series Preferred Series F2025-03-310001280784Equity Investments Software and Total SingleStore, Inc.2025-03-310001280784Equity Investments Software and SirionLabs Pte. Ltd., Equity, Acquisition Date 6/30/2024, Series Preferred Series F12025-01-012025-03-310001280784Equity Investments Software and SirionLabs Pte. Ltd., Equity, Acquisition Date 6/30/2024, Series Preferred Series F12025-03-310001280784Equity Investments Software and Verana Health, Inc., Equity, Acquisition Date 7/8/2021, Series Common Stock2025-01-012025-03-310001280784Equity Investments Software and Verana Health, Inc., Equity, Acquisition Date 7/8/2021, Series Common Stock2025-03-310001280784Equity Investments Software (0.81%)2025-03-310001280784Equity Investments Sustainable and Renewable Technology and Impossible Foods, Inc., Equity, Acquisition Date 5/10/2019, Series Preferred Series E-12025-01-012025-03-310001280784Equity Investments Sustainable and Renewable Technology and Impossible Foods, Inc., Equity, Acquisition Date 5/10/2019, Series Preferred Series E-12025-03-310001280784Equity Investments Sustainable and Renewable Technology and Modumetal, Inc., Equity, Acquisition Date 6/1/2015, Series Common Stock2025-01-012025-03-310001280784Equity Investments Sustainable and Renewable Technology and Modumetal, Inc., Equity, Acquisition Date 6/1/2015, Series Common Stock2025-03-310001280784Equity Investments Sustainable and Renewable Technology and Pivot Bio, Inc., Equity, Acquisition Date 6/28/2021, Series Preferred Series D2025-01-012025-03-310001280784Equity Investments Sustainable and Renewable Technology and Pivot Bio, Inc., Equity, Acquisition Date 6/28/2021, Series Preferred Series D2025-03-310001280784Equity Investments Sustainable and Renewable Technology and SUNation Energy, Inc., Equity, Acquisition Date 12/10/2020, Series Common Stock2025-01-012025-03-310001280784Equity Investments Sustainable and Renewable Technology and SUNation Energy, Inc., Equity, Acquisition Date 12/10/2020, Series Common Stock2025-03-310001280784Equity Investments Sustainable and Renewable Technology (0.11%)2025-03-310001280784Equity Investments (7.34%)2025-03-310001280784Warrant Investments and Biotechnology Tools and Alamar Biosciences, Inc., Warrant, Acquisition Date 6/21/2022, Series Preferred Series C2025-01-012025-03-310001280784Warrant Investments and Biotechnology Tools and Alamar Biosciences, Inc., Warrant, Acquisition Date 6/21/2022, Series Preferred Series C2025-03-310001280784Warrant Investments and Biotechnology Tools and PathAI, Inc., Warrant, Acquisition Date 12/23/2022, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Biotechnology Tools and PathAI, Inc., Warrant, Acquisition Date 12/23/2022, Series Common Stock2025-03-310001280784Warrant Investments and Biotechnology Tools (0.01%)2025-03-310001280784Warrant Investments and Communications & Networking and Aryaka Networks, Inc., Warrant, Acquisition Date 6/28/2022, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Communications & Networking and Aryaka Networks, Inc., Warrant, Acquisition Date 6/28/2022, Series Common Stock2025-03-310001280784Warrant Investments and Communications & Networking (0.01%)2025-03-310001280784Warrant Investments and Consumer & Business Products and Gadget Guard, LLC, Warrant, Acquisition Date 6/3/2014, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Consumer & Business Products and Gadget Guard, LLC, Warrant, Acquisition Date 6/3/2014, Series Common Stock2025-03-310001280784Warrant Investments and Consumer & Business Products and Whoop, Inc., Warrant, Acquisition Date 6/27/2018, Series Preferred Series C2025-01-012025-03-310001280784Warrant Investments and Consumer & Business Products and Whoop, Inc., Warrant, Acquisition Date 6/27/2018, Series Preferred Series C2025-03-310001280784Warrant Investments and Consumer & Business Products (0.04%)2025-03-310001280784Warrant Investments and Consumer & Business Services and Altumint, Inc., Warrant, Acquisition Date 10/31/2024, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Consumer & Business Services and Altumint, Inc., Warrant, Acquisition Date 10/31/2024, Series Common Stock2025-03-310001280784Warrant Investments and Consumer & Business Services and Carwow LTD, Warrant, Acquisition Date 12/14/2021, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Consumer & Business Services and Carwow LTD, Warrant, Acquisition Date 12/14/2021, Series Common Stock2025-03-310001280784Warrant Investments and Consumer & Business Services and Carwow LTD, Warrant, Acquisition Date 2/13/2024, Series Preferred Series D-42025-01-012025-03-310001280784Warrant Investments and Consumer & Business Services and Carwow LTD, Warrant, Acquisition Date 2/13/2024, Series Preferred Series D-42025-03-310001280784Warrant Investments and Consumer & Business Services and Total Carwow LTD2025-03-310001280784Warrant Investments and Consumer & Business Services and Houzz, Inc., Warrant, Acquisition Date 10/29/2019, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Consumer & Business Services and Houzz, Inc., Warrant, Acquisition Date 10/29/2019, Series Common Stock2025-03-310001280784Warrant Investments and Consumer & Business Services and Landing Holdings Inc., Warrant, Acquisition Date 3/12/2021, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Consumer & Business Services and Landing Holdings Inc., Warrant, Acquisition Date 3/12/2021, Series Common Stock2025-03-310001280784Warrant Investments and Consumer & Business Services and Lendio, Inc., Warrant, Acquisition Date 3/29/2019, Series Preferred Series D2025-01-012025-03-310001280784Warrant Investments and Consumer & Business Services and Lendio, Inc., Warrant, Acquisition Date 3/29/2019, Series Preferred Series D2025-03-310001280784Warrant Investments and Consumer & Business Services and Plentific Ltd, Warrant, Acquisition Date 10/3/2023, Series Ordinary Shares2025-01-012025-03-310001280784Warrant Investments and Consumer & Business Services and Plentific Ltd, Warrant, Acquisition Date 10/3/2023, Series Ordinary Shares2025-03-310001280784Warrant Investments and Consumer & Business Services and Provi, Warrant, Acquisition Date 12/22/2022, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Consumer & Business Services and Provi, Warrant, Acquisition Date 12/22/2022, Series Common Stock2025-03-310001280784Warrant Investments and Consumer & Business Services and Rhino Labs, Inc., Warrant, Acquisition Date 3/12/2021, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Consumer & Business Services and Rhino Labs, Inc., Warrant, Acquisition Date 3/12/2021, Series Common Stock2025-03-310001280784Warrant Investments and Consumer & Business Services and SeatGeek, Inc., Warrant, Acquisition Date 6/12/2019, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Consumer & Business Services and SeatGeek, Inc., Warrant, Acquisition Date 6/12/2019, Series Common Stock2025-03-310001280784Warrant Investments and Consumer & Business Services and Skyword, Inc., Warrant, Acquisition Date 11/14/2022, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Consumer & Business Services and Skyword, Inc., Warrant, Acquisition Date 11/14/2022, Series Common Stock2025-03-310001280784Warrant Investments and Consumer & Business Services and Skyword, Inc., Warrant, Acquisition Date 8/23/2019, Series Preferred Series B2025-01-012025-03-310001280784Warrant Investments and Consumer & Business Services and Skyword, Inc., Warrant, Acquisition Date 8/23/2019, Series Preferred Series B2025-03-310001280784Warrant Investments and Consumer & Business Services and Total Skyword, Inc.2025-03-310001280784Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 4/20/2020, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 4/20/2020, Series Common Stock2025-03-310001280784Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 6/30/2016, Series Preferred Series A2025-01-012025-03-310001280784Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 6/30/2016, Series Preferred Series A2025-03-310001280784Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 8/1/2018, Series Preferred Series B2025-01-012025-03-310001280784Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 8/1/2018, Series Preferred Series B2025-03-310001280784Warrant Investments and Consumer & Business Services and Total Snagajob.com, Inc.2025-03-310001280784Warrant Investments and Consumer & Business Services and Thumbtack, Inc., Warrant, Acquisition Date 5/1/2018, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Consumer & Business Services and Thumbtack, Inc., Warrant, Acquisition Date 5/1/2018, Series Common Stock2025-03-310001280784Warrant Investments and Consumer & Business Services and Veem, Inc., Warrant, Acquisition Date 3/31/2022, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Consumer & Business Services and Veem, Inc., Warrant, Acquisition Date 3/31/2022, Series Common Stock2025-03-310001280784Warrant Investments and Consumer & Business Services and Worldremit Group Limited, Warrant, Acquisition Date 2/11/2021, Series Preferred Series D2025-01-012025-03-310001280784Warrant Investments and Consumer & Business Services and Worldremit Group Limited, Warrant, Acquisition Date 2/11/2021, Series Preferred Series D2025-03-310001280784Warrant Investments and Consumer & Business Services and Worldremit Group Limited, Warrant, Acquisition Date 8/27/2021, Series Preferred Series E2025-01-012025-03-310001280784Warrant Investments and Consumer & Business Services and Worldremit Group Limited, Warrant, Acquisition Date 8/27/2021, Series Preferred Series E2025-03-310001280784Warrant Investments and Consumer & Business Services and Total Worldremit Group Limited2025-03-310001280784Warrant Investments and Consumer & Business Services (0.28%)2025-03-310001280784Warrant Investments and Diversified Financial Services and Next Insurance, Inc., Warrant, Acquisition Date 2/3/2023, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Diversified Financial Services and Next Insurance, Inc., Warrant, Acquisition Date 2/3/2023, Series Common Stock2025-03-310001280784Warrant Investments and Diversified Financial Services (0.07%)2025-03-310001280784Warrant Investments and Drug Discovery & Development and Akero Therapeutics, Inc., Warrant, Acquisition Date 6/15/2022, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Drug Discovery & Development and Akero Therapeutics, Inc., Warrant, Acquisition Date 6/15/2022, Series Common Stock2025-03-310001280784 Warrant Investments and Drug Discovery & Development and AmplifyBio, LLC, Warrant, Acquisition Date 12/27/2022, Series Class A Units2025-01-012025-03-310001280784 Warrant Investments and Drug Discovery & Development and AmplifyBio, LLC, Warrant, Acquisition Date 12/27/2022, Series Class A Units2025-03-310001280784Warrant Investments and Drug Discovery & Development and Axsome Therapeutics, Inc., Warrant, Acquisition Date 9/25/2020, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Drug Discovery & Development and Axsome Therapeutics, Inc., Warrant, Acquisition Date 9/25/2020, Series Common Stock2025-03-310001280784Warrant Investments and Drug Discovery & Development and blubird bio, Inc., Warrant, Acquisition Date 3/15/2024, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Drug Discovery & Development and blubird bio, Inc., Warrant, Acquisition Date 3/15/2024, Series Common Stock2025-03-310001280784Warrant Investments and Drug Discovery & Development and Cellarity, Inc., Warrant, Acquisition Date 12/8/2021, Series Preferred Series B2025-01-012025-03-310001280784Warrant Investments and Drug Discovery & Development and Cellarity, Inc., Warrant, Acquisition Date 12/8/2021, Series Preferred Series B2025-03-310001280784Warrant Investments and Drug Discovery & Development and Century Therapeutics, Inc., Warrant, Acquisition Date 9/14/2020, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Drug Discovery & Development and Century Therapeutics, Inc., Warrant, Acquisition Date 9/14/2020, Series Common Stock2025-03-310001280784Warrant Investments and Drug Discovery & Development and COMPASS Pathways plc, Warrant, Acquisition Date 6/30/2023, Series Ordinary Shares2025-01-012025-03-310001280784Warrant Investments and Drug Discovery & Development and COMPASS Pathways plc, Warrant, Acquisition Date 6/30/2023, Series Ordinary Shares2025-03-310001280784Warrant Investments and Drug Discovery & Development and Curevo, Inc., Warrant, Acquisition Date 6/9/2023, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Drug Discovery & Development and Curevo, Inc., Warrant, Acquisition Date 6/9/2023, Series Common Stock2025-03-310001280784Warrant Investments and Drug Discovery & Development and enGene, Inc., Warrant, Acquisition Date 12/22/2023, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Drug Discovery & Development and enGene, Inc., Warrant, Acquisition Date 12/22/2023, Series Common Stock2025-03-310001280784Warrant Investments and Drug Discovery & Development and Heron Therapeutics, Inc., Warrant, Acquisition Date 8/9/2023, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Drug Discovery & Development and Heron Therapeutics, Inc., Warrant, Acquisition Date 8/9/2023, Series Common Stock2025-03-310001280784Warrant Investments and Drug Discovery & Development and Kineta, Inc., Warrant, Acquisition Date 12/20/2019, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Drug Discovery & Development and Kineta, Inc., Warrant, Acquisition Date 12/20/2019, Series Common Stock2025-03-310001280784Warrant Investments and Drug Discovery & Development and Kura Oncology, Inc., Warrant, Acquisition Date 11/2/2022, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Drug Discovery & Development and Kura Oncology, Inc., Warrant, Acquisition Date 11/2/2022, Series Common Stock2025-03-310001280784Warrant Investments and Drug Discovery & Development and Madrigal Pharmaceutical, Inc., Warrant, Acquisition Date 5/9/2022, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Drug Discovery & Development and Madrigal Pharmaceutical, Inc., Warrant, Acquisition Date 5/9/2022, Series Common Stock2025-03-310001280784Warrant Investments and Drug Discovery & Development and Phathom Pharmaceuticals, Inc., Warrant, Acquisition Date 9/17/2021, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Drug Discovery & Development and Phathom Pharmaceuticals, Inc., Warrant, Acquisition Date 9/17/2021, Series Common Stock2025-03-310001280784Warrant Investments and Drug Discovery & Development and Redshift Bioanalytics, Inc., Warrant, Acquisition Date 3/23/2022, Series Preferred Series E2025-01-012025-03-310001280784Warrant Investments and Drug Discovery & Development and Redshift Bioanalytics, Inc., Warrant, Acquisition Date 3/23/2022, Series Preferred Series E2025-03-310001280784Warrant Investments and Drug Discovery & Development and Scynexis, Inc., Warrant, Acquisition Date 5/14/2021, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Drug Discovery & Development and Scynexis, Inc., Warrant, Acquisition Date 5/14/2021, Series Common Stock2025-03-310001280784Warrant Investments and Drug Discovery & Development and SynOx Therapeutics Limited, Warrant, Acquisition Date 4/18/2024, Series Preferred Series B2025-01-012025-03-310001280784Warrant Investments and Drug Discovery & Development and SynOx Therapeutics Limited, Warrant, Acquisition Date 4/18/2024, Series Preferred Series B2025-03-310001280784Warrant Investments and Drug Discovery & Development and TG Therapeutics, Inc., Warrant, Acquisition Date 12/30/2021, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Drug Discovery & Development and TG Therapeutics, Inc., Warrant, Acquisition Date 12/30/2021, Series Common Stock2025-03-310001280784Warrant Investments and Drug Discovery & Development and Valo Health, LLC, Warrant, Acquisition Date 6/15/2020, Series Common Units2025-01-012025-03-310001280784Warrant Investments and Drug Discovery & Development and Valo Health, LLC, Warrant, Acquisition Date 6/15/2020, Series Common Units2025-03-310001280784Warrant Investments and Drug Discovery & Development and X4 Pharmaceuticals, Inc., Warrant, Acquisition Date 3/18/2019, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Drug Discovery & Development and X4 Pharmaceuticals, Inc., Warrant, Acquisition Date 3/18/2019, Series Common Stock2025-03-310001280784Warrant Investments and Drug Discovery & Development (0.46%)2025-03-310001280784Warrant Investments and Electronics & Computer Hardware and 908 Devices, Inc., Warrant, Acquisition Date 3/15/2017, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Electronics & Computer Hardware and 908 Devices, Inc., Warrant, Acquisition Date 3/15/2017, Series Common Stock2025-03-310001280784Warrant Investments and Electronics & Computer Hardware and Locus Robotics Corp., Warrant, Acquisition Date 6/21/2022, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Electronics & Computer Hardware and Locus Robotics Corp., Warrant, Acquisition Date 6/21/2022, Series Common Stock2025-03-310001280784Warrant Investments and Electronics & Computer Hardware and Skydio, Inc., Warrant, Acquisition Date 11/08/2021, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Electronics & Computer Hardware and Skydio, Inc., Warrant, Acquisition Date 11/08/2021, Series Common Stock2025-03-310001280784Warrant Investments and Electronics & Computer Hardware (0.01%)2025-03-310001280784Warrant Investments and Healthcare Services, Other and Curana Health Holdings, LLC., Warrant, Acquisition Date 1/4/2024, Series Common Units2025-01-012025-03-310001280784Warrant Investments and Healthcare Services, Other and Curana Health Holdings, LLC., Warrant, Acquisition Date 1/4/2024, Series Common Units2025-03-310001280784Warrant Investments and Healthcare Services, Other and Modern Life, Inc., Warrant, Acquisition Date 3/30/2023, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Healthcare Services, Other and Modern Life, Inc., Warrant, Acquisition Date 3/30/2023, Series Common Stock2025-03-310001280784Warrant Investments and Healthcare Services, Other and NeueHealth, Inc., Warrant, Acquisition Date 6/21/2024, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Healthcare Services, Other and NeueHealth, Inc., Warrant, Acquisition Date 6/21/2024, Series Common Stock2025-03-310001280784Warrant Investments and Healthcare Services, Other and Recover Together, Inc.., Warrant, Acquisition Date 7/3/2023, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Healthcare Services, Other and Recover Together, Inc.., Warrant, Acquisition Date 7/3/2023, Series Common Stock2025-03-310001280784Warrant Investments and Healthcare Services, Other and Strive Health Holdings, LLC., Warrant, Acquisition Date 9/28/2023, Series Common Units2025-01-012025-03-310001280784Warrant Investments and Healthcare Services, Other and Strive Health Holdings, LLC., Warrant, Acquisition Date 9/28/2023, Series Common Units2025-03-310001280784Warrant Investments and Healthcare Services, Other and Vida Health, Inc., Warrant, Acquisition Date 3/28/2022, Series Preferred Series E2025-01-012025-03-310001280784Warrant Investments and Healthcare Services, Other and Vida Health, Inc., Warrant, Acquisition Date 3/28/2022, Series Preferred Series E2025-03-310001280784Warrant Investments and Healthcare Services, Other (0.11%)2025-03-310001280784Warrant Investments and Information Services and NetBase Quid, Inc., Warrant, Acquisition Date 8/22/2017, Series Preferred Series 12025-01-012025-03-310001280784Warrant Investments and Information Services and NetBase Quid, Inc., Warrant, Acquisition Date 8/22/2017, Series Preferred Series 12025-03-310001280784Warrant Investments and Information Services and Signal Media Limited, Warrant, Acquisition Date 6/29/2022, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Information Services and Signal Media Limited, Warrant, Acquisition Date 6/29/2022, Series Common Stock2025-03-310001280784Warrant Investments and Information Services (0.00%)2025-03-310001280784Warrant Investments and Manufacturing Technology and Bright Machines, Inc., Warrant, Acquisition Date 3/31/2022, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Manufacturing Technology and Bright Machines, Inc., Warrant, Acquisition Date 3/31/2022, Series Common Stock2025-03-310001280784Warrant Investments and Manufacturing Technology and MacroFab, Inc., Warrant, Acquisition Date 3/23/2022, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Manufacturing Technology and MacroFab, Inc., Warrant, Acquisition Date 3/23/2022, Series Common Stock2025-03-310001280784Warrant Investments and Manufacturing Technology and VulcanForms Inc., Warrant, Acquisition Date 1/30/2025, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Manufacturing Technology and VulcanForms Inc., Warrant, Acquisition Date 1/30/2025, Series Common Stock2025-03-310001280784Warrant Investments and Manufacturing Technology (0.04%)2025-03-310001280784Warrant Investments and Media/Content/Info and Fever Labs, Inc., Warrant, Acquisition Date 12/30/2022, Series Preferred Series E-12025-01-012025-03-310001280784Warrant Investments and Media/Content/Info and Fever Labs, Inc., Warrant, Acquisition Date 12/30/2022, Series Preferred Series E-12025-03-310001280784Warrant Investments and Media/Content/Info (0.01%)2025-03-310001280784Warrant Investments and Medical Devices & Equipment and Orchestra BioMed Holdings, Inc., Warrant, Acquisition Date 11/6/2024, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Medical Devices & Equipment and Orchestra BioMed Holdings, Inc., Warrant, Acquisition Date 11/6/2024, Series Common Stock2025-03-310001280784Warrant Investments and Medical Devices & Equipment and Outset Medical, Inc., Warrant, Acquisition Date 9/27/2013, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Medical Devices & Equipment and Outset Medical, Inc., Warrant, Acquisition Date 9/27/2013, Series Common Stock2025-03-310001280784Warrant Investments and Medical Devices & Equipment and Senseonics Holdings, Inc., Warrant, Acquisition Date 9/8/2023, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Medical Devices & Equipment and Senseonics Holdings, Inc., Warrant, Acquisition Date 9/8/2023, Series Common Stock2025-03-310001280784Warrant Investments and Medical Devices & Equipment and Sight Sciences, Inc., Warrant, Acquisition Date 1/22/2024, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Medical Devices & Equipment and Sight Sciences, Inc., Warrant, Acquisition Date 1/22/2024, Series Common Stock2025-03-310001280784Warrant Investments and Medical Devices & Equipment and Tela Bio, Inc., Warrant, Acquisition Date 3/31/2017, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Medical Devices & Equipment and Tela Bio, Inc., Warrant, Acquisition Date 3/31/2017, Series Common Stock2025-03-310001280784Warrant Investments and Medical Devices & Equipment (0.03%)2025-03-310001280784Warrant Investments and Semiconductors and Achronix Semiconductor Corporation, Warrant, Acquisition Date 6/26/2015, Series Preferred Series D-22025-01-012025-03-310001280784Warrant Investments and Semiconductors and Achronix Semiconductor Corporation, Warrant, Acquisition Date 6/26/2015, Series Preferred Series D-22025-03-310001280784Warrant Investments and Semiconductors (0.02%)2025-03-310001280784Warrant Investments and Software and Aria Systems, Inc., Warrant, Acquisition Date 5/22/2015, Series Preferred Series G2025-01-012025-03-310001280784Warrant Investments and Software and Aria Systems, Inc., Warrant, Acquisition Date 5/22/2015, Series Preferred Series G2025-03-310001280784Warrant Investments and Software and Automation Anywhere, Inc., Warrant, Acquisition Date 9/23/2022, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Software and Automation Anywhere, Inc., Warrant, Acquisition Date 9/23/2022, Series Common Stock2025-03-310001280784Warrant Investments and Software and Bitsight Technologies, Inc., Warrant, Acquisition Date 11/18/2020, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Software and Bitsight Technologies, Inc., Warrant, Acquisition Date 11/18/2020, Series Common Stock2025-03-310001280784Warrant Investments and Software and Brain Corporation, Warrant, Acquisition Date 10/4/2021, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Software and Brain Corporation, Warrant, Acquisition Date 10/4/2021, Series Common Stock2025-03-310001280784Warrant Investments and Software and Carbyne, Inc., Warrant, Acquisition Date 2/24/2025 Series Ordinary Shares2025-01-012025-03-310001280784Warrant Investments and Software and Carbyne, Inc., Warrant, Acquisition Date 2/24/2025 Series Ordinary Shares2025-03-310001280784Warrant Investments and Software and CloudBolt Software, Inc., Warrant, Acquisition Date 9/30/2020, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Software and CloudBolt Software, Inc., Warrant, Acquisition Date 9/30/2020, Series Common Stock2025-03-310001280784Warrant Investments and Software and Cloudian, Inc., Warrant, Acquisition Date 11/6/2018, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Software and Cloudian, Inc., Warrant, Acquisition Date 11/6/2018, Series Common Stock2025-03-310001280784Warrant Investments and Software and Cloudpay, Inc., Warrant, Acquisition Date 4/10/2018, Series Preferred Series B2025-01-012025-03-310001280784Warrant Investments and Software and Cloudpay, Inc., Warrant, Acquisition Date 4/10/2018, Series Preferred Series B2025-03-310001280784Warrant Investments and Software and Coronet Cyber Security Ltd., Warrant, Acquisition Date 9/26/2024, Ordinary Shares2025-01-012025-03-310001280784Warrant Investments and Software and Coronet Cyber Security Ltd., Warrant, Acquisition Date 9/26/2024, Ordinary Shares2025-03-310001280784Warrant Investments and Software and Couchbase, Inc., Warrant, Acquisition Date 4/25/2019, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Software and Couchbase, Inc., Warrant, Acquisition Date 4/25/2019, Series Common Stock2025-03-310001280784Warrant Investments and Software and Cutover, Inc., Warrant, Acquisition Date 9/21/2022, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Software and Cutover, Inc., Warrant, Acquisition Date 9/21/2022, Series Common Stock2025-03-310001280784Warrant Investments and Software and Dashlane, Inc., Warrant, Acquisition Date 3/11/2019, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Software and Dashlane, Inc., Warrant, Acquisition Date 3/11/2019, Series Common Stock2025-03-310001280784Warrant Investments and Software and Demandbase, Inc., Warrant, Acquisition Date 8/2/2021, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Software and Demandbase, Inc., Warrant, Acquisition Date 8/2/2021, Series Common Stock2025-03-310001280784Warrant Investments and Software and Dragos, Inc., Warrant, Acquisition Date 6/28/2023, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Software and Dragos, Inc., Warrant, Acquisition Date 6/28/2023, Series Common Stock2025-03-310001280784Warrant Investments and Software and DroneDeploy, Inc., Warrant, Acquisition Date 6/30/2022, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Software and DroneDeploy, Inc., Warrant, Acquisition Date 6/30/2022, Series Common Stock2025-03-310001280784Warrant Investments and Software and Earnix, Inc., Warrant, Acquisition Date 6/6/2024, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Software and Earnix, Inc., Warrant, Acquisition Date 6/6/2024, Series Common Stock2025-03-310001280784Warrant Investments and Software and Elation Health, Inc., Warrant, Acquisition Date 9/12/2022, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Software and Elation Health, Inc., Warrant, Acquisition Date 9/12/2022, Series Common Stock2025-03-310001280784Warrant Investments and Software and First Insight, Inc., Warrant, Acquisition Date 5/10/2018, Series Preferred Series B2025-01-012025-03-310001280784Warrant Investments and Software and First Insight, Inc., Warrant, Acquisition Date 5/10/2018, Series Preferred Series B2025-03-310001280784Warrant Investments and Software and Fulfil Solutions, Inc., Warrant, Acquisition Date 7/29/2022, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Software and Fulfil Solutions, Inc., Warrant, Acquisition Date 7/29/2022, Series Common Stock2025-03-310001280784Warrant Investments and Software and Harness, Inc., Warrant, Acquisition Date 3/12/2024, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Software and Harness, Inc., Warrant, Acquisition Date 3/12/2024, Series Common Stock2025-03-310001280784Warrant Investments and Software and Kore.ai, Inc., Warrant, Acquisition Date 3/31/2023, Series Preferred Series C2025-01-012025-03-310001280784Warrant Investments and Software and Kore.ai, Inc., Warrant, Acquisition Date 3/31/2023, Series Preferred Series C2025-03-310001280784Warrant Investments and Software and Leapwork ApS, Warrant, Acquisition Date 1/23/2023, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Software and Leapwork ApS, Warrant, Acquisition Date 1/23/2023, Series Common Stock2025-03-310001280784Warrant Investments and Software and Lightbend, Inc., Warrant, Acquisition Date 2/14/2018, Series Preferred Series LB-22025-01-012025-03-310001280784Warrant Investments and Software and Lightbend, Inc., Warrant, Acquisition Date 2/14/2018, Series Preferred Series LB-22025-03-310001280784Warrant Investments and Software and Mixpanel, Inc., Warrant, Acquisition Date 9/30/2020, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Software and Mixpanel, Inc., Warrant, Acquisition Date 9/30/2020, Series Common Stock2025-03-310001280784Warrant Investments and Software and Morphisec Information Security 2014 Ltd., Warrant, Acquisition Date 10/1/2024, Series Ordinary Shares2025-01-012025-03-310001280784Warrant Investments and Software and Morphisec Information Security 2014 Ltd., Warrant, Acquisition Date 10/1/2024, Series Ordinary Shares2025-03-310001280784Warrant Investments and Software and Pindrop Security, Inc., Warrant, Acquisition Date 6/26/2024, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Software and Pindrop Security, Inc., Warrant, Acquisition Date 6/26/2024, Series Common Stock2025-03-310001280784Warrant Investments and Software and Reltio, Inc., Warrant, Acquisition Date 6/30/2020, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Software and Reltio, Inc., Warrant, Acquisition Date 6/30/2020, Series Common Stock2025-03-310001280784Warrant Investments and Software and Semperis Technologies Inc., Warrant, Acquisition Date 4/23/2024, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Software and Semperis Technologies Inc., Warrant, Acquisition Date 4/23/2024, Series Common Stock2025-03-310001280784Warrant Investments and Software and Simon Data, Inc., Warrant, Acquisition Date 3/22/2023, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Software and Simon Data, Inc., Warrant, Acquisition Date 3/22/2023, Series Common Stock2025-03-310001280784Warrant Investments and Software and SingleStore, Inc., Warrant, Acquisition Date 4/28/2020, Series Preferred Series D2025-01-012025-03-310001280784Warrant Investments and Software and SingleStore, Inc., Warrant, Acquisition Date 4/28/2020, Series Preferred Series D2025-03-310001280784Warrant Investments and Software and Sisense Ltd., Warrant, Acquisition Date 6/28/2023, Series Ordinary Shares2025-01-012025-03-310001280784Warrant Investments and Software and Sisense Ltd., Warrant, Acquisition Date 6/28/2023, Series Ordinary Shares2025-03-310001280784Warrant Investments and Software and Suzy, Inc. Warrant, Acquisition Date 8/24/2023, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Software and Suzy, Inc. Warrant, Acquisition Date 8/24/2023, Series Common Stock2025-03-310001280784Warrant Investments and Software and Tipalti Solutions Ltd., Warrant, Acquisition Date 3/22/2023, Series Ordinary Shares2025-01-012025-03-310001280784Warrant Investments and Software and Tipalti Solutions Ltd., Warrant, Acquisition Date 3/22/2023, Series Ordinary Shares2025-03-310001280784Warrant Investments and Software and Tipalti Solutions Ltd., Warrant, Acquisition Date 3/27/2025, Series Ordinary Shares2025-01-012025-03-310001280784Warrant Investments and Software and Tipalti Solutions Ltd., Warrant, Acquisition Date 3/27/2025, Series Ordinary Shares2025-03-310001280784Warrant Investments and Software and Total Tipalti Solutions Ltd.2025-03-310001280784Warrant Investments and Software and VideoAmp, Inc., Warrant, Acquisition Date 1/21/2022, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Software and VideoAmp, Inc., Warrant, Acquisition Date 1/21/2022, Series Common Stock2025-03-310001280784Warrant Investments and Software (0.48%)2025-03-310001280784Warrant Investments and Space Technologies and Capella Space Corp., Warrant, Acquisition Date 10/21/2021, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Space Technologies and Capella Space Corp., Warrant, Acquisition Date 10/21/2021, Series Common Stock2025-03-310001280784Warrant Investments and Space Technologies (0.00%)2025-03-310001280784Warrant Investments and Sustainable and Renewable Technology and Ampion, PBC, Warrant, Acquisition Date 4/15/2022, Series Common Stock2025-01-012025-03-310001280784Warrant Investments and Sustainable and Renewable Technology and Ampion, PBC, Warrant, Acquisition Date 4/15/2022, Series Common Stock2025-03-310001280784Warrant Investments and Sustainable and Renewable Technology and Electric Hydrogen Co., Warrant, Acquisition Date 3/27/2024, Series Common stock2025-01-012025-03-310001280784Warrant Investments and Sustainable and Renewable Technology and Electric Hydrogen Co., Warrant, Acquisition Date 3/27/2024, Series Common stock2025-03-310001280784Warrant Investments and Sustainable and Renewable Technology (0.02%)2025-03-310001280784Warrant Investments (1.57%)2025-03-310001280784Investments in Securities (195.81%)2025-03-310001280784Investment Funds & Vehicles Investments and Drug Discovery & Development and Forbion Growth Opportunities Fund I C.V., Investment Funds & Vehicles, Acquisition Date 11/16/20202025-01-012025-03-310001280784Investment Funds & Vehicles Investments and Drug Discovery & Development and Forbion Growth Opportunities Fund I C.V., Investment Funds & Vehicles, Acquisition Date 11/16/20202025-03-310001280784Investment Funds & Vehicles Investments and Drug Discovery & Development and Forbion Growth Opportunities Fund II C.V., Investment Funds & Vehicles, Acquisition Date 6/23/20222025-01-012025-03-310001280784Investment Funds & Vehicles Investments and Drug Discovery & Development and Forbion Growth Opportunities Fund II C.V., Investment Funds & Vehicles, Acquisition Date 6/23/20222025-03-310001280784Investment Funds & Vehicles Investments and Drug Discovery & Development (0.33%)2025-03-310001280784Investment Funds & Vehicles Investments and Software and Liberty Zim Co-Invest L.P., Investment Funds & Vehicles, Acquisition Date 7/21/20222025-01-012025-03-310001280784Investment Funds & Vehicles Investments and Software and Liberty Zim Co-Invest L.P., Investment Funds & Vehicles, Acquisition Date 7/21/20222025-03-310001280784Investment Funds & Vehicles Investments and Software (0.02%)2025-03-310001280784Investment Funds & Vehicles Investments (0.35%)2025-03-310001280784Investments before Cash & Cash Equivalents (196.16%)2025-03-310001280784Investment Funds and Cash & Cash Equivalent and GS Financial Square Government Fund, Series FGTXX/38141W2732025-03-310001280784Investment Fund In Cash & Cash Equivalents (1.30%)2025-03-310001280784Investment Fund After Cash & Cash Equivalents (197.46%)2025-03-310001280784Foreign Currency Exchange Contracts, Great British Pound (GBP) Counterparty Goldman Sachs Bank USA Settlement Date 6/3/20242025-01-012025-03-310001280784Foreign Currency Exchange Contracts, Great British Pound (GBP) Counterparty Goldman Sachs Bank USA Settlement Date 6/3/20242025-03-310001280784Total Foreign Currency Forward ((0.02%))2025-03-310001280784htgc:OneMonthSOFRMember2025-03-310001280784htgc:ThreeMonthSOFRMember2025-03-310001280784htgc:SixMonthSOFRMember2025-03-310001280784us-gaap:FairValueInputsLevel1Memberus-gaap:WarrantMember2025-03-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:CommonStockMember2025-03-310001280784htgc:BlackCrowAIIncMemberhtgc:PromissoryNotesMember2025-03-310001280784htgc:RoyaltyContractMemberhtgc:PhathomPharmaceuticalsIncMember2025-03-310001280784Debt Investments Biotechnology Tools and PathAI, Inc., Senior Secured, Maturity Date January 2027, Prime + 2.15%, Floor rate 9.15%, 7.85% Exit Fee2024-12-310001280784Debt Investments Biotechnology Tools (1.70%)2024-12-310001280784Debt Investments Communications and Networking and Aryaka Networks, Inc., Senior Secured, Maturity Date December 2028, Prime + 1.80%, Floor rate 9.30%, PIK Interest 1.25%, 6.73% Exit Fee2024-12-310001280784Debt Investment Communications & Networking (1.38%)2024-12-310001280784Debt Investment Consumer & Business Services and Altumint, Inc., Senior Secured, Maturity Date December 2027, Prime + 3.65%, Floor rate 12.15%, 2.50% Exit Fee2024-12-310001280784Debt Investment Consumer & Business Services and Carwow LTD, Senior Secured, Maturity Date December 2027, Prime + 4.70%, Floor rate 11.45%, PIK Interest 1.45%, 4.95% Exit Fee2024-12-310001280784Debt Investment Consumer & Business Services and GoEuro Travel GmbH, Senior Secured, Maturity Date November 2029, Prime + 3.45%, Floor rate 10.45%, 4.50% Exit Fee2024-12-310001280784Debt Investments Consumer & Business Services and Houzz, Inc., Convertible Debt, Maturity Date May 2028, PIK Interest 11.50%2024-12-310001280784Debt Investments Consumer & Business Services and Jobandtalent USA, Inc., Senior Secured, Maturity Date August 2025, 1-month SOFR + 8.86% Floor rate 9.75%, 2.89% Exit Fee2024-12-310001280784Debt Investments Consumer & Business Services and Plentific Ltd, Senior Secured, Maturity Date October 2026, Prime + 2.55%, Floor rate 11.05%, 2.95% Exit Fee2024-12-310001280784Debt Investments Consumer & Business Services and Provi, Senior Secured, Maturity Date December 2026, Prime + 4.40%, Floor rate 10.65%, 2.95% Exit Fee2024-12-310001280784Debt Investments Consumer & Business Services and Riviera Partners LLC, Senior Secured, Maturity Date April 2027, 3-month SOFR + 8.27%, Floor rate 9.27%2024-12-310001280784Debt Investments Consumer & Business Services and RVShare, LLC, Senior Secured, Maturity Date December 2026, 3-month SOFR + 5.50%, Floor rate 6.50%, PIK Interest 4.00%2024-12-310001280784Debt Investment Consumer & Business Services and SeatGeek, Inc., Senior Secured, Maturity Date May 2026, Prime + 7.00%, Floor rate 10.50%, PIK Interest 0.50%, 4.00% Exit Fee2024-12-310001280784Debt Investment Consumer & Business Services and SeatGeek, Inc., Senior Secured, Maturity Date July 2026, Prime + 2.50%, Floor rate 10.75%, PIK Interest 0.50%, 3.00% Exit Fee2024-12-310001280784Debt Investment Consumer & Business Services and Total SeatGeek, Inc2024-12-310001280784Debt Investment Consumer & Business Services and Skyword, Inc., Senior Secured, Maturity Date November 2027, Prime + 2.75%, Floor rate 9.25%, PIK Interest 1.75%, 3.00% Exit Fee2024-12-310001280784Debt Investment Consumer & Business Services and Tectura Corporation, Senior Secured, Maturity Date January 2027, FIXED 8.25%2024-12-310001280784Debt Investment Consumer & Business Services and Thumbtack, Inc., Senior Secured, Maturity Date March 2028, Prime + 2.45%, Floor rate 10.95%, PIK Interest 1.50%2024-12-310001280784Debt Investment Consumer & Business Services and Veem, Inc., Senior Secured, Maturity Date March 2027, Prime + 4.00%, Floor rate 12.00%, PIK Interest 1.25%, 4.50% Exit Fee2024-12-310001280784Debt Investment Consumer & Business Services and Veem, Inc., Senior Secured, Maturity Date March 2027, Prime + 4.70%, Floor rate 12.70%, PIK Interest 1.50%, 4.50% Exit Fee2024-12-310001280784Debt Investment Consumer & Business Services and Total Veem, Inc.,2024-12-310001280784Debt Investment Consumer & Business Services (18.03%)2024-12-310001280784Debt Investments Diversified Financial Services and Gibraltar Acquisition, LLC, Unsecured, Maturity Date September 2026, FIXED 3.45%, PIK Interest 8.05%2024-12-310001280784Debt Investments Diversified Financial Services and Gibraltar Acquisition, LLC, Unsecured, Maturity Date September 2026, FIXED 11.95%2024-12-310001280784Debt Investment Diversified Financial Services and Total Gibraltar Acquisition, LLC2024-12-310001280784Debt Investment Diversified Financial Services and Hercules Adviser LLC, Unsecured, Maturity Date June 2025, FIXED 5.00%2024-12-310001280784Debt Investment Diversified Financial Services and Next Insurance, Inc., Senior Secured, Maturity Date February 2028, Prime - 1.50%, Floor rate 4.75%, PIK Interest 5.50%2024-12-310001280784Debt Investment Diversified Financial Services (2.98%)2024-12-310001280784Debt Investments Drug Discovery & Development and Adaptimmune Therapeutics plc, Inc., Senior Secured, Maturity Date June 2029, Prime + 1.15%, Floor rate 9.65%, PIK Interest 2.00%, 5.85% Exit Fee2024-12-310001280784Debt Investment Drug Discovery & Development and Akero Therapeutics, Inc., Senior Secured, Maturity Date March 2027, Prime + 3.65%, Floor rate 7.65%, 5.85% Exit Fee2024-12-310001280784Debt Investments Drug Discovery & Development and Aldeyra Therapeutics, Inc., Senior Secured, Maturity Date April 2026, Prime + 3.10%, Floor rate 11.10%, 8.90% Exit Fee2024-12-310001280784Debt Investments Drug Discovery & Development and Alector, Inc., Senior Secured, Maturity Date December 2028, Prime + 1.05%, Floor rate 8.05%, 4.75% Exit Fee2024-12-310001280784Debt Investment Drug Discovery & Development and AmplifyBio, LLC, Senior Secured, Maturity Date January 2027, Prime + 2.50%, Floor rate 9.50%, Cap rate 10.75%, 5.85% Exit Fee2024-12-310001280784Debt Investments Drug Discovery & Development and Arcus Biosciences, Inc., Senior Secured, Maturity Date September 2029, Prime + 1.95%, Floor rate 10.45%, 7.75% Exit Fee2024-12-310001280784Debt Investments Drug Discovery & Development and ATAI Life Sciences N.V., Senior Secured, Maturity Date August 2026, Prime + 4.30%, Floor rate 9.05%, 6.95% Exit Fee2024-12-310001280784Debt Investments Drug Discovery & Development and Axsome Therapeutics, Inc., Senior Secured, Maturity Date January 2028, Prime + 2.20%, Floor rate 9.95%, Cap rate 10.70%, 5.78% Exit Fee2024-12-310001280784Debt Investments Drug Discovery & Development and bluebird bio, Inc., Senior Secured, Maturity Date April 2029, Prime + 1.45%, Floor rate 9.95%, PIK Interest 2.45%, 6.45% Exit Fee2024-12-310001280784Debt Investments Drug Discovery & Development and Braeburn, Inc., Senior Secured, Maturity Date October 2028, Prime + 2.45%, Floor rate 10.95%, PIK Interest 1.10%, 5.45% Exit Fee2024-12-310001280784Debt Investments Drug Discovery & Development and COMPASS Pathways plc, Senior Secured, Maturity Date July 2027, Prime + 1.50%, Floor rate 9.75%, PIK Interest 1.40%, 4.75% Exit Fee2024-12-310001280784Debt Investments Drug Discovery & Development and Corium, Inc., Senior Secured, Maturity Date September 2026, Prime + 5.70%, Floor rate 8.95%, 7.75% Exit Fee2024-12-310001280784Debt Investments Drug Discovery & Development and Disc Medicine, Inc., Senior Secured, Maturity Date December 2029, Prime + 1.75%, Floor rate 8.25%, 6.75% Exit Fee2024-12-310001280784Debt Investments Drug Discovery & Development and Eloxx Pharmaceuticals, Inc., Senior Secured, Maturity Date April 2025, Prime + 6.25%, Floor rate 9.50%, 4.00% Exit Fee2024-12-310001280784Debt Investments Drug Discovery & Development and enGene, Inc., Senior Secured, Maturity Date January 2028, Prime + 0.75%, Floor rate 9.25%, Cap rate 9.75%, PIK Interest 1.15%, 5.50% Exit Fee2024-12-310001280784Debt Investments Drug Discovery & Development and Heron Therapeutics, Inc., Senior Secured, Maturity Date February 2026, Prime + 1.70%, Floor rate 9.95%, PIK Interest 1.50%, 3.00% Exit Fee2024-12-310001280784Debt Investments Drug Discovery & Development and Hibercell, Inc., Senior Secured, Maturity Date May 2025, Prime + 5.40%, Floor rate 8.65%, 4.95% Exit Fee2024-12-310001280784Debt Investments Drug Discovery & Development and Kura Oncology, Inc., Senior Secured, Maturity Date November 2027, Prime + 2.40%, Floor rate 8.65%, 6.05% Exit Fee2024-12-310001280784Debt Investments Drug Discovery & Development and Madrigal Pharmaceutical, Inc., Senior Secured, Maturity Date May 2027, Prime + 2.45%, Floor rate 8.25%, 5.35% Exit Fee2024-12-310001280784Debt Investments Drug Discovery & Development and NorthSea Therapeutics, Convertible Debt, Maturity Date December 2025, FIXED 6.00%2024-12-310001280784Debt Investments Drug Discovery & Development and Phathom Pharmaceuticals, Inc., Senior Secured, Maturity Date December 2027, Prime + 1.35%, Floor rate 9.85%, Cap rate 10.35%, PIK Interest 2.15%, 6.22% Exit Fee2024-12-310001280784Debt Investments Drug Discovery & Development and Replimune Group, Inc., Senior Secured, Maturity Date October 2027, Prime + 1.75%, Floor rate 7.25%, Cap rate 9.00%, PIK Interest 1.50%, 4.95% Exit Fee2024-12-310001280784Debt Investments Drug Discovery & Development and SynOx Therapeutics Limited, Senior Secured, Maturity Date May 2027, Prime + 1.40%, Floor rate 9.90%, 7.25% Exit Fee2024-12-310001280784Debt Investments Drug Discovery & Development and uniQure B.V., Senior Secured, Maturity Date January 2027, Prime + 4.70%, Floor rate 7.95%, 6.10% Exit Fee2024-12-310001280784Debt Investments Drug Discovery & Development and Viridian Therapeutics, Inc., Senior Secured, Maturity Date October 2026, Prime + 4.20%, Floor rate 7.45%, Cap rate 8.95%, 6.00% Exit Fee2024-12-310001280784Debt Investments Drug Discovery & Development and X4 Pharmaceuticals, Inc., Senior Secured, Maturity Date July 2027, Prime + 3.15%, Floor rate 10.15%, 3.72% Exit Fee2024-12-310001280784Debt Investments Drug Discovery & Development (52.10%)2024-12-310001280784Debt Investments Electronics & Computer Hardware and Locus Robotics Corp., Senior Secured, Maturity Date December 2028, Prime + 3.00%, Floor rate 9.50%, 4.00% Exit Fee2024-12-310001280784Debt Investments Electronics & Computer Hardware and Shield AI, Inc., Senior Secured, Maturity Date February 2029, Prime + 0.85%, Floor rate 6.85%, Cap rate 9.60%, PIK Interest 2.50%, 2.50% Exit Fee2024-12-310001280784Debt Investments Electronics & Computer Hardware (8.13%)2024-12-310001280784Debt Investments Healthcare Services, Other and Blue Sprig Pediatrics, Inc., Senior Secured, Maturity Date November 2026, 3-month SOFR + 5.26%, Floor rate 6.00%, PIK Interest 4.45%2024-12-310001280784Debt Investments Healthcare Services, Other and Carbon Health Technologies, Inc., Senior Secured, Maturity Date June 2026, Prime -1.50%, Floor rate 7.00%, PIK Interest 7.00%, 5.64% Exit Fee2024-12-310001280784Debt Investments Healthcare Services, Other and Carbon Health Technologies, Inc., Convertible Debt, Maturity Date December 2025, FIXED 12.00%2024-12-310001280784Debt Investments Healthcare Services, Other and Total Carbon Health Technologies, Inc.2024-12-310001280784Debt Investments Healthcare Services, Other and Curana Health Holdings, LLC, Senior Secured, Maturity Date January 2028, Prime + 1.45%, Floor rate 9.20%, 4.95% Exit Fee2024-12-310001280784Debt Investments Healthcare Services, Other and Equality Health, LLC, Senior Secured, Maturity Date February 2026, Prime + 4.25%, Floor rate 9.50%, PIK Interest 1.55%, 1.11% Exit Fee2024-12-310001280784Debt Investments Healthcare Services, Other and Main Street Rural, Inc., Senior Secured, Maturity Date July 2027, Prime + 1.95%, Floor rate 9.95%, 6.85% Exit Fee2024-12-310001280784Debt Investments Healthcare Services, Other and Marathon Health, LLC, Senior Secured, Maturity Date February 2029, Prime - 0.90%, Floor rate 7.10%, PIK Interest 4.00%, 3.00% Exit Fee2024-12-310001280784Debt Investments Healthcare Services, Other and Marathon Health, LLC, Senior Secured, Maturity Date February 2029, Prime + 3.00%, Floor rate 11.00%2024-12-310001280784Debt Investments Healthcare Services, Other and Marathon Health, LLC.2024-12-310001280784Debt Investment Healthcare Services, Other and Modern Life, Inc., Senior Secured, Maturity Date February 2027, Prime + 2.75%, Floor rate 8.75%, 5.00% Exit Fee2024-12-310001280784Debt Investments Healthcare Services, Other and NeueHealth, Inc., Maturity Date June 2028, Prime + 1.15%, Floor rate 9.65%, PIK Interest 2.50%, 2.50% Exit Fee2024-12-310001280784Debt Investment Healthcare Services, Other and Recover Together, Inc., Senior Secured, Maturity Date July 2027, Prime + 1.90%, Floor rate 10.15%, 7.50% Exit Fee2024-12-310001280784Debt Investment Healthcare Services, Other and Strive Health Holdings, LLC, Senior Secured, Maturity Date September 2027, Prime + 0.70%, Floor rate 9.20%, 5.95% Exit Fee2024-12-310001280784Debt Investments Healthcare Services, Other and Vida Health, Inc., Senior Secured, Maturity Date October 2026, Prime - 2.75%, Floor rate 5.75%, PIK Interest 5.35%, 4.95% Exit Fee2024-12-310001280784Debt Investments Healthcare Services, Other and WellBe Senior Medical LLC, Senior Secured, Maturity Date May 2029, Prime + 0.75%, Floor rate 7.75%, PIK Interest 2.65%, 6.75% Exit Fee2024-12-310001280784Debt Investments Healthcare Services, Other (30.19%)2024-12-310001280784Debt Investments Information Services and Saama Technologies, LLC, Senior Secured, Maturity Date July 2027, Prime + 0.70%, Floor rate 8.95%, PIK Interest 2.00%, 2.95% Exit Fee2024-12-310001280784Debt Investments Information Services (1.03%)2024-12-310001280784Debt Investments Medical Devices & Equipment and Orchestra BioMed Holdings, Inc., Senior Secured, Maturity Date November 2028, Prime + 2.00%, Floor rate 9.50%, 6.35% Exit Fee2024-12-310001280784Debt Investments Medical Devices & Equipment and Senseonics Holdings, Inc., Senior Secured, Maturity Date September 2027, Prime + 1.40%, Floor rate 9.90%, 6.95% Exit Fee2024-12-310001280784Debt Investments Medical Devices & Equipment and Sight Sciences, Inc., Senior Secured, Maturity Date July 2028, Prime + 2.35%, Floor rate 10.35%, 5.95% Exit Fee2024-12-310001280784Debt Investments Medical Devices & Equipment (3.74%)2024-12-310001280784Debt Investments Software and 3GTMS, LLC, Senior Secured, Maturity Date February 2025, 3-month SOFR + 10.40%, Floor rate 11.30%2024-12-310001280784Debt Investments Software and 3GTMS, LLC, Senior Secured, Maturity Date February 2025, 3-month SOFR + 7.25%, Floor rate 8.15%2024-12-310001280784Debt Investment Software and Total 3GTMS, LLC2024-12-310001280784Debt Investments Software and Alchemer LLC, Senior Secured, Maturity Date May 2028, 3-month SOFR + 8.14%, Floor rate 9.14%2024-12-310001280784Debt Investments Software and Allvue Systems, LLC, Senior Secured, Maturity Date September 2029, 3-month SOFR + 6.25%, Floor rate 7.25%2024-12-310001280784Debt Investments Software and AlphaSense, Inc., Senior Secured, Maturity Date June 2029, 3-month SOFR + 6.25%, Floor rate 8.25%2024-12-310001280784Debt Investments Software and Annex Cloud, Senior Secured, Maturity Date February 2027, 3-month SOFR + 10.00%, Floor rate 11.00%2024-12-310001280784Debt Investments Software and Armis, Inc., Senior Secured, Maturity Date March 2028, Prime + 0.00%, Floor rate 7.50%, PIK Interest 2.00%, 2.25% Exit Fee2024-12-310001280784Debt Investments Software and Armis, Inc., Senior Secured, Maturity Date March 2028, Prime +1.25%, Floor rate 7.50%, PIK Interest 2.00%, 2.25% Exit Fee2024-12-310001280784Debt Investments Software and Total Armis, Inc.2024-12-310001280784Debt Investments Software and Babel Street, Senior Secured, Maturity Date December 2027, 3-month SOFR + 8.01%, Floor rate 9.01%2024-12-310001280784Debt Investments Software and Behavox Limited, Senior Secured, Maturity Date September 2027, Prime - 0.55%, Floor rate 7.45%, PIK Interest 3.00%, 4.95% Exit Fee2024-12-310001280784Debt Investments Software and Brain Corporation, Senior Secured, Maturity Date September 2028, Prime + 1.35%, Floor rate 9.85%, PIK Interest 2.50%, 3.95% Exit Fee2024-12-310001280784Debt Investments Software and Ceros, Inc., Senior Secured, Maturity Date September 2026, 3-month SOFR + 8.99%, Floor rate 9.89%2024-12-310001280784Debt Investments Software and Copper CRM, Inc, Senior Secured, Maturity Date March 2025, Prime + 4.50%, Floor rate 8.25%, Cap rate 10.25%, PIK Interest 1.95%, 4.50% Exit Fee2024-12-310001280784Debt Investments Software and CoreView USA, Inc., Senior Secured, Maturity Date January 2029, Prime +2.75%, Floor rate 9.25%, 4.95% Exit Fee2024-12-310001280784Debt Investments Software and Coronet Cyber Security Ltd., Senior Secured, Maturity Date October 2028, Prime - 2.95%, Floor rate 3.55%, PIK Interest 5.85%2024-12-310001280784Debt Investments Software and Cutover, Inc., Senior Secured, Maturity Date October 2025, Prime + 5.20%, Floor rate 9.95%, 4.95% Exit Fee, 12024-12-310001280784Debt Investments Software and Cutover, Inc., Senior Secured, Maturity Date October 2025, Prime + 5.20%, Floor rate 9.95%, 4.95% Exit Fee, 22024-12-310001280784Debt Investments Software and Total Cutover, Inc., 2024-12-310001280784Debt Investments Software and Dashlane, Inc., Senior Secured, Maturity Date December 2027, Prime + 3.05%, Floor rate 11.55%, PIK Interest 1.10%, 6.28% Exit Fee2024-12-310001280784Debt Investments Software and Dispatch Technologies, Inc., Senior Secured, Maturity Date April 2028, 3-month SOFR + 8.01%, Floor rate 8.76%2024-12-310001280784Debt Investments Software and Dragos, Inc., Senior Secured, Maturity Date July 2027, Prime + 2.00%, Floor rate 8.75%, PIK Interest 2.00%, 2.00% Exit Fee2024-12-310001280784Debt Investments Software and DroneDeploy, Inc., Senior Secured, Maturity Date November 2028, Prime + 2.45%, Floor rate 9.95%, 5.00% Exit Fee2024-12-310001280784Debt Investments Software and Earnix, Inc., Senior Secured, Maturity Date June 2029, Prime - 1.15%, Floor rate 5.35%, PIK Interest 4.45%2024-12-310001280784Debt Investments Software and Elation Health, Inc., Senior Secured, Maturity Date March 2026, Prime + 4.25%, Floor rate 9.00%, PIK Interest 1.95%, 3.95% Exit Fee2024-12-310001280784Debt Investments Software and Flight Schedule Pro, LLC, Senior Secured, Maturity Date October 2027, 1-month SOFR + 7.80%, Floor rate 8.70%2024-12-310001280784Debt Investments Software and Fortified Health Security, Senior Secured, Maturity Date December 2027, 1-month SOFR + 7.64%, Floor rate 8.54%2024-12-310001280784Debt Investments Software and Harness, Inc., Senior Secured, Maturity Date March 2029, Prime - 2.25%, Floor rate 5.25%, Cap rate 6.50%, PIK Interest 6.25%, 1.00% Exit Fee2024-12-310001280784Debt Investments Software and iGrafx, LLC, Senior Secured, Maturity Date May 2027, 1-month SOFR + 8.61%, Floor rate 9.51%, 0.47% Exit Fee2024-12-310001280784Debt Investments Software and Khoros, Senior Secured, Maturity Date January 2025, 3-month SOFR + 4.50%, Floor rate 5.50%, PIK Interest 4.50%2024-12-310001280784Debt Investments Software and Leapwork ApS, Senior Secured, Maturity Date February 2026, Prime + 0.25%, Floor rate 7.00%, PIK Interest 1.95%, 2.70% Exit Fee2024-12-310001280784Debt Investments Software and LinenMaster, LLC, Senior Secured, Maturity Date August 2028, 1-month SOFR + 6.25%, Floor rate 7.25%, PIK Interest 2.15%2024-12-310001280784Debt Investment Software and Loftware, Inc., Senior Secured, Maturity Date March 2028, 3-month SOFR + 7.88%, Floor rate 8.88%2024-12-310001280784Debt Investment Software and LogicSource, Senior Secured, Maturity Date July 2027, 1-month SOFR + 8.93%, Floor rate 9.93%2024-12-310001280784Debt Investments Software and LogRhythm, Inc., Senior Secured, Maturity Date July 2029, 1-month SOFR + 7.50%, Floor rate 8.50%2024-12-310001280784Debt Investments Software and Marigold Group, Inc. (p.k.a. Campaign Monitor Limited), Senior Secured, Maturity Date November 2026, PIK Interest 6-month SOFR + 10.55%, Floor rate 11.55%2024-12-310001280784Debt Investments Software and Mobile Solutions Services, Senior Secured, Maturity Date December 2025, 3-month SOFR + 9.21%, Floor rate 10.06%2024-12-310001280784Debt Investments Software and Morphisec Information Security 2014 Ltd., Senior Secured, Maturity Date October 2027, Prime + 3.45%, Floor rate 11.70%, 5.95% Exit Fee2024-12-310001280784Debt Investments Software and New Relic, Inc., Senior Secured, Maturity Date November 2030, 1-month SOFR + 6.75%, Floor rate 7.75%2024-12-310001280784Debt Investments Software and Omeda Holdings, LLC, Senior Secured, Maturity Date July 2027, 3-month SOFR + 8.05%, Floor rate 9.05%2024-12-310001280784Debt Investments Software and PayIt, LLC, Senior Secured, Maturity Date December 2028, Prime + 1.45%, Floor rate 7.95%, PIK Interest 1.50%, 5.00% Exit Fee2024-12-310001280784Debt Investments Software and Pindrop Security, Inc., Senior Secured, Maturity Date June 2029, Prime + 3.50%, Floor rate 10.00%, 2.00% Exit Fee2024-12-310001280784Debt Investments Software and Remodel Health Holdco, LLC, Senior Secured, Maturity Date December 2028, Prime + 2.35%, Floor rate 10.35%, 6.50% Exit Fee2024-12-310001280784Debt Investments Software and Reveleer, Senior Secured, Maturity Date February 2027, Prime + 0.65%, Floor rate 9.15%, PIK Interest 2.00%, 5.05% Exit Fee2024-12-310001280784Debt Investments Software and Semperis Technologies Inc., Senior Secured, Maturity Date April 2028, Prime - 1.75%, Floor rate 6.75%, PIK Interest 3.25%2024-12-310001280784Debt Investments Software and ShadowDragon, LLC, Senior Secured, Maturity Date December 2026, 3-month SOFR + 8.88%, Floor rate 9.78%2024-12-310001280784Debt Investments Software and Simon Data, Inc., Senior Secured, Maturity Date March 2027, Prime + 1.00%, Floor rate 8.75%, PIK Interest 1.95%, 2.95% Exit Fee2024-12-310001280784Debt Investments Software and Sisense Ltd., Senior Secured, Maturity Date July 2027, Prime + 1.50%, Floor rate 9.50%, PIK Interest 1.95%, 5.95% Exit Fee2024-12-310001280784Debt Investments Software and Streamline Healthcare Solutions, Senior Secured, Maturity Date March 2028, 3-month SOFR + 7.25%, Floor rate 8.25%2024-12-310001280784Debt Investments Software and Sumo Logic, Inc., Senior Secured, Maturity Date March 2030, 3-month SOFR + 6.50%, Floor rate 7.50%2024-12-310001280784Debt Investments Software and Suzy, Inc., Senior Secured, Maturity Date August 2027, Prime + 1.75%, Floor rate 10.00%, PIK Interest 1.95%, 3.45% Exit Fee2024-12-310001280784Debt Investments Software and TaxCalc, Senior Secured, Maturity Date November 2029, 3-month SONIA + 8.05%, Floor rate 8.55%2024-12-310001280784Debt Investments Software and ThreatConnect, Inc., Senior Secured, Maturity Date May 2026, 3-month SOFR + 9.15%, Floor rate 10.00%2024-12-310001280784Debt Investments Software and Tipalti Solutions Ltd., Senior Secured, Maturity Date April 2027, Prime + 0.45%, Floor rate 6.45%, PIK Interest 2.00%, 3.75% Exit Fee2024-12-310001280784Debt Investments Software and Zappi, Inc., Senior Secured, Maturity Date December 2027, 3-month SOFR + 8.03%, Floor rate 9.03%2024-12-310001280784Debt Investments Software and Zimperium, Inc., Senior Secured, Maturity Date May 2027, 3-month SOFR + 8.31%, Floor rate 9.31%2024-12-310001280784Debt Investments Software (52.80%)2024-12-310001280784Debt Investments Space Technologies and Voyager Technologies, Inc., Senior Secured, Maturity Date July 2028, Prime + 1.25%, Floor rate 9.75%, PIK Interest 2.50%, 5.50% Exit Fee2024-12-310001280784Debt Investments Space Technologies (2.30%)2024-12-310001280784Debt Investments Sustainable and Renewable Technology and Ampion, PBC, Senior Secured, Maturity Date May 2025, Prime + 4.70%, Floor rate 7.95%, PIK Interest 1.45%, 3.95% Exit Fee2024-12-310001280784Debt Investments Sustainable and Renewable Technology and Electric Hydrogen Co., Senior Secured, Maturity Date May 2028, Prime + 2.25%, Floor rate 10.75%, PIK Interest 1.25%, 4.89% Exit Fee2024-12-310001280784Debt Investments Sustainable and Renewable Technology and SUNation Energy, Inc. (p.k.a. Pineapple Energy LLC), Senior Secured, Maturity Date June 2027, FIXED 10.00%2024-12-310001280784Debt Investments Sustainable and Renewable Technology (1.27%)2024-12-310001280784Total Debt Investments (175.65%)2024-12-310001280784Equity Investments Biotechnology Tools and Alamar Biosciences, Inc., Equity, Acquisition Date 2/21/2024, Series Preferred Series C2024-01-012024-12-310001280784Equity Investments Biotechnology Tools and Alamar Biosciences, Inc., Equity, Acquisition Date 2/21/2024, Series Preferred Series C2024-12-310001280784Equity Investments Biotechnology Tools (0.07%)2024-12-310001280784Equity Investments Consumer & Business Products and Fabletics, Inc., Equity, Acquisition Date 4/30/2010, Series Common Stock2024-01-012024-12-310001280784Equity Investments Consumer & Business Products and Fabletics, Inc., Equity, Acquisition Date 4/30/2010, Series Common Stock2024-12-310001280784Equity Investments Consumer & Business Products and Fabletics, Inc. Equity, Acquisition Date 7/16/2013, Series Preferred Series B2024-01-012024-12-310001280784Equity Investments Consumer & Business Products and Fabletics, Inc. Equity, Acquisition Date 7/16/2013, Series Preferred Series B2024-12-310001280784Equity Investments Consumer & Business Products and Total Fabletics, Inc.2024-12-310001280784Equity Investments Consumer & Business Products and Grove Collaborative, Inc., Equity, Acquisition Date 4/30/2021, Series Common Stock2024-01-012024-12-310001280784Equity Investments Consumer & Business Products and Grove Collaborative, Inc., Equity, Acquisition Date 4/30/2021, Series Common Stock2024-12-310001280784Equity Investments Consumer & Business Products and Savage X Holding, LLC, Equity, Acquisition Date 4/30/2010, Series Class A Units2024-01-012024-12-310001280784Equity Investments Consumer & Business Products and Savage X Holding, LLC, Equity, Acquisition Date 4/30/2010, Series Class A Units2024-12-310001280784Equity Investments Consumer & Business Products (0.04%)2024-12-310001280784Equity Investments Consumer & Business Services and Carwow LTD, Equity, Acquisition Date 12/15/2021, Series Preferred Series D-42024-01-012024-12-310001280784Equity Investments Consumer & Business Services and Carwow LTD, Equity, Acquisition Date 12/15/2021, Series Preferred Series D-42024-12-310001280784Equity Investments Consumer & Business Services and Lyft, Inc., Equity, Acquisition Date 12/26/2018, Series Common Stock2024-01-012024-12-310001280784Equity Investments Consumer & Business Services and Lyft, Inc., Equity, Acquisition Date 12/26/2018, Series Common Stock2024-12-310001280784Equity Investments Consumer & Business Services and Nerdy Inc., Equity, Acquisition Date 9/17/2021, Series Common Stock2024-01-012024-12-310001280784Equity Investments Consumer & Business Services and Nerdy Inc., Equity, Acquisition Date 9/17/2021, Series Common Stock2024-12-310001280784Equity Investments Consumer & Business Services and OfferUp, Inc., Equity, Acquisition Date 10/25/2016, Series Preferred Series A2024-01-012024-12-310001280784Equity Investments Consumer & Business Services and OfferUp, Inc., Equity, Acquisition Date 10/25/2016, Series Preferred Series A2024-12-310001280784Equity, Investments Consumer & Business Services and OfferUp, Inc., Equity, Acquisition Date 10/25/2016, Series Preferred Series A-12024-01-012024-12-310001280784Equity, Investments Consumer & Business Services and OfferUp, Inc., Equity, Acquisition Date 10/25/2016, Series Preferred Series A-12024-12-310001280784Equity Investments Consumer & Business Services and Total OfferUp, Inc.2024-12-310001280784Equity Investments Consumer & Business Services and Oportun, Equity, Acquisition Date 6/28/2013, Series Common Stock2024-01-012024-12-310001280784Equity Investments Consumer & Business Services and Oportun, Equity, Acquisition Date 6/28/2013, Series Common Stock2024-12-310001280784Equity Investments Consumer & Business Services and Reischling Press, Inc., Equity, Acquisition Date 7/31/2020, Series Common Stock2024-01-012024-12-310001280784Equity Investments Consumer & Business Services and Reischling Press, Inc., Equity, Acquisition Date 7/31/2020, Series Common Stock2024-12-310001280784Equity Investments Consumer & Business Services and Rhino Labs, Inc., Equity, Acquisition Date 1/24/2022, Series Common Stock2024-01-012024-12-310001280784Equity Investments Consumer & Business Services and Rhino Labs, Inc., Equity, Acquisition Date 1/24/2022, Series Common Stock2024-12-310001280784Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 5/23/2018, Series Common Stock2024-01-012024-12-310001280784Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 5/23/2018, Series Common Stock2024-12-310001280784Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 6/6/2016, Series Preferred Series BB2024-01-012024-12-310001280784Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 6/6/2016, Series Preferred Series BB2024-12-310001280784Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 12/29/2023, Series Preferred Series C2024-01-012024-12-310001280784Equity Investments Consumer & Business Services and Tectura Corporation, Equity, Acquisition Date 12/29/2023, Series Preferred Series C2024-12-310001280784Equity Investments Consumer & Business Services and Total Tectura Corporation2024-12-310001280784Equity Investments Consumer & Business Services and Worldremit Group Limited, Equity, Acquisition Date 6/24/2024, Series Preferred Series X2024-01-012024-12-310001280784Equity Investments Consumer & Business Services and Worldremit Group Limited, Equity, Acquisition Date 6/24/2024, Series Preferred Series X2024-12-310001280784Equity Investments Consumer & Business Services (0.38%)2024-12-310001280784Equity Investments Diversified Financial Services and Gibraltar Acquisition, Equity, Acquisition Date 3/1/2018, Series Member Units2024-01-012024-12-310001280784Equity Investments Diversified Financial Services and Gibraltar Acquisition, Equity, Acquisition Date 3/1/2018, Series Member Units2024-12-310001280784Equity Investments Diversified Financial Services and Hercules Adviser LLC, Equity, Acquisition Date 3/26/2021, Series Member Units2024-01-012024-12-310001280784Equity Investments Diversified Financial Services and Hercules Adviser LLC, Equity, Acquisition Date 3/26/2021, Series Member Units2024-12-310001280784Equity Investments Diversified Financial Services, Newfront Insurance Holdings, Inc., Equity, Acquisition Date 9/30/2021, Series Preferred Series D-22024-01-012024-12-310001280784Equity Investments Diversified Financial Services, Newfront Insurance Holdings, Inc., Equity, Acquisition Date 9/30/2021, Series Preferred Series D-22024-12-310001280784Equity Investments Diversified Financial Services (2.70%)2024-12-310001280784Equity Investments Drug Delivery and Aytu BioScience, Inc., Equity, Acquisition Date 3/28/2014, Series Common Stock2024-01-012024-12-310001280784Equity Investments Drug Delivery and Aytu BioScience, Inc., Equity, Acquisition Date 3/28/2014, Series Common Stock2024-12-310001280784Equity Investments Drug Delivery and BioQ Pharma Incorporated, Equity, Acquisition Date 12/8/2015, Series Preferred Series D2024-01-012024-12-310001280784Equity Investments Drug Delivery and BioQ Pharma Incorporated, Equity, Acquisition Date 12/8/2015, Series Preferred Series D2024-12-310001280784Equity Investments Drug Delivery and PDS Biotechnology Corporation, Equity, Acquisition Date 4/6/2015, Series Common Stock2024-01-012024-12-310001280784Equity Investments Drug Delivery and PDS Biotechnology Corporation, Equity, Acquisition Date 4/6/2015, Series Common Stock2024-12-310001280784Equity Investments Drug Delivery and Talphera, Inc., Equity, Acquisition Date 12/10/2018, Series Common Stock2024-01-012024-12-310001280784Equity Investments Drug Delivery and Talphera, Inc., Equity, Acquisition Date 12/10/2018, Series Common Stock2024-12-310001280784Equity Investments Drug Delivery (0.00%)2024-12-310001280784Equity Investments Drug Discovery & Development and Akero Therapeutics, Inc., Equity, Acquisition Date 3/8/2024, Series Common Stock2024-01-012024-12-310001280784Equity Investments Drug Discovery & Development and Akero Therapeutics, Inc., Equity, Acquisition Date 3/8/2024, Series Common Stock2024-12-310001280784Equity Investments Drug Discovery & Development and Avalo Therapeutics, Inc., Equity, Acquisition Date 8/19/2014, Series Common Stock2024-01-012024-12-310001280784Equity Investments Drug Discovery & Development and Avalo Therapeutics, Inc., Equity, Acquisition Date 8/19/2014, Series Common Stock2024-12-310001280784Equity Investments Drug Discovery & Development and Axsome Therapeutics, Inc.., Equity, Acquisition Date 5/9/2022, Series Common Stock2024-01-012024-12-310001280784Equity Investments Drug Discovery & Development and Axsome Therapeutics, Inc.., Equity, Acquisition Date 5/9/2022, Series Common Stock2024-12-310001280784Equity Investments Drug Discovery & Development and Bicycle Therapeutics PLC, Equity, Acquisition Date 10/05/2020, Series Common Stock2024-01-012024-12-310001280784Equity Investments Drug Discovery & Development and Bicycle Therapeutics PLC, Equity, Acquisition Date 10/05/2020, Series Common Stock2024-12-310001280784Equity Investments Drug Discovery & Development and BridgeBio Pharma, Inc., Equity, Acquisition Date 6/21/2018, Series Common Stock2024-01-012024-12-310001280784Equity Investments Drug Discovery & Development and BridgeBio Pharma, Inc., Equity, Acquisition Date 6/21/2018, Series Common Stock2024-12-310001280784Equity Investments Drug Discovery & Development and Cyclo Therapeutics, Inc., Equity, Acquisition Date 4/06/2021, Series Common Stock2024-01-012024-12-310001280784Equity Investments Drug Discovery & Development and Cyclo Therapeutics, Inc., Equity, Acquisition Date 4/06/2021, Series Common Stock2024-12-310001280784Equity Investments Drug Discovery & Development and Dare Biosciences, Inc., Equity, Acquisition Date 1/8/2015, Series Common Stock2024-01-012024-12-310001280784Equity Investments Drug Discovery & Development and Dare Biosciences, Inc., Equity, Acquisition Date 1/8/2015, Series Common Stock2024-12-310001280784Equity Investments Drug Discovery & Development and Dynavax Technologies, Equity, Acquisition Date 7/22/2015, Series Common Stock2024-01-012024-12-310001280784Equity Investments Drug Discovery & Development and Dynavax Technologies, Equity, Acquisition Date 7/22/2015, Series Common Stock2024-12-310001280784Equity Investments Drug Discovery & Development and Heron Therapeutics, Inc., Equity, Acquisition Date 7/25/2023, Series Common Stock2024-01-012024-12-310001280784Equity Investments Drug Discovery & Development and Heron Therapeutics, Inc., Equity, Acquisition Date 7/25/2023, Series Common Stock2024-12-310001280784Equity Investments Drug Discovery & Development and Hibercell, Inc., Equity, Acquisition Date 5/7/2021, Series Preferred Series B2024-01-012024-12-310001280784Equity Investments Drug Discovery & Development and Hibercell, Inc., Equity, Acquisition Date 5/7/2021, Series Preferred Series B2024-12-310001280784Equity Investments Drug Discovery & Development and HilleVax, Inc., Equity, Acquisition Date 5/3/2022, Series Common Stock2024-01-012024-12-310001280784Equity Investments Drug Discovery & Development and HilleVax, Inc., Equity, Acquisition Date 5/3/2022, Series Common Stock2024-12-310001280784Equity Investments Drug Discovery & Development and Kura Oncology, Inc., Equity, Acquisition Date 6/16/2023, Series Common Stock2024-01-012024-12-310001280784Equity Investments Drug Discovery & Development and Kura Oncology, Inc., Equity, Acquisition Date 6/16/2023, Series Common Stock2024-12-310001280784Equity Investments Drug Discovery & Development and Madrigal Pharmaceutical, Inc., Equity, Acquisition Date 9/29/2023, Series Common Stock2024-01-012024-12-310001280784Equity Investments Drug Discovery & Development and Madrigal Pharmaceutical, Inc., Equity, Acquisition Date 9/29/2023, Series Common Stock2024-12-310001280784Equity Investments Drug Discovery & Development and NorthSea Therapeutics, Equity, Acquisition Date 12/15/2021, Series Preferred Series C2024-01-012024-12-310001280784Equity Investments Drug Discovery & Development and NorthSea Therapeutics, Equity, Acquisition Date 12/15/2021, Series Preferred Series C2024-12-310001280784Equity Investments Drug Discovery & Development and Phathom Pharmaceuticals, Inc., Equity, Acquisition Date 6/9/2023, Series Common Stock2024-01-012024-12-310001280784Equity Investments Drug Discovery & Development and Phathom Pharmaceuticals, Inc., Equity, Acquisition Date 6/9/2023, Series Common Stock2024-12-310001280784Equity Investments Drug Discovery & Development and Rocket Pharmaceuticals, Ltd., Equity, Acquisition Date 8/22/2007, Series Common Stock2024-01-012024-12-310001280784Equity Investments Drug Discovery & Development and Rocket Pharmaceuticals, Ltd., Equity, Acquisition Date 8/22/2007, Series Common Stock2024-12-310001280784Equity Investments Drug Discovery & Development and Savara, Inc., Equity, Acquisition Date 8/11/2015, Series Common Stock2024-01-012024-12-310001280784Equity Investments Drug Discovery & Development and Savara, Inc., Equity, Acquisition Date 8/11/2015, Series Common Stock2024-12-310001280784Equity Investments Drug Discovery & Development and uniQure B.V., Equity, Acquisition Date 1/31/2019, Series Common Stock2024-01-012024-12-310001280784Equity Investments Drug Discovery & Development and uniQure B.V., Equity, Acquisition Date 1/31/2019, Series Common Stock2024-12-310001280784Equity Investments Drug Discovery & Development and Valo Health, LLC, Equity, Acquisition Date 12/11/2020, Series Preferred Series B2024-01-012024-12-310001280784Equity Investments Drug Discovery & Development and Valo Health, LLC, Equity, Acquisition Date 12/11/2020, Series Preferred Series B2024-12-310001280784Equity Investments Drug Discovery & Development and Valo Health, LLC, Equity, Acquisition Date 10/31/2022, Series Preferred Series C2024-01-012024-12-310001280784Equity Investments Drug Discovery & Development and Valo Health, LLC, Equity, Acquisition Date 10/31/2022, Series Preferred Series C2024-12-310001280784Equity Investments Drug Discovery & Development and Total Valo Health, LLC2024-12-310001280784Equity Investments Drug Discovery & Development and Verge Analytics, Inc., Equity, Acquisition Date 9/6/2023, Series Preferred Series C2024-01-012024-12-310001280784Equity Investments Drug Discovery & Development and Verge Analytics, Inc., Equity, Acquisition Date 9/6/2023, Series Preferred Series C2024-12-310001280784Equity Investments Drug Discovery & Development and Viridian Therapeutics, Inc., Equity, Acquisition Date 11/6/2023, Series Common Stock2024-01-012024-12-310001280784Equity Investments Drug Discovery & Development and Viridian Therapeutics, Inc., Equity, Acquisition Date 11/6/2023, Series Common Stock2024-12-310001280784Equity Investments Drug Discovery & Development and X4 Pharmaceuticals, Inc., Equity, Acquisition Date 11/26/2019, Series Common Stock2024-01-012024-12-310001280784Equity Investments Drug Discovery & Development and X4 Pharmaceuticals, Inc., Equity, Acquisition Date 11/26/2019, Series Common Stock2024-12-310001280784Equity Investments Drug Discovery & Development (1.56%)2024-12-310001280784Equity Investments Electronics & Computer Hardware and Locus Robotics Corp., Equity, Acquisition Date 11/17/2022, Series Preferred Series F2024-01-012024-12-310001280784Equity Investments Electronics & Computer Hardware and Locus Robotics Corp., Equity, Acquisition Date 11/17/2022, Series Preferred Series F2024-12-310001280784Equity Investments Electronics & Computer Hardware and Skydio, Inc., Equity, Acquisition Date 3/8/2022, Series Preferred Series E2024-01-012024-12-310001280784Equity Investments Electronics & Computer Hardware and Skydio, Inc., Equity, Acquisition Date 3/8/2022, Series Preferred Series E2024-12-310001280784Equity Investments Electronics & Computer Hardware (0.05%)2024-12-310001280784Equity Investments Healthcare Services, Other and 23andMe, Inc., Equity, Acquisition Date 3/11/2019, Series Common Stock2024-01-012024-12-310001280784Equity Investments Healthcare Services, Other and 23andMe, Inc., Equity, Acquisition Date 3/11/2019, Series Common Stock2024-12-310001280784Equity Investments Healthcare Services, Other and Carbon Health Technologies, Inc., Equity, Acquisition Date 3/30/2021, Series Preferred Series C2024-01-012024-12-310001280784Equity Investments Healthcare Services, Other and Carbon Health Technologies, Inc., Equity, Acquisition Date 3/30/2021, Series Preferred Series C2024-12-310001280784Equity Investments Healthcare Services, Other and Click Therapeutics, Inc., Equity, Acquisition Date 5/20/2024, Series Common Stock2024-01-012024-12-310001280784Equity Investments Healthcare Services, Other and Click Therapeutics, Inc., Equity, Acquisition Date 5/20/2024, Series Common Stock2024-12-310001280784Equity Investments Healthcare Services, Other and Curana Health Holdings, LLC, Equity, Acquisition Date 5/13/2024, Series Common Units2024-01-012024-12-310001280784Equity Investments Healthcare Services, Other and Curana Health Holdings, LLC, Equity, Acquisition Date 5/13/2024, Series Common Units2024-12-310001280784Equity Investments Healthcare Services, Other and Main Street Rural, Inc., Equity, Acquisition Date 10/28/2024, Series Preferred Series D2024-01-012024-12-310001280784Equity Investments Healthcare Services, Other and Main Street Rural, Inc., Equity, Acquisition Date 10/28/2024, Series Preferred Series D2024-12-310001280784Equity Investments Healthcare Services, Other and WellBe Senior Medical, LLC, Equity, Acquisition Date 6/10/2024, Series Common Units2024-01-012024-12-310001280784Equity Investments Healthcare Services, Other and WellBe Senior Medical, LLC, Equity, Acquisition Date 6/10/2024, Series Common Units2024-12-310001280784Equity Investments Healthcare Services, Other (0.38%)2024-12-310001280784Equity Investments Information Services and Yipit, LLC, Equity, Acquisition Date 12/30/2021, Series Preferred Series E2024-01-012024-12-310001280784Equity Investments Information Services and Yipit, LLC, Equity, Acquisition Date 12/30/2021, Series Preferred Series E2024-12-310001280784Equity Investments Information Services (0.20%)2024-12-310001280784Equity Investments Medical Devices & Equipment and Coronado Aesthetics, LLC, Equity, Acquisition Date 10/15/2021, Series Common Units2024-01-012024-12-310001280784Equity Investments Medical Devices & Equipment and Coronado Aesthetics, LLC, Equity, Acquisition Date 10/15/2021, Series Common Units2024-12-310001280784Equity Investments Medical Devices & Equipment and Coronado Aesthetics, LLC, Equity, Acquisition Date 10/15/2021, Series Preferred Series A-22024-01-012024-12-310001280784Equity Investments Medical Devices & Equipment and Coronado Aesthetics, LLC, Equity, Acquisition Date 10/15/2021, Series Preferred Series A-22024-12-310001280784Equity Investments Medical Devices & Equipment and Total Coronado Aesthetics, LLC2024-12-310001280784Equity Investments Medical Devices & Equipment (0.00%)2024-12-310001280784Equity Investments Semiconductors and Achronix Semiconductor Corporation, Equity, Acquisition Date 7/1/2011, Series Preferred Series C2024-01-012024-12-310001280784Equity Investments Semiconductors and Achronix Semiconductor Corporation, Equity, Acquisition Date 7/1/2011, Series Preferred Series C2024-12-310001280784Equity Investments Semiconductors (0.01%)2024-12-310001280784Equity Investments Software and 3GTMS, LLC, Equity, Acquisition Date 8/9/2021, Series Common Stock2024-01-012024-12-310001280784Equity Investments Software and 3GTMS, LLC, Equity, Acquisition Date 8/9/2021, Series Common Stock2024-12-310001280784Equity Investments Software and Armis, Inc., Equity, Acquisition Date 10/18/2024, Series Preferred Series D2024-01-012024-12-310001280784Equity Investments Software and Armis, Inc., Equity, Acquisition Date 10/18/2024, Series Preferred Series D2024-12-310001280784Equity Investments Software and Black Crow AI, Inc. affiliates, Equity, Acquisition Date 3/24/2021, Series Preferred Note2024-01-012024-12-310001280784Equity Investments Software and Black Crow AI, Inc. affiliates, Equity, Acquisition Date 3/24/2021, Series Preferred Note2024-12-310001280784Equity Investments Software and CapLinked, Inc., Equity, Acquisition Date 10/26/2012, Series Preferred Series A-32024-01-012024-12-310001280784Equity Investments Software and CapLinked, Inc., Equity, Acquisition Date 10/26/2012, Series Preferred Series A-32024-12-310001280784Equity Investments Software and Contentful Global, Inc., Equity, Acquisition Date 12/22/2020, Series Preferred Series C2024-01-012024-12-310001280784Equity Investments Software and Contentful Global, Inc., Equity, Acquisition Date 12/22/2020, Series Preferred Series C2024-12-310001280784Equity Investments Software and Contentful Global, Inc., Equity, Acquisition Date 11/20/2018, Series Preferred Series D2024-01-012024-12-310001280784Equity Investments Software and Contentful Global, Inc., Equity, Acquisition Date 11/20/2018, Series Preferred Series D2024-12-310001280784Equity Investments Software and Total Contentful Global, Inc.2024-12-310001280784Equity Investments Software and DNAnexus, Inc., Equity, Acquisition Date 3/21/2014, Series Preferred Series C2024-01-012024-12-310001280784Equity Investments Software and DNAnexus, Inc., Equity, Acquisition Date 3/21/2014, Series Preferred Series C2024-12-310001280784Equity Investments Software and Docker, Inc., Equity, Acquisition Date 11/29/2018, Series Common Stock2024-01-012024-12-310001280784Equity Investments Software and Docker, Inc., Equity, Acquisition Date 11/29/2018, Series Common Stock2024-12-310001280784Equity Investments Software and Druva Holdings, Inc., Equity, Acquisition Date 10/22/2015, Series Preferred Series 22024-01-012024-12-310001280784Equity Investments Software and Druva Holdings, Inc., Equity, Acquisition Date 10/22/2015, Series Preferred Series 22024-12-310001280784Equity Investments Software and Druva Holdings, Inc., Equity, Acquisition Date 8/24/2017, Series Preferred Series 32024-01-012024-12-310001280784Equity Investments Software and Druva Holdings, Inc., Equity, Acquisition Date 8/24/2017, Series Preferred Series 32024-12-310001280784Equity Investments Software and Total Druva Holdings, Inc.2024-12-310001280784Equity Investments Software and HighRoads, Inc., Equity, Acquisition Date 1/18/2013, Series Common Stock2024-01-012024-12-310001280784Equity Investments Software and HighRoads, Inc., Equity, Acquisition Date 1/18/2013, Series Common Stock2024-12-310001280784Equity Investments Software and Leapwork ApS, Equity, Acquisition Date 8/25/2023, Preferred Series B22024-01-012024-12-310001280784Equity Investments Software and Leapwork ApS, Equity, Acquisition Date 8/25/2023, Preferred Series B22024-12-310001280784Equity Investments Software and Lightbend, Inc., Equity, Acquisition Date 12/4/2020, Series Common Stock2024-01-012024-12-310001280784Equity Investments Software and Lightbend, Inc., Equity, Acquisition Date 12/4/2020, Series Common Stock2024-12-310001280784Equity Investments Software and Nextdoor.com, Inc., Equity, Acquisition Date 8/1/2018, Series Common Stock2024-01-012024-12-310001280784Equity Investments Software and Nextdoor.com, Inc., Equity, Acquisition Date 8/1/2018, Series Common Stock2024-12-310001280784Equity Investments Software and SingleStore, Inc., Equity, Acquisition Date 11/25/2020, Series Preferred Series E2024-01-012024-12-310001280784Equity Investments Software and SingleStore, Inc., Equity, Acquisition Date 11/25/2020, Series Preferred Series E2024-12-310001280784Equity Investments Software and SingleStore, Inc., Equity, Acquisition Date 8/12/2021, Series Preferred Series F2024-01-012024-12-310001280784Equity Investments Software and SingleStore, Inc., Equity, Acquisition Date 8/12/2021, Series Preferred Series F2024-12-310001280784Equity Investments Software and Total SingleStore, Inc.2024-12-310001280784Equity Investments Software and SirionLabs Pte. Ltd., Equity, Acquisition Date 6/30/2024, Series Preferred Series F12024-01-012024-12-310001280784Equity Investments Software and SirionLabs Pte. Ltd., Equity, Acquisition Date 6/30/2024, Series Preferred Series F12024-12-310001280784Equity Investments Software and Verana Health, Inc., Equity, Acquisition Date 7/8/2021, Series Preferred Series E2024-01-012024-12-310001280784Equity Investments Software and Verana Health, Inc., Equity, Acquisition Date 7/8/2021, Series Preferred Series E2024-12-310001280784Equity Investments Software (0.99%)2024-12-310001280784Equity Investments Sustainable and Renewable Technology and Impossible Foods, Inc., Equity, Acquisition Date 5/10/2019, Series Preferred Series E-12024-01-012024-12-310001280784Equity Investments Sustainable and Renewable Technology and Impossible Foods, Inc., Equity, Acquisition Date 5/10/2019, Series Preferred Series E-12024-12-310001280784Equity Investments Sustainable and Renewable Technology and Modumetal, Inc., Equity, Acquisition Date 6/1/2015, Series Common Stock2024-01-012024-12-310001280784Equity Investments Sustainable and Renewable Technology and Modumetal, Inc., Equity, Acquisition Date 6/1/2015, Series Common Stock2024-12-310001280784Equity Investments Sustainable and Renewable Technology and Pivot Bio, Inc., Equity, Acquisition Date 6/28/2021, Series Preferred Series D2024-01-012024-12-310001280784Equity Investments Sustainable and Renewable Technology and Pivot Bio, Inc., Equity, Acquisition Date 6/28/2021, Series Preferred Series D2024-12-310001280784Equity Investments Sustainable and Renewable Technology and SUNation Energy, Inc. (p.k.a. Pineapple Energy LLC), Equity, Acquisition Date 12/10/2020, Series Common Stock2024-01-012024-12-310001280784Equity Investments Sustainable and Renewable Technology and SUNation Energy, Inc. (p.k.a. Pineapple Energy LLC), Equity, Acquisition Date 12/10/2020, Series Common Stock2024-12-310001280784Equity Investments Sustainable and Renewable Technology (0.10%)2024-12-310001280784Equity Investments (6.47%)2024-12-310001280784Warrant Investments and Biotechnology Tools and Alamar Biosciences, Inc., Warrant, Acquisition Date 6/21/2022, Series Preferred Series C2024-01-012024-12-310001280784Warrant Investments and Biotechnology Tools and Alamar Biosciences, Inc., Warrant, Acquisition Date 6/21/2022, Series Preferred Series C2024-12-310001280784Warrant Investments and Biotechnology Tools and PathAI, Inc., Warrant, Acquisition Date 12/23/2022, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Biotechnology Tools and PathAI, Inc., Warrant, Acquisition Date 12/23/2022, Series Common Stock2024-12-310001280784Warrant Investments and Biotechnology Tools (0.01%)2024-12-310001280784Warrant Investments and Communications & Networking and Aryaka Networks, Inc., Warrant, Acquisition Date 6/28/2022, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Communications & Networking and Aryaka Networks, Inc., Warrant, Acquisition Date 6/28/2022, Series Common Stock2024-12-310001280784Warrant Investments and Communications & Networking (0.01%)2024-12-310001280784Warrant Investments and Consumer & Business Products and Gadget Guard, LLC, Warrant, Acquisition Date 6/3/2014, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Consumer & Business Products and Gadget Guard, LLC, Warrant, Acquisition Date 6/3/2014, Series Common Stock2024-12-310001280784Warrant Investments and Consumer & Business Products and Whoop, Inc., Warrant, Acquisition Date 6/27/2018, Series Preferred Series C2024-01-012024-12-310001280784Warrant Investments and Consumer & Business Products and Whoop, Inc., Warrant, Acquisition Date 6/27/2018, Series Preferred Series C2024-12-310001280784Warrant Investments and Consumer & Business Products (0.04%)2024-12-310001280784Warrant Investments and Consumer & Business Services and Altumint, Inc., Warrant, Acquisition Date 10/31/2024, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Consumer & Business Services and Altumint, Inc., Warrant, Acquisition Date 10/31/2024, Series Common Stock2024-12-310001280784Warrant Investments and Consumer & Business Services and Carwow LTD, Warrant, Acquisition Date 12/14/2021, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Consumer & Business Services and Carwow LTD, Warrant, Acquisition Date 12/14/2021, Series Common Stock2024-12-310001280784Warrant Investments and Consumer & Business Services and Carwow LTD, Warrant, Acquisition Date 2/13/2024, Series Preferred Series D-42024-01-012024-12-310001280784Warrant Investments and Consumer & Business Services and Carwow LTD, Warrant, Acquisition Date 2/13/2024, Series Preferred Series D-42024-12-310001280784Warrant Investments and Consumer & Business Services and Total Carwow LTD2024-12-310001280784Warrant Investments and Consumer & Business Services and Houzz, Inc., Warrant, Acquisition Date 10/29/2019, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Consumer & Business Services and Houzz, Inc., Warrant, Acquisition Date 10/29/2019, Series Common Stock2024-12-310001280784Warrant Investments and Consumer & Business Services and Landing Holdings Inc., Warrant, Acquisition Date 3/12/2021, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Consumer & Business Services and Landing Holdings Inc., Warrant, Acquisition Date 3/12/2021, Series Common Stock2024-12-310001280784Warrant Investments and Consumer & Business Services and Lendio, Inc., Warrant, Acquisition Date 3/29/2019, Series Preferred Series D2024-01-012024-12-310001280784Warrant Investments and Consumer & Business Services and Lendio, Inc., Warrant, Acquisition Date 3/29/2019, Series Preferred Series D2024-12-310001280784Warrant Investments and Consumer & Business Services and Plentific Ltd, Warrant, Acquisition Date 10/3/2023, Series Ordinary shares2024-01-012024-12-310001280784Warrant Investments and Consumer & Business Services and Plentific Ltd, Warrant, Acquisition Date 10/3/2023, Series Ordinary shares2024-12-310001280784Warrant Investments and Consumer & Business Services and Provi., Warrant, Acquisition Date 12/22/2022, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Consumer & Business Services and Provi., Warrant, Acquisition Date 12/22/2022, Series Common Stock2024-12-310001280784Warrant Investments and Consumer & Business Services and Rhino Labs, Inc., Warrant, Acquisition Date 3/12/2021, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Consumer & Business Services and Rhino Labs, Inc., Warrant, Acquisition Date 3/12/2021, Series Common Stock2024-12-310001280784Warrant Investments and Consumer & Business Services and SeatGeek, Inc., Warrant, Acquisition Date 6/12/2019, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Consumer & Business Services and SeatGeek, Inc., Warrant, Acquisition Date 6/12/2019, Series Common Stock2024-12-310001280784Warrant Investments and Consumer & Business Services and Skyword, Inc., Warrant, Acquisition Date 11/14/2022, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Consumer & Business Services and Skyword, Inc., Warrant, Acquisition Date 11/14/2022, Series Common Stock2024-12-310001280784Warrant Investments and Consumer & Business Services and Skyword, Inc., Warrant, Acquisition Date 8/23/2019, Series Preferred Series B2024-01-012024-12-310001280784Warrant Investments and Consumer & Business Services and Skyword, Inc., Warrant, Acquisition Date 8/23/2019, Series Preferred Series B2024-12-310001280784Warrant Investments and Consumer & Business Services and Total Skyword, Inc.2024-12-310001280784Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 4/20/2020, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 4/20/2020, Series Common Stock2024-12-310001280784Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 6/30/2016, Series Preferred Series A2024-01-012024-12-310001280784Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 6/30/2016, Series Preferred Series A2024-12-310001280784Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 8/1/2018, Series Preferred Series B2024-01-012024-12-310001280784Warrant Investments and Consumer & Business Services and Snagajob.com, Inc., Warrant, Acquisition Date 8/1/2018, Series Preferred Series B2024-12-310001280784Warrant Investments and Consumer & Business Services and Total Snagajob.com, Inc.2024-12-310001280784Warrant Investments and Consumer & Business Services and Thumbtack, Inc., Warrant, Acquisition Date 5/1/2018, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Consumer & Business Services and Thumbtack, Inc., Warrant, Acquisition Date 5/1/2018, Series Common Stock2024-12-310001280784Warrant Investments and Consumer & Business Services and Veem, Inc., Warrant, Acquisition Date 3/31/2022, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Consumer & Business Services and Veem, Inc., Warrant, Acquisition Date 3/31/2022, Series Common Stock2024-12-310001280784Warrant Investments and Consumer & Business Services and Worldremit Group Limited, Warrant, Acquisition Date 2/11/2021, Series Preferred Series D2024-01-012024-12-310001280784Warrant Investments and Consumer & Business Services and Worldremit Group Limited, Warrant, Acquisition Date 2/11/2021, Series Preferred Series D2024-12-310001280784Warrant Investments and Consumer & Business Services and Worldremit Group Limited, Warrant, Acquisition Date 8/27/2021, Series Preferred Series E2024-01-012024-12-310001280784Warrant Investments and Consumer & Business Services and Worldremit Group Limited, Warrant, Acquisition Date 8/27/2021, Series Preferred Series E2024-12-310001280784Warrant Investments and Consumer & Business Services and Total Worldremit Group Limited2024-12-310001280784Warrant Investments and Consumer & Business Services (0.32%)2024-12-310001280784Warrant Investments and Diversified Financial Services and Next Insurance, Inc., Warrant, Acquisition Date 2/3/2023, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Diversified Financial Services and Next Insurance, Inc., Warrant, Acquisition Date 2/3/2023, Series Common Stock2024-12-310001280784Warrant Investments and Diversified Financial Services (0.02%)2024-12-310001280784Warrant Investments and Drug Discovery & Development and Akero Therapeutics, Inc., Warrant, Acquisition Date 6/15/2022, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Drug Discovery & Development and Akero Therapeutics, Inc., Warrant, Acquisition Date 6/15/2022, Series Common Stock2024-12-310001280784Warrant Investments and Drug Discovery & Development and AmplifyBio, Warrant, Acquisition Date 12/27/2022, Series Class A Units2024-01-012024-12-310001280784Warrant Investments and Drug Discovery & Development and AmplifyBio, Warrant, Acquisition Date 12/27/2022, Series Class A Units2024-12-310001280784Warrant Investments and Drug Discovery & Development and Axsome Therapeutics, Inc., Warrant, Acquisition Date 9/25/2020, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Drug Discovery & Development and Axsome Therapeutics, Inc., Warrant, Acquisition Date 9/25/2020, Series Common Stock2024-12-310001280784Warrant Investments and Drug Discovery & Development and bluebird bio, Inc., Warrant, Acquisition Date 3/15/2024, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Drug Discovery & Development and bluebird bio, Inc., Warrant, Acquisition Date 3/15/2024, Series Common Stock2024-12-310001280784Warrant Investments and Drug Discovery & Development and Cellarity, Inc., Warrant, Acquisition Date 12/8/2021, Series Preferred Series B2024-01-012024-12-310001280784Warrant Investments and Drug Discovery & Development and Cellarity, Inc., Warrant, Acquisition Date 12/8/2021, Series Preferred Series B2024-12-310001280784Warrant Investments and Drug Discovery & Development and Century Therapeutics, Inc., Warrant, Acquisition Date 9/14/2020, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Drug Discovery & Development and Century Therapeutics, Inc., Warrant, Acquisition Date 9/14/2020, Series Common Stock2024-12-310001280784Warrant Investments and Drug Discovery & Development and COMPASS Pathways plc, Warrant, Acquisition Date 6/30/2023, Series Ordinary Shares2024-01-012024-12-310001280784Warrant Investments and Drug Discovery & Development and COMPASS Pathways plc, Warrant, Acquisition Date 6/30/2023, Series Ordinary Shares2024-12-310001280784Warrant Investments and Drug Discovery & Development and Cuervo, Inc., Warrant, Acquisition Date 6/9/2023, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Drug Discovery & Development and Cuervo, Inc., Warrant, Acquisition Date 6/9/2023, Series Common Stock2024-12-310001280784Warrant Investments and Drug Discovery & Development and enGene, Inc., Warrant, Acquisition Date 12/22/2023, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Drug Discovery & Development and enGene, Inc., Warrant, Acquisition Date 12/22/2023, Series Common Stock2024-12-310001280784Warrant Investments and Drug Discovery & Development and Fresh Tracks Therapeutics, Inc., Warrant, Acquisition Date 2/18/2016, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Drug Discovery & Development and Fresh Tracks Therapeutics, Inc., Warrant, Acquisition Date 2/18/2016, Series Common Stock2024-12-310001280784Warrant Investments and Drug Discovery & Development and Heron Therapeutics, Inc., Warrant, Acquisition Date 8/9/2023, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Drug Discovery & Development and Heron Therapeutics, Inc., Warrant, Acquisition Date 8/9/2023, Series Common Stock2024-12-310001280784Warrant Investments and Drug Discovery & Development and Kineta, Inc., Warrant, Acquisition Date 12/20/2019, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Drug Discovery & Development and Kineta, Inc., Warrant, Acquisition Date 12/20/2019, Series Common Stock2024-12-310001280784Warrant Investments and Drug Discovery & Development and Kura Oncology, Inc., Warrant, Acquisition Date 11/2/2022, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Drug Discovery & Development and Kura Oncology, Inc., Warrant, Acquisition Date 11/2/2022, Series Common Stock2024-12-310001280784Warrant Investments and Drug Discovery & Development and Madrigal Pharmaceutical, Inc., Warrant, Acquisition Date 5/9/2022, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Drug Discovery & Development and Madrigal Pharmaceutical, Inc., Warrant, Acquisition Date 5/9/2022, Series Common Stock2024-12-310001280784Warrant Investments and Drug Discovery & Development and Phathom Pharmaceuticals, Inc., Warrant, Acquisition Date 9/17/2021, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Drug Discovery & Development and Phathom Pharmaceuticals, Inc., Warrant, Acquisition Date 9/17/2021, Series Common Stock2024-12-310001280784Warrant Investments and Drug Discovery & Development and Redshift Bioanalytics, Inc., Warrant, Acquisition Date 3/23/2022, Series Preferred Series E2024-01-012024-12-310001280784Warrant Investments and Drug Discovery & Development and Redshift Bioanalytics, Inc., Warrant, Acquisition Date 3/23/2022, Series Preferred Series E2024-12-310001280784Warrant Investments and Drug Discovery & Development and Scynexis, Inc., Warrant, Acquisition Date 5/14/2021, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Drug Discovery & Development and Scynexis, Inc., Warrant, Acquisition Date 5/14/2021, Series Common Stock2024-12-310001280784Warrant Investments and Drug Discovery & Development and SynOx Therapeutics Limited, Warrant, Acquisition Date 4/18/2024, Series Preferred Series B2024-01-012024-12-310001280784Warrant Investments and Drug Discovery & Development and SynOx Therapeutics Limited, Warrant, Acquisition Date 4/18/2024, Series Preferred Series B2024-12-310001280784Warrant Investments and Drug Discovery & Development and TG Therapeutics, Inc., Warrant, Acquisition Date 12/30/2021, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Drug Discovery & Development and TG Therapeutics, Inc., Warrant, Acquisition Date 12/30/2021, Series Common Stock2024-12-310001280784Warrant Investments and Drug Discovery & Development and Valo Health, LLC, Warrant, Acquisition Date 6/15/2020, Series Common Units2024-01-012024-12-310001280784Warrant Investments and Drug Discovery & Development and Valo Health, LLC, Warrant, Acquisition Date 6/15/2020, Series Common Units2024-12-310001280784Warrant Investments and Drug Discovery & Development and X4 Pharmaceuticals, Inc., Warrant, Acquisition Date 3/18/2019, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Drug Discovery & Development and X4 Pharmaceuticals, Inc., Warrant, Acquisition Date 3/18/2019, Series Common Stock2024-12-310001280784Warrant Investments and Drug Discovery & Development (0.35%)2024-12-310001280784Warrant Investments and Electronics & Computer Hardware and 908 Devices, Inc., Warrant, Acquisition Date 3/15/2017, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Electronics & Computer Hardware and 908 Devices, Inc., Warrant, Acquisition Date 3/15/2017, Series Common Stock2024-12-310001280784Warrant Investments and Electronics & Computer Hardware and Locus Robotics Corp., Warrant, Acquisition Date 6/21/2022, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Electronics & Computer Hardware and Locus Robotics Corp., Warrant, Acquisition Date 6/21/2022, Series Common Stock2024-12-310001280784Warrant Investments and Electronics & Computer Hardware and Skydio, Inc., Warrant, Acquisition Date 11/08/2021, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Electronics & Computer Hardware and Skydio, Inc., Warrant, Acquisition Date 11/08/2021, Series Common Stock2024-12-310001280784Warrant Investments and Electronics & Computer Hardware (0.01%)2024-12-310001280784Warrant Investments and Healthcare Services, Other and Curana Health Holdings, LLC, Warrant, Acquisition Date 1/4/2024, Series Common Units2024-01-012024-12-310001280784Warrant Investments and Healthcare Services, Other and Curana Health Holdings, LLC, Warrant, Acquisition Date 1/4/2024, Series Common Units2024-12-310001280784Warrant Investments and Healthcare Services, Other and Modern Life, Inc, Warrant, Acquisition Date 3/30/2023, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Healthcare Services, Other and Modern Life, Inc, Warrant, Acquisition Date 3/30/2023, Series Common Stock2024-12-310001280784Warrant Investments and Healthcare Services, Other and NeueHealth, Inc., Warrant, Acquisition Date 6/21/2024, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Healthcare Services, Other and NeueHealth, Inc., Warrant, Acquisition Date 6/21/2024, Series Common Stock2024-12-310001280784Warrant Investments and Healthcare Services, Other and Recover Together, Inc., Warrant, Acquisition Date 7/3/2023, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Healthcare Services, Other and Recover Together, Inc., Warrant, Acquisition Date 7/3/2023, Series Common Stock2024-12-310001280784Warrant Investments and Healthcare Services, Other and Strive Health Holdings, LLC, Warrant, Acquisition Date 9/28/2023, Series Common Units2024-01-012024-12-310001280784Warrant Investments and Healthcare Services, Other and Strive Health Holdings, LLC, Warrant, Acquisition Date 9/28/2023, Series Common Units2024-12-310001280784Warrant Investments and Healthcare Services, Other and Vida Health, Inc., Warrant, Acquisition Date 3/28/2022, Series Preferred Series E2024-01-012024-12-310001280784Warrant Investments and Healthcare Services, Other and Vida Health, Inc., Warrant, Acquisition Date 3/28/2022, Series Preferred Series E2024-12-310001280784Warrant Investments and Healthcare Services, Other (0.11%)2024-12-310001280784Warrant Investments and Information Services and NetBase Quid, Inc. (p.k.a NetBase Solutions), Warrant, Acquisition Date 8/22/2017, Series Preferred Series 12024-01-012024-12-310001280784Warrant Investments and Information Services and NetBase Quid, Inc. (p.k.a NetBase Solutions), Warrant, Acquisition Date 8/22/2017, Series Preferred Series 12024-12-310001280784Warrant Investments and Information Services and Signal Media Limited, Warrant, Acquisition Date 6/29/2022, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Information Services and Signal Media Limited, Warrant, Acquisition Date 6/29/2022, Series Common Stock2024-12-310001280784Warrant Investments and Information Services (0.00%)2024-12-310001280784Warrant Investments and Manufacturing Technology and Bright Machines, Inc., Warrant, Acquisition Date 3/31/2022, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Manufacturing Technology and Bright Machines, Inc., Warrant, Acquisition Date 3/31/2022, Series Common Stock2024-12-310001280784Warrant Investments and Manufacturing Technology and MacroFab, Inc., Warrant, Acquisition Date 3/23/2022, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Manufacturing Technology and MacroFab, Inc., Warrant, Acquisition Date 3/23/2022, Series Common Stock2024-12-310001280784Warrant Investments and Manufacturing Technology (0.06%)2024-12-310001280784Warrant Investments and Media/Content/Info and Fever Labs, Inc., Warrant, Acquisition Date 12/30/2022, Series Preferred Series E-12024-01-012024-12-310001280784Warrant Investments and Media/Content/Info and Fever Labs, Inc., Warrant, Acquisition Date 12/30/2022, Series Preferred Series E-12024-12-310001280784Warrant Investments and Media/Content/Info (0.00%)2024-12-310001280784Warrant Investments and Medical Devices & Equipment and Orchestra BioMed Holdings, Inc., Warrant, Acquisition Date 11/6/2024, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Medical Devices & Equipment and Orchestra BioMed Holdings, Inc., Warrant, Acquisition Date 11/6/2024, Series Common Stock2024-12-310001280784Warrant Investments and Medical Devices & Equipment and Outset Medical Inc, Warrant, Acquisition Date 9/27/2013, Series Common stock2024-01-012024-12-310001280784Warrant Investments and Medical Devices & Equipment and Outset Medical Inc, Warrant, Acquisition Date 9/27/2013, Series Common stock2024-12-310001280784Warrant Investments and Medical Devices & Equipment and Senseonics Holdings, Inc, Warrant, Acquisition Date 9/8/2023, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Medical Devices & Equipment and Senseonics Holdings, Inc, Warrant, Acquisition Date 9/8/2023, Series Common Stock2024-12-310001280784Warrant Investments and Medical Devices & Equipment and Sight Sciences, Inc., Warrant, Acquisition Date 1/22/2024, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Medical Devices & Equipment and Sight Sciences, Inc., Warrant, Acquisition Date 1/22/2024, Series Common Stock2024-12-310001280784Warrant Investments and Medical Devices & Equipment and Tela Bio, Inc., Warrant, Acquisition Date 3/31/2017, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Medical Devices & Equipment and Tela Bio, Inc., Warrant, Acquisition Date 3/31/2017, Series Common Stock2024-12-310001280784Warrant Investments and Medical Devices & Equipment (0.03%)2024-12-310001280784Warrant Investments and Semiconductors and Achronix Semiconductor Corporation, Warrant, Acquisition Date 6/26/2015, Series Preferred Series D-22024-01-012024-12-310001280784Warrant Investments and Semiconductors and Achronix Semiconductor Corporation, Warrant, Acquisition Date 6/26/2015, Series Preferred Series D-22024-12-310001280784Warrant Investments and Semiconductors (0.02%)2024-12-310001280784Warrant Investments and Software and Aria Systems, Inc., Warrant, Acquisition Date 5/22/2015, Series Preferred Series G2024-01-012024-12-310001280784Warrant Investments and Software and Aria Systems, Inc., Warrant, Acquisition Date 5/22/2015, Series Preferred Series G2024-12-310001280784Warrant Investments and Software and Automation Anywhere, Inc., Warrant, Acquisition Date 9/23/2022, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Software and Automation Anywhere, Inc., Warrant, Acquisition Date 9/23/2022, Series Common Stock2024-12-310001280784Warrant Investments and Software and Bitsight Technologies, Inc., Warrant, Acquisition Date 11/18/2020, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Software and Bitsight Technologies, Inc., Warrant, Acquisition Date 11/18/2020, Series Common Stock2024-12-310001280784Warrant Investments and Software and Brain Corporation, Warrant, Acquisition Date 10/4/2021, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Software and Brain Corporation, Warrant, Acquisition Date 10/4/2021, Series Common Stock2024-12-310001280784Warrant Investments and Software and CloudBolt Software, Inc., Warrant, Acquisition Date 9/30/2020, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Software and CloudBolt Software, Inc., Warrant, Acquisition Date 9/30/2020, Series Common Stock2024-12-310001280784Warrant Investments and Software and Cloudian, Inc., Warrant, Acquisition Date 11/6/2018, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Software and Cloudian, Inc., Warrant, Acquisition Date 11/6/2018, Series Common Stock2024-12-310001280784Warrant Investments and Software and Cloudpay, Inc., Warrant, Acquisition Date 4/10/2018, Series Preferred Series B2024-01-012024-12-310001280784Warrant Investments and Software and Cloudpay, Inc., Warrant, Acquisition Date 4/10/2018, Series Preferred Series B2024-12-310001280784Warrant Investments and Software and Coronet Cyber Security Ltd., Warrant, Acquisition Date 9/26/2024, Series Ordinary Shares2024-01-012024-12-310001280784Warrant Investments and Software and Coronet Cyber Security Ltd., Warrant, Acquisition Date 9/26/2024, Series Ordinary Shares2024-12-310001280784Warrant Investments and Software and Couchbase, Inc., Warrant, Acquisition Date 4/25/2019, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Software and Couchbase, Inc., Warrant, Acquisition Date 4/25/2019, Series Common Stock2024-12-310001280784Warrant Investments and Software and Cutover, Inc., Warrant, Acquisition Date 9/21/2022, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Software and Cutover, Inc., Warrant, Acquisition Date 9/21/2022, Series Common Stock2024-12-310001280784Warrant Investments and Software and Dashlane, Inc., Warrant, Acquisition Date 3/11/2019, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Software and Dashlane, Inc., Warrant, Acquisition Date 3/11/2019, Series Common Stock2024-12-310001280784Warrant Investments and Software and Demandbase, Inc., Warrant, Acquisition Date 8/2/2021, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Software and Demandbase, Inc., Warrant, Acquisition Date 8/2/2021, Series Common Stock2024-12-310001280784Warrant Investments and Software and Dragos, Inc., Warrant, Acquisition Date 6/28/2023, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Software and Dragos, Inc., Warrant, Acquisition Date 6/28/2023, Series Common Stock2024-12-310001280784Warrant Investments and Software and DroneDeploy, Inc., Warrant, Acquisition Date 6/30/2022, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Software and DroneDeploy, Inc., Warrant, Acquisition Date 6/30/2022, Series Common Stock2024-12-310001280784Warrant Investments and Software and Earnix, Inc., Warrant, Acquisition Date 6/6/2024, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Software and Earnix, Inc., Warrant, Acquisition Date 6/6/2024, Series Common Stock2024-12-310001280784Warrant Investments and Software and Elation Health, Inc., Warrant, Acquisition Date 9/12/2022, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Software and Elation Health, Inc., Warrant, Acquisition Date 9/12/2022, Series Common Stock2024-12-310001280784Warrant Investments and Software and First Insight, Inc., Warrant, Acquisition Date 5/10/2018, Series Preferred Series B2024-01-012024-12-310001280784Warrant Investments and Software and First Insight, Inc., Warrant, Acquisition Date 5/10/2018, Series Preferred Series B2024-12-310001280784Warrant Investments and Software and Fulfil Solutions, Inc., Warrant, Acquisition Date 7/29/2022, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Software and Fulfil Solutions, Inc., Warrant, Acquisition Date 7/29/2022, Series Common Stock2024-12-310001280784Warrant Investments and Software and Harness, Inc., Warrant, Acquisition Date 3/12/2024, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Software and Harness, Inc., Warrant, Acquisition Date 3/12/2024, Series Common Stock2024-12-310001280784Warrant Investments and Software and Kore, ai, Inc., Warrant, Acquisition Date 3/31/2023, Series Preferred Series C2024-01-012024-12-310001280784Warrant Investments and Software and Kore, ai, Inc., Warrant, Acquisition Date 3/31/2023, Series Preferred Series C2024-12-310001280784Warrant Investments and Software and Leapwork ApS, Warrant, Acquisition Date 1/23/2023, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Software and Leapwork ApS, Warrant, Acquisition Date 1/23/2023, Series Common Stock2024-12-310001280784Warrant Investments and Software and Lightbend, Inc., Warrant, Acquisition Date 2/14/2018, Series Preferred Series LB-22024-01-012024-12-310001280784Warrant Investments and Software and Lightbend, Inc., Warrant, Acquisition Date 2/14/2018, Series Preferred Series LB-22024-12-310001280784Warrant Investments and Software and Mixpanel, Inc., Warrant, Acquisition Date 9/30/2020, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Software and Mixpanel, Inc., Warrant, Acquisition Date 9/30/2020, Series Common Stock2024-12-310001280784Debt Investments Software and Morphisec Information Security 2014 Ltd., Warrant, Acquisition Date 10/1/2024, Series Ordinary Shares2024-01-012024-12-310001280784Debt Investments Software and Morphisec Information Security 2014 Ltd., Warrant, Acquisition Date 10/1/2024, Series Ordinary Shares2024-12-310001280784Warrant Investments and Software and Pindrop Security, Inc., Warrant, Acquisition Date 6/26/2024, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Software and Pindrop Security, Inc., Warrant, Acquisition Date 6/26/2024, Series Common Stock2024-12-310001280784Warrant Investments and Software and Reltio, Inc., Warrant, Acquisition Date 6/30/2020, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Software and Reltio, Inc., Warrant, Acquisition Date 6/30/2020, Series Common Stock2024-12-310001280784Warrant Investments and Software and Semperis Technologies Inc., Warrant, Acquisition Date 4/23/2024, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Software and Semperis Technologies Inc., Warrant, Acquisition Date 4/23/2024, Series Common Stock2024-12-310001280784Warrant Investments and Software and Simon Data, Inc., Warrant, Acquisition Date 3/22/2023, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Software and Simon Data, Inc., Warrant, Acquisition Date 3/22/2023, Series Common Stock2024-12-310001280784Warrant Investments and Software and SingleStore, Inc., Warrant, Acquisition Date 4/28/2020, Series Preferred Series D2024-01-012024-12-310001280784Warrant Investments and Software and SingleStore, Inc., Warrant, Acquisition Date 4/28/2020, Series Preferred Series D2024-12-310001280784Warrant Investments and Software and Sisense Ltd., Warrant, Acquisition Date 6/8/2023, Series Ordinary Shares2024-01-012024-12-310001280784Warrant Investments and Software and Sisense Ltd., Warrant, Acquisition Date 6/8/2023, Series Ordinary Shares2024-12-310001280784Warrant Investments and Software and Suzy Inc, Warrant, Acquisition Date 8/24/2023, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Software and Suzy Inc, Warrant, Acquisition Date 8/24/2023, Series Common Stock2024-12-310001280784Warrant Investments and Software and Tipalti Solutions Ltd., Warrant, Acquisition Date 3/22/2023, Series Ordinary Shares2024-01-012024-12-310001280784Warrant Investments and Software and Tipalti Solutions Ltd., Warrant, Acquisition Date 3/22/2023, Series Ordinary Shares2024-12-310001280784Warrant Investments and Software and VideoAmp, Inc., Warrant, Acquisition Date 1/21/2022, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Software and VideoAmp, Inc., Warrant, Acquisition Date 1/21/2022, Series Common Stock2024-12-310001280784Warrant Investments and Software (0.53%)2024-12-310001280784Warrant Investments and Space Technologies and Capella Space Corp., Warrant, Acquisition Date 10/21/2021, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Space Technologies and Capella Space Corp., Warrant, Acquisition Date 10/21/2021, Series Common Stock2024-12-310001280784Warrant Investments and Space Technologies (0.00%)2024-12-310001280784Warrant Investments and Sustainable and Renewable Technology and Ampion, PBC, Warrant, Acquisition Date 4/15/2022, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Sustainable and Renewable Technology and Ampion, PBC, Warrant, Acquisition Date 4/15/2022, Series Common Stock2024-12-310001280784Warrant Investments and Sustainable and Renewable Technology and Electric Hydrogen Co., Warrant, Acquisition Date 3/27/2024, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Sustainable and Renewable Technology and Electric Hydrogen Co., Warrant, Acquisition Date 3/27/2024, Series Common Stock2024-12-310001280784Warrant Investments and Sustainable and Renewable Technology and Halio, Inc., Warrant, Acquisition Date 4/7/2015, Series Common Stock2024-01-012024-12-310001280784Warrant Investments and Sustainable and Renewable Technology and Halio, Inc., Warrant, Acquisition Date 4/7/2015, Series Common Stock2024-12-310001280784Warrant Investments and Sustainable and Renewable Technology (0.02%)2024-12-310001280784Total Warrant Investments (1.53%)2024-12-310001280784Investments in Securities (183.64%)2024-12-310001280784Investment Funds & Vehicles Investments and Drug Discovery & Development and Forbion Growth Opportunities Fund I C.V., Investment Funds & Vehicles, Acquisition Date 11/16/20202024-01-012024-12-310001280784Investment Funds & Vehicles Investments and Drug Discovery & Development and Forbion Growth Opportunities Fund I C.V., Investment Funds & Vehicles, Acquisition Date 11/16/20202024-12-310001280784Investment Funds & Vehicles Investments and Drug Discovery & Development and Forbion Growth Opportunities Fund II C.V., Investment Funds & Vehicles, Acquisition Date 6/23/20222024-01-012024-12-310001280784Investment Funds & Vehicles Investments and Drug Discovery & Development and Forbion Growth Opportunities Fund II C.V., Investment Funds & Vehicles, Acquisition Date 6/23/20222024-12-310001280784Investment Funds & Vehicles Investments and Drug Discovery & Development (0.29%)2024-12-310001280784nvestment Funds & Vehicles Investments and Software and Liberty Zim Co-Invest L.P., Investment Funds & Vehicles, Acquisition Date 7/21/20222024-01-012024-12-310001280784nvestment Funds & Vehicles Investments and Software and Liberty Zim Co-Invest L.P., Investment Funds & Vehicles, Acquisition Date 7/21/20222024-12-310001280784Investment Funds & Vehicles Investments and Software (0.02%)2024-12-310001280784Investment Funds & Vehicles Investments (0.31%)2024-12-310001280784Investments before Cash & Cash Equivalents (183.96%)2024-12-310001280784Investment Fund Cash & Cash Equivalent and GS Financial Square Government Fund, Series FGTXX/38141W2732024-12-310001280784Investment Fund In Cash & Cash Equivalents (1.06%)2024-12-310001280784Investments After Cash & Cash Equivalents (185.02%)2024-12-310001280784Foreign Currency Exchange Contracts, Great British Pound (GBP) Counterparty Goldman Sachs Bank USA Settlement Date 6/3/20252024-01-012024-06-300001280784Foreign Currency Exchange Contracts, Great British Pound (GBP) Counterparty Goldman Sachs Bank USA Settlement Date 6/3/20252024-12-310001280784Total Foreign Currency Forward (0.03%)2024-12-310001280784htgc:OneMonthSOFRMember2024-12-310001280784htgc:ThreeMonthSOFRMember2024-12-310001280784htgc:SixMonthSOFRMember2024-12-310001280784us-gaap:FairValueInputsLevel1Memberus-gaap:WarrantMember2024-12-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:CommonStockMember2024-12-310001280784htgc:BlackCrowAIIncMemberhtgc:PromissoryNotesMember2024-12-310001280784htgc:RoyaltyContractMemberhtgc:PhathomPharmaceuticalsIncMember2024-12-310001280784us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2025-03-310001280784us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2025-03-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2025-03-310001280784us-gaap:FairValueMeasurementsRecurringMemberhtgc:EscrowAndOtherInvestmentReceivableMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberhtgc:EscrowAndOtherInvestmentReceivableMember2025-03-310001280784us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001280784us-gaap:FairValueMeasurementsRecurringMemberhtgc:SeniorSecuredDebtMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberhtgc:SeniorSecuredDebtMember2025-03-310001280784us-gaap:FairValueMeasurementsRecurringMemberus-gaap:UnsecuredDebtMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:UnsecuredDebtMember2025-03-310001280784us-gaap:FairValueMeasurementsRecurringMemberus-gaap:PreferredStockMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:PreferredStockMember2025-03-310001280784us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommonStockMember2025-03-310001280784us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommonStockMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommonStockMember2025-03-310001280784us-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2025-03-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2025-03-310001280784us-gaap:FairValueMeasurementsRecurringMember2025-03-310001280784us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001280784us-gaap:FairValueMeasurementsRecurringMemberus-gaap:PrivateEquityFundsForeignMember2025-03-310001280784us-gaap:FairValueMeasurementsRecurringMemberhtgc:IncludingCashAndCashEquivalentMember2025-03-310001280784us-gaap:FairValueMeasurementsRecurringMemberhtgc:DerivativeInstrumentMember2025-03-310001280784us-gaap:FairValueMeasurementsRecurringMemberhtgc:IncludingCashAndCashEquivalentsAndDerivativeInstrumentsMember2025-03-310001280784us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-12-310001280784us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-12-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-12-310001280784us-gaap:FairValueMeasurementsRecurringMemberhtgc:EscrowAndOtherInvestmentReceivableMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberhtgc:EscrowAndOtherInvestmentReceivableMember2024-12-310001280784us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001280784us-gaap:FairValueMeasurementsRecurringMemberhtgc:SeniorSecuredDebtMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberhtgc:SeniorSecuredDebtMember2024-12-310001280784us-gaap:FairValueMeasurementsRecurringMemberus-gaap:UnsecuredDebtMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:UnsecuredDebtMember2024-12-310001280784us-gaap:FairValueMeasurementsRecurringMemberus-gaap:PreferredStockMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:PreferredStockMember2024-12-310001280784us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommonStockMember2024-12-310001280784us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommonStockMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommonStockMember2024-12-310001280784us-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2024-12-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2024-12-310001280784us-gaap:FairValueMeasurementsRecurringMember2024-12-310001280784us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001280784us-gaap:FairValueMeasurementsRecurringMemberus-gaap:PrivateEquityFundsForeignMember2024-12-310001280784us-gaap:FairValueMeasurementsRecurringMemberhtgc:IncludingCashAndCashEquivalentMember2024-12-310001280784us-gaap:FairValueMeasurementsRecurringMemberhtgc:DerivativeInstrumentMember2024-12-310001280784us-gaap:FairValueMeasurementsRecurringMemberhtgc:IncludingCashAndCashEquivalentsAndDerivativeInstrumentsMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:SeniorSecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:SeniorSecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2025-01-012025-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:SeniorSecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:UnsecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:UnsecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2025-01-012025-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:UnsecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:PreferredStockMember2025-01-012025-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommonStockMember2025-01-012025-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2025-01-012025-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:EscrowAndOtherInvestmentReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:EscrowAndOtherInvestmentReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2025-01-012025-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:EscrowAndOtherInvestmentReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2025-01-012025-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2025-01-012025-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:SeniorSecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:SeniorSecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2024-01-012024-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:SeniorSecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:UnsecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:UnsecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2024-01-012024-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:UnsecuredDebtMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:PreferredStockMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:PreferredStockMember2024-01-012024-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:PreferredStockMember2024-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommonStockMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommonStockMember2024-01-012024-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommonStockMember2024-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2024-01-012024-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2024-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:EscrowAndOtherInvestmentReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:EscrowAndOtherInvestmentReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2024-01-012024-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:EscrowAndOtherInvestmentReceivableMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-01-012024-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:DebtInvestmentsMember2025-01-012025-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:DebtInvestmentsMember2024-01-012024-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:PreferredStockInvestmentMember2025-01-012025-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:PreferredStockInvestmentMember2024-01-012024-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:CommonStockInvestmentMember2025-01-012025-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:CommonStockInvestmentMember2024-01-012024-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:WarrantInvestmentMember2025-01-012025-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:WarrantInvestmentMember2024-01-012024-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberus-gaap:MarketApproachValuationTechniqueMemberhtgc:DebtInvestmentsMember2025-03-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:ValuationTechniqueLiquidationMemberhtgc:DebtInvestmentsMember2025-03-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2025-03-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2025-03-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberus-gaap:MarketApproachValuationTechniqueMemberhtgc:DebtInvestmentsMember2025-03-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberus-gaap:IncomeApproachValuationTechniqueMemberhtgc:DebtInvestmentsMember2025-03-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberus-gaap:IncomeApproachValuationTechniqueMember2025-03-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberus-gaap:IncomeApproachValuationTechniqueMember2025-03-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberus-gaap:IncomeApproachValuationTechniqueMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:ValuationTechniqueLiquidationMemberhtgc:DebtInvestmentsMember2025-03-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2025-03-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2025-03-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:SustainableAndRenewableTechnologyMemberus-gaap:MarketApproachValuationTechniqueMemberhtgc:DebtInvestmentsMember2025-03-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:SustainableAndRenewableTechnologyMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:SustainableAndRenewableTechnologyMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:SustainableAndRenewableTechnologyMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:SustainableAndRenewableTechnologyMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:SustainableAndRenewableTechnologyMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:SustainableAndRenewableTechnologyMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:MedicalDevicesMemberus-gaap:MarketApproachValuationTechniqueMemberhtgc:DebtInvestmentsMember2025-03-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:MedicalDevicesMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:MedicalDevicesMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:MedicalDevicesMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:MedicalDevicesMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:MedicalDevicesMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:MedicalDevicesMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:LowerMiddleMarketMemberus-gaap:MarketApproachValuationTechniqueMemberhtgc:DebtInvestmentsMember2025-03-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:LowerMiddleMarketMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:LowerMiddleMarketMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:LowerMiddleMarketMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:LowerMiddleMarketMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:LowerMiddleMarketMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:LowerMiddleMarketMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:CostApproachValuationTechniqueMemberhtgc:DebtInvestmentsMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:DebtInvestmentsImminentPayoffsMemberhtgc:DebtInvestmentsMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:DebtMaturingWithinOneYearMemberhtgc:DebtInvestmentsMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:DebtInvestmentsInWhollyOwnedSubsidiariesMemberhtgc:DebtInvestmentsMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:DebtInvestmentsMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueExpectedProceedsMemberhtgc:EscrowAndOtherInvestmentReceivableMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueLiquidationMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2025-03-310001280784srt:MinimumMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2025-03-310001280784srt:MaximumMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2025-03-310001280784srt:WeightedAverageMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:DebtInvestmentsAndOtherInvestmentReceivablesMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberus-gaap:MarketApproachValuationTechniqueMemberhtgc:DebtInvestmentsMember2024-12-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:ValuationTechniqueLiquidationMemberhtgc:DebtInvestmentsMember2024-12-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2024-12-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2024-12-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:PharmaceuticalsMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberus-gaap:MarketApproachValuationTechniqueMemberhtgc:DebtInvestmentsMember2024-12-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberus-gaap:IncomeApproachValuationTechniqueMemberhtgc:DebtInvestmentsMember2024-12-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberus-gaap:IncomeApproachValuationTechniqueMember2024-12-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberus-gaap:IncomeApproachValuationTechniqueMember2024-12-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberus-gaap:IncomeApproachValuationTechniqueMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:ValuationTechniqueLiquidationMemberhtgc:DebtInvestmentsMember2024-12-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2024-12-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2024-12-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:TechnologyMemberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:SustainableAndRenewableTechnologyMemberus-gaap:MarketApproachValuationTechniqueMemberhtgc:DebtInvestmentsMember2024-12-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:SustainableAndRenewableTechnologyMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:SustainableAndRenewableTechnologyMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:SustainableAndRenewableTechnologyMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:SustainableAndRenewableTechnologyMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:SustainableAndRenewableTechnologyMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:SustainableAndRenewableTechnologyMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:MedicalDevicesMemberus-gaap:MarketApproachValuationTechniqueMemberhtgc:DebtInvestmentsMember2024-12-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:MedicalDevicesMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:MedicalDevicesMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:MedicalDevicesMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:MedicalDevicesMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:MedicalDevicesMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:MedicalDevicesMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:LowerMiddleMarketMemberus-gaap:MarketApproachValuationTechniqueMemberhtgc:DebtInvestmentsMember2024-12-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:LowerMiddleMarketMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:LowerMiddleMarketMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:LowerMiddleMarketMemberhtgc:MeasurementInputHypotheticalMarketYieldMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:MinimumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:LowerMiddleMarketMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:MaximumMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:LowerMiddleMarketMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:WeightedAverageMemberhtgc:DebtInvestmentsMemberus-gaap:FairValueInputsLevel3Memberhtgc:LowerMiddleMarketMemberhtgc:MeasurementInputPremiumDiscountNettingMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:CostApproachValuationTechniqueMemberhtgc:DebtInvestmentsMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:DebtInvestmentsImminentPayoffsMemberhtgc:DebtInvestmentsMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:DebtMaturingWithinOneYearMemberhtgc:DebtInvestmentsMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:DebtInvestmentsInWhollyOwnedSubsidiariesMemberhtgc:DebtInvestmentsMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:DebtInvestmentsMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueLiquidationMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2024-12-310001280784srt:MinimumMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2024-12-310001280784srt:MaximumMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2024-12-310001280784srt:WeightedAverageMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputsProbabilityWeightingOfAlternativeOutcomesMemberhtgc:ValuationTechniqueLiquidationMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:DebtInvestmentsAndOtherInvestmentReceivablesMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMemberus-gaap:EquitySecuritiesMember2025-03-310001280784srt:MinimumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:MaximumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:WeightedAverageMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:MinimumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputTangibleBookValueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:MaximumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputTangibleBookValueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:WeightedAverageMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputTangibleBookValueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:MinimumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:MaximumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:WeightedAverageMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:EquitySecuritiesMember2025-03-310001280784srt:MinimumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:ValuationTechniqueOptionPricingModelMember2025-03-310001280784srt:MaximumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:ValuationTechniqueOptionPricingModelMember2025-03-310001280784srt:WeightedAverageMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:ValuationTechniqueOptionPricingModelMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:EquitySecuritiesMember2025-03-310001280784srt:MinimumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2025-03-310001280784srt:MaximumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2025-03-310001280784srt:WeightedAverageMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueOtherMemberus-gaap:EquitySecuritiesMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMemberus-gaap:WarrantMember2025-03-310001280784srt:MinimumMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:MaximumMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:WeightedAverageMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:MinimumMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:MaximumMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784srt:WeightedAverageMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:MarketApproachValuationTechniqueMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:WarrantMember2025-03-310001280784srt:MinimumMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:ValuationTechniqueOptionPricingModelMember2025-03-310001280784srt:MaximumMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:ValuationTechniqueOptionPricingModelMember2025-03-310001280784srt:WeightedAverageMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:ValuationTechniqueOptionPricingModelMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:EquityAndWarrantInvestmentsMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMemberus-gaap:EquitySecuritiesMember2024-12-310001280784srt:MinimumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:MaximumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:WeightedAverageMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:MinimumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputTangibleBookValueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:MaximumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputTangibleBookValueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:WeightedAverageMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputTangibleBookValueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:MinimumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:MaximumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:WeightedAverageMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:EquitySecuritiesMember2024-12-310001280784srt:MinimumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:ValuationTechniqueOptionPricingModelMember2024-12-310001280784srt:MaximumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:ValuationTechniqueOptionPricingModelMember2024-12-310001280784srt:WeightedAverageMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:ValuationTechniqueOptionPricingModelMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueDiscountedCashFlowMemberus-gaap:EquitySecuritiesMember2024-12-310001280784srt:MinimumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2024-12-310001280784srt:MaximumMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2024-12-310001280784srt:WeightedAverageMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:ValuationTechniqueOtherMemberus-gaap:EquitySecuritiesMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:MarketApproachValuationTechniqueMemberus-gaap:WarrantMember2024-12-310001280784srt:MinimumMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:MaximumMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:WeightedAverageMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRevenueMultipleMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:MinimumMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:MaximumMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784srt:WeightedAverageMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputDiscountForLackOfMarketabilityMemberus-gaap:MarketApproachValuationTechniqueMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:WarrantMember2024-12-310001280784srt:MinimumMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:ValuationTechniqueOptionPricingModelMember2024-12-310001280784srt:MaximumMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:ValuationTechniqueOptionPricingModelMember2024-12-310001280784srt:WeightedAverageMemberus-gaap:WarrantMemberus-gaap:FairValueInputsLevel3Memberhtgc:MeasurementInputMarketEquityAdjustmentMemberus-gaap:ValuationTechniqueOptionPricingModelMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberhtgc:EquityAndWarrantInvestmentsMember2024-12-310001280784htgc:TwoThousandThirtyThreeNotesMember2025-03-310001280784htgc:TwoThousandThirtyThreeNotesMember2024-12-310001280784htgc:UnderwritingMemberhtgc:TwoThousandThirtyThreeNotesMember2024-12-310001280784htgc:UnderwritingMemberhtgc:TwoThousandThirtyThreeNotesMember2025-03-310001280784htgc:TwoThousandThirtyOneAssetBackedNotesMember2025-03-310001280784htgc:TwoThousandThirtyOneAssetBackedNotesMember2024-12-310001280784htgc:TwoThousandTwentyEightConvertibleNotesMember2025-03-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:SBADebenturesMember2025-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SBADebenturesMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SBADebenturesMember2025-03-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:JuneTwoThousandTwentyFiveNotesMember2025-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:JuneTwoThousandTwentyFiveNotesMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:JuneTwoThousandTwentyFiveNotesMember2025-03-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2025-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2025-03-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:MarchTwoThousandTwentySixANotesMember2025-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:MarchTwoThousandTwentySixANotesMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:MarchTwoThousandTwentySixANotesMember2025-03-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:MarchTwoThousandTwentySixBNotesMember2025-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:MarchTwoThousandTwentySixBNotesMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:MarchTwoThousandTwentySixBNotesMember2025-03-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:SeptemberTwoThousandTwentySixNotesMember2025-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SeptemberTwoThousandTwentySixNotesMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SeptemberTwoThousandTwentySixNotesMember2025-03-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:JanuaryTwoThousandTwentySevenNotesMember2025-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:JanuaryTwoThousandTwentySevenNotesMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:JanuaryTwoThousandTwentySevenNotesMember2025-03-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:TwoThousandTwentyEightConvertibleNotesMember2025-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:TwoThousandTwentyEightConvertibleNotesMember2025-03-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:TwoThousandTwentyEightConvertibleNotesMember2025-03-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:TwoThousandThirtyOneAssetBackedNotesMember2025-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:TwoThousandThirtyOneAssetBackedNotesMember2025-03-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:TwoThousandThirtyOneAssetBackedNotesMember2025-03-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:TwoThousandThirtyThreeNotesMember2025-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:TwoThousandThirtyThreeNotesMember2025-03-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:TwoThousandThirtyThreeNotesMember2025-03-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:MUFGBankFacilityMember2025-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:MUFGBankFacilityMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:MUFGBankFacilityMember2025-03-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:SMBCFacilityMember2025-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SMBCFacilityMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SMBCFacilityMember2025-03-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMember2025-03-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMember2025-03-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2025-03-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2025-03-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:SBADebenturesMember2024-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SBADebenturesMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SBADebenturesMember2024-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:FebruaryTwoThousandTwentyFiveNotesMember2024-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:FebruaryTwoThousandTwentyFiveNotesMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:FebruaryTwoThousandTwentyFiveNotesMember2024-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:JuneTwoThousandTwentyFiveNotesMember2024-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:JuneTwoThousandTwentyFiveNotesMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:JuneTwoThousandTwentyFiveNotesMember2024-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2024-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2024-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:MarchTwoThousandTwentySixANotesMember2024-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:MarchTwoThousandTwentySixANotesMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:MarchTwoThousandTwentySixANotesMember2024-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:MarchTwoThousandTwentySixBNotesMember2024-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:MarchTwoThousandTwentySixBNotesMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:MarchTwoThousandTwentySixBNotesMember2024-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:SeptemberTwoThousandTwentySixNotesMember2024-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SeptemberTwoThousandTwentySixNotesMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SeptemberTwoThousandTwentySixNotesMember2024-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:JanuaryTwoThousandTwentySevenNotesMember2024-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:JanuaryTwoThousandTwentySevenNotesMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:JanuaryTwoThousandTwentySevenNotesMember2024-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:TwoThousandThirtyOneAssetBackedNotesMember2024-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:TwoThousandThirtyOneAssetBackedNotesMember2024-12-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:TwoThousandThirtyOneAssetBackedNotesMember2024-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:TwoThousandThirtyThreeNotesMember2024-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:TwoThousandThirtyThreeNotesMember2024-12-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:TwoThousandThirtyThreeNotesMember2024-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:MUFGBankFacilityMember2024-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:MUFGBankFacilityMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:MUFGBankFacilityMember2024-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMemberhtgc:SMBCFacilityMember2024-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SMBCFacilityMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMemberhtgc:SMBCFacilityMember2024-12-310001280784us-gaap:CarryingReportedAmountFairValueDisclosureMember2024-12-310001280784us-gaap:EstimateOfFairValueFairValueDisclosureMember2024-12-310001280784us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-12-310001280784us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-12-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMember2025-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMember2025-01-012025-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMember2025-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMember2025-01-012025-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMember2025-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMember2025-01-012025-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMember2025-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMember2025-01-012025-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMember2024-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMember2024-01-012024-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMember2024-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMember2024-01-012024-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMember2024-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMember2024-01-012024-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMember2024-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMember2024-01-012024-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMember2024-03-310001280784htgc:SeniorSecuredDebtMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2025-03-310001280784htgc:SeniorSecuredDebtMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2025-01-012025-03-310001280784htgc:SeniorSecuredDebtMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2024-12-310001280784htgc:SeniorSecuredDebtMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2024-01-012024-12-310001280784us-gaap:UnsecuredDebtMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2025-03-310001280784us-gaap:UnsecuredDebtMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2025-01-012025-03-310001280784us-gaap:UnsecuredDebtMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2024-12-310001280784us-gaap:UnsecuredDebtMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2024-01-012024-12-310001280784us-gaap:PreferredStockMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2025-03-310001280784us-gaap:PreferredStockMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2025-01-012025-03-310001280784us-gaap:PreferredStockMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2024-12-310001280784us-gaap:PreferredStockMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2024-01-012024-12-310001280784us-gaap:CommonStockMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2025-03-310001280784us-gaap:CommonStockMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2025-01-012025-03-310001280784us-gaap:CommonStockMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2024-12-310001280784us-gaap:CommonStockMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2024-01-012024-12-310001280784htgc:WarrantInvestmentMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2025-03-310001280784htgc:WarrantInvestmentMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2025-01-012025-03-310001280784htgc:WarrantInvestmentMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2024-12-310001280784htgc:WarrantInvestmentMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2024-01-012024-12-310001280784htgc:InvestmentFundsAndVehiclesMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2025-03-310001280784htgc:InvestmentFundsAndVehiclesMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2025-01-012025-03-310001280784htgc:InvestmentFundsAndVehiclesMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2024-12-310001280784htgc:InvestmentFundsAndVehiclesMemberhtgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2024-01-012024-12-310001280784htgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2025-03-310001280784htgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2025-01-012025-03-310001280784htgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2024-12-310001280784htgc:InvestmentTypeConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkMember2024-01-012024-12-310001280784country:USus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-03-310001280784country:USus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-01-012025-03-310001280784country:USus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-12-310001280784country:USus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-01-012024-12-310001280784country:NLus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-03-310001280784country:NLus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-01-012025-03-310001280784country:NLus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-12-310001280784country:NLus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-01-012024-12-310001280784country:GBus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-03-310001280784country:GBus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-01-012025-03-310001280784country:GBus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-12-310001280784country:GBus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-01-012024-12-310001280784country:CHus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-03-310001280784country:CHus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-01-012025-03-310001280784country:CHus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-12-310001280784country:CHus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-01-012024-12-310001280784country:DEus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-03-310001280784country:DEus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-01-012025-03-310001280784country:DEus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-12-310001280784country:DEus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-01-012024-12-310001280784country:ILus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-03-310001280784country:ILus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-01-012025-03-310001280784country:ILus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-12-310001280784country:ILus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-01-012024-12-310001280784country:CAus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-03-310001280784country:CAus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-01-012025-03-310001280784country:CAus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-12-310001280784country:CAus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-01-012024-12-310001280784country:DKus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-03-310001280784country:DKus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-01-012025-03-310001280784country:DKus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-12-310001280784country:DKus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-01-012024-12-310001280784country:IEus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-03-310001280784country:IEus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-01-012025-03-310001280784country:IEus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-12-310001280784country:IEus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-01-012024-12-310001280784country:SGus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-03-310001280784country:SGus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-01-012025-03-310001280784country:SGus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-12-310001280784country:SGus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-01-012024-12-310001280784htgc:OtherCountriesMemberus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-03-310001280784htgc:OtherCountriesMemberus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-01-012025-03-310001280784htgc:OtherCountriesMemberus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-12-310001280784htgc:OtherCountriesMemberus-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-01-012024-12-310001280784us-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-03-310001280784us-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2025-01-012025-03-310001280784us-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-12-310001280784us-gaap:GeographicConcentrationRiskMemberhtgc:TotalInvestmentsBenchmarkGeographicalMember2024-01-012024-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:SoftwareMember2025-03-310001280784htgc:SoftwareMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2025-01-012025-03-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:SoftwareMember2024-12-310001280784htgc:SoftwareMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2024-01-012024-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:DrugDiscoveryAndDevelopmentMember2025-03-310001280784htgc:DrugDiscoveryAndDevelopmentMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2025-01-012025-03-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:DrugDiscoveryAndDevelopmentMember2024-12-310001280784htgc:DrugDiscoveryAndDevelopmentMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2024-01-012024-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:HealthcareServicesOtherMember2025-03-310001280784htgc:HealthcareServicesOtherMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2025-01-012025-03-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:HealthcareServicesOtherMember2024-12-310001280784htgc:HealthcareServicesOtherMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2024-01-012024-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:ConsumerAndBusinessServicesMember2025-03-310001280784htgc:ConsumerAndBusinessServicesMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2025-01-012025-03-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:ConsumerAndBusinessServicesMember2024-12-310001280784htgc:ConsumerAndBusinessServicesMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2024-01-012024-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:ElectronicsComputerHardwareMember2025-03-310001280784htgc:ElectronicsComputerHardwareMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2025-01-012025-03-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:ElectronicsComputerHardwareMember2024-12-310001280784htgc:ElectronicsComputerHardwareMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2024-01-012024-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:DiversifiedFinancialServicesMember2025-03-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2025-01-012025-03-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:DiversifiedFinancialServicesMember2024-12-310001280784htgc:DiversifiedFinancialServicesMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2024-01-012024-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:MedicalDevicesAndEquipmentMember2025-03-310001280784htgc:MedicalDevicesAndEquipmentMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2025-01-012025-03-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:MedicalDevicesAndEquipmentMember2024-12-310001280784htgc:MedicalDevicesAndEquipmentMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2024-01-012024-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:SpaceTechnologiesMember2025-03-310001280784htgc:SpaceTechnologiesMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2025-01-012025-03-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:SpaceTechnologiesMember2024-12-310001280784htgc:SpaceTechnologiesMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2024-01-012024-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:BiotechnologyToolsMember2025-03-310001280784htgc:BiotechnologyToolsMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2025-01-012025-03-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:BiotechnologyToolsMember2024-12-310001280784htgc:BiotechnologyToolsMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2024-01-012024-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:CommunicationsAndNetworkingMember2025-03-310001280784htgc:CommunicationsAndNetworkingMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2025-01-012025-03-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:CommunicationsAndNetworkingMember2024-12-310001280784htgc:CommunicationsAndNetworkingMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2024-01-012024-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:InformationServicesMember2025-03-310001280784htgc:InformationServicesMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2025-01-012025-03-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:InformationServicesMember2024-12-310001280784htgc:InformationServicesMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2024-01-012024-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:SustainableAndRenewableTechnologyMember2025-03-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2025-01-012025-03-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:SustainableAndRenewableTechnologyMember2024-12-310001280784htgc:SustainableAndRenewableTechnologyMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2024-01-012024-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:ManufacturingTechnologyMember2025-03-310001280784htgc:ManufacturingTechnologyMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2025-01-012025-03-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:ManufacturingTechnologyMember2024-12-310001280784htgc:ManufacturingTechnologyMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2024-01-012024-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:ConsumerAndBusinessProductsMember2025-03-310001280784htgc:ConsumerAndBusinessProductsMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2025-01-012025-03-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:ConsumerAndBusinessProductsMember2024-12-310001280784htgc:ConsumerAndBusinessProductsMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2024-01-012024-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:SemiconductorsMember2025-03-310001280784htgc:SemiconductorsMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2025-01-012025-03-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:SemiconductorsMember2024-12-310001280784htgc:SemiconductorsMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2024-01-012024-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:MediaContentInfoMember2025-03-310001280784htgc:MediaContentInfoMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2025-01-012025-03-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:MediaContentInfoMember2024-12-310001280784htgc:MediaContentInfoMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2024-01-012024-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:DrugDeliveryMember2025-03-310001280784htgc:DrugDeliveryMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2025-01-012025-03-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:DrugDeliveryMember2024-12-310001280784htgc:DrugDeliveryMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2024-01-012024-12-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:TotalIndustrySectorsMember2025-03-310001280784htgc:TotalIndustrySectorsMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2025-01-012025-03-310001280784htgc:IndustrySectorConcentrationRiskMemberhtgc:TotalIndustrySectorsMember2024-12-310001280784htgc:TotalIndustrySectorsMemberhtgc:IndustrySectorConcentrationRiskMemberhtgc:IndustrySectorInvestmentsBenchmarkMember2024-01-012024-12-310001280784us-gaap:CreditConcentrationRiskMember2025-03-310001280784us-gaap:CreditConcentrationRiskMember2024-12-310001280784htgc:SeniorSecuredFirstLienMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:AllAssetsIncludingIntellectualPropertyMemberhtgc:DebtInvestmentsBenchmarkMember2025-01-012025-03-310001280784htgc:SeniorSecuredFirstLienMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:AllAssetsIncludingIntellectualPropertyMemberhtgc:DebtInvestmentsBenchmarkMember2024-01-012024-12-310001280784htgc:SeniorSecuredFirstLienMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:AllAssetsWithNegativePledgeOnIntellectualPropertyMemberhtgc:DebtInvestmentsBenchmarkMember2025-01-012025-03-310001280784htgc:SeniorSecuredFirstLienMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:AllAssetsWithNegativePledgeOnIntellectualPropertyMemberhtgc:DebtInvestmentsBenchmarkMember2024-01-012024-12-310001280784htgc:SeniorSecuredFirstLienMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:LastOutWithSecurityInterestInAllOfTheAssetsMemberhtgc:DebtInvestmentsBenchmarkMember2025-01-012025-03-310001280784htgc:SeniorSecuredFirstLienMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:LastOutWithSecurityInterestInAllOfTheAssetsMemberhtgc:DebtInvestmentsBenchmarkMember2024-01-012024-12-310001280784htgc:SeniorSecuredFirstLienMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:DebtInvestmentsBenchmarkMember2025-01-012025-03-310001280784htgc:SeniorSecuredFirstLienMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:DebtInvestmentsBenchmarkMember2024-01-012024-12-310001280784htgc:SecondLienMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:DebtInvestmentsBenchmarkMember2025-01-012025-03-310001280784htgc:SecondLienMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:DebtInvestmentsBenchmarkMember2024-01-012024-12-310001280784htgc:UnsecuredMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:DebtInvestmentsBenchmarkMember2025-01-012025-03-310001280784htgc:UnsecuredMemberhtgc:CollateralTypeConcentrationRiskMemberhtgc:DebtInvestmentsBenchmarkMember2024-01-012024-12-310001280784htgc:CollateralTypeConcentrationRiskMemberhtgc:DebtInvestmentsBenchmarkMember2025-01-012025-03-310001280784htgc:CollateralTypeConcentrationRiskMemberhtgc:DebtInvestmentsBenchmarkMember2024-01-012024-12-310001280784us-gaap:ForeignExchangeForwardMember2024-12-310001280784us-gaap:ForeignExchangeForwardMember2025-03-310001280784us-gaap:ForeignExchangeForwardMember2025-01-012025-03-310001280784us-gaap:ForeignExchangeForwardMember2024-01-012024-03-310001280784htgc:ContractualInterestIncomeMember2025-01-012025-03-310001280784htgc:ContractualInterestIncomeMember2024-01-012024-03-310001280784htgc:ExitFeeMember2025-01-012025-03-310001280784htgc:ExitFeeMember2024-01-012024-03-310001280784htgc:PIKInterestMember2025-01-012025-03-310001280784htgc:PIKInterestMember2024-01-012024-03-310001280784htgc:DividendIncomeMember2025-01-012025-03-310001280784htgc:DividendIncomeMember2024-01-012024-03-310001280784htgc:OtherInterestIncomeMember2025-01-012025-03-310001280784htgc:OtherInterestIncomeMember2024-01-012024-03-310001280784htgc:RecurringFeeIncomeMember2025-01-012025-03-310001280784htgc:RecurringFeeIncomeMember2024-01-012024-03-310001280784htgc:AcceleratedFeeIncomeExpiredCommitmentsMember2025-01-012025-03-310001280784htgc:AcceleratedFeeIncomeExpiredCommitmentsMember2024-01-012024-03-310001280784htgc:AcceleratedFeeIncomeEarlyRepaymentsMember2025-01-012025-03-310001280784htgc:AcceleratedFeeIncomeEarlyRepaymentsMember2024-01-012024-03-310001280784htgc:IncludedInCostMember2025-03-310001280784htgc:IncludedInCostMember2024-12-310001280784htgc:DeferredFeesMember2025-03-310001280784htgc:DeferredFeesMember2024-12-310001280784htgc:SBADebenturesMember2025-03-310001280784htgc:SBADebenturesMember2024-12-310001280784htgc:FebruaryTwoThousandTwentyFiveNotesMember2025-03-310001280784htgc:FebruaryTwoThousandTwentyFiveNotesMember2024-12-310001280784htgc:JuneTwoThousandTwentyFiveNotesMember2025-03-310001280784htgc:JuneTwoThousandTwentyFiveNotesMember2024-12-310001280784htgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2025-03-310001280784htgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2024-12-310001280784htgc:MarchTwoThousandTwentySixANotesMember2025-03-310001280784htgc:MarchTwoThousandTwentySixANotesMember2024-12-310001280784htgc:MarchTwoThousandTwentySixBNotesMember2025-03-310001280784htgc:MarchTwoThousandTwentySixBNotesMember2024-12-310001280784htgc:SeptemberTwoThousandTwentySixNotesMember2025-03-310001280784htgc:SeptemberTwoThousandTwentySixNotesMember2024-12-310001280784htgc:JanuaryTwoThousandTwentySevenNotesMember2025-03-310001280784htgc:JanuaryTwoThousandTwentySevenNotesMember2024-12-310001280784htgc:TwoThousandTwentyEightConvertibleNotesMember2025-03-310001280784htgc:TwoThousandTwentyEightConvertibleNotesMember2024-12-310001280784htgc:TwoThousandThirtyOneAssetBackedNotesMember2025-03-310001280784htgc:TwoThousandThirtyOneAssetBackedNotesMember2024-12-310001280784htgc:TwoThousandThirtyThreeNotesMember2025-03-310001280784htgc:TwoThousandThirtyThreeNotesMember2024-12-310001280784htgc:MUFGBankFacilityMember2025-03-310001280784htgc:MUFGBankFacilityMember2024-12-310001280784htgc:SMBCFacilityMember2025-03-310001280784htgc:SMBCFacilityMember2024-12-310001280784htgc:SMBCFacilityMemberhtgc:SmbcLcFacilityMember2025-03-310001280784htgc:SMBCFacilityMemberhtgc:SmbcLcFacilityMember2024-12-310001280784htgc:SBADebenturesMemberhtgc:HerculesCapitalFourLPMember2025-03-310001280784htgc:SBADebenturesMemberhtgc:HerculesCapitalFourLPMember2024-12-310001280784htgc:SBADebenturesMemberhtgc:HerculesSBICVL.P.Member2025-03-310001280784htgc:SBADebenturesMemberhtgc:HerculesSBICVL.P.Member2024-12-310001280784htgc:SMBCFacilityMemberhtgc:TermLoanMember2025-03-310001280784htgc:SMBCFacilityMemberhtgc:TermLoanMember2024-12-310001280784htgc:DebtIssuanceCostsNetAndOtherAssetsMember2025-03-310001280784htgc:DebtIssuanceCostsNetAndOtherAssetsMember2024-12-310001280784htgc:SMBCFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2025-03-310001280784htgc:SMBCFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-12-310001280784htgc:SBADebenturesMember2025-01-012025-03-310001280784htgc:FebruaryTwoThousandTwentyFiveNotesMember2025-01-012025-03-310001280784htgc:JuneTwoThousandTwentyFiveNotesMember2025-01-012025-03-310001280784htgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2025-01-012025-03-310001280784htgc:MarchTwoThousandTwentySixANotesMember2025-01-012025-03-310001280784htgc:MarchTwoThousandTwentySixBNotesMember2025-01-012025-03-310001280784htgc:SeptemberTwoThousandTwentySixNotesMember2025-01-012025-03-310001280784htgc:JanuaryTwoThousandTwentySevenNotesMember2025-01-012025-03-310001280784htgc:TwoThousandTwentyEightConvertibleNotesMember2025-01-012025-03-310001280784htgc:TwoThousandThirtyOneAssetBackedNotesMember2025-01-012025-03-310001280784htgc:TwoThousandThirtyThreeNotesMember2025-01-012025-03-310001280784htgc:MUFGBankFacilityMember2025-01-012025-03-310001280784htgc:SMBCFacilityMember2025-01-012025-03-310001280784htgc:SBADebenturesMember2024-01-012024-03-310001280784htgc:JulyTwoThousandTwentyFourNotesMember2024-01-012024-03-310001280784htgc:FebruaryTwoThousandTwentyFiveNotesMember2024-01-012024-03-310001280784htgc:JuneTwoThousandTwentyFiveNotesMember2024-01-012024-03-310001280784htgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2024-01-012024-03-310001280784htgc:MarchTwoThousandTwentySixANotesMember2024-01-012024-03-310001280784htgc:MarchTwoThousandTwentySixBNotesMember2024-01-012024-03-310001280784htgc:SeptemberTwoThousandTwentySixNotesMember2024-01-012024-03-310001280784htgc:JanuaryTwoThousandTwentySevenNotesMember2024-01-012024-03-310001280784htgc:TwoThousandThirtyOneAssetBackedNotesMember2024-01-012024-03-310001280784htgc:TwoThousandThirtyThreeNotesMember2024-01-012024-03-310001280784htgc:MUFGBankFacilityMember2024-01-012024-03-310001280784htgc:SMBCFacilityMember2024-01-012024-03-310001280784htgc:SBADebenturesIssuedOnMarchTwentySixTwoThousandAndTwentyOneMember2025-01-012025-03-310001280784htgc:SBADebenturesIssuedOnMarchTwentySixTwoThousandAndTwentyOneMember2025-03-310001280784htgc:SBADebenturesIssuedOnMarchTwentySixTwoThousandAndTwentyOneMember2024-12-310001280784htgc:SBADebenturesIssuedOnJuneTwentyFiveTwoThousandAndTwentyOneMember2025-01-012025-03-310001280784htgc:SBADebenturesIssuedOnJuneTwentyFiveTwoThousandAndTwentyOneMember2025-03-310001280784htgc:SBADebenturesIssuedOnJuneTwentyFiveTwoThousandAndTwentyOneMember2024-12-310001280784htgc:SBADebenturesIssuedOnJulyTwentyEightTwoThousandAndTwentyOneMember2025-01-012025-03-310001280784htgc:SBADebenturesIssuedOnJulyTwentyEightTwoThousandAndTwentyOneMember2025-03-310001280784htgc:SBADebenturesIssuedOnJulyTwentyEightTwoThousandAndTwentyOneMember2024-12-310001280784htgc:SBADebenturesIssuedOnAugustTwentyTwoThousandAndTwentyOneMember2025-01-012025-03-310001280784htgc:SBADebenturesIssuedOnAugustTwentyTwoThousandAndTwentyOneMember2025-03-310001280784htgc:SBADebenturesIssuedOnAugustTwentyTwoThousandAndTwentyOneMember2024-12-310001280784htgc:SBADebenturesIssuedOnOctoberTwentyOneTwoThousandAndTwentyOneMember2025-01-012025-03-310001280784htgc:SBADebenturesIssuedOnOctoberTwentyOneTwoThousandAndTwentyOneMember2025-03-310001280784htgc:SBADebenturesIssuedOnOctoberTwentyOneTwoThousandAndTwentyOneMember2024-12-310001280784htgc:SBADebenturesIssuedOnNovemberOneTwoThousandAndTwentyOneMember2025-01-012025-03-310001280784htgc:SBADebenturesIssuedOnNovemberOneTwoThousandAndTwentyOneMember2025-03-310001280784htgc:SBADebenturesIssuedOnNovemberOneTwoThousandAndTwentyOneMember2024-12-310001280784htgc:SBADebenturesIssuedOnNovemberFifteenTwoThousandAndTwentyOneMember2025-01-012025-03-310001280784htgc:SBADebenturesIssuedOnNovemberFifteenTwoThousandAndTwentyOneMember2025-03-310001280784htgc:SBADebenturesIssuedOnNovemberFifteenTwoThousandAndTwentyOneMember2024-12-310001280784htgc:SBADebenturesIssuedOnNovemberThirtyTwoThousandAndTwentyOneMember2025-01-012025-03-310001280784htgc:SBADebenturesIssuedOnNovemberThirtyTwoThousandAndTwentyOneMember2025-03-310001280784htgc:SBADebenturesIssuedOnNovemberThirtyTwoThousandAndTwentyOneMember2024-12-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyTwoThousandAndTwentyOneMember2025-01-012025-03-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyTwoThousandAndTwentyOneMember2025-03-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyTwoThousandAndTwentyOneMember2024-12-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyThreeTwoThousandAndTwentyOneMember2025-01-012025-03-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyThreeTwoThousandAndTwentyOneMember2025-03-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyThreeTwoThousandAndTwentyOneMember2024-12-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyEightTwoThousandAndTwentyOneMember2025-01-012025-03-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyEightTwoThousandAndTwentyOneMember2025-03-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyEightTwoThousandAndTwentyOneMember2024-12-310001280784htgc:SBADebenturesIssuedOnJanuaryFourteenTwoThousandAndTwentyTwoMember2025-01-012025-03-310001280784htgc:SBADebenturesIssuedOnJanuaryFourteenTwoThousandAndTwentyTwoMember2025-03-310001280784htgc:SBADebenturesIssuedOnJanuaryFourteenTwoThousandAndTwentyTwoMember2024-12-310001280784htgc:SBADebenturesIssuedOnJanuaryTwentyOneTwoThousandAndTwentyTwoMember2025-01-012025-03-310001280784htgc:SBADebenturesIssuedOnJanuaryTwentyOneTwoThousandAndTwentyTwoMember2025-03-310001280784htgc:SBADebenturesIssuedOnJanuaryTwentyOneTwoThousandAndTwentyTwoMember2024-12-310001280784htgc:SBADebenturesIssuedOnNovemberEightTwoThousandAndTwentyFourMember2025-01-012025-03-310001280784htgc:SBADebenturesIssuedOnNovemberEightTwoThousandAndTwentyFourMember2025-03-310001280784htgc:SBADebenturesIssuedOnNovemberEightTwoThousandAndTwentyFourMember2024-12-310001280784htgc:SBADebenturesIssuedOnDecemberSixTwoThousandAndTwentyFourMember2025-01-012025-03-310001280784htgc:SBADebenturesIssuedOnDecemberSixTwoThousandAndTwentyFourMember2025-03-310001280784htgc:SBADebenturesIssuedOnDecemberSixTwoThousandAndTwentyFourMember2024-12-310001280784htgc:SBADebenturesIssuedOnDecemberTwelveTwoThousandAndTwentyFourMember2025-01-012025-03-310001280784htgc:SBADebenturesIssuedOnDecemberTwelveTwoThousandAndTwentyFourMember2025-03-310001280784htgc:SBADebenturesIssuedOnDecemberTwelveTwoThousandAndTwentyFourMember2024-12-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyTwoThousandAndTwentyFourMember2025-01-012025-03-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyTwoThousandAndTwentyFourMember2025-03-310001280784htgc:SBADebenturesIssuedOnDecemberTwentyTwoThousandAndTwentyFourMember2024-12-310001280784htgc:SBADebenturesIssuedOnFebruaryFiveTwoThousandAndTwentyFiveMember2025-01-012025-03-310001280784htgc:SBADebenturesIssuedOnFebruaryFiveTwoThousandAndTwentyFiveMember2025-03-310001280784htgc:SBADebenturesIssuedOnFebruaryFiveTwoThousandAndTwentyFiveMember2024-12-310001280784htgc:SBADebenturesIssuedOnMarchTwentyEightTwoThousandAndTwentyFiveMember2025-01-012025-03-310001280784htgc:SBADebenturesIssuedOnMarchTwentyEightTwoThousandAndTwentyFiveMember2025-03-310001280784htgc:SBADebenturesIssuedOnMarchTwentyEightTwoThousandAndTwentyFiveMember2024-12-310001280784htgc:SBADebenturesMemberhtgc:HerculesCapitalFourLPMember2025-01-012025-03-310001280784htgc:SBADebenturesMemberhtgc:HerculesSBICVL.P.Member2025-01-012025-03-310001280784htgc:SBADebenturesMemberhtgc:HerculesCapitalFourLPMember2020-10-272020-10-270001280784htgc:SBADebenturesMemberhtgc:HerculesSBICVL.P.Member2024-07-092024-07-090001280784htgc:SBADebenturesMemberhtgc:HerculesSBICVL.P.Member2024-07-090001280784htgc:SBADebenturesMemberhtgc:HerculesCapitalFourLPMember2020-10-270001280784htgc:HerculesCapitalFourLPMember2025-03-310001280784htgc:HerculesSBICVL.P.Member2025-03-310001280784htgc:HerculesCapitalFourLPMember2024-12-310001280784htgc:HerculesSBICVL.P.Member2024-12-310001280784htgc:JulyTwoThousandTwentyFourNotesMember2025-01-012025-03-310001280784htgc:JulyTwoThousandTwentyFourNotesMember2019-07-160001280784htgc:JulyTwoThousandTwentyFourNotesMember2019-07-162019-07-160001280784htgc:JulyTwoThousandTwentyFourNotesMember2024-07-162024-07-160001280784htgc:FebruaryTwoThousandTwentyFiveNotesMember2020-02-050001280784htgc:FebruaryTwoThousandTwentyFiveNotesMember2025-02-052025-02-050001280784htgc:JuneTwoThousandTwentyFiveNotesMember2020-06-030001280784htgc:JuneTwoThousandTwentyFiveThreeYearNotesMember2022-06-230001280784htgc:MarchTwoThousandTwentySixANotesMember2020-11-040001280784htgc:MarchTwoThousandTwentySixBNotesMember2021-03-040001280784htgc:SeptemberTwoThousandTwentySixNotesMember2021-09-160001280784htgc:JanuaryTwoThousandTwentySevenNotesMember2022-01-200001280784htgc:TwoThousandTwentyEightConvertibleNotesMember2025-03-100001280784htgc:TwoThousandThirtyOneAssetBackedNotesMember2022-06-220001280784htgc:TwoThousandThirtyOneAssetBackedNotesMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2025-03-310001280784htgc:TwoThousandThirtyOneAssetBackedNotesMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-12-310001280784htgc:TwoThousandThirtyOneAssetBackedNotesMember2024-01-012024-12-310001280784htgc:TwoThousandThirtyThreeNotesMember2018-09-240001280784us-gaap:RevolvingCreditFacilityMember2025-01-012025-03-310001280784us-gaap:RevolvingCreditFacilityMember2024-01-012024-12-310001280784htgc:MUFGBankFacilityMemberhtgc:MUFGBankFacilityMember2025-03-310001280784htgc:MUFGBankFacilityMemberhtgc:MUFGBankFacilityMembersrt:MaximumMember2025-03-310001280784htgc:MUFGBankFacilityMemberhtgc:MUFGBankFacilityMember2025-01-012025-03-310001280784htgc:SmbcLcFacilityMember2025-03-310001280784htgc:SMBCFacilityMemberhtgc:SmbcLcFacilityMembersrt:MaximumMember2025-03-310001280784htgc:SMBCFacilityMemberhtgc:SmbcLcFacilityMember2025-01-012025-03-310001280784htgc:SMBCFacilityMemberhtgc:SmbcLcFacilityMembersrt:MinimumMember2025-01-012025-03-310001280784htgc:SMBCFacilityMemberhtgc:SmbcLcFacilityMembersrt:MaximumMember2025-01-012025-03-310001280784htgc:SMBCFacilityMemberhtgc:SmbcLcFacilityMemberhtgc:TermLoanMember2024-11-260001280784htgc:SMBCFacilityMemberhtgc:SmbcLcFacilityMemberhtgc:TermLoanMember2024-11-262024-11-260001280784htgc:SMBCFacilityMemberhtgc:SmbcLcFacilityMember2025-02-052025-02-050001280784htgc:SMBCFacilityMemberhtgc:SmbcLcFacilityMember2025-02-050001280784htgc:TwoThousandTwentyEightConvertibleNotesMember2025-03-102025-03-100001280784us-gaap:CommonStockMemberhtgc:TwoThousandTwentyFourEquityDistributionAgreementMember2024-12-120001280784htgc:CommonGrossProceedsMember2025-01-012025-03-310001280784htgc:CommonOfferingExpensesMember2025-01-012025-03-310001280784htgc:CommonGrossProceedsMember2024-01-012024-03-310001280784htgc:CommonOfferingExpensesMember2024-01-012024-03-310001280784htgc:O2024Q1DividendsMember2024-01-012024-03-310001280784htgc:S2024Q1DividendsMember2024-01-012024-03-310001280784htgc:O2024Q2DividendsMember2024-04-012024-06-300001280784htgc:S2024Q2DividendsMember2024-04-012024-06-300001280784htgc:O2024Q3DividendsMember2024-07-012024-09-300001280784htgc:S2024Q3DividendsMember2024-07-012024-09-300001280784htgc:O2024Q4DividendsMember2024-10-012024-12-310001280784htgc:S2024Q4DividendsMember2024-10-012024-12-310001280784htgc:O2025Q1DividendsMember2025-01-012025-03-310001280784htgc:S2025Q1DividendsMember2025-01-012025-03-310001280784htgc:SpilloveramountpershareMember2025-03-310001280784us-gaap:CommonStockMemberhtgc:TwoThousandEighteenPlanMember2018-06-280001280784us-gaap:CommonStockMemberhtgc:DirectorPlanMember2018-06-280001280784us-gaap:CommonStockMemberhtgc:TwoThousandEighteenPlanMember2025-03-310001280784us-gaap:CommonStockMemberhtgc:DirectorPlanMember2025-03-310001280784htgc:ServiceVestingAwardsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2025-01-012025-03-310001280784htgc:ServiceVestingAwardsMemberhtgc:ShareBasedPaymentArrangementTrancheTwoAndThreeMember2025-01-012025-03-310001280784htgc:ServiceVestingAwardsMembersrt:MaximumMember2025-01-012025-03-310001280784htgc:ServiceVestingAwardsMember2025-01-012025-03-310001280784htgc:ServiceVestingAwardsMember2024-01-012024-03-310001280784us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001280784us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001280784htgc:LiabilityClassifiedAwardsMember2025-01-012025-03-310001280784htgc:OtherLiabilityClassifiedAwardsMember2025-01-012025-03-310001280784htgc:LiabilityClassifiedAwardsMember2024-03-310001280784htgc:LiabilityClassifiedAwardsMember2024-01-012024-03-310001280784htgc:ServiceVestingAwardsMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2025-01-012025-03-310001280784htgc:ServiceVestingAwardsMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2025-01-012025-03-310001280784htgc:TwoThousandTwentyEightConvertibleNotesMember2024-01-012024-03-310001280784us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001280784us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001280784htgc:UnvestedRestrictedStockAwardsMember2025-01-012025-03-310001280784htgc:UnvestedRestrictedStockAwardsMember2024-01-012024-03-310001280784htgc:NetInvestmentIncomeMember2025-01-012025-03-310001280784htgc:NetInvestmentIncomeMember2024-01-012024-03-310001280784htgc:RealizedGainLossMember2025-01-012025-03-310001280784htgc:RealizedGainLossMember2024-01-012024-03-310001280784htgc:UnrealizedGainLossMember2025-01-012025-03-310001280784htgc:UnrealizedGainLossMember2024-01-012024-03-310001280784htgc:EarnixInc.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:EarnixInc.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:ArcusBiosciencesInc.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:ArcusBiosciencesInc.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:ThumbtackInc.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:ThumbtackInc.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:HarnessInc.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:HarnessInc.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:ArmisInc.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:ArmisInc.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:DiscMedicineInc.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:DiscMedicineInc.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:PindropSecurityInc.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:PindropSecurityInc.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:CoronetCyberSecurityLtd.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:CoronetCyberSecurityLtd.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:MarathonHealthLLCMemberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:MarathonHealthLLCMemberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:LocusRoboticsCorp.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:LocusRoboticsCorp.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:AkeroTherapeuticsInc.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:AkeroTherapeuticsInc.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:DragosInc.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:DragosInc.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:AryakaNetworksInc.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:AryakaNetworksInc.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:GoEuroTravelGmbHMemberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:GoEuroTravelGmbHMemberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:WellBeSeniorMedicalLLCMemberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:WellBeSeniorMedicalLLCMemberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:SemperisTechnologiesInc.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:SemperisTechnologiesInc.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:AlectorInc.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:AlectorInc.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:DocPlannerMemberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:DocPlannerMemberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:CoreViewUSAInc.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:CoreViewUSAInc.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:ISpot.tvInc.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:ISpot.tvInc.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:SuzyInc.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:SuzyInc.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:PayItLLCMemberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:PayItLLCMemberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:HeronTherapeuticsInc.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:HeronTherapeuticsInc.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:CuranaHealthHoldingsLLCMemberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:CuranaHealthHoldingsLLCMemberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:SmartSheetInc.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:SmartSheetInc.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:EnnobleCareLLCMemberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:EnnobleCareLLCMemberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:BabelStreetMemberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:BabelStreetMemberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:AlphaSenseInc.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:AlphaSenseInc.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:ReveleerMemberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:ReveleerMemberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:AllvueSystemsLLCMemberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:AllvueSystemsLLCMemberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:BehavoxLimitedMemberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:BehavoxLimitedMemberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:LogRhythmInc.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:LogRhythmInc.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:ZappiInc.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:ZappiInc.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:DashlaneInc.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:DashlaneInc.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:LoftwareInc.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:LoftwareInc.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:StreamlineHealthcareSolutionsMemberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:StreamlineHealthcareSolutionsMemberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:NewRelicInc.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:NewRelicInc.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:SumoLogicInc.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:SumoLogicInc.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:LogicSourceMemberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:LogicSourceMemberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:TaxCalcMemberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:TaxCalcMemberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:LinenMasterLLCMemberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:LinenMasterLLCMemberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:AlchemerLLCMemberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:AlchemerLLCMemberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:MainStreetRuralInc.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:MainStreetRuralInc.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:FortifiedHealthSecurityMemberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:FortifiedHealthSecurityMemberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:DispatchTechnologiesInc.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:DispatchTechnologiesInc.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:OmedaHoldingsLLCMemberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:OmedaHoldingsLLCMemberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:DronedeployInc.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:DronedeployInc.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:ShadowDragonLLCMemberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:ShadowDragonLLCMemberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:ZimperiumInc.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:ZimperiumInc.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:StriveHealthHoldingsLLCMemberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:StriveHealthHoldingsLLCMemberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:ViridianTherapeuticsInc.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:ViridianTherapeuticsInc.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:ATAILifeSciencesN.V.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:ATAILifeSciencesN.V.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:SaamaTechnologiesLLCMemberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:SaamaTechnologiesLLCMemberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:CerosInc.Memberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:CerosInc.Memberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:A3GTMSLLCMemberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:A3GTMSLLCMemberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:FlightScheduleProLLCMemberhtgc:DebtInvestmentsMember2025-03-310001280784htgc:FlightScheduleProLLCMemberhtgc:DebtInvestmentsMember2024-12-310001280784htgc:DebtInvestmentsMember2025-03-310001280784htgc:DebtInvestmentsMember2024-12-310001280784htgc:ForbionGrowthOpportunitiesFundIC.V.Memberhtgc:InvestmentFundsAndVehiclesMember2025-03-310001280784htgc:ForbionGrowthOpportunitiesFundIC.V.Memberhtgc:InvestmentFundsAndVehiclesMember2024-12-310001280784htgc:ForbionGrowthOpportunitiesFundIIC.V.Memberhtgc:InvestmentFundsAndVehiclesMember2025-03-310001280784htgc:ForbionGrowthOpportunitiesFundIIC.V.Memberhtgc:InvestmentFundsAndVehiclesMember2024-12-310001280784htgc:InvestmentFundsAndVehiclesMember2025-03-310001280784htgc:InvestmentFundsAndVehiclesMember2024-12-310001280784htgc:AdviserFundsMember2025-03-310001280784htgc:AdviserFundsMember2024-12-310001280784htgc:LeaseAndLicenseObligationsMember2025-03-310001280784htgc:LeaseAndLicenseObligationsMember2024-12-310001280784htgc:AdviserSubsidiaryMemberhtgc:AdviserSubsidiaryMember2025-01-012025-03-310001280784htgc:AdviserSubsidiaryMemberhtgc:AdviserSubsidiaryMember2024-01-012024-03-310001280784htgc:AdviserSubsidiaryMember2025-01-012025-03-310001280784htgc:AdviserSubsidiaryMember2024-01-012024-03-310001280784htgc:AdviserSubsidiaryMember2025-03-310001280784htgc:AdviserSubsidiaryMember2024-12-310001280784htgc:AdviserFundsMember2025-01-012025-03-310001280784htgc:AdviserFundsMember2024-01-012024-03-310001280784us-gaap:SubsequentEventMemberhtgc:O2025Q1DividendsMember2025-04-230001280784us-gaap:SubsequentEventMemberhtgc:S2025ADividendsMember2025-01-012025-12-310001280784us-gaap:SubsequentEventMemberhtgc:S2025Q2DividendsMember2025-04-012025-06-300001280784us-gaap:SubsequentEventMemberhtgc:S2025Q3DividendsMember2025-07-012025-09-300001280784us-gaap:SubsequentEventMemberhtgc:S2025Q4DividendsMember2025-10-012025-12-310001280784us-gaap:SubsequentEventMemberhtgc:S2025Q2DividendsMember2025-04-230001280784htgc:S2025Q1DividendsMember2025-02-062025-02-060001280784us-gaap:SubsequentEventMember2025-04-2300012807842025-02-062025-02-060001280784us-gaap:SubsequentEventMember2025-04-292025-04-290001280784htgc:SignificantPortfolioInvestmentMember2025-01-012025-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:PreferredStockMember2025-01-012025-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:PreferredStockMember2024-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:PreferredStockMember2025-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:CommonStockMember2025-01-012025-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:CommonStockMember2024-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:CommonStockMember2025-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:UnsecuredDebtMember2025-01-012025-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:UnsecuredDebtMember2024-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:UnsecuredDebtMember2025-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:MemberUnitsMember2025-01-012025-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:MemberUnitsMember2024-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:MemberUnitsMember2025-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberus-gaap:UnsecuredDebtMember2025-01-012025-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberus-gaap:UnsecuredDebtMember2024-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberus-gaap:UnsecuredDebtMember2025-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberus-gaap:MemberUnitsMember2025-01-012025-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberus-gaap:MemberUnitsMember2024-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberus-gaap:MemberUnitsMember2025-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-01-012025-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2024-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-03-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberhtgc:SeniorSecuredDebtMember2025-01-012025-03-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberhtgc:SeniorSecuredDebtMember2024-12-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberhtgc:SeniorSecuredDebtMember2025-03-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberus-gaap:PreferredStockMember2025-01-012025-03-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberus-gaap:PreferredStockMember2024-12-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberus-gaap:PreferredStockMember2025-03-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberus-gaap:CommonStockMember2025-01-012025-03-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberus-gaap:CommonStockMember2024-12-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberus-gaap:CommonStockMember2025-03-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-01-012025-03-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2024-12-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2025-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:PreferredStockMember2024-01-012024-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:PreferredStockMember2023-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:PreferredStockMember2024-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:CommonStockMember2024-01-012024-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:CommonStockMember2023-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:CommonStockMember2024-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:UnsecuredDebtMember2024-01-012024-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:UnsecuredDebtMember2023-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:UnsecuredDebtMember2024-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:MemberUnitsMember2024-01-012024-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:MemberUnitsMember2023-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberus-gaap:MemberUnitsMember2024-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberus-gaap:UnsecuredDebtMember2024-01-012024-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberus-gaap:UnsecuredDebtMember2023-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberus-gaap:UnsecuredDebtMember2024-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberus-gaap:MemberUnitsMember2024-01-012024-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberus-gaap:MemberUnitsMember2023-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberus-gaap:MemberUnitsMember2024-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2024-01-012024-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2023-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2024-03-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberhtgc:SeniorSecuredDebtMember2024-01-012024-03-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberhtgc:SeniorSecuredDebtMember2023-12-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberhtgc:SeniorSecuredDebtMember2024-03-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberus-gaap:PreferredStockMember2024-01-012024-03-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberus-gaap:PreferredStockMember2023-12-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberus-gaap:PreferredStockMember2024-03-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberus-gaap:CommonStockMember2024-01-012024-03-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberus-gaap:CommonStockMember2023-12-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberus-gaap:CommonStockMember2024-03-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2024-01-012024-03-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2023-12-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMember2024-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMember2023-12-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:SeriesAPreferredStockMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:MedicalDevicesAndEquipmentMemberus-gaap:PreferredStockMember2025-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:MedicalDevicesAndEquipmentMemberus-gaap:CommonStockMember2025-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberhtgc:MedicalDevicesAndEquipmentMember2025-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:DiversifiedFinancialServicesMemberhtgc:UnsecuredDebtOneMember2025-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:DiversifiedFinancialServicesMemberhtgc:UnsecuredDebtTwoMember2025-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:DiversifiedFinancialServicesMemberus-gaap:MemberUnitsMember2025-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberhtgc:DiversifiedFinancialServicesMember2025-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:DiversifiedFinancialServicesMemberus-gaap:MemberUnitsMember2025-03-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberhtgc:DiversifiedFinancialServicesMember2025-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberhtgc:OtherControlInvestmentsMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMember2025-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberhtgc:OtherControlInvestmentsMemberhtgc:ConsumerAndBusinessServicesMemberus-gaap:CommonStockMember2025-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberhtgc:PreferredSeriesBBMemberhtgc:OtherControlInvestmentsMemberhtgc:ConsumerAndBusinessServicesMemberus-gaap:PreferredStockMember2025-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberus-gaap:SeriesCPreferredStockMemberhtgc:OtherControlInvestmentsMemberhtgc:ConsumerAndBusinessServicesMemberus-gaap:PreferredStockMember2025-03-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberhtgc:ConsumerAndBusinessServicesMember2025-03-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberus-gaap:SeriesAPreferredStockMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:MedicalDevicesAndEquipmentMemberus-gaap:PreferredStockMember2024-12-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:MedicalDevicesAndEquipmentMemberus-gaap:CommonStockMember2024-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:CoronadoAestheticsLLCMemberhtgc:MedicalDevicesAndEquipmentMember2024-12-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:DiversifiedFinancialServicesMemberhtgc:UnsecuredDebtOneMember2024-12-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:DiversifiedFinancialServicesMemberhtgc:UnsecuredDebtTwoMember2024-12-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:DiversifiedFinancialServicesMemberus-gaap:MemberUnitsMember2024-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:GibraltarAcquisitionLLCMemberhtgc:DiversifiedFinancialServicesMember2024-12-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:DiversifiedFinancialServicesMemberus-gaap:UnsecuredDebtMember2024-12-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberhtgc:MajorityOwnedControlInvestmentsMemberhtgc:DiversifiedFinancialServicesMemberus-gaap:MemberUnitsMember2024-12-310001280784htgc:MajorityOwnedControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:HerculesAdviserLLCMemberhtgc:DiversifiedFinancialServicesMember2024-12-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberhtgc:OtherControlInvestmentsMemberhtgc:ConsumerAndBusinessServicesMemberhtgc:SeniorSecuredDebtMember2024-12-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberhtgc:OtherControlInvestmentsMemberhtgc:ConsumerAndBusinessServicesMemberus-gaap:CommonStockMember2024-12-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberhtgc:PreferredSeriesBBMemberhtgc:OtherControlInvestmentsMemberhtgc:ConsumerAndBusinessServicesMemberus-gaap:PreferredStockMember2024-12-310001280784us-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberus-gaap:SeriesCPreferredStockMemberhtgc:OtherControlInvestmentsMemberhtgc:ConsumerAndBusinessServicesMemberus-gaap:PreferredStockMember2024-12-310001280784htgc:OtherControlInvestmentsMemberus-gaap:InvestmentAffiliatedIssuerControlledMemberhtgc:TecturaCorporationMemberhtgc:ConsumerAndBusinessServicesMember2024-12-31


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
_________________________________________________
FORM 10-Q
_________________________________________________
(Mark One)
x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For The Quarterly Period Ended March 31, 2025
OR
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 814-00702
_________________________________________________
HERCULES CAPITAL, INC.
(Exact Name of Registrant as Specified in its Charter)
_________________________________________________
Maryland74-3113410
(State or Jurisdiction of
Incorporation or Organization)
(IRS Employer
Identification Number)
1 North B Street., Suite 2000
San Mateo, California
(Address of Principal Executive Offices)
94401
(Zip Code)
(650) 289-3060
(Registrant’s Telephone Number, Including Area Code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per share
HTGCNew York Stock Exchange
6.25% Notes due 2033HCXYNew York Stock Exchange
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this Chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
xAccelerated filero
Non-accelerated fileroSmaller reporting companyo
Emerging growth companyo
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with a new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
On April 24, 2025, there were 175,426,129 shares outstanding of the Registrant’s common stock, $0.001 par value.



HERCULES CAPITAL, INC.
FORM 10-Q TABLE OF CONTENTS


Table of Contents
PART I: FINANCIAL INFORMATION
In this Quarterly Report, the “Company,” “Hercules,” “we,” “us” and “our” refer to Hercules Capital, Inc., its wholly owned subsidiaries, and its affiliated securitization trust unless the context otherwise requires.
ITEM 1.    CONSOLIDATED FINANCIAL STATEMENTS

HERCULES CAPITAL, INC.
CONSOLIDATED STATEMENTS OF ASSETS AND LIABILITIES
(in thousands, except per share data)
March 31, 2025
(unaudited)
December 31, 2024
Assets
Investments, at fair value:
Non-control/Non-affiliate investments (cost of $3,889,588 and $3,603,961, respectively)
$3,808,716 $3,546,799 
Control investments (cost of $105,494 and $104,916, respectively)
115,734 113,179 
Total investments, at fair value (cost of $3,995,082 and $3,708,877, respectively; fair value amounts related to a VIE $220,231 and $229,486, respectively)
3,924,450 3,659,978 
Cash and cash equivalents49,379 42,679 
Foreign cash (cost of $1,762 and $70,445, respectively)
1,780 70,445 
Restricted cash (amounts related to a VIE $3,162 and $3,297, respectively)
3,162 3,297 
Interest receivable33,096 32,578 
Right of use asset16,309 16,778 
Other assets3,035 5,836 
Total assets$4,031,211 $3,831,591 
Liabilities
Debt (net of unamortized debt issuance costs of $22,728 and $14,310, respectively; amounts related to a VIE $116,272 and $118,769, respectively)
$1,976,623 $1,768,955 
Accounts payable and accrued liabilities36,747 54,861 
Operating lease liability17,211 18,194 
Total liabilities$2,030,581 $1,842,010 
Net assets consist of:
Common stock, par value$174 $171 
Capital in excess of par value1,942,583 1,900,490 
Total distributable earnings57,873 88,920 
Total net assets$2,000,630 $1,989,581 
Total liabilities and net assets$4,031,211 $3,831,591 
Shares of common stock outstanding ($0.001 par value and 300,000 authorized)
173,285170,575
Net asset value per share$11.55 $11.66 
See notes to consolidated financial statements
3

Table of Contents
HERCULES CAPITAL, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share data)Three Months Ended March 31,
20252024
Investment income:
Interest and dividend income:
Excluding payment-in-kind (PIK) interest income
Non-control/Non-affiliate investments$98,996 $102,925 
Control investments3,103 2,957 
Total interest and dividend income, excluding PIK interest income102,099 105,882 
PIK interest income
Non-control/Non-affiliate investments12,939 9,897 
Control investments534  
Total PIK interest income13,473 9,897 
Total interest and dividend income115,572 115,779 
Fee income:
Non-control/Non-affiliate investments3,900 5,738 
Control investments39 36 
Total fee income3,939 5,774 
Total investment income119,511 121,553 
Operating expenses:
Interest19,698 17,624 
Loan fees2,398 2,397 
General and administrative4,812 5,058 
Tax expenses912 711 
Employee compensation:
Compensation and benefits13,914 16,344 
Stock-based compensation3,602 3,134 
Total employee compensation17,516 19,478 
Total gross operating expenses45,336 45,268 
Expenses allocated to the Adviser Subsidiary(3,283)(2,877)
Total net operating expenses42,053 42,391 
Net investment income77,458 79,162 
Net realized gain (loss) and net change in unrealized appreciation (depreciation):
Net realized gain (loss):
Non-control/Non-affiliate investments(1,541)8,168 
Loss on extinguishment of debt(15) 
Total net realized gain (loss)(1,556)8,168 
Net change in unrealized appreciation (depreciation):
Non-control/Non-affiliate investments(27,542)6,463 
Control investments1,977 (2,829)
Total net change in unrealized appreciation (depreciation)(25,565)3,634 
Total net realized gain (loss) and net change in unrealized appreciation (depreciation)(27,121)11,802 
Net increase (decrease) in net assets resulting from operations$50,337 $90,964 
Net investment income before gains and losses per common share:
Basic$0.45 $0.50 
Change in net assets resulting from operations per common share:
Basic$0.29 $0.57 
Diluted$0.29 $0.57 
Weighted average shares outstanding:    
Basic171,494157,445
Diluted175,383157,920
Distributions paid per common share:
Basic$0.47 $0.48 
See notes to consolidated financial statements
4

Table of Contents
HERCULES CAPITAL, INC.
CONSOLIDATED STATEMENTS OF CHANGES IN NET ASSETS
(unaudited)
(in thousands)Common StockCapital in
excess
of par value
Distributable
Earnings
(loss)
Net
Assets
For the Three Months Ended March 31, 2025Shares Par Value
Balance as of December 31, 2024170,575$171 $1,900,490 $88,920 $1,989,581 
Net increase (decrease) in net assets resulting from operations— — 50,337 50,337 
Public offering, net of offering expenses2,0002 39,415 — 39,417 
Issuance of common stock under equity-based award plans7891 86 — 87 
Shares retired on vesting of equity-based awards(201)— (3,556)— (3,556)
Distributions reinvested in common stock122— 2,511 — 2,511 
Distributions— — (81,384)(81,384)
Stock-based compensation(1)
— 3,637 — 3,637 
Balance as of March 31, 2025173,285$174 $1,942,583 $57,873 $2,000,630 
(1)Stock-based compensation includes $35 thousand of restricted stock and option expense related to director compensation for the three months ended March 31, 2025.
(in thousands)Common StockCapital in
excess
of par value
Distributable
Earnings
(loss)
Net
Assets
For the Three Months Ended March 31, 2024Shares Par Value
Balance as of December 31, 2023157,758$158 $1,662,535 $140,013 $1,802,706 
Net increase (decrease) in net assets resulting from operations— — 90,964 90,964 
Public offering, net of offering expenses3,7254 66,404 — 66,408 
Issuance of common stock under equity-based award plans8581 477 — 478 
Shares retired on vesting of equity-based awards(210)— (3,179)— (3,179)
Distributions reinvested in common stock99— 1,780 — 1,780 
Distributions— — (76,031)(76,031)
Stock-based compensation(1)
— 2,812 — 2,812 
Balance as of March 31, 2024162,230$163 $1,730,829 $154,946 $1,885,938 
(1)Stock-based compensation includes $35 thousand of restricted stock and option expense related to director compensation for the three months ended March 31, 2024.

See notes to consolidated financial statements
5

Table of Contents
HERCULES CAPITAL, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in thousands)For the Three Months Ended March 31,
20252024
Cash flows provided by (used in) operating activities:
Net increase in net assets resulting from operations$50,337 $90,964 
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used in) operating activities:
Purchases of investments(1)
(415,033)(605,239)
Fundings assigned to Adviser Funds(1)
 113,379 
Principal and fee repayments received and proceeds from the sale of debt investments144,483 174,100 
Proceeds from the sale of equity and warrant investments329 12,026 
Net change in unrealized (appreciation) depreciation25,565 (3,634)
Net realized (gain) loss1,541 (8,168)
Accretion of paid-in-kind interest(13,473)(9,897)
Accretion of loan discounts(1,109)(901)
Accretion of loan discounts on convertible notes68  
Loss on extinguishment of debt15  
Accretion of loan exit fees(7,436)(6,736)
Change in loan income, net of collections4,365 4,529 
Unearned fees related to unfunded commitments1,102 841 
Amortization of debt fees and issuance costs1,842 1,759 
Depreciation and amortization89 186 
Stock-based compensation and amortization of restricted stock grants(2)
3,637 2,812 
Change in operating assets and liabilities:
Interest receivable(1,215)(2,743)
Other assets2,041 (2,915)
Accrued liabilities(19,345)(1,254)
Net cash (used in) operating activities(222,197)(240,891)
Cash flows provided by (used in) investing activities:
Purchases of capital equipment(8)(292)
Net cash (used in) investing activities(8)(292)
Cash flows provided by (used in) financing activities:
Issuance of common stock40,160 67,275 
Offering expenses(743)(867)
Retirement of employee shares, net(3,469)(2,701)
Distributions paid(78,873)(74,251)
Issuance of debt569,188 403,000 
Repayment of debt(360,812)(207,000)
Debt issuance costs(4,927) 
Fees paid for credit facilities(419) 
Net cash provided by financing activities160,105 185,456 
Net increase (decrease) in cash, cash equivalents, foreign cash and restricted cash(62,100)(55,727)
Cash, cash equivalents, foreign cash and restricted cash at beginning of period116,421 116,013 
Cash, cash equivalents, foreign cash and restricted cash at end of period$54,321 $60,286 
Supplemental disclosures of cash flow information and non-cash investing and financing activities:
Interest paid$25,580 $24,084 
Income tax, including excise tax, paid$6,033 $4,902 
Distributions reinvested$2,511 $1,780 
(1)Excluded from the amounts presented are certain investment funding allocations of $124.1 million, which were directly funded by the Adviser Funds (as defined in "Note 1 – Description of Business") during the three month period ended March 31, 2025. Refer to Note 12 – Related Party Transaction for additional information.
(2)Stock-based compensation includes $35 thousand and $35 thousand of restricted stock and option expense related to director compensation for the three months ended March 31, 2025 and 2024, respectively.
The following table presents a reconciliation of cash, cash equivalents, foreign cash and restricted cash reported within the Consolidated Statements of Assets and Liabilities that sum to the total of the same such amounts in the Consolidated Statements of Cash Flows:
(in thousands)For the Three Months Ended March 31,
20252024
Cash and cash equivalents$49,379 $49,588 
Foreign cash1,780 588 
Restricted cash3,162 10,110 
Total cash, cash equivalents, foreign cash and restricted cash presented in the Consolidated Statements of Cash Flows$54,321 $60,286 
See “Note 2 – Summary of Significant Accounting Policies” for a description of cash, cash equivalents, foreign cash and restricted cash.
See notes to consolidated financial statements
6

Table of Contents
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
March 31, 2025 (unaudited)
(dollars in thousands)
Portfolio CompanyType of
Investment
Maturity Date
Interest Rate and Floor(1)
Principal
Amount
Cost(2)
ValueFootnotes
Debt Investments
Biotechnology Tools
PathAI, Inc.Senior SecuredJanuary 2027
Prime + 2.15%, Floor rate 9.15%, 7.85% Exit Fee
$32,000 $33,032 $33,739 (12)(13)
Subtotal: Biotechnology Tools (1.69%)*
  33,032 33,739 
Communications & Networking    
Aryaka Networks, Inc.Senior SecuredDecember 2028
Prime + 1.80%, Floor rate 9.30%, PIK Interest 1.25%, 6.73% Exit Fee
$28,003 27,886 27,443 (12)(14)(17)(19)
Subtotal: Communications & Networking (1.37%)*
27,886 27,443 
Consumer & Business Services
Altumint, Inc.Senior SecuredDecember 2027
Prime + 3.65%, Floor rate 12.15%, 2.50% Exit Fee
$10,000 9,940 10,127 (15)
Carwow LTDSenior SecuredDecember 2027
Prime + 4.70%, Floor rate 11.45%, PIK Interest 1.45%, 4.95% Exit Fee
£20,435 27,981 26,219 (5)(10)(14)
GoEuro Travel GmbHSenior SecuredNovember 2029
Prime + 3.45%, Floor rate 10.45%, 4.50% Exit Fee
$48,750 48,387 48,387 (5)(10)(17)
Houzz, Inc.Convertible DebtMay 2028
PIK Interest 11.50%
$26,426 26,425 27,673 (9)(14)
Jobandtalent USA, Inc.Senior SecuredOctober 2028
1-month SOFR + 0.00%, Floor rate 1.00%, PIK Interest 7.00%, 5.33% Exit Fee
$13,536 13,874 13,148 (5)(10)(14)
Plentific LtdSenior SecuredOctober 2026
Prime + 2.55%, Floor rate 11.05%, 2.95% Exit Fee
$3,325 3,300 3,347 (5)(10)(13)
ProviSenior SecuredDecember 2026
Prime + 4.40%, Floor rate 10.65%, 2.95% Exit Fee
$15,000 15,145 15,198 (15)
Riviera Partners LLCSenior SecuredMarch 2028
3-month SOFR + 8.27%, Floor rate 9.27%
$36,401 36,047 35,175 (18)
RVShare, LLCSenior SecuredDecember 2026
3-month SOFR + 5.50%, Floor rate 6.50%, PIK Interest 4.00%
$30,374 30,148 29,473 (13)(14)(15)
SeatGeek, Inc.Senior SecuredMay 2026
Prime + 7.00%, Floor rate 10.50%, PIK Interest 0.50%, 4.00% Exit Fee
$25,359 25,514 25,832 (11)(14)(16)
Senior SecuredJuly 2026
Prime + 2.50%, Floor rate 10.75%, PIK Interest 0.50%, 3.00% Exit Fee
$78,135 77,744 79,570 (12)(14)(16)
Total SeatGeek, Inc.$103,494 103,258 105,402  
Skyword, Inc.Senior SecuredNovember 2027
Prime + 2.75%, Floor rate 9.25%, PIK Interest 1.75%, 3.00% Exit Fee
$6,616 6,760 6,691 (13)(14)
Tectura CorporationSenior SecuredJanuary 2027
FIXED 8.25%
$8,250 8,250 8,032 (7)
Thumbtack, Inc.Senior SecuredMarch 2028
Prime + 2.45%, Floor rate 10.95%, PIK Interest 1.50%
$20,996 20,661 21,208 (11)(14)(17)
Veem, Inc.Senior SecuredMarch 2027
Prime + 4.00%, Floor rate 12.00%, PIK Interest 1.25%
$5,413 5,401 5,342 (13)(14)
Senior SecuredMarch 2027
Prime + 4.70%, Floor rate 12.70%, PIK Interest 1.50%
$5,433 5,421 5,366 (12)(14)
Total Veem, Inc.$10,846 10,822 10,708 
Subtotal: Consumer & Business Services (18.03%)*
360,998 360,788 
Diversified Financial Services
Gibraltar Acquisition, LLCUnsecuredSeptember 2026
FIXED 3.45%, PIK Interest 8.05%
$27,104 26,899 26,899 (7)(14)(20)
UnsecuredSeptember 2026
FIXED 11.95%
$10,000 9,891 9,891 (7)(20)
Total Gibraltar Acquisition, LLC$37,104 36,790 36,790 
Next Insurance, Inc.Senior SecuredFebruary 2028
Prime - 1.50%, Floor rate 4.75%, PIK Interest 5.50%
$11,223 11,080 11,662 (13)(14)(19)
Subtotal: Diversified Financial Services (2.42%)*
 47,870 48,452 
Drug Discovery & Development
Adaptimmune Therapeutics plcSenior SecuredJune 2029
Prime + 1.15%, Floor rate 9.65%, PIK Interest 2.00%, 5.85% Exit Fee
$15,167 15,126 15,050 (5)(10)(11)(14)
Akero Therapeutics, Inc.Senior SecuredMarch 2027
Prime + 3.65%, Floor rate 7.65%, 5.85% Exit Fee
$17,500 17,811 17,994 (10)(13)(17)
Aldeyra Therapeutics, Inc.Senior SecuredApril 2026
Prime + 3.10%, Floor rate 11.10%, 8.90% Exit Fee
$15,000 15,093 15,134 (11)
Alector, Inc.Senior SecuredDecember 2028
Prime + 1.05%, Floor rate 8.05%, 4.75% Exit Fee
$7,000 6,957 6,957 (6)(10)(15)(17)
See notes to consolidated financial statements
7

Table of Contents
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
March 31, 2025 (unaudited)
(dollars in thousands)
Portfolio CompanyType of
Investment
Maturity Date
Interest Rate and Floor(1)
Principal
Amount
Cost(2)
ValueFootnotes
AmplifyBio, LLCSenior SecuredJanuary 2027
Prime + 2.50%, Floor rate 9.50%, Cap rate 10.75%, 5.85% Exit Fee
$22,458 $23,247 $13,095 (14)(15)
Arcus Biosciences, Inc.Senior SecuredSeptember 2029
Prime + 1.95%, Floor rate 10.45%, 7.75% Exit Fee
$37,500 37,511 38,913 (6)(10)(15)(17)
ATAI Life Sciences N.V.Senior SecuredAugust 2026
Prime + 4.30%, Floor rate 9.05%, 6.95% Exit Fee
$14,000 14,538 14,452 (5)(10)
Axsome Therapeutics, Inc.Senior SecuredJanuary 2028
Prime + 2.20%, Floor rate 9.95%, Cap rate 10.70%, 5.78% Exit Fee
$143,350 145,929 153,070 (10)(11)(12)(16)
bluebird bio, Inc.Senior SecuredApril 2029
Prime + 1.45%, Floor rate 9.95%, PIK Interest 2.45%, 6.45% Exit Fee
$66,058 64,724 60,624 (14)
Braeburn, Inc.Senior SecuredOctober 2028
Prime + 2.45%, Floor rate 10.95%, PIK Interest 1.10%, 5.45% Exit Fee
$53,339 53,669 55,350 (14)
COMPASS Pathways plcSenior SecuredJuly 2027
Prime + 1.50%, Floor rate 9.75%, PIK Interest 1.40%, 4.75% Exit Fee
$24,576 24,826 25,453 (5)(10)(11)(14)
Corium, Inc.Senior SecuredSeptember 2026
Prime + 5.70%, Floor rate 8.95%, 7.75% Exit Fee
$86,925 90,906 90,279 (13)
Disc Medicine, Inc.Senior SecuredDecember 2029
Prime + 1.75%, Floor rate 8.25%, 6.75% Exit Fee
$22,500 22,433 22,755 (6)(10)(15)(17)
enGene, Inc.Senior SecuredJanuary 2028
Prime + 0.75%, Floor rate 9.25%, Cap rate 9.75%, PIK Interest 1.15%, 5.50% Exit Fee
$15,970 16,133 16,177 (5)(10)(14)
Heron Therapeutics, Inc.Senior SecuredMay 2026
Prime + 1.70%, Floor rate 9.95%, PIK Interest 1.50%, 3.00% Exit Fee
$20,480 20,654 20,660 (14)(15)(17)
Hibercell, Inc.Senior SecuredMay 2025
Prime + 5.40%, Floor rate 8.65%, 4.95% Exit Fee
$1,612 2,442 2,442 (13)(15)
Kura Oncology, Inc.Senior SecuredNovember 2027
Prime + 2.40%, Floor rate 8.65%, 6.05% Exit Fee
$5,500 5,646 5,707 (10)(15)
Madrigal Pharmaceutical, Inc.Senior SecuredMay 2027
Prime + 2.45%, Floor rate 8.25%, 5.35% Exit Fee
$78,200 80,159 82,430 (10)(13)
MoonLake ImmunotherapeuticsSenior SecuredApril 2030
Prime + 1.45%, Floor rate 8.45%, 6.95% Exit Fee
$57,000 56,421 56,421 (5)(10)
NorthSea TherapeuticsConvertible DebtDecember 2025
FIXED 6.00%
$273 273 273 (5)(9)(10)
Phathom Pharmaceuticals, Inc.Senior SecuredDecember 2027
Prime + 1.35%, Floor rate 9.85%, Cap rate 10.35%, PIK Interest 2.15%, 7.06% Exit Fee
$138,620 141,882 142,910 (6)(10)(12)(14)(15) (16)(22)
Senior SecuredDecember 2027
Prime + 1.35%, Floor rate 9.85%, Cap rate 10.35%, PIK Interest 2.15%, 3.00% Exit Fee
$31,385 31,224 31,510 (14)(15)(16)
Total Phathom Pharmaceuticals, Inc.$170,005 173,106 174,420 
Replimune Group, Inc.Senior SecuredOctober 2027
Prime + 1.75%, Floor rate 7.25%, Cap rate 9.00%, PIK Interest 1.50%, 4.95% Exit Fee
$32,009 32,513 33,866 (10)(12)(13)(14)
Savara, Inc.Senior SecuredApril 2030
Prime + 1.45%, Floor rate 7.45%, 6.95% Exit Fee
$21,450 21,334 21,334 (6)(10)(15)
SynOx Therapeutics LimitedSenior SecuredMay 2027
Prime + 1.40%, Floor rate 9.90%, 7.25% Exit Fee
$4,500 4,511 4,579 (5)(10)(11)
uniQure B.V.Senior SecuredJanuary 2027
Prime + 4.70%, Floor rate 7.95%, 6.10% Exit Fee
$35,000 36,243 37,135 (5)(10)(11)(12)
Viridian Therapeutics, Inc.Senior SecuredOctober 2026
Prime + 4.20%, Floor rate 7.45%, Cap rate 8.95%, 6.00% Exit Fee
$8,000 8,268 8,481 (10)(13)
X4 Pharmaceuticals, Inc.Senior SecuredJuly 2027
Prime + 3.15%, Floor rate 10.15%, 3.72% Exit Fee
$75,000 75,735 74,933 (11)(12)(13)
Subtotal: Drug Discovery & Development (53.38%)*
1,066,208 1,067,984 
Electronics & Computer Hardware
Locus Robotics Corp.Senior SecuredDecember 2028
Prime + 3.00%, Floor rate 9.50%, 4.00% Exit Fee
$48,750 48,665 48,981 (6)(15)(17)
Shield AI, Inc.Senior SecuredFebruary 2029
Prime + 0.85%, Floor rate 6.85%, Cap rate 9.60%, PIK Interest 2.50%, 2.50% Exit Fee
$114,471 113,782 115,062 (12)(14)(16)
Subtotal: Electronics & Computer Hardware (8.20%)*
162,447 164,043 
Healthcare Services, Other
Blue Sprig Pediatrics, Inc.Senior SecuredNovember 2026
3-month SOFR + 5.26%, Floor rate 6.00%, PIK Interest 4.45%
$73,027 72,543 71,114 (11)(12)(13)(14)
Carbon Health Technologies, Inc.Senior SecuredFebruary 2028
Prime + 3.10%, Floor rate 8.10%, 3.78% Exit Fee
$42,125 42,482 40,351 (11)(13)(14)
Curana Health Holdings, LLCSenior SecuredJanuary 2028
Prime + 1.45%, Floor rate 9.20%, 4.95% Exit Fee
$27,500 27,814 28,113 (13)(17)(19)
Ennoble Care LLCSenior SecuredFebruary 2030
Prime + 2.60%, Floor rate 10.35%, 7.95% Exit Fee
$9,000 8,916 8,916 (6)(15)(17)
See notes to consolidated financial statements
8

Table of Contents
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
March 31, 2025 (unaudited)
(dollars in thousands)
Portfolio CompanyType of
Investment
Maturity Date
Interest Rate and Floor(1)
Principal
Amount
Cost(2)
ValueFootnotes
Equality Health, LLCSenior SecuredFebruary 2026
Prime + 4.25%, Floor rate 9.50%, PIK Interest 1.55%
$70,952 $70,976 $70,976 (11)(12)(14)
Main Street Rural, Inc.Senior SecuredJuly 2027
Prime + 1.95%, Floor rate 9.95%, 6.85% Exit Fee
$38,500 39,321 39,614 (13)(15)(17)
Marathon Health, LLCSenior SecuredFebruary 2029
Prime + 0.75%, Floor rate 8.75%, PIK Interest 2.25%, 3.00% Exit Fee
$168,301 167,702 168,880 (14)(16)(17)
Senior SecuredFebruary 2029
Prime + 3.00%, Floor rate 11.00%
$5,000 5,000 5,000 (16)(17)
Total Marathon Health, LLC$173,301 172,702 173,880 
Modern Life, Inc.Senior SecuredFebruary 2027
Prime + 2.75%, Floor rate 8.75%, 5.00% Exit Fee
$18,200 18,391 18,402 (13)
NeueHealth, Inc.Senior SecuredJune 2028
Prime + 1.15%, Floor rate 9.65%, PIK Interest 2.50%, 2.50% Exit Fee
$25,188 24,483 24,449 (12)(14)
Recover Together, Inc.Senior SecuredJuly 2027
Prime + 1.90%, Floor rate 10.15%, 7.50% Exit Fee
$45,000 45,705 44,769 (13)
Strive Health Holdings, LLCSenior SecuredSeptember 2027
Prime + 0.70%, Floor rate 9.20%, 5.95% Exit Fee
$30,000 29,905 30,521 (15)
Vida Health, Inc.Senior SecuredOctober 2026
Prime - 2.75% Floor rate 5.75%, PIK Interest 5.35%, 4.95% Exit Fee
$37,248 38,018 37,396 (11)(14)
WellBe Senior Medical, LLCSenior SecuredMay 2029
Prime + 0.75%, Floor rate 7.75%, PIK Interest 2.65%, 6.75% Exit Fee
$28,468 28,413 27,410 (14)(15)(17)
Subtotal: Healthcare Services, Other (30.79%)*
619,669 615,911 
Information Services
Saama Technologies, LLCSenior SecuredJuly 2027
Prime + 0.70%, Floor rate 8.95%, PIK Interest 2.00%, 2.95% Exit Fee
$19,878 19,891 20,313 (12)(14)
Subtotal: Information Services (1.02%)*
19,891 20,313 
Manufacturing Technology
VulcanForms Inc.Senior SecuredJanuary 2028
Prime + 4.25%, Floor rate 11.25%, 4.25% Exit Fee
$20,000 19,860 19,860 (19)
Subtotal: Manufacturing Technology (0.99%)*
19,860 19,860 
Medical Devices & Equipment
Orchestra BioMed Holdings, Inc.Senior SecuredNovember 2028
Prime + 2.00%, Floor rate 9.50%, 6.35% Exit Fee
$15,000 14,821 14,821 (6)(15)
Senseonics Holdings, Inc.Senior SecuredSeptember 2027
Prime + 1.40%, Floor rate 9.90%, 6.95% Exit Fee
$30,625 31,011 31,621 (11)
Sight Sciences, Inc.Senior SecuredJuly 2028
Prime + 2.35%, Floor rate 10.35%, 5.95% Exit Fee
$28,000 27,967 28,230 (6)
Subtotal: Medical Devices & Equipment (3.73%)*
73,799 74,672 
Software
Alchemer LLCSenior SecuredMay 2028
1-month SOFR + 8.14%, Floor rate 9.14%
$20,310 20,002 20,310 (13)(17)(18)
Allvue Systems, LLCSenior SecuredSeptember 2029
3-month SOFR + 6.50%, Floor rate 7.50%
$42,564 41,738 41,783 (17)
AlphaSense, Inc.Senior SecuredJune 2029
3-month SOFR + 6.25%, Floor rate 8.25%
$20,000 19,823 19,824 (11)(17)
Annex CloudSenior SecuredFebruary 2027
3-month SOFR + 10.00%, Floor rate 11.00%
$11,007 10,874 3,404 (8)(13)(18)
Armis, Inc.Senior SecuredMarch 2028
Prime + 0.00%, Floor rate 7.50%, PIK Interest 2.00%, 2.25% Exit Fee
$50,987 50,838 51,220 (12)(14)(17)
Senior SecuredMarch 2028
Prime + 1.25%, Floor rate 7.50%, PIK Interest 2.00%, 2.25% Exit Fee
$25,276 25,141 25,048 (14)(17)
Total Armis, Inc.$76,263 75,979 76,268 
Babel StreetSenior SecuredDecember 2027
3-month SOFR + 8.00%, Floor rate 9.00%
$65,173 63,986 64,584 (15)(17)(18)
Behavox LimitedSenior SecuredSeptember 2027
Prime - 0.55%, Floor rate 7.45%, PIK Interest 3.00%, 4.95% Exit Fee
$10,626 10,618 10,475 (5)(10)(14)(17)
Brain CorporationSenior SecuredSeptember 2028
Prime + 1.35%, Floor rate 9.85%, PIK Interest 2.50%, 3.95% Exit Fee
$32,209 31,984 32,171 (13)(14)
Carbyne, Inc.Senior SecuredFebruary 2029
Prime + 3.50%, Floor rate 10.00%, 3.50% Exit Fee
$7,450 7,367 7,367 
Ceros, Inc.Senior SecuredSeptember 2026
3-month SOFR + 8.99%, Floor rate 9.89%
$22,762 22,548 22,146 (18)
CoreView USA, Inc.Senior SecuredJanuary 2029
Prime + 2.75%, Floor rate 9.25%, 4.95% Exit Fee
$25,000 24,805 24,805 (6)(17)
Coronet Cyber Security Ltd.Senior SecuredOctober 2028
Prime - 2.95%, Floor rate 3.55%, PIK Interest 5.85%
$8,718 8,579 8,359 (14)(17)
See notes to consolidated financial statements
9

Table of Contents
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
March 31, 2025 (unaudited)
(dollars in thousands)
Portfolio CompanyType of
Investment
Maturity Date
Interest Rate and Floor(1)
Principal
Amount
Cost(2)
ValueFootnotes
Dashlane, Inc.Senior SecuredDecember 2027
Prime + 3.05%, Floor rate 11.55%, PIK Interest 1.10%, 6.28% Exit Fee
$45,601 $46,814 $47,902 (11)(13)(14)(17)(19)
Dispatch Technologies, Inc.Senior SecuredApril 2028
3-month SOFR + 8.01%, Floor rate 8.76%
$8,628 8,478 8,312 (17)(18)
DocPlannerSenior SecuredJanuary 2030
Prime + 2.75%, Floor rate 9.75%, 4.25% Exit Fee
68,200 69,353 73,090 (5)(10)(17)
Dragos, Inc.Senior SecuredJuly 2027
Prime + 2.00%, Floor rate 8.75%, PIK Interest 2.00%, 2.00% Exit Fee
$13,079 12,512 12,544 (14)(17)
DroneDeploy, Inc.Senior SecuredNovember 2028
Prime + 2.45%, Floor rate 9.95%, 5.00% Exit Fee
$9,375 9,292 9,286 (13)(17)
Earnix, Inc.Senior SecuredJune 2029
Prime - 1.15%, Floor rate 5.35%, PIK Interest 4.45%
$19,380 19,082 19,161 (11)(14)(17)
Elation Health, Inc.Senior SecuredApril 2029
Prime + 1.75%, Floor rate 9.25%, PIK Interest 1.30%, 3.95% Exit Fee
$13,456 13,020 13,020 (11)(19)
Fortified Health SecuritySenior SecuredDecember 2027
1-month SOFR + 7.64%, Floor rate 8.54%
$6,983 6,873 6,919 (11)(17)(18)
Harness, Inc.Senior SecuredMarch 2029
Prime - 2.25%, Floor rate 5.25%, Cap rate 6.50%, PIK Interest 6.25%, 1.00% Exit Fee
$29,994 29,677 29,811 (14)(17)(19)
iGrafx, LLCSenior SecuredMay 2027
1-month SOFR + 8.61%, Floor rate 9.51%, 0.47% Exit Fee
$4,937 4,875 4,856 (18)
iSpot.tv, Inc.Senior SecuredJanuary 2029
Prime + 2.25%, Floor rate 8.75%, PIK Interest 1.00%, 5.70% Exit Fee
$8,257 8,178 8,178 (14)(17)(19)
KhorosSenior SecuredJanuary 2025
3-month SOFR + 4.50%, Floor rate 5.50%, PIK Interest 4.50%
$61,341 61,317 16,180 (8)(14)(24)
Leapwork ApSSenior SecuredFebruary 2026
Prime + 0.25%, Floor rate 7.00%, PIK Interest 1.95%, 2.70% Exit Fee
$8,929 8,974 8,974 (5)(10)(12)(14)
LinenMaster, LLCSenior SecuredAugust 2028
1-month SOFR + 6.25%, Floor rate 7.25%, PIK Interest 2.15%
$15,512 15,285 15,515 (12)(14)(17)
Loftware, Inc.Senior SecuredMarch 2028
3-month SOFR + 7.88%, Floor rate 8.88%
$27,206 26,757 27,206 (17)(18)
LogicSourceSenior SecuredJuly 2027
1-month SOFR + 8.93%, Floor rate 9.93%
$13,111 12,955 13,111 (17)(18)
LogRhythm, Inc.Senior SecuredJuly 2029
3-month SOFR + 7.50%, Floor rate 8.50%
$25,000 24,334 24,346 (17)
Marigold Group, Inc.Senior SecuredNovember 2026
PIK Interest 6-month SOFR + 10.55%, Floor rate 11.55%
$40,264 39,822 34,001 (13)(14)(19)
Mobile Solutions ServicesSenior SecuredDecember 2025
6-month SOFR + 9.31%, Floor rate 10.06%
$18,366 18,270 17,716 (18)
Morphisec Information Security 2014 Ltd.Senior SecuredOctober 2027
Prime + 3.45%, Floor rate 11.70%, 5.95% Exit Fee
$10,000 9,926 9,926 (5)(10)
New Relic, Inc.Senior SecuredNovember 2030
1-month SOFR + 6.75%, Floor rate 7.75%
$21,890 21,417 21,346 (17)
Omeda Holdings, LLCSenior SecuredJuly 2027
3-month SOFR + 8.05%, Floor rate 9.05%
$7,631 7,493 7,631 (11)(17)(18)
PayIt, LLCSenior SecuredDecember 2028
Prime +1.45%, Floor rate 7.95%, PIK Interest 1.50%, 5.00% Exit Fee
$12,048 11,961 11,961 (6)(14)(15)(17)(19)
Pindrop Security, Inc.Senior SecuredJune 2029
Prime + 3.50%, Floor rate 10.00%, 2.00% Exit Fee
$31,000 30,611 30,849 (15)(17)
Remodel Health Holdco, LLCSenior SecuredDecember 2028
Prime + 2.35%, Floor rate 10.35%, 6.50% Exit Fee
$25,000 24,818 24,399 (6)(15)
ReveleerSenior SecuredFebruary 2027
Prime + 0.65%, Floor rate 9.15%, PIK Interest 2.00%, 5.05% Exit Fee
$36,528 36,765 36,825 (14)(15)(17)
Semperis Technologies Inc.Senior SecuredApril 2028
Prime - 1.75%, Floor rate 6.75%, PIK Interest 3.25%
$22,936 22,787 23,464 (11)(14)(17)(19)
ShadowDragon, LLCSenior SecuredDecember 2026
3-month SOFR + 8.88%, Floor rate 9.78%
$6,000 5,927 5,925 (17)(18)
Simon Data, Inc.Senior SecuredMarch 2027
Prime + 1.00%, Floor rate 8.75%, PIK Interest 1.95%, 2.95% Exit Fee
$12,919 13,020 12,881 (12)(14)
Sisense Ltd.Senior SecuredJuly 2027
Prime + 1.50%, Floor rate 9.50%, PIK Interest 1.95%, 5.95% Exit Fee
$33,638 34,189 34,212 (5)(10)(14)
Smartsheet Inc.Senior SecuredJanuary 2031
3-month SOFR + 6.50%, Floor rate 7.25%
$46,785 45,870 45,870 (17)
Snappt, Inc.Senior SecuredApril 2029
Prime + 2.35%, Floor rate 8.85%, PIK Interest 1.00%, 4.25% Exit Fee
$20,000 19,769 19,769 (6)(15)
Streamline Healthcare SolutionsSenior SecuredMarch 2028
3-month SOFR + 7.25%, Floor rate 8.25%
$17,600 17,342 17,514 (11)(13)(17)(18)
Sumo Logic, Inc.Senior SecuredMay 2030
6-month SOFR + 6.50%, Floor rate 7.50%
$23,000 22,537 22,625 (17)
Suzy, Inc.Senior SecuredAugust 2027
Prime + 1.75%, Floor rate 10.00%, PIK Interest 1.95%, 3.45% Exit Fee
$24,460 24,237 24,686 (6)(14)(15)(17)
TaxCalcSenior SecuredNovember 2029
Daily SONIA + 8.17%, Floor rate 8.67%
£7,500 9,527 9,502 (5)(10)(17)(18)
ThreatConnect, Inc.Senior SecuredMay 2026
3-month SOFR + 9.15%, Floor rate 10.00%
$12,254 12,158 12,241 (18)
See notes to consolidated financial statements
10

Table of Contents
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
March 31, 2025 (unaudited)
(dollars in thousands)
Portfolio CompanyType of
Investment
Maturity Date
Interest Rate and Floor(1)
Principal
Amount
Cost(2)
ValueFootnotes
Tipalti Solutions Ltd.Senior SecuredApril 2029
Prime + 0.45%, Floor rate 6.45%, PIK Interest 2.30%
$75,000 $74,571 $74,571 (16)
Senior SecuredApril 2029
Prime + 0.45%, Floor rate 6.45%, PIK Interest 2.30%, 3.75% Exit Fee
$42,000 41,763 41,763 (16)
Total Tipalti Solutions Ltd.$117,000 116,334 116,334 
Zappi, Inc.Senior SecuredDecember 2027
3-month SOFR + 8.03%, Floor rate 9.03%
$12,696 12,505 12,667 (5)(10)(13)(17)(18)
Zimperium, Inc.Senior SecuredMay 2027
3-month SOFR + 8.31%, Floor rate 9.31%
$14,790 14,633 14,370 (17)(18)
Subtotal: Software (61.81%)*
1,287,997 1,236,621 
Space Technologies
Voyager Technologies, Inc.Senior SecuredJuly 2028
Prime + 1.25%, Floor rate 9.75%, PIK Interest 2.50%, 5.50% Exit Fee
$45,724 45,767 49,505 (11)(14)(15)
Subtotal: Space Technologies (2.47%)*
45,767 49,505 
Sustainable and Renewable Technology
Electric Hydrogen Co.Senior SecuredMay 2028
Prime + 2.25%, Floor rate 10.75%, PIK Interest 1.25%, 4.89% Exit Fee
$20,190 19,866 19,903 (14)(15)(19)
Subtotal: Sustainable and Renewable Technology (0.99%)*
19,866 19,903 
Total: Debt Investments (186.90%)*
$3,785,290 $3,739,234 
Portfolio CompanyType of
Investment
Acquisition Date(4)
Series (3)
Shares
Cost (2)
ValueFootnotes
Equity Investments
Biotechnology Tools
Alamar Biosciences, Inc.Equity2/21/2024Preferred Series C503,778$1,500 $970 
Subtotal: Biotechnology Tools (0.05%)*
1,500 970 
Consumer & Business Products
Fabletics, Inc. Equity4/30/2010Common Stock42,989128 19 
Equity7/16/2013Preferred Series B130,1911,101 172 
Total Fabletics, Inc. 173,1801,229 191 
Grove Collaborative, Inc.Equity4/30/2021Common Stock12,260433 17 (4)
Savage X Holding, LLCEquity4/30/2010Class A Units172,32813 158 
Subtotal: Consumer & Business Products (0.02%)*
1,675 366 
Consumer & Business Services
Carwow LTDEquity12/15/2021Preferred Series D-4216,0731,151 632 (5)(10)
Jobandtalent USA, Inc.Equity2/11/2025Preferred Series F47,754563 563 (5)(10)
Lyft, Inc.Equity12/26/2018Common Stock100,7385,263 1,196 (4)
Nerdy Inc.Equity9/17/2021Common Stock100,0001,000 142 (4)
OfferUp, Inc.Equity10/25/2016Preferred Series A286,0801,663 405 
Equity10/25/2016Preferred Series A-1108,710632 154 
Total OfferUp, Inc.   394,7902,295 559 
OportunEquity6/28/2013Common Stock48,365577 266 (4)
Reischling Press, Inc.Equity7/31/2020Common Stock3,09539  
Rhino Labs, Inc.Equity1/24/2022Common Stock7,0631,000  
See notes to consolidated financial statements
11

Table of Contents
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
March 31, 2025 (unaudited)
(dollars in thousands)
Portfolio CompanyType of
Investment
Acquisition Date(4)
Series (3)
Shares
Cost (2)
ValueFootnotes
Tectura CorporationEquity5/23/2018Common Stock414,994,863$900 $2 (7)
Equity6/6/2016Preferred Series BB1,000,000 7 (7)
Equity12/29/2023Preferred Series C3,235,29813,263 3,729 (7)
Total Tectura Corporation419,230,16114,163 3,738 
Worldremit Group LimitedEquity6/24/2024Preferred Series X9,737922 977 (5)(10)
Subtotal: Consumer & Business Services (0.40%)*
26,973 8,073 
Diversified Financial Services
Gibraltar Acquisition, LLCEquity3/1/2018Member Units134,006 22,110 (7)(20)
Hercules Adviser LLCEquity3/26/2021Member Units112,035 45,017 (7)(23)
Newfront Insurance Holdings, Inc.Equity9/30/2021Preferred Series D-2210,282403 456 
Subtotal: Diversified Financial Services (3.38%)*
46,444 67,583 
Drug Delivery
Aytu BioScience, Inc.Equity3/28/2014Common Stock6801,500 1 (4)
BioQ Pharma IncorporatedEquity12/8/2015Preferred Series D165,000500  
PDS Biotechnology CorporationEquity4/6/2015Common Stock2,498309 3 (4)
Talphera, Inc.Equity12/10/2018Common Stock8,8361,329 4 (4)
Subtotal: Drug Delivery (0.00%)*
3,638 8 
Drug Discovery & Development
Akero Therapeutics, Inc.Equity3/8/2024Common Stock34,4831,000 1,396 (4)(10)
Arcus Biosciences, Inc.Equity2/19/2025Common Stock204,5452,250 1,606 (4)(10)
Avalo Therapeutics, Inc.Equity8/19/2014Common Stock421,000  (4)
Axsome Therapeutics, Inc.Equity5/9/2022Common Stock127,0214,165 14,815 (4)(10)(16)
Bicycle Therapeutics PLCEquity10/5/2020Common Stock98,1001,871 833 (4)(5)(10)
BridgeBio Pharma, Inc.Equity6/21/2018Common Stock231,3292,255 7,997 (4)
Dare Biosciences, Inc.Equity1/8/2015Common Stock1,1291,000 3 (4)
Dynavax TechnologiesEquity7/22/2015Common Stock20,000550 259 (4)(10)
Heron Therapeutics, Inc.Equity7/25/2023Common Stock364,963500 803 (4)
Hibercell, Inc.Equity5/7/2021Preferred Series B3,466,8404,250 217 (15)
HilleVax, Inc.Equity5/3/2022Common Stock235,2954,000 341 (4)
Kura Oncology, Inc.Equity6/16/2023Common Stock47,826550 316 (4)(10)
Madrigal Pharmaceutical, Inc.Equity9/29/2023Common Stock5,100774 1,689 (4)(10)
NorthSea TherapeuticsEquity12/15/2021Preferred Series C9832,000 1,134 (5)(10)
Phathom Pharmaceuticals, Inc.Equity6/9/2023Common Stock147,2331,730 923 (4)(10)(16)
Rafael Holdings, Inc. (p.k.a. Cyclo Therapeutics, Inc.)Equity4/6/2021Common Stock4742  (4)(10)
Rocket Pharmaceuticals, Ltd.Equity8/22/2007Common Stock9441,500 6 (4)
Savara, Inc.Equity8/11/2015Common Stock11,119203 31 (4)
uniQure B.V.Equity1/31/2019Common Stock17,175332 182 (4)(5)(10)
See notes to consolidated financial statements
12

Table of Contents
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
March 31, 2025 (unaudited)
(dollars in thousands)
Portfolio CompanyType of
Investment
Acquisition Date(4)
Series (3)
Shares
Cost (2)
ValueFootnotes
Valo Health, LLCEquity12/11/2020Preferred Series B510,308$3,000 $748  
 Equity10/31/2022Preferred Series C170,1021,000 630  
Total Valo Health, LLC   680,4104,000 1,378  
Verge Analytics, Inc.Equity9/6/2023Preferred Series C208,5881,500 1,446 
Viridian Therapeutics, Inc.Equity11/6/2023Common Stock32,310400 436 (4)(10)
X4 Pharmaceuticals, Inc.Equity11/26/2019Common Stock1,566,0642,945 370 (4)
Subtotal: Drug Discovery & Development (1.81%)*
38,817 36,181  
Electronics & Computer Hardware    
Locus Robotics Corp.Equity11/17/2022Preferred Series F15,116650 267 
Shield AI, Inc.Equity2/7/2025Preferred Series F128,9002,250 2,250 (16)
Skydio, Inc.Equity3/8/2022Preferred Series E248,9001,500 543 
Subtotal: Electronics & Computer Hardware (0.15%)*
4,400 3,060  
Healthcare Services, Other    
23andMe, Inc.Equity3/11/2019Common Stock41,2865,094  
Carbon Health Technologies, Inc.Equity3/30/2021Common Stock390,8091,910  
Click Therapeutics, Inc.Equity5/20/2024Common Stock560,0001,662 1,900 (15)
Curana Health Holdings, LLCEquity5/13/2024Common Units1,114,3802,500 2,983 
Main Street Rural, Inc.Equity10/28/2024Preferred Series D496873 1,018 
WellBe Senior Medical, LLCEquity6/10/2024Common Units181,1631,600 1,535 
Subtotal: Healthcare Services, Other (0.37%)*
13,639 7,436  
Information Services      
Yipit, LLCEquity12/30/2021Preferred Series E41,0213,825 4,604  
Subtotal: Information Services (0.23%)*
3,825 4,604  
Medical Devices & Equipment     
Coronado Aesthetics, LLCEquity10/15/2021Common Units180,000  (7)
 Equity10/15/2021Preferred Series A-25,000,000250 47 (7)
Total Coronado Aesthetics, LLC   5,180,000250 47  
Subtotal: Medical Devices & Equipment (0.00%)*
250 47  
Semiconductors     
Achronix Semiconductor CorporationEquity7/1/2011Preferred Series C277,995160 97  
Subtotal: Semiconductors (0.00%)*
160 97  
Software    
Armis, Inc.Equity10/18/2024Preferred Series D294,2132,000 1,765 
Black Crow AI, Inc. affiliatesEquity3/24/2021Preferred Note32,406 2,406 (21)
CapLinked, Inc.Equity10/26/2012Preferred Series A-353,61451   
Contentful Global, Inc.Equity12/22/2020Preferred Series C41,000138 270 (5)(10)
 Equity11/20/2018Preferred Series D108,500500 759 (5)(10)
Total Contentful Global, Inc.   149,500638 1,029  
See notes to consolidated financial statements
13

Table of Contents
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
March 31, 2025 (unaudited)
(dollars in thousands)
Portfolio CompanyType of
Investment
Acquisition Date(4)
Series (3)
Shares
Cost (2)
ValueFootnotes
DNAnexus, Inc.Equity3/21/2014Preferred Series C51,948$97 $4 
Docker, Inc.Equity11/29/2018Common Stock20,0004,284 164  
Druva Holdings, Inc.Equity10/22/2015Preferred Series 2458,8411,000 4,481  
 Equity8/24/2017Preferred Series 393,620300 931  
Total Druva Holdings, Inc.   552,4611,300 5,412  
HighRoads, Inc.Equity1/18/2013Common Stock190307   
Leapwork ApSEquity8/25/2023Preferred Series B2183,073250 113 (5)(10)
Lightbend, Inc.Equity12/4/2020Common Stock38,461265 26  
Nextdoor.com, Inc.Equity8/1/2018Common Stock1,019,2554,854 1,559 (4)
SingleStore, Inc.Equity11/25/2020Preferred Series E580,9832,000 1,850  
 Equity8/12/2021Preferred Series F52,956280 206  
Total SingleStore, Inc.   633,9392,280 2,056  
SirionLabs Pte. Ltd.Equity6/30/2024Preferred Series F1152,2501,792 1,590 (5)(10)
Verana Health, Inc.Equity7/8/2021Common Stock23,8142,000 79  
Subtotal: Software (0.81%)*
22,524 16,203  
Sustainable and Renewable Technology     
Impossible Foods, Inc.Equity5/10/2019Preferred Series E-1188,6112,000 115 
Modumetal, Inc.Equity6/1/2015Common Stock1,035500  
Pivot Bio, Inc.Equity6/28/2021Preferred Series D593,0804,500 2,007  
SUNation Energy, Inc.Equity12/10/2020Common Stock4053,153  (4)
Subtotal: Sustainable and Renewable Technology (0.11%)*
10,153 2,122  
Total: Equity Investments (7.34%)*
$173,998 $146,750  
Warrant Investments
Biotechnology Tools
Alamar Biosciences, Inc.Warrant6/21/2022Preferred Series C75,56736 60  
PathAI, Inc.Warrant12/23/2022Common Stock53,418460 50 (12)
Subtotal: Biotechnology Tools (0.01%)*
496 110  
Communications & Networking    
Aryaka Networks, Inc.Warrant6/28/2022Common Stock486,097242 158 (12)
Subtotal: Communications & Networking (0.01%)*
242 158  
Consumer & Business Products    
Gadget Guard, LLCWarrant6/3/2014Common Stock1,662,441228   
Whoop, Inc.Warrant6/27/2018Preferred Series C686,27017 773  
Subtotal: Consumer & Business Products (0.04%)*
245 773  
Consumer & Business Services    
Altumint, Inc.Warrant10/31/2024Common Stock1,701127 97 (15)
Carwow LTDWarrant12/14/2021Common Stock174,163164 46 (5)(10)
See notes to consolidated financial statements
14

Table of Contents
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
March 31, 2025 (unaudited)
(dollars in thousands)
Portfolio CompanyType of
Investment
Acquisition Date(4)
Series (3)
Shares
Cost (2)
ValueFootnotes
Warrant2/13/2024Preferred Series D-4109,257$20 $8 (5)(10)
Total Carwow LTD283,420184 54 
Houzz, Inc.Warrant10/29/2019Common Stock529,66120   
Landing Holdings Inc.Warrant3/12/2021Common Stock11,806116 101 (15)
Lendio, Inc.Warrant3/29/2019Preferred Series D127,03239 8  
Plentific LtdWarrant10/3/2023Ordinary Shares27,29860 28 (5)(10)
ProviWarrant12/22/2022Common Stock117,042166 28 (15)
Rhino Labs, Inc.Warrant3/12/2021Common Stock13,106470  (15)
SeatGeek, Inc.Warrant6/12/2019Common Stock1,604,7241,242 4,342 (12)(16)
Skyword, Inc.Warrant11/14/2022Common Stock1,607,14357 9  
 Warrant8/23/2019Preferred Series B444,44483 1  
Total Skyword, Inc.   2,051,587140 10  
Snagajob.com, Inc.Warrant4/20/2020Common Stock600,00016   
 Warrant6/30/2016Preferred Series A1,800,000782   
 Warrant8/1/2018Preferred Series B1,211,53762   
Total Snagajob.com, Inc.   3,611,537860   
Thumbtack, Inc.Warrant5/1/2018Common Stock343,497985 938 
Veem, Inc.Warrant3/31/2022Common Stock98,428126 4 (12)
Worldremit Group LimitedWarrant2/11/2021Preferred Series D77,215129 90 (5)(10)
 Warrant8/27/2021Preferred Series E1,86826  (5)(10)
Total Worldremit Group Limited   79,083155 90  
Subtotal: Consumer & Business Services (0.28%)*
4,690 5,700  
Diversified Financial Services    
Next Insurance, Inc.Warrant2/3/2023Common Stock522,930214 1,331  
Subtotal: Diversified Financial Services (0.07%)*
214 1,331  
Drug Discovery & Development      
Akero Therapeutics, Inc.Warrant6/15/2022Common Stock32,129330 812 (4)(10)
AmplifyBio, LLCWarrant12/27/2022Class A Units69,239238  (15)
Axsome Therapeutics, Inc.Warrant9/25/2020Common Stock61,0041,290 2,842 (4)(10)(12)(16)
bluebird bio, Inc.Warrant3/15/2024Common Stock111,2061,744  
Cellarity, Inc.Warrant12/8/2021Preferred Series B100,000287 27 (15)
Century Therapeutics, Inc.Warrant9/14/2020Common Stock16,11237  (4)
COMPASS Pathways plcWarrant6/30/2023Ordinary Shares75,376278 21 (4)(5)(10)
Curevo, Inc.Warrant6/9/2023Common Stock95,221233 313 (15)
enGene, Inc.Warrant12/22/2023Common Stock43,689118 52 (4)(5)(10)
Heron Therapeutics, Inc.Warrant8/9/2023Common Stock238,095228 257 (4)(15)
Kineta, Inc.Warrant12/20/2019Common Stock2,202110  (4)
Kura Oncology, Inc.Warrant11/2/2022Common Stock14,34288 6 (4)(10)(15)
See notes to consolidated financial statements
15

Table of Contents
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
March 31, 2025 (unaudited)
(dollars in thousands)
Portfolio CompanyType of
Investment
Acquisition Date(4)
Series (3)
Shares
Cost (2)
ValueFootnotes
Madrigal Pharmaceutical, Inc.Warrant5/9/2022Common Stock13,229$570 $2,309 (4)(10)
Phathom Pharmaceuticals, Inc.Warrant9/17/2021Common Stock64,687848 5 (4)(10)(12)(15)(16)
Redshift Bioanalytics, Inc.Warrant3/23/2022Preferred Series E475,51020 17 (15)
Scynexis, Inc.Warrant5/14/2021Common Stock106,035296  (4)
SynOx Therapeutics LimitedWarrant4/18/2024Preferred Series B251,19583 68 (5)(10)
TG Therapeutics, Inc.Warrant12/30/2021Common Stock117,168721 2,387 (4)(10)
Valo Health, LLCWarrant6/15/2020Common Units102,216256 18  
X4 Pharmaceuticals, Inc.Warrant3/18/2019Common Stock1,392,787510 19 (4)
Subtotal: Drug Discovery & Development (0.46%)*
8,285 9,153  
Electronics & Computer Hardware     
908 Devices, Inc.Warrant3/15/2017Common Stock49,078101 21 (4)
Locus Robotics Corp.Warrant6/21/2022Common Stock8,50334 45  
Skydio, Inc.Warrant11/8/2021Common Stock622,255557 201  
Subtotal: Electronics & Computer Hardware (0.01%)*
692 267  
Healthcare Services, Other    
Curana Health Holdings, LLCWarrant1/4/2024Common Units447,410156 666 
Modern Life, Inc.Warrant3/30/2023Common Stock52,665210 117  
NeueHealth, Inc.Warrant6/21/2024Common Stock185,625716 940 (4)(12)
Recover Together, Inc.Warrant7/3/2023Common Stock194,830382 128 
Strive Health Holdings, LLCWarrant9/28/2023Common Units129,400278 358 (15)
Vida Health, Inc.Warrant3/28/2022Preferred Series E192,431121   
Subtotal: Healthcare Services, Other (0.11%)*
1,863 2,209  
Information Services     
NetBase Quid, Inc.Warrant8/22/2017Preferred Series 160,000356   
Signal Media LimitedWarrant6/29/2022Common Stock129,63857 6 (5)(10)
Subtotal: Information Services (0.00%)*
413 6  
Manufacturing Technology     
Bright Machines, Inc.Warrant3/31/2022Common Stock392,308537 615  
MacroFab, Inc.Warrant3/23/2022Common Stock1,111,111528 147  
VulcanForms Inc.Warrant1/30/2025Common Stock83,26237 31 
Subtotal: Manufacturing Technology (0.04%)*
1,102 793  
Media/Content/Info   
Fever Labs, Inc.Warrant12/30/2022Preferred Series E-1369,37067 114  
Subtotal: Media/Content/Info (0.01%)*
67 114  
Medical Devices & Equipment   
Orchestra BioMed Holdings, Inc.Warrant11/6/2024Common Stock52,264180 105 (4)(6)(15)
Outset Medical, Inc.Warrant9/27/2013Common Stock4,185401 4 (4)
Senseonics Holdings, Inc.Warrant9/8/2023Common Stock1,032,718276 302 (4)
See notes to consolidated financial statements
16

Table of Contents
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
March 31, 2025 (unaudited)
(dollars in thousands)
Portfolio CompanyType of
Investment
Acquisition Date(4)
Series (3)
Shares
Cost (2)
ValueFootnotes
Sight Sciences, Inc.Warrant1/22/2024Common Stock113,247$363 $108 (4)(6)
Tela Bio, Inc.Warrant3/31/2017Common Stock15,71261  (4)
Subtotal: Medical Devices & Equipment (0.03%)*
1,281 519  
Semiconductors
Achronix Semiconductor CorporationWarrant6/26/2015Preferred Series D-2750,00099 328  
Subtotal: Semiconductors (0.02%)*
99 328  
Software
Aria Systems, Inc.Warrant5/22/2015Preferred Series G231,53574  
Automation Anywhere, Inc.Warrant9/23/2022Common Stock254,778448 277 
Bitsight Technologies, Inc.Warrant11/18/2020Common Stock29,691284 581 
Brain CorporationWarrant10/4/2021Common Stock435,396215 118 
Carbyne, Inc.Warrant2/24/2025Ordinary Shares11,40824 19 
CloudBolt Software, Inc.Warrant9/30/2020Common Stock211,342117 52 
Cloudian, Inc.Warrant11/6/2018Common Stock477,45471  
Cloudpay, Inc.Warrant4/10/2018Preferred Series B6,76354 790 (5)(10)
Coronet Cyber Security Ltd.Warrant9/26/2024Ordinary Shares39,183254 208 
Couchbase, Inc.Warrant4/25/2019Common Stock105,350462 698 (4)
Cutover, Inc.Warrant9/21/2022Common Stock102,89826 51 (5)(10)(12)
Dashlane, Inc.Warrant3/11/2019Common Stock770,838461 1,149 
Demandbase, Inc.Warrant8/2/2021Common Stock727,047545 74 
Dragos, Inc.Warrant6/28/2023Common Stock57,5281,575 936 
DroneDeploy, Inc.Warrant6/30/2022Common Stock95,911278 339 
Earnix, Inc.Warrant6/6/2024Common Stock20,762219 313 
Elation Health, Inc.Warrant9/12/2022Common Stock612,166739 382 
First Insight, Inc.Warrant5/10/2018Preferred Series B75,91796 10 
Fulfil Solutions, Inc.Warrant7/29/2022Common Stock84,995325 231 
Harness, Inc.Warrant3/12/2024Common Stock193,618534 480 
Kore.ai, Inc.Warrant3/31/2023Preferred Series C64,293208 79 
Leapwork ApSWarrant1/23/2023Common Stock93,21139 24 (5)(10)(12)
Lightbend, Inc.Warrant2/14/2018Preferred Series LB-286,984131 26 
Mixpanel, Inc.Warrant9/30/2020Common Stock82,362252 275 
Morphisec Information Security 2014 Ltd.Warrant10/1/2024Ordinary Shares200,115104 120 (5)(10)
Pindrop Security, Inc.Warrant6/26/2024Common Stock134,542494 417 (15)
Reltio, Inc.Warrant6/30/2020Common Stock69,120215 589 
Semperis Technologies Inc.Warrant4/23/2024Common Stock72,122114 191 
Simon Data, Inc.Warrant3/22/2023Common Stock77,93496 14 (12)
SingleStore, Inc.Warrant4/28/2020Preferred Series D312,596103 452 
Sisense Ltd.Warrant6/8/2023Ordinary Shares321,956174 62 (5)(10)
See notes to consolidated financial statements
17

Table of Contents
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
March 31, 2025 (unaudited)
(dollars in thousands)
Portfolio CompanyType of
Investment
Acquisition Date(4)
Series (3)
Shares
Cost (2)
ValueFootnotes
Suzy, Inc.Warrant8/24/2023Common Stock292,936$367 $256 (6)(15)
Tipalti Solutions Ltd.Warrant3/22/2023Ordinary Shares509,753360 274 (10)(16)
Warrant3/27/2025Ordinary Shares473,266136 128 (16)
Total Tipalti Solutions Ltd.983,019496402
VideoAmp, Inc.Warrant1/21/2022Common Stock152,0481,275 4 (15)
Subtotal: Software (0.48%)*
10,869 9,619 
Space Technologies
Capella Space Corp.Warrant10/21/2021Common Stock176,200207 22 (15)
Subtotal: Space Technologies (0.00%)*
207 22 
Sustainable and Renewable Technology  
Ampion, PBCWarrant4/15/2022Common Stock18,47252 83 
Electric Hydrogen Co.Warrant3/27/2024Common Stock246,618507 288 (15)
Subtotal: Sustainable and Renewable Technology (0.02%)*
559 371 
Total: Warrant Investments (1.57%)*
$31,324 $31,473 
Total Investments in Securities (195.81%)*
$3,990,612 $3,917,457 
Investment Funds & Vehicles Investments
Drug Discovery & Development
Forbion Growth Opportunities Fund I C.V.Investment Funds & Vehicles11/16/2020 $2,847 $5,236 (5)(10)(17)
Forbion Growth Opportunities Fund II C.V.Investment Funds & Vehicles6/23/2022 1,242 1,387 (5)(10)(17)
Subtotal: Drug Discovery & Development (0.33%)*
4,089 6,623  
Software
Liberty Zim Co-Invest L.P.Investment Funds & Vehicles7/21/2022381 370 (5)(10)
Subtotal: Software (0.02%)*
381 370 
Total: Investment Funds & Vehicles Investments (0.35%)*
$4,470 $6,993 
Total Investments before Cash & Cash Equivalents (196.16%)*
$3,995,082 $3,924,450 
Cash & Cash Equivalents
GS Financial Square Government FundCash & Cash EquivalentsFGTXX/38141W273$26,000 $26,000 
Total: Investments in Cash & Cash Equivalents (1.30%)*
$26,000 $26,000 
Total: Investments after Cash & Cash Equivalents (197.46%)*
$4,021,082 $3,950,450 
Foreign Currency Forward Contracts
Foreign CurrencySettlement DateCounterpartyAmountTransactionUS $ Value at Settlement DateValue
Great British Pound (GBP)6/3/2025Goldman Sachs Bank USA£20,511 Sold$26,178 $(301)
Total Foreign Currency Forward ((0.02%))*
  $26,178 $(301)

See notes to consolidated financial statements
18

Table of Contents
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
March 31, 2025 (unaudited)
(dollars in thousands)
*Value as a percent of net assets. All amounts are stated in U.S. Dollars unless otherwise noted. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies.
(1)Prime represents 7.50% as of March 31, 2025. 1-month SOFR, 3-month SOFR and 6-month SOFR represent 4.32%, 4.29%, and 4.19%, respectively, as of March 31, 2025.
(2)Gross unrealized appreciation, gross unrealized depreciation, and net unrealized depreciation for federal income tax purposes totaled $110.7 million, $181.0 million and $70.3 million, respectively. The tax cost of investments is $4.0 billion.
(3)Preferred and common stock, warrants, and equity interests are generally non-income producing.
(4)Except for warrants in 21 publicly traded companies and common stock in 28 publicly traded companies, all investments are restricted as of March 31, 2025 and were valued at fair value using Level 3 significant unobservable inputs as determined in good faith by the Company’s valuation committee (the “Valuation Committee”) and approved by the board of directors (the “Board”).
(5)Non-U.S. company or the company’s principal place of business is outside the United States.
(6)Denotes that all or a portion of the investment in this portfolio company is held by Hercules SBIC V, L.P., the Company’s wholly owned small business investment company.
(7)Control investment as defined under the 1940 Act in which Hercules owns at least 25% of the company’s voting securities or has greater than 50% representation on its board.
(8)Debt is on non-accrual status as of March 31, 2025, and is therefore considered non-income producing.
(9)Denotes that all or a portion of the debt investment is convertible debt.
(10)Indicates assets that the Company deems not “qualifying assets” under section 55(a) of 1940 Act. Qualifying assets must represent at least 70% of the Company’s total assets at the time of acquisition of any additional non-qualifying assets.
(11)Denotes that all or a portion of the debt investment is pledged as collateral under the SMBC Facility (as defined in “Note 5 — Debt”).
(12)Denotes that all or a portion of the investment is pledged as collateral under the MUFG Bank Facility (as defined in “Note 5 — Debt”).
(13)Denotes that all or a portion of the debt investment secures the 2031 Asset-Backed Notes (as defined in “Note 5 — Debt”).
(14)Denotes that all or a portion of the debt investment principal includes accumulated PIK interest and is net of repayments.
(15)Denotes that all or a portion of the investment in this portfolio company is held by Hercules Capital IV, L.P., the Company’s wholly owned small business investment company.
(16)Denotes that the fair value of the Company’s total investments in this portfolio company represent greater than 5% of the Company’s total net assets as of March 31, 2025.
(17)Denotes that there is an unfunded contractual commitment available at the request of this portfolio company as of March 31, 2025 (Refer to “Note 11 - Commitments and Contingencies”).
(18)Denotes unitranche debt with first lien “last-out” senior secured position and security interest in all assets of the portfolio company whereby the “last-out” portion will be subordinated to the “first-out” portion in a liquidation, sale or other disposition.
(19)Denotes second lien senior secured debt.
(20)Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC.
(21)Denotes investment in a non-voting security in the form of a promissory note. The terms of the notes provide the Company with a lien on the issuers' shares of Common Stock for Black Crow AI, Inc., subject to release upon repayment of the outstanding balance of the notes. As of March 31, 2025, the Black Crow AI, Inc. affiliates promissory notes had an outstanding balance of $2.4 million.
(22)Denotes the security holds rights to royalty fee income associated with certain products of the portfolio company. The approximate cost and fair value of the royalty contract are $11.9 million and $11.7 million, respectively.
(23)Hercules Adviser LLC is owned by Hercules Capital Management LLC and presented with Hercules Partner Holdings, LLC which are both wholly owned by the Company. Please refer to “Note 1 – Description of Business” for additional disclosure.
(24)Denotes that the debt investment remains outstanding beyond its stated maturity date as it is subject to an ongoing workout process.
See notes to consolidated financial statements
19

Table of Contents
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2024
(dollars in thousands)
Portfolio CompanyType of
Investment
Maturity Date
Interest Rate and Floor (1)
Principal
Amount
Cost (2)
ValueFootnotes
Debt Investments
Biotechnology Tools
PathAI, Inc.Senior SecuredJanuary 2027
Prime + 2.15%, Floor rate 9.15%, 7.85% Exit Fee
$32,000 $32,801 $33,788 (12)(13)
Subtotal: Biotechnology Tools (1.70%)*
 32,801 33,788 
Communications & Networking   
Aryaka Networks, Inc.Senior SecuredDecember 2028
Prime + 1.80%, Floor rate 9.30%, PIK Interest 1.25%, 6.73% Exit Fee
$27,926 27,693 27,491 (17)(19)
Subtotal: Communications & Networking (1.38%)*
 27,693 27,491 
Consumer & Business Services   
Altumint, Inc.Senior SecuredDecember 2027
Prime + 3.65%, Floor rate 12.15%, 2.50% Exit Fee
$10,000 9,916 10,140 (15)
Carwow LTDSenior SecuredDecember 2027
Prime + 4.70%, Floor rate 11.45%, PIK Interest 1.45%, 4.95% Exit Fee
£20,361 27,818 25,264 (5)(10)(14)
GoEuro Travel GmbHSenior SecuredNovember 2029
Prime + 3.45%, Floor rate 10.45%, 4.50% Exit Fee
$48,750 48,276 48,276 (5)(10)(17)
Houzz, Inc.Convertible DebtMay 2028
PIK Interest 11.50%
$25,687 25,687 26,869 (9)(14)
Jobandtalent USA, Inc.Senior SecuredAugust 2025
1-month SOFR + 8.86%, Floor rate 9.75%, 2.89% Exit Fee
$13,011 13,276 12,994 (5)(10)
Plentific LtdSenior SecuredOctober 2026
Prime + 2.55%, Floor rate 11.05%, 2.95% Exit Fee
$3,325 3,282 3,340 (5)(10)(13)
ProviSenior SecuredDecember 2026
Prime + 4.40%, Floor rate 10.65%, 2.95% Exit Fee
$15,000 15,093 15,176 (15)
Riviera Partners LLCSenior SecuredApril 2027
3-month SOFR + 8.27%, Floor rate 9.27%
$36,493 36,104 35,017 (18)
RVShare, LLCSenior SecuredDecember 2026
3-month SOFR + 5.50%, Floor rate 6.50%, PIK Interest 4.00%
$30,073 29,798 29,678 (13)(14)(15)
SeatGeek, Inc.Senior SecuredMay 2026
Prime + 7.00%, Floor rate 10.50%, PIK Interest 0.50%, 4.00% Exit Fee
$25,327 25,413 25,821 (11)(14)(16)
Senior SecuredJuly 2026
Prime + 2.50%, Floor rate 10.75%, PIK Interest 0.50%, 3.00% Exit Fee
$78,038 77,438 79,691 (12)(14)(16)
Total SeatGeek, Inc.$103,365 102,851 105,512  
Skyword, Inc.Senior SecuredNovember 2027
Prime + 2.75%, Floor rate 9.25%, PIK Interest 1.75%, 3.00% Exit Fee
$6,587 6,715 6,637 (13)(14)
Tectura CorporationSenior SecuredJanuary 2027
FIXED 8.25%
$8,250 8,250 8,027 (7)
Thumbtack, Inc.Senior SecuredMarch 2028
Prime + 2.45%, Floor rate 10.95%, PIK Interest 1.50%
$20,918 20,561 21,192 (11)(14)(17)
Veem, Inc.Senior SecuredMarch 2027
Prime + 4.00%, Floor rate 12.00%, PIK Interest 1.25%, 4.50% Exit Fee
$5,172 5,350 5,322 (13)(14)
Senior SecuredMarch 2027
Prime + 4.70%, Floor rate 12.70%, PIK Interest 1.50%, 4.50% Exit Fee
$5,188 5,370 5,342 (12)(14)
Total Veem, Inc.$10,360 10,720 10,664  
Subtotal: Consumer & Business Services (18.03%)*
 358,347 358,786  
Diversified Financial Services    
Gibraltar Acquisition, LLCUnsecuredSeptember 2026
FIXED 3.45%, PIK Interest 8.05%
$26,569 26,337 26,337 (7)(14)(20)
 UnsecuredSeptember 2026
FIXED 11.95%
$10,000 9,875 9,875 (7)(20)
Total Gibraltar Acquisition, LLC$36,569 36,212 36,212  
Hercules Adviser LLCUnsecuredJune 2025
FIXED 5.00%
$12,000 12,000 12,000 (7)(23)
Next Insurance, Inc.Senior SecuredFebruary 2028
Prime - 1.50%, Floor rate 4.75%, PIK Interest 5.50%
$11,070 10,918 11,174 (13)(14)(19)
Subtotal: Diversified Financial Services (2.98%)*
  59,130 59,386  
Drug Discovery & Development
Adaptimmune Therapeutics plcSenior SecuredJune 2029
Prime + 1.15%, Floor rate 9.65%, PIK Interest 2.00%, 5.85% Exit Fee
$30,260 30,121 31,198 (5)(10)(11)(14)
Akero Therapeutics, Inc.Senior SecuredMarch 2027
Prime + 3.65%, Floor rate 7.65%, 5.85% Exit Fee
$17,500 17,706 18,005 (10)(13)(17)
Aldeyra Therapeutics, Inc.Senior SecuredApril 2026
Prime + 3.10%, Floor rate 11.10%, 8.90% Exit Fee
$15,000 15,046 15,153 (11)
Alector, Inc.Senior SecuredDecember 2028
Prime + 1.05%, Floor rate 8.05%, 4.75% Exit Fee
$7,000 6,930 6,930 (6)(10)(15)(17)
See notes to consolidated financial statements
20

Table of Contents
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2024
(dollars in thousands)
Portfolio CompanyType of
Investment
Maturity Date
Interest Rate and Floor (1)
Principal
Amount
Cost (2)
ValueFootnotes
AmplifyBio, LLCSenior SecuredJanuary 2027
Prime + 2.50%, Floor rate 9.50%, Cap rate 10.75%, 5.85% Exit Fee
$24,000 $24,640 $24,940 (15)
Arcus Biosciences, Inc.Senior SecuredSeptember 2029
Prime + 1.95%, Floor rate 10.45%, 7.75% Exit Fee
$37,500 37,379 37,379 (6)(10)(15)(17)
ATAI Life Sciences N.V.Senior SecuredAugust 2026
Prime + 4.30%, Floor rate 9.05%, 6.95% Exit Fee
$14,000 14,442 14,385 (5)(10)(17)
Axsome Therapeutics, Inc.Senior SecuredJanuary 2028
Prime + 2.20%, Floor rate 9.95%, Cap rate 10.70%, 5.78% Exit Fee
$143,350 145,451 152,945 (10)(11)(12)(16)
bluebird bio, Inc.Senior SecuredApril 2029
Prime + 1.45%, Floor rate 9.95%, PIK Interest 2.45%, 6.45% Exit Fee
$65,655 64,028 55,344 (14)
Braeburn, Inc.Senior SecuredOctober 2028
Prime + 2.45%, Floor rate 10.95%, PIK Interest 1.10%, 5.45% Exit Fee
$53,192 53,374 55,626 (14)
COMPASS Pathways plcSenior SecuredJuly 2027
Prime + 1.50%, Floor rate 9.75%, PIK Interest 1.40%, 4.75% Exit Fee
$24,490 24,613 25,608 (5)(10)(11)(14)
Corium, Inc.Senior SecuredSeptember 2026
Prime + 5.70%, Floor rate 8.95%, 7.75% Exit Fee
$105,225 109,543 109,178 (13)(16)
Disc Medicine, Inc.Senior SecuredDecember 2029
Prime + 1.75%, Floor rate 8.25%, 6.75% Exit Fee
$22,500 22,363 22,363 (6)(10)(15)(17)
Eloxx Pharmaceuticals, Inc.Senior SecuredApril 2025
Prime + 6.25%, Floor rate 9.50%, 4.00% Exit Fee
$489 988 988 (15)
enGene, Inc.Senior SecuredJanuary 2028
Prime + 0.75%, Floor rate 9.25%, Cap rate 9.75%, PIK Interest 1.15%, 5.50% Exit Fee
$15,924 16,015 16,149 (5)(10)(14)
Heron Therapeutics, Inc.Senior SecuredFebruary 2026
Prime + 1.70%, Floor rate 9.95%, PIK Interest 1.50%, 3.00% Exit Fee
$20,404 20,484 21,014 (14)(15)(17)
Hibercell, Inc.Senior SecuredMay 2025
Prime + 5.40%, Floor rate 8.65%, 4.95% Exit Fee
$3,963 4,755 4,749 (13)(15)
Kura Oncology, Inc.Senior SecuredNovember 2027
Prime + 2.40%, Floor rate 8.65%, 6.05% Exit Fee
$5,500 5,622 5,721 (10)(15)
Madrigal Pharmaceutical, Inc.Senior SecuredMay 2027
Prime + 2.45%, Floor rate 8.25%, 5.35% Exit Fee
$78,200 79,896 82,775 (10)(13)
NorthSea TherapeuticsConvertible DebtDecember 2025
FIXED 6.00%
$273 273 273 (5)(9)(10)
Phathom Pharmaceuticals, Inc.Senior SecuredDecember 2027
Prime + 1.35%, Floor rate 9.85%, Cap rate 10.35%, PIK Interest 2.15%, 6.22% Exit Fee
$169,234 171,805 176,130 (6)(10)(12)(14) (15)(16)(22)
Replimune Group, Inc.Senior SecuredOctober 2027
Prime + 1.75%, Floor rate 7.25%, Cap rate 9.00%, PIK Interest 1.50%, 4.95% Exit Fee
$31,889 32,294 33,745 (10)(12)(13)(14)
SynOx Therapeutics LimitedSenior SecuredMay 2027
Prime + 1.40%, Floor rate 9.90%, 7.25% Exit Fee
$4,500 4,471 4,573 (5)(10)(11)
uniQure B.V.Senior SecuredJanuary 2027
Prime + 4.70%, Floor rate 7.95%, 6.10% Exit Fee
$35,000 36,102 37,135 (5)(10)(11)(12)
Viridian Therapeutics, Inc.Senior SecuredOctober 2026
Prime + 4.20%, Floor rate 7.45%, Cap rate 8.95%, 6.00% Exit Fee
$8,000 8,231 8,523 (10)(13)(17)
X4 Pharmaceuticals, Inc.Senior SecuredJuly 2027
Prime + 3.15%, Floor rate 10.15%, 3.72% Exit Fee
$75,000 75,512 75,725 (11)(12)(13)
Subtotal: Drug Discovery & Development (52.10%)*
 1,022,084 1,036,554  
Electronics & Computer Hardware    
Locus Robotics Corp.Senior SecuredDecember 2028
Prime + 3.00%, Floor rate 9.50%, 4.00% Exit Fee
$48,750 48,557 47,986 (6)(15)(17)
Shield AI, Inc.Senior SecuredFebruary 2029
Prime + 0.85%, Floor rate 6.85%, Cap rate 9.60%, PIK Interest 2.50%, 2.50% Exit Fee
$113,766 112,911 113,701 (12)(14)(16)
Subtotal: Electronics & Computer Hardware (8.13%)*
 161,468 161,687  
Healthcare Services, Other    
Blue Sprig Pediatrics, Inc.Senior SecuredNovember 2026
3-month SOFR + 5.26%, Floor rate 6.00%, PIK Interest 4.45%
$72,220 71,677 70,459 (11)(12)(13)(14)
Carbon Health Technologies, Inc.Senior SecuredJune 2026
Prime - 1.50%, Floor rate 7.00%, PIK Interest 7.00%, 5.64% Exit Fee
$41,473 43,348 41,610 (11)(13)(14)
Convertible DebtDecember 2025
FIXED 12.00%
$202 202 202 (9)
Total Carbon Health Technologies, Inc.$41,675 43,550 41,812 
Curana Health Holdings, LLCSenior SecuredJanuary 2028
Prime + 1.45%, Floor rate 9.20%, 4.95% Exit Fee
$27,500 27,722 28,207 (13)(17)(19)
Equality Health, LLCSenior SecuredFebruary 2026
Prime + 4.25%, Floor rate 9.50%, PIK Interest 1.55%, 1.11% Exit Fee
$70,678 70,473 70,062 (11)(12)(14)
Main Street Rural, Inc.Senior SecuredJuly 2027
Prime + 1.95%, Floor rate 9.95%, 6.85% Exit Fee
$38,500 39,089 39,582 (13)(15)(17)
See notes to consolidated financial statements
21

Table of Contents
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2024
(dollars in thousands)
Portfolio CompanyType of
Investment
Maturity Date
Interest Rate and Floor (1)
Principal
Amount
Cost (2)
ValueFootnotes
Marathon Health, LLCSenior SecuredFebruary 2029
Prime - 0.90%, Floor rate 7.10%, PIK Interest 4.00%, 3.00% Exit Fee
$159,176 $158,410 $161,882 (14)(16)(17)
Senior SecuredFebruary 2029
Prime + 3.00%, Floor rate 11.00%
$5,000 5,000 5,000 (16)(17)
Total Marathon Health, LLC$164,176 163,410 166,882 
Modern Life, Inc.Senior SecuredFebruary 2027
Prime + 2.75%, Floor rate 8.75%, 5.00% Exit Fee
$18,200 18,299 18,340 (13)
NeueHealth, Inc.Senior SecuredJune 2028
Prime + 1.15%, Floor rate 9.65%, PIK Interest 2.50%, 2.50% Exit Fee
$25,031 24,236 24,587 (12)(14)
Recover Together, Inc.Senior SecuredJuly 2027
Prime + 1.90%, Floor rate 10.15%, 7.50% Exit Fee
$45,000 45,431 45,741 (13)
Strive Health Holdings, LLCSenior SecuredSeptember 2027
Prime + 0.70%, Floor rate 9.20%, 5.95% Exit Fee
$30,000 29,742 30,587 (15)(17)
Vida Health, Inc.Senior SecuredOctober 2026
Prime - 2.75%, Floor rate 5.75%, PIK Interest 5.35%, 4.95% Exit Fee
$36,761 37,367 36,772 (11)(14)
WellBe Senior Medical, LLCSenior SecuredMay 2029
Prime + 0.75%, Floor rate 7.75%, PIK Interest 2.65%, 6.75% Exit Fee
$28,283 28,144 27,551 (14)(15)(17)
Subtotal: Healthcare Services, Other (30.19%)*
 599,140 600,582  
Information Services    
Saama Technologies, LLCSenior SecuredJuly 2027
Prime + 0.70%, Floor rate 8.95%, PIK Interest 2.00%, 2.95% Exit Fee
$19,779 19,741 20,445 (12)(14)(17)
Subtotal: Information Services (1.03%)*
 19,741 20,445  
Medical Devices & Equipment
Orchestra BioMed Holdings, Inc.Senior SecuredNovember 2028
Prime + 2.00%, Floor rate 9.50%, 6.35% Exit Fee
$15,000 14,740 14,740 (6)(15)
Senseonics Holdings, Inc.Senior SecuredSeptember 2027
Prime + 1.40%, Floor rate 9.90%, 6.95% Exit Fee
$30,625 30,830 31,519 (11)
Sight Sciences, Inc.Senior SecuredJuly 2028
Prime + 2.35%, Floor rate 10.35%, 5.95% Exit Fee
$28,000 27,830 28,127 (6)
Subtotal: Medical Devices & Equipment (3.74%)*
73,400 74,386 
Software   
3GTMS, LLCSenior SecuredFebruary 2025
3-month SOFR + 10.40%, Floor rate 11.30%
$13,279 13,268 13,268 (11)(17)(18)
Senior SecuredFebruary 2025
3-month SOFR + 7.25%, Floor rate 8.15%
$6,194 6,185 6,185 (17)(18)
Total 3GTMS, LLC$19,473 19,453 19,453  
Alchemer LLCSenior SecuredMay 2028
3-month SOFR + 8.14%, Floor rate 9.14%
$21,251 20,923 21,251 (13)(18)
Allvue Systems, LLCSenior SecuredSeptember 2029
3-month SOFR + 6.25%, Floor rate 7.25%
$42,564 41,704 41,628 (17)
AlphaSense, Inc.Senior SecuredJune 2029
3-month SOFR + 6.25%, Floor rate 8.25%
$20,000 19,816 19,578 (17)
Annex CloudSenior SecuredFebruary 2027
3-month SOFR + 10.00%, Floor rate 11.00%
$11,338 11,205 10,556 (13)(18)
Armis, Inc.Senior SecuredMarch 2028
Prime + 0.00%, Floor rate 7.50%, PIK Interest 2.00%, 2.25% Exit Fee
$50,733 50,496 51,357 (12)(14)(17)
Senior SecuredMarch 2028
Prime + 1.25%, Floor rate 7.50%, PIK Interest 2.00%, 2.25% Exit Fee
$25,150 24,968 25,082 (14)(17)
Total Armis, Inc.$75,883 75,464 76,439 
Babel StreetSenior SecuredDecember 2027
3-month SOFR + 8.01%, Floor rate 9.01%
$65,336 64,061 65,263 (15)(17)(18)
Behavox LimitedSenior SecuredSeptember 2027
Prime - 0.55%, Floor rate 7.45%, PIK Interest 3.00%, 4.95% Exit Fee
$10,550 10,534 10,360 (5)(10)(14)
Brain CorporationSenior SecuredSeptember 2028
Prime + 1.35%, Floor rate 9.85%, PIK Interest 2.50%, 3.95% Exit Fee
$32,009 31,704 31,984 (13)(14)
Ceros, Inc.Senior SecuredSeptember 2026
3-month SOFR + 8.99%, Floor rate 9.89%
$22,762 22,515 22,183 (17)(18)
Copper CRM, IncSenior SecuredMarch 2025
Prime + 4.50%, Floor rate 8.25%, Cap rate 10.25%, PIK Interest 1.95%, 4.50% Exit Fee
$8,515 8,839 8,839 (11)(14)
CoreView USA, Inc.Senior SecuredJanuary 2029
Prime + 2.75%, Floor rate 9.25%, 4.95% Exit Fee
$25,000 24,731 24,731 (6)(17)
Coronet Cyber Security Ltd.Senior SecuredOctober 2028
Prime - 2.95%, Floor rate 3.55%, PIK Interest 5.85%
$8,591 8,446 8,446 (14)(17)
Cutover, Inc.Senior SecuredOctober 2025
Prime + 5.20%, Floor rate 9.95%, 4.95% Exit Fee
$5,500 5,667 5,667 (5)(10)(12)
See notes to consolidated financial statements
22

Table of Contents
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2024
(dollars in thousands)
Portfolio CompanyType of
Investment
Maturity Date
Interest Rate and Floor (1)
Principal
Amount
Cost (2)
ValueFootnotes
Senior SecuredOctober 2025
Prime + 5.20%, Floor rate 9.95%, 4.95% Exit Fee
£1,250 $1,612 $1,594 (5)(10)
Total Cutover, Inc.7,279 7,261 
Dashlane, Inc.Senior SecuredDecember 2027
Prime + 3.05%, Floor rate 11.55%, PIK Interest 1.10%, 6.28% Exit Fee
$45,476 46,450 47,708 (11)(13)(14)(17)(19)
Dispatch Technologies, Inc.Senior SecuredApril 2028
3-month SOFR + 8.01%, Floor rate 8.76%
$8,896 8,758 8,641 (17)(18)
Dragos, Inc.Senior SecuredJuly 2027
Prime + 2.00%, Floor rate 8.75%, PIK Interest 2.00%, 2.00% Exit Fee
$13,022 12,383 12,431 (14)(17)
DroneDeploy, Inc.Senior SecuredNovember 2028
Prime + 2.45%, Floor rate 9.95%, 5.00% Exit Fee
$9,375 9,255 9,274 (13)(17)
Earnix, Inc.Senior SecuredJune 2029
Prime - 1.15%, Floor rate 5.35%, PIK Interest 4.45%
$19,166 18,856 18,838 (11)(14)(17)
Elation Health, Inc.Senior SecuredMarch 2026
Prime + 4.25%, Floor rate 9.00%, PIK Interest 1.95%, 3.95% Exit Fee
$12,878 12,860 13,215 (11)(14)(19)
Flight Schedule Pro, LLCSenior SecuredOctober 2027
1-month SOFR + 7.80%, Floor rate 8.70%
$7,297 7,145 7,271 (17)(18)
Fortified Health SecuritySenior SecuredDecember 2027
1-month SOFR + 7.64%, Floor rate 8.54%
$7,000 6,882 6,950 (11)(17)(18)
Harness, Inc.Senior SecuredMarch 2029
Prime - 2.25%, Floor rate 5.25%, Cap rate 6.50%, PIK Interest 6.25%, 1.00% Exit Fee
$18,132 17,947 18,060 (14)(17)(19)
iGrafx, LLCSenior SecuredMay 2027
1-month SOFR + 8.61%, Floor rate 9.51%, 0.47% Exit Fee
$4,950 4,879 4,869 (18)
KhorosSenior SecuredJanuary 2025
3-month SOFR + 4.50%, Floor rate 5.50%, PIK Interest 4.50%
$61,341 61,317 18,231 (8)(14)
Leapwork ApSSenior SecuredFebruary 2026
Prime + 0.25%, Floor rate 7.00%, PIK Interest 1.95%, 2.70% Exit Fee
$8,890 8,883 9,117 (5)(10)(12)(14)
LinenMaster, LLCSenior SecuredAugust 2028
1-month SOFR + 6.25%, Floor rate 7.25%, PIK Interest 2.15%
$15,428 15,189 15,481 (12)(14)(17)
Loftware, Inc.Senior SecuredMarch 2028
3-month SOFR + 7.88%, Floor rate 8.88%
$27,206 26,726 27,399 (17)(18)
LogicSourceSenior SecuredJuly 2027
1-month SOFR + 8.93%, Floor rate 9.93%
$13,145 12,974 13,145 (17)(18)
LogRhythm, Inc.Senior SecuredJuly 2029
1-month SOFR + 7.50%, Floor rate 8.50%
$25,000 24,305 24,305 (17)
Marigold Group, Inc. (p.k.a. Campaign Monitor Limited)Senior SecuredNovember 2026
PIK Interest 6-month SOFR + 10.55%, Floor rate 11.55%
$38,828 38,336 32,773 (13)(14)(19)
Mobile Solutions ServicesSenior SecuredDecember 2025
3-month SOFR + 9.21%, Floor rate 10.06%
$18,366 18,237 17,616 (18)
Morphisec Information Security 2014 Ltd.Senior SecuredOctober 2027
Prime + 3.45%, Floor rate 11.70%, 5.95% Exit Fee
$10,000 9,861 9,861 (5)(10)
New Relic, Inc.Senior SecuredNovember 2030
1-month SOFR + 6.75%, Floor rate 7.75%
$21,890 21,402 21,644 (17)
Omeda Holdings, LLCSenior SecuredJuly 2027
3-month SOFR + 8.05%, Floor rate 9.05%
$7,669 7,518 7,669 (11)(17)(18)
PayIt, LLCSenior SecuredDecember 2028
Prime + 1.45%, Floor rate 7.95%, PIK Interest 1.50%, 5.00% Exit Fee
$12,003 11,881 11,881 (6)(14)(15)(17)(19)
Pindrop Security, Inc.Senior SecuredJune 2029
Prime + 3.50%, Floor rate 10.00%, 2.00% Exit Fee
$31,000 30,566 30,671 (15)(17)
Remodel Health Holdco, LLCSenior SecuredDecember 2028
Prime + 2.35%, Floor rate 10.35%, 6.50% Exit Fee
$25,000 24,723 24,723 (6)(15)
ReveleerSenior SecuredFebruary 2027
Prime + 0.65%, Floor rate 9.15%, PIK Interest 2.00%, 5.05% Exit Fee
$36,345 36,403 36,525 (14)(15)
Semperis Technologies Inc.Senior SecuredApril 2028
Prime - 1.75%, Floor rate 6.75%, PIK Interest 3.25%
$22,754 22,596 23,066 (11)(14)(19)
ShadowDragon, LLCSenior SecuredDecember 2026
3-month SOFR + 8.88%, Floor rate 9.78%
$6,000 5,918 5,953 (17)(18)
Simon Data, Inc.Senior SecuredMarch 2027
Prime + 1.00%, Floor rate 8.75%, PIK Interest 1.95%, 2.95% Exit Fee
$13,087 13,152 13,175 (12)(14)
Sisense Ltd.Senior SecuredJuly 2027
Prime + 1.50%, Floor rate 9.50%, PIK Interest 1.95%, 5.95% Exit Fee
$33,760 34,152 34,193 (5)(10)(14)
Streamline Healthcare SolutionsSenior SecuredMarch 2028
3-month SOFR + 7.25%, Floor rate 8.25%
$17,600 17,324 17,688 (11)(13)(17)(18)
Sumo Logic, Inc.Senior SecuredMay 2030
3-month SOFR + 6.50%, Floor rate 7.50%
$23,000 22,521 23,113 (17)
Suzy, Inc.Senior SecuredAugust 2027
Prime + 1.75%, Floor rate 10.00%, PIK Interest 1.95%, 3.45% Exit Fee
$24,345 24,031 24,935 (6)(14)(15)(17)
TaxCalcSenior SecuredNovember 2029
3-month SONIA + 8.05%, Floor rate 8.55%
£7,500 9,518 9,198 (5)(10)(17)(18)
ThreatConnect, Inc.Senior SecuredMay 2026
3-month SOFR + 9.15%, Floor rate 10.00%
$12,324 12,208 12,324 (18)
See notes to consolidated financial statements
23

Table of Contents
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2024
(dollars in thousands)
Portfolio CompanyType of
Investment
Maturity Date
Interest Rate and Floor (1)
Principal
Amount
Cost (2)
ValueFootnotes
Tipalti Solutions Ltd.Senior SecuredApril 2027
Prime + 0.45%, Floor rate 6.45%, PIK Interest 2.00%, 3.75% Exit Fee
$42,670 $42,379 $43,448 (5)(10)(14)
Zappi, Inc.Senior SecuredDecember 2027
3-month SOFR + 8.03%, Floor rate 9.03%
$12,729 12,522 12,756 (5)(10)(13)(17)(18)
Zimperium, Inc.Senior SecuredMay 2027
3-month SOFR + 8.31%, Floor rate 9.31%
$14,790 14,618 14,444 (17)(18)
Subtotal: Software (52.80%)*
 1,091,349 1,050,563  
Space Technologies
Voyager Technologies, Inc.Senior SecuredJuly 2028
Prime + 1.25%, Floor rate 9.75%, PIK Interest 2.50%, 5.50% Exit Fee
$45,439 45,302 45,690 (11)(14)(15)
Subtotal: Space Technologies (2.30%)*
45,302 45,690 
Sustainable and Renewable Technology    
Ampion, PBCSenior SecuredMay 2025
Prime + 4.70%, Floor rate 7.95%, PIK Interest 1.45%, 3.95% Exit Fee
$3,984 4,102 4,141 (13)(14)
Electric Hydrogen Co.Senior SecuredMay 2028
Prime + 2.25%, Floor rate 10.75%, PIK Interest 1.25%, 4.89% Exit Fee
$20,127 19,687 19,830 (14)(15)(19)
SUNation Energy, Inc. (p.k.a. Pineapple Energy LLC)Senior SecuredJune 2027
FIXED 10.00%
$1,296 1,297 1,272 (19)
Subtotal: Sustainable and Renewable Technology (1.27%)*
 25,086 25,243  
Total: Debt Investments (175.65%)*
 $3,515,541 $3,494,601  
Portfolio CompanyType of
Investment
Acquisition Date(4)
Series (3)
Shares
Cost (2)
ValueFootnotes
Equity Investments
Biotechnology Tools
Alamar Biosciences, Inc.Equity2/21/2024Preferred Series C503,778 $1,500 $1,423 
Subtotal: Biotechnology Tools (0.07%)*
1,500 1,423 
Consumer & Business Products
Fabletics, Inc.Equity4/30/2010Common Stock42,989128 46 
Equity7/16/2013Preferred Series B130,1911,101 299  
Total Fabletics, Inc.173,180 1,229 345  
Grove Collaborative, Inc.Equity4/30/2021Common Stock12,260433 17 (4)
Savage X Holding, LLCEquity4/30/2010Class A Units172,32813 421 
Subtotal: Consumer & Business Products (0.04%)*
1,675 783  
Consumer & Business Services
Carwow LTDEquity12/15/2021Preferred Series D-4216,0731,151 627 (5)(10)
Lyft, Inc.Equity12/26/2018Common Stock100,7385,263 1,299 (4)
Nerdy Inc.Equity9/17/2021Common Stock100,0001,000 162 (4)
OfferUp, Inc.Equity10/25/2016Preferred Series A286,0801,663 467  
Equity10/25/2016Preferred Series A-1108,710632 177  
Total OfferUp, Inc.394,7902,295 644 
OportunEquity6/28/2013Common Stock48,365577 188 (4)
Reischling Press, Inc.Equity7/31/2020Common Stock3,09539  
Rhino Labs, Inc.Equity1/24/2022Common Stock7,0631,000   
Tectura CorporationEquity5/23/2018Common Stock414,994,863900 7 (7)
See notes to consolidated financial statements
24

Table of Contents
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2024
(dollars in thousands)
Portfolio CompanyType of
Investment
Acquisition Date(4)
Series (3)
Shares
Cost (2)
ValueFootnotes
Equity6/6/2016Preferred Series BB1,000,000$ $17 (7)
Equity12/29/2023Preferred Series C3,235,29813,263 3,606 (7)
Total Tectura Corporation 419,230,16114,163 3,630  
Worldremit Group LimitedEquity6/24/2024Preferred Series X9,737922 952 (5)(10)
Subtotal: Consumer & Business Services (0.38%)*
26,410 7,502  
Diversified Financial Services      
Gibraltar Acquisition, LLCEquity3/1/2018Member Units134,006 23,051 (7)(20)
Hercules Adviser LLCEquity3/26/2021Member Units135 30,190 (7)(23)
Newfront Insurance Holdings, Inc.Equity9/30/2021Preferred Series D-2210,282403 404 
Subtotal: Diversified Financial Services (2.70%)*
34,444 53,645  
Drug Delivery   
Aytu BioScience, Inc.Equity3/28/2014Common Stock6801,500 1 (4)
BioQ Pharma IncorporatedEquity12/8/2015Preferred Series D165,000500  
PDS Biotechnology CorporationEquity4/6/2015Common Stock2,498309 4 (4)
Talphera, Inc.Equity12/10/2018Common Stock8,8361,329 5 (4)
Subtotal: Drug Delivery (0.00%)*
3,638 10  
Drug Discovery & Development     
Akero Therapeutics, Inc.Equity3/8/2024Common Stock34,4831,000 959 (4)(10)
Avalo Therapeutics, Inc.Equity8/19/2014Common Stock421,000  (4)
Axsome Therapeutics, Inc.Equity5/9/2022Common Stock127,0214,165 10,747 (4)(10)(16)
Bicycle Therapeutics PLCEquity10/5/2020Common Stock98,1001,871 1,373 (4)(5)(10)
BridgeBio Pharma, Inc.Equity6/21/2018Common Stock231,3292,255 6,348 (4)
Cyclo Therapeutics, Inc.Equity4/6/2021Common Stock13442  (4)(10)
Dare Biosciences, Inc.Equity1/8/2015Common Stock1,1291,000 4 (4)
Dynavax TechnologiesEquity7/22/2015Common Stock20,000550 256 (4)(10)
Heron Therapeutics, Inc.Equity7/25/2023Common Stock364,963500 558 (4)
Hibercell, Inc.Equity5/7/2021Preferred Series B3,466,8404,250 328 (15)
HilleVax, Inc.Equity5/3/2022Common Stock235,2954,000 487 (4)
Kura Oncology, Inc.Equity6/16/2023Common Stock47,826550 417 (4)(10)
Madrigal Pharmaceutical, Inc.Equity9/29/2023Common Stock5,100773 1,574 (4)(10)
NorthSea TherapeuticsEquity12/15/2021Preferred Series C9832,000 1,241 (5)(10)
Phathom Pharmaceuticals, Inc.Equity6/9/2023Common Stock147,2331,730 1,196 (4)(10)(16)
Rocket Pharmaceuticals, Ltd.Equity8/22/2007Common Stock9441,500 12 (4)
Savara, Inc.Equity8/11/2015Common Stock11,119203 34 (4)
uniQure B.V.Equity1/31/2019Common Stock17,175332 303 (4)(5)(10)
Valo Health, LLCEquity12/11/2020Preferred Series B510,3083,000 1,134 
Equity10/31/2022Preferred Series C170,1021,000 762 
Total Valo Health, LLC680,4104,000 1,896  
See notes to consolidated financial statements
25

Table of Contents
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2024
(dollars in thousands)
Portfolio CompanyType of
Investment
Acquisition Date(4)
Series (3)
Shares
Cost (2)
ValueFootnotes
Verge Analytics, Inc.Equity9/6/2023Preferred Series C208,588$1,500 $1,519  
Viridian Therapeutics, Inc.Equity11/6/2023Common Stock32,310400 619 (4)(10)
X4 Pharmaceuticals, Inc.Equity11/26/2019Common Stock1,566,0642,945 1,149 (4)
Subtotal: Drug Discovery & Development (1.56%)*
36,566 31,020  
Electronics & Computer Hardware
Locus Robotics Corp.Equity11/17/2022Preferred Series F15,116650 294  
Skydio, Inc.Equity3/8/2022Preferred Series E248,9001,500 643  
Subtotal: Electronics & Computer Hardware (0.05%)*
2,150 937  
Healthcare Services, Other
23andMe, Inc.Equity3/11/2019Common Stock41,2865,094 134 (4)
Carbon Health Technologies, Inc.Equity3/30/2021Preferred Series C217,8801,687 2  
Click Therapeutics, Inc.Equity5/20/2024Common Stock560,0001,662 1,825 (15)
Curana Health Holdings, LLCEquity5/13/2024Common Units1,114,3802,500 2,603 
Main Street Rural, Inc.Equity10/28/2024Preferred Series D496874 874 
WellBe Senior Medical, LLCEquity6/10/2024Common Units181,1631,600 2,065 
Subtotal: Healthcare Services, Other (0.38%)*
13,417 7,503  
Information Services      
Yipit, LLCEquity12/30/2021Preferred Series E41,0213,825 3,898  
Subtotal: Information Services (0.20%)*
3,825 3,898  
Medical Devices & Equipment     
Coronado Aesthetics, LLCEquity10/15/2021Common Units180,000  (7)
Equity10/15/2021Preferred Series A-25,000,000250 69 (7)
Total Coronado Aesthetics, LLC   5,180,000250 69  
Subtotal: Medical Devices & Equipment (0.00%)*
250 69  
Semiconductors     
Achronix Semiconductor CorporationEquity7/1/2011Preferred Series C277,995160 210  
Subtotal: Semiconductors (0.01%)*
160 210  
Software     
3GTMS, LLCEquity8/9/2021Common Stock1,000,0001,000 666  
Armis, Inc.Equity10/18/2024Preferred Series D294,2132,000 2,000 
Black Crow AI, Inc. affiliatesEquity3/24/2021Preferred Note32,406 2,406 (21)
CapLinked, Inc.Equity10/26/2012Preferred Series A-353,61451   
Contentful Global, Inc.Equity12/22/2020Preferred Series C41,000138 257 (5)(10)
Equity11/20/2018Preferred Series D108,500500 722 (5)(10)
Total Contentful Global, Inc.   149,500638 979  
DNAnexus, Inc.Equity3/21/2014Preferred Series C51,94897 5 
Docker, Inc.Equity11/29/2018Common Stock20,0004,284 198  
Druva Holdings, Inc.Equity10/22/2015Preferred Series 2458,8411,000 5,194  
See notes to consolidated financial statements
26

Table of Contents
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2024
(dollars in thousands)
Portfolio CompanyType of
Investment
Acquisition Date(4)
Series (3)
Shares
Cost (2)
ValueFootnotes
 Equity8/24/2017Preferred Series 393,620$300 $1,075  
Total Druva Holdings, Inc.   552,4611,300 6,269  
HighRoads, Inc.Equity1/18/2013Common Stock190307   
Leapwork ApSEquity8/25/2023Preferred Series B2183,073250 132 (5)(10)
Lightbend, Inc.Equity12/4/2020Common Stock38,461265 24 
Nextdoor.com, Inc.Equity8/1/2018Common Stock1,019,2554,854 2,416 (4)
SingleStore, Inc.Equity11/25/2020Preferred Series E580,9832,000 1,988  
Equity8/12/2021Preferred Series F52,956280 216  
Total SingleStore, Inc.633,9392,280 2,204 
SirionLabs Pte. Ltd.Equity6/30/2024Preferred Series F1152,2501,792 1,996 (5)(10)
Verana Health, Inc.Equity7/8/2021Preferred Series E952,5622,000 370  
Subtotal: Software (0.99%)*
23,524 19,665  
Sustainable and Renewable Technology     
Impossible Foods, Inc.Equity5/10/2019Preferred Series E-1188,6112,000 106  
Modumetal, Inc.Equity6/1/2015Common Stock1,035500   
Pivot Bio, Inc.Equity6/28/2021Preferred Series D593,080 4,500 1,885 
SUNation Energy, Inc. (p.k.a. Pineapple Energy LLC)Equity12/10/2020Common Stock4053,153 1 (4)
Subtotal: Sustainable and Renewable Technology (0.10%)*
10,153 1,992  
Total: Equity Investments (6.47%)*
 $157,712 $128,657  
Warrant Investments
Biotechnology Tools
Alamar Biosciences, Inc.Warrant6/21/2022Preferred Series C75,567$36 $122 
PathAI, Inc.Warrant12/23/2022Common Stock53,418460 101 (12)
Subtotal: Biotechnology Tools (0.01%)*
496 223 
Communications & Networking 
Aryaka Networks, Inc.Warrant6/28/2022Common Stock486,097242 209 (12)
Subtotal: Communications & Networking (0.01%)*
242 209 
Consumer & Business Products
Gadget Guard, LLCWarrant6/3/2014Common Stock1,662,441228  
Whoop, Inc.Warrant6/27/2018Preferred Series C686,27017 714 
Subtotal: Consumer & Business Products (0.04%)*
245 714 
Consumer & Business Services
Altumint, Inc.Warrant10/31/2024Common Stock1,701127 129 (15)
Carwow LTDWarrant12/14/2021Common Stock174,163164 55 (5)(10)
Warrant2/13/2024Preferred Series D-4109,25720 11 (5)(10)
Total Carwow LTD283,420184 66 
Houzz, Inc.Warrant10/29/2019Common Stock529,66120   
See notes to consolidated financial statements
27

Table of Contents
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2024
(dollars in thousands)
Portfolio CompanyType of
Investment
Acquisition Date(4)
Series (3)
Shares
Cost (2)
ValueFootnotes
Landing Holdings Inc.Warrant3/12/2021Common Stock11,806$116 $115 (15)
Lendio, Inc.Warrant3/29/2019Preferred Series D127,03239 10  
Plentific LtdWarrant10/3/2023Ordinary Shares27,29860 38 (5)(10)
ProviWarrant12/22/2022Common Stock117,042166 77 (15)
Rhino Labs, Inc.Warrant3/12/2021Common Stock13,106470  (15)
SeatGeek, Inc.Warrant6/12/2019Common Stock1,604,7241,242 4,901 (12)(16)
Skyword, Inc.Warrant11/14/2022Common Stock1,607,14357 28  
Warrant8/23/2019Preferred Series B444,44483 3  
Total Skyword, Inc.2,051,587140 31  
Snagajob.com, Inc.Warrant4/20/2020Common Stock600,00016   
Warrant6/30/2016Preferred Series A1,800,000782   
 Warrant8/1/2018Preferred Series B1,211,53762   
Total Snagajob.com, Inc.   3,611,537860   
Thumbtack, Inc.Warrant5/1/2018Common Stock343,497985 878 
Veem, Inc.Warrant3/31/2022Common Stock98,428126 13 (12)
Worldremit Group LimitedWarrant2/11/2021Preferred Series D77,215129 95 (5)(10)
 Warrant8/27/2021Preferred Series E1,86826  (5)(10)
Total Worldremit Group Limited   79,083155 95  
Subtotal: Consumer & Business Services (0.32%)*
4,690 6,353  
Diversified Financial Services
Next Insurance, Inc.Warrant2/3/2023Common Stock522,930214 460 
Subtotal: Diversified Financial Services (0.02%)*
214 460 
Drug Discovery & Development      
Akero Therapeutics, Inc.Warrant6/15/2022Common Stock32,190330 519 (4)(10)
AmplifyBio, LLCWarrant12/27/2022Class A Units69,239238 151 (15)
Axsome Therapeutics, Inc.Warrant9/25/2020Common Stock61,0041,290 1,528 (4)(10)(12)(16)
bluebird bio, Inc.Warrant3/15/2024Common Stock111,2061,744  
Cellarity, Inc.Warrant12/8/2021Preferred Series B100,000287 103 (15)
Century Therapeutics, Inc.Warrant9/14/2020Common Stock16,11237  (4)
COMPASS Pathways plcWarrant6/30/2023Ordinary Shares75,376278 48 (4)(5)(10)
Curevo, Inc.Warrant6/9/2023Common Stock95,221233 154 (15)
enGene, Inc.Warrant12/22/2023Common Stock43,689118 102 (4)(5)(10)
Fresh Tracks Therapeutics, Inc.Warrant2/18/2016Common Stock201119  (4)
Heron Therapeutics, Inc.Warrant8/9/2023Common Stock238,095228 166 (4)(15)
Kineta, Inc.Warrant12/20/2019Common Stock2,202110  (4)
Kura Oncology, Inc.Warrant11/2/2022Common Stock14,34288 16 (4)(10)(15)
Madrigal Pharmaceutical, Inc.Warrant5/9/2022Common Stock13,229570 2,133 (4)(10)
Phathom Pharmaceuticals, Inc.Warrant9/17/2021Common Stock64,687848 22 (4)(10)(12)(15)(16)
See notes to consolidated financial statements
28

Table of Contents
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2024
(dollars in thousands)
Portfolio CompanyType of
Investment
Acquisition Date(4)
Series (3)
Shares
Cost (2)
ValueFootnotes
Redshift Bioanalytics, Inc.Warrant3/23/2022Preferred Series E475,510$20 $22 (15)
Scynexis, Inc.Warrant5/14/2021Common Stock106,035296 2 (4)
SynOx Therapeutics LimitedWarrant4/18/2024Preferred Series B251,19583 76 (5)(10)
TG Therapeutics, Inc.Warrant12/30/2021Common Stock117,168721 1,730 (4)(10)
Valo Health, LLCWarrant6/15/2020Common Units102,216256 39 
X4 Pharmaceuticals, Inc.Warrant3/18/2019Common Stock1,392,787510 185 (4)
Subtotal: Drug Discovery & Development (0.35%)*
8,404 6,996  
Electronics & Computer Hardware      
908 Devices, Inc.Warrant3/15/2017Common Stock49,078101 1 (4)
Locus Robotics Corp.Warrant6/21/2022Common Stock8,50334 51  
Skydio, Inc.Warrant11/8/2021Common Stock622,255557 212  
Subtotal: Electronics & Computer Hardware (0.01%)*
692 264  
Healthcare Services, Other      
Curana Health Holdings, LLCWarrant1/4/2024Common Units447,410156 492 
Modern Life, Inc.Warrant3/30/2023Common Stock52,665210 169  
NeueHealth, Inc.Warrant6/21/2024Common Stock185,625716 1,032 (4)(12)
Recover Together, Inc.Warrant7/3/2023Common Stock194,830382 79 
Strive Health Holdings, LLCWarrant9/28/2023Common Units129,400278 325 (15)
Vida Health, Inc.Warrant3/28/2022Preferred Series E192,431121 2 
Subtotal: Healthcare Services, Other (0.11%)*
1,863 2,099  
Information Services      
NetBase Quid, Inc. (p.k.a NetBase Solutions)Warrant8/22/2017Preferred Series 160,000356   
Signal Media LimitedWarrant6/29/2022Common Stock129,63857 13 (5)(10)
Subtotal: Information Services (0.00%)*
413 13  
Manufacturing Technology      
Bright Machines, Inc.Warrant3/31/2022Common Stock392,308537 871  
MacroFab, Inc.Warrant3/23/2022Common Stock1,111,111528 291  
Subtotal: Manufacturing Technology (0.06%)*
1,065 1,162  
Media/Content/Info      
Fever Labs, Inc.Warrant12/30/2022Preferred Series E-1369,37067 63  
Subtotal: Media/Content/Info (0.00%)*
67 63  
Medical Devices & Equipment      
Orchestra BioMed Holdings, Inc.Warrant11/6/2024Common Stock52,264180 102 (4)(6)(15)
Outset Medical, Inc.Warrant9/27/2013Common Stock62,794401 7 (4)
Senseonics Holdings, Inc.Warrant9/8/2023Common Stock1,032,718276 203 (4)
Sight Sciences, Inc.Warrant1/22/2024Common Stock113,247363 195 (4)(6)
See notes to consolidated financial statements
29

Table of Contents
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2024
(dollars in thousands)
Portfolio CompanyType of
Investment
Acquisition Date(4)
Series (3)
Shares
Cost (2)
ValueFootnotes
Tela Bio, Inc.Warrant3/31/2017Common Stock15,712$61 $ (4)
Subtotal: Medical Devices & Equipment (0.03%)*
1,281 507  
Semiconductors      
Achronix Semiconductor CorporationWarrant6/26/2015Preferred Series D-2750,00099 494  
Subtotal: Semiconductors (0.02%)*
99 494  
Software     
Aria Systems, Inc.Warrant5/22/2015Preferred Series G231,53574   
Automation Anywhere, Inc.Warrant9/23/2022Common Stock254,778448 421  
Bitsight Technologies, Inc.Warrant11/18/2020Common Stock29,691284 442  
Brain CorporationWarrant10/4/2021Common Stock435,396215 84 
CloudBolt Software, Inc.Warrant9/30/2020Common Stock211,342117 9  
Cloudian, Inc.Warrant11/6/2018Common Stock477,45471   
Cloudpay, Inc.Warrant4/10/2018Preferred Series B6,76354 908 (5)(10)
Coronet Cyber Security Ltd.Warrant9/26/2024Ordinary Shares39,183254 266 
Couchbase, Inc.Warrant4/25/2019Common Stock105,350462 686 (4)
Cutover, Inc.Warrant9/21/2022Common Stock102,89826 83 (5)(10)(12)
Dashlane, Inc.Warrant3/11/2019Common Stock770,838461 1,102 
Demandbase, Inc.Warrant8/2/2021Common Stock727,047545 234  
Dragos, Inc.Warrant6/28/2023Common Stock57,5281,575 984  
DroneDeploy, Inc.Warrant6/30/2022Common Stock95,911278 417  
Earnix, Inc.Warrant6/6/2024Common Stock20,762220 327 
Elation Health, Inc.Warrant9/12/2022Common Stock362,837583 236  
First Insight, Inc.Warrant5/10/2018Preferred Series B75,91796 33  
Fulfil Solutions, Inc.Warrant7/29/2022Common Stock84,995325 274  
Harness, Inc.Warrant3/12/2024Common Stock193,618534 632 
Kore.ai, Inc.Warrant3/31/2023Preferred Series C64,293208 142  
Leapwork ApSWarrant1/23/2023Common Stock93,21139 35 (5)(10)(12)
Lightbend, Inc.Warrant2/14/2018Preferred Series LB-286,984131 26  
Mixpanel, Inc.Warrant9/30/2020Common Stock82,362252 264  
Morphisec Information Security 2014 Ltd.Warrant10/1/2024Ordinary Shares200,115104 108 (5)(10)
Pindrop Security, Inc.Warrant6/26/2024Common Stock134,542494 496 (15)
Reltio, Inc.Warrant6/30/2020Common Stock69,120215 698  
Semperis Technologies Inc.Warrant4/23/2024Common Stock72,122115 213 
Simon Data, Inc.Warrant3/22/2023Common Stock77,93496 22 (12)
SingleStore, Inc.Warrant4/28/2020Preferred Series D312,596103 551 
Sisense Ltd.Warrant6/8/2023Ordinary Shares321,956174 61 (5)(10)
Suzy, Inc.Warrant8/24/2023Common Stock292,936367 291 (6)(15)
Tipalti Solutions Ltd.Warrant3/22/2023Ordinary Shares509,753359 395 (5)(10)
See notes to consolidated financial statements
30

Table of Contents
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2024
(dollars in thousands)
Portfolio CompanyType of
Investment
Acquisition Date(4)
Series (3)
Shares
Cost (2)
ValueFootnotes
VideoAmp, Inc.Warrant1/21/2022Common Stock152,048$1,275 $32 (15)
Subtotal: Software (0.53%)*
10,554 10,472  
Space Technologies
Capella Space Corp.Warrant10/21/2021Common Stock176,200 207 10 (15)
Subtotal: Space Technologies (0.00%)*
207 10 
Sustainable and Renewable Technology      
Ampion, PBCWarrant4/15/2022Common Stock18,47252 67  
Electric Hydrogen Co.Warrant3/27/2024Common Stock246,618507 394 (15)
Halio, Inc.Warrant4/7/2015Common Stock144,91463   
Subtotal: Sustainable and Renewable Technology (0.02%)*
622 461  
Total: Warrant Investments (1.53%)*
$31,154 $30,500  
Total Investments in Securities (183.64%)*
$3,704,407 $3,653,758  
Investment Funds & Vehicles Investments   
Drug Discovery & Development      
Forbion Growth Opportunities Fund I C.V.Investment Funds & Vehicles11/16/2020 $2,847 $4,382 (5)(10)(17)
Forbion Growth Opportunities Fund II C.V.Investment Funds & Vehicles6/23/2022 1,242 1,438 (5)(10)(17)
Subtotal: Drug Discovery & Development (0.29%)*
4,089 5,820  
Software      
Liberty Zim Co-Invest L.P.Investment Funds & Vehicles7/21/2022 381 400 (5)(10)
Subtotal: Software (0.02%)*
381 400  
Total: Investment Funds & Vehicles Investments (0.31%)*
$4,470 $6,220  
Total Investments before Cash & Cash Equivalents (183.96%)*
$3,708,877 $3,659,978  
Cash & Cash Equivalents
GS Financial Square Government FundCash & Cash EquivalentsFGTXX/38141W273$21,100 $21,100 
Total: Investments in Cash & Cash Equivalents (1.06%)*
$21,100 $21,100 
Total: Investments after Cash & Cash Equivalents (185.02%)*
$3,729,977 $3,681,078 
Foreign Currency Forward Contracts
Foreign CurrencySettlement DateCounterpartyAmountTransaction
US $ Notional Value at Settlement Date
Value
Great British Pound (GBP)6/3/2025Goldman Sachs Bank USA£20,511 Sold$26,178 $538 
Total Foreign Currency Forward (0.03%)*
$26,178 $538 
See notes to consolidated financial statements
31

Table of Contents
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS
December 31, 2024
(dollars in thousands)
*Value as a percent of net assets. All amounts are stated in U.S. Dollars unless otherwise noted. The Company uses the Standard Industrial Code for classifying the industry grouping of its portfolio companies.
(1)Prime represents 7.50% as of December 31, 2024. 1-month SOFR, 3-month SOFR, and 6-month SOFR represent 4.33%, 4.31%, and 4.25%, respectively, as of December 31, 2024.
(2)Gross unrealized appreciation, gross unrealized depreciation, and net unrealized depreciation for federal income tax purposes totaled $108.4 million, $156.5 million, and $48.1 million, respectively. The tax cost of investments is $3.7 billion.
(3)Preferred and common stock, warrants, and equity interests are generally non-income producing.
(4)Except for warrants in 23 publicly traded companies and common stock in 28 publicly traded companies, all investments are restricted as of December 31, 2024 and were valued at fair value using Level 3 significant unobservable inputs as determined in good faith by the Company’s valuation committee (the "Valuation Committee") and approved by the board of directors (the "Board").
(5)Non-U.S. company or the company’s principal place of business is outside the United States.
(6)Denotes that all or a portion of the investment in this portfolio company is held by SBIC V, L.P., the Company's wholly owned small business investment company.
(7)Control investment as defined under the 1940 Act in which Hercules owns at least 25% of the company’s voting securities or has greater than 50% representation on its board.
(8)Debt is on non-accrual status as of December 31, 2024, and is therefore considered non-income producing.
(9)Denotes that all or a portion of the debt investment is convertible debt.
(10)Indicates assets that the Company deems not “qualifying assets” under section 55(a) of 1940 Act. Qualifying assets must represent at least 70% of the Company’s total assets at the time of acquisition of any additional non-qualifying assets.
(11)Denotes that all or a portion of the debt investment is pledged as collateral under the SMBC Facility (as defined in “Note 5 — Debt”).
(12)Denotes that all or a portion of the investment is pledged as collateral under the MUFG Bank Facility (as defined in “Note 5 — Debt”).
(13)Denotes that all or a portion of the debt investment secures the 2031 Asset-Backed Notes (as defined in “Note 5 — Debt”).
(14)Denotes that all or a portion of the debt investment principal includes accumulated PIK interest and is net of repayments.
(15)Denotes that all or a portion of the investment in this portfolio company is held by Hercules Capital IV, L.P., the Company’s wholly owned small business investment company.
(16)Denotes that the fair value of the Company’s total investments in this portfolio company represent greater than 5% of the Company’s total net assets as of December 31, 2024.
(17)Denotes that there is an unfunded contractual commitment available at the request of this portfolio company as of December 31, 2024 (Refer to “Note 11 — Commitments and Contingencies”).
(18)Denotes unitranche debt with first lien “last-out” senior secured position and security interest in all assets of the portfolio company whereby the “last-out” portion will be subordinated to the “first-out” portion in a liquidation, sale or other disposition.
(19)Denotes second lien senior secured debt.
(20)Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC.
(21)Denotes investment in a non-voting security in the form of a promissory note. The terms of the notes provide the Company with a lien on the issuers' shares of Common Stock for Black Crow AI, Inc., subject to release upon repayment of the outstanding balance of the notes. As of December 31, 2024, the Black Crow AI, Inc. affiliates promissory notes had an outstanding balance of $2.4 million.
(22)Denotes the security holds rights to royalty fee income associated with certain products of the portfolio company. The approximate cost and fair value of the royalty contract are $11.9 million and $11.6 million, respectively.
(23)Hercules Adviser LLC is owned by Hercules Capital Management LLC and presented with Hercules Partner Holdings, LLC which are both wholly owned by the Company. Please refer to “Note 1” for additional disclosure.
See notes to consolidated financial statements
32

Table of Contents
HERCULES CAPITAL, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
1. Description of Business
Hercules Capital, Inc. (the “Company”) is a specialty finance company focused on providing senior secured loans to high-growth, innovative venture capital-backed and institutional-backed companies in a variety of technology and life sciences industries. The Company sources its investments through its principal office located in San Mateo, CA, as well as through its additional offices in Boston, MA, New York, NY, San Diego, CA, Denver, CO, and London, United Kingdom. The Company was incorporated under the General Corporation Law of the State of Maryland in December 2003.
The Company is an internally managed, non-diversified closed-end investment company that has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). Effective January 1, 2006, the Company elected to be treated for U.S. federal income tax purposes as a regulated investment company (“RIC”) under Subchapter M Part I of the Internal Revenue Code of 1986, as amended (the “Code”) (see “Note 6 - Income Taxes”).
The Company is not registered with the Commodity Futures Trading Commission (“CFTC”). The Company has claimed an exclusion from the definition of the term “commodity pool operator” under the Commodity Exchange Act (“CEA”), pursuant to Rule 4.5 under the CEA. Therefore, the Company is not, subject to registration or regulation as a “commodity pool operator” under the CEA.
Hercules Capital IV, L.P. (“HC IV”) and Hercules SBIC V, L.P. (“SBIC V”) are our wholly owned Delaware limited partnerships that were formed in December 2010 and September 2023, respectively. HC IV and SBIC V have each received licenses to operate as a Small Business Investment Company (“SBIC”) under the authority of the Small Business Administration (“SBA”) on October 27, 2020 and July 9, 2024, respectively. Our SBICs are subject to a variety of regulations concerning, among other things, the size and nature of the companies in which they may invest and the structure of those investments. Hercules Technology SBIC Management, LLC (“HTM”), is a wholly owned limited liability company subsidiary of the Company, which was formed in November 2003 and serves as the general partner of HC IV and SBIC V.
The Company has also established certain wholly owned subsidiaries, all of which are structured as Delaware corporations or limited liability companies (“LLCs”), to hold portfolio companies organized as LLCs (or other forms of pass-through entities). These subsidiaries are consolidated for financial reporting purposes in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). Certain of the subsidiaries are taxable and not consolidated with Hercules for income tax purposes and may generate income tax expense, or benefit, and tax assets and liabilities as a result of their ownership of certain portfolio investments.
The Company formed Hercules Capital Management LLC and Hercules Adviser LLC in 2020 as wholly owned Delaware limited liability subsidiaries. The Company was granted no-action relief by the staff of the Securities and Exchange Commission (“SEC”) to allow Hercules Adviser LLC (the “Adviser Subsidiary”) to register as a registered investment adviser under the Investment Advisers Act of 1940, as amended (“Advisers Act”). The Adviser Subsidiary provides investment advisory and related services to investment vehicles (“Adviser Funds”) owned by one or more unrelated third-party investors (“External Parties”). The Adviser Subsidiary is owned by Hercules Capital Management LLC and collectively held and presented with Hercules Partner Holdings, LLC, which separately wholly owns the general partnership interests to each of the Adviser Funds.
2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying consolidated interim financial statements have been prepared in accordance with U.S. GAAP for interim financial information, and pursuant to the requirements for reporting on Form 10-Q and Articles 6, 10 and 12 of Regulation S-X. Accordingly, certain disclosures accompanying annual consolidated financial statements prepared in accordance with U.S. GAAP are omitted. In the opinion of management, all adjustments consisting solely of normal recurring accruals considered necessary for the fair statement of consolidated financial statements for the interim periods have been included. The current period’s results of operations are not necessarily indicative of results that ultimately may be achieved for the full fiscal year. Therefore, the interim unaudited consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2024. The year-end Consolidated Statements of Assets and Liabilities data was derived from audited financial statements but does not include all disclosures required by U.S. GAAP. The Company’s functional currency is U.S. dollars (“USD”) and these consolidated financial statements have been prepared in that currency.
33

Table of Contents
As an investment company, the Company follows accounting and reporting guidance as set forth in Topic 946, Financial Services – Investment Companies (“ASC Topic 946”) of the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification, as amended (“ASC”). As provided under Regulation S-X and ASC Topic 946, the Company will not consolidate its investment in a portfolio company other than an investment company subsidiary or a controlled operating company whose business consists of providing services to the Company. Rather, an investment company’s interest in portfolio companies that are not investment companies should be measured at fair value in accordance with ASC Topic 946. The Adviser Subsidiary is not an investment company as defined in ASC Topic 946 and further, the Adviser Subsidiary provides investment advisory services exclusively to the Adviser Funds which are owned by External Parties. As such, pursuant to ASC Topic 946, the Adviser Subsidiary is accounted for as a portfolio investment of the Company held at fair value and is not consolidated.
Financial statements prepared on a U.S. GAAP basis require management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of income, expenses, gains and losses during the reported periods. Changes in the economic and regulatory environment, financial markets, the credit worthiness of our portfolio companies, other macro-economic developments (for example, global pandemics, natural disasters, terrorism, international conflicts and war), and any other parameters used in determining these estimates and assumptions could cause actual results to differ from these estimates and assumptions.
Principles of Consolidation
The Consolidated Financial Statements include the accounts of the Company, its consolidated subsidiaries, and all Variable Interest Entities (“VIE”) of which the Company is the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation.
A VIE is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. The primary beneficiary of a VIE is the party with both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and the obligation to absorb the losses or the right to receive benefits that could be significant to the VIE.
To assess whether the Company has the power to direct the activities of a VIE that most significantly impact its economic performance, the Company considers all the facts and circumstances including its role in establishing the VIE and its ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE’s economic performance and identifying which party, if any, has power over those activities. In general, the party that makes the most significant decisions affecting the VIE is determined to have the power to direct the activities of a VIE. To assess whether the Company has the obligation to absorb the losses or the right to receive benefits that could potentially be significant to the VIE, the Company considers all of its economic interests, including debt and equity interests, servicing rights and fee arrangements, and any other variable interests in the VIE. If the Company determines that it is the party with the power to make the most significant decisions affecting the VIE, and the Company has a potentially significant interest in the VIE, then it consolidates the VIE.
The Company performs periodic reassessments, usually quarterly, of whether it is the primary beneficiary of a VIE. The reassessment process considers whether the Company has acquired or divested the power to direct the activities of the VIE through changes in governing documents or other circumstances. The Company also reconsiders whether entities previously determined not to be VIEs have become VIEs, based on certain events, and therefore are subject to the VIE consolidation framework.
The Company's Consolidated Financial Statements included the accounts of the securitization trust, a VIE, formed in 2022 in conjunction with the issuance of the 2031 Asset-Backed Notes (as defined in “Note 5 – Debt”). The assets of the Company's securitization VIE are restricted to be used to settle obligations of its consolidated securitization VIE, which are disclosed parenthetically on the Consolidated Statements of Assets and Liabilities. The liabilities are the only obligations of its consolidated securitization VIE, and the creditors (or beneficial interest holders) do not have recourse to the Company's general credit.




34

Table of Contents
Fair Value Measurements
The Company follows guidance in ASC Topic 820, Fair Value Measurement (“ASC Topic 820”), where fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes a framework for measuring the fair value of assets and liabilities and outlines a three-tier hierarchy which maximizes the use of observable market data input and minimizes the use of unobservable inputs to establish a classification of fair value measurements. Inputs refer broadly to the assumptions that market participants would use in pricing the asset or liability, including assumptions about risk, such as the risk inherent in a particular valuation technique used to measure fair value using a pricing model and/or the risk inherent in the inputs for the valuation technique. Inputs may be observable or unobservable. Observable inputs reflect the assumptions market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company’s own assumptions about the assumptions market participants would use in pricing the asset or liability based on the information available. The inputs or methodology used for valuing assets or liabilities may not be an indication of the risks associated with investing in those assets or liabilities. ASC Topic 820 also requires disclosure for fair value measurements based on the level within the hierarchy of the information used in the valuation. ASC Topic 820 applies whenever other standards require (or permit) assets or liabilities to be measured at fair value.
The Company categorizes all investments recorded at fair value in accordance with ASC Topic 820 based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, defined by ASC Topic 820 and directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows:
Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets at the measurement date. The types of assets carried at Level 1 fair value generally are equities listed in active markets.
Level 2—Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset in connection with market data at the measurement date and for the extent of the instrument’s anticipated life. Fair valued assets that are generally included in this category are publicly held debt investments and warrants held in a public company.
Level 3—Inputs reflect management’s best estimate of what market participants would use in pricing the asset at the measurement date. It includes prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. Generally, assets carried at fair value and included in this category are the debt investments and warrants and equities held in a private company.
Valuation of Investments
The most significant estimate inherent in the preparation of the Company’s consolidated financial statements is the valuation of investments and the related amounts of unrealized appreciation and depreciation of investments recorded.
Pursuant to Rule 2a-5 of the 1940 Act, the Board has designated the Company’s Valuation Committee as the “valuation designee”. As of March 31, 2025, approximately 97.4% of the Company’s total assets represented investments in portfolio companies whose fair value is determined in good faith by the Company's Valuation Committee and approved by the Board. Fair Value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market price for those securities for which a market quotation is readily available and (ii) for all other securities and assets, fair value is as determined in good faith by the Valuation Committee, as valuation designee of the Board. The Company’s investments are carried at fair value in accordance with Rule 2a-5 under the 1940 Act and ASC Topic 946. Given the Company's investment strategy, nature of investments, and types of businesses in which it invests, substantially all of the Company’s investments are considered Level 3 assets under ASC Topic 820 because there generally is no known or accessible market or market indexes for these investment securities to be traded or exchanged. As such, the Company values substantially all of its investments at fair value as determined in good faith pursuant to the valuation guidelines approved by the Board in accordance with the provisions of ASC Topic 820 and the 1940 Act. Due to the inherent uncertainty in determining the fair value of investments that do not have a readily available market values, the fair value of the Company’s investments may differ significantly from the value that would have been used had a readily available market existed for such investments, and the differences could be material.
In accordance with procedures approved by its Board, the Company values investments on a quarterly basis following a multistep valuation process. The quarterly Board approved multi-step valuation process is described below:
(1)The Company’s quarterly valuation process begins with each portfolio company being initially valued by the investment professionals responsible for the portfolio investment;
35

Table of Contents
(2)Preliminary valuation conclusions and business-based assumptions, along with any applicable fair value marks provided by an independent firm, are reviewed with the Company’s investment committee and certain member(s) of credit group as necessary;
(3)The Valuation Committee reviews the preliminary valuations recommended by the investment committee and certain member(s) of the credit group of each investment in the portfolio and determines the fair value of each investment in the Company’s portfolio in good faith and recommends the valuation determinations to the Audit Committee of the Board;
(4)The Audit Committee of the Board provides oversight of the quarterly valuation process in accordance with Rule 2a-5, which includes a review of the quarterly reports prepared by the Valuation Committee, reviews the fair valuation determinations made by the Valuation Committee, and approves such valuations for inclusion in public reporting and disclosures, as appropriate; and
(5)The Board, upon the recommendation of the Audit Committee, discusses valuations and approves the fair value of each investment in the Company’s portfolio.
Investments purchased within the preceding two calendar quarters before the valuation date and debt investments with remaining maturities within 12 months or less may each be valued at cost with interest accrued or discount accreted/premium amortized to the date of maturity, unless such valuation, in the judgment of the Company, does not represent fair value. In this case such investments shall be valued at fair value as determined in good faith by the Valuation Committee and approved by the Board. Investments that are not publicly traded or whose market quotations are not readily available are valued at fair value as determined in good faith by the Valuation Committee subject to oversight and approval of the Board.
As part of the overall process noted above, the Company engages one or more independent valuation firm(s) to provide management with assistance in determining the fair value of selected portfolio investments each quarter. In selecting which portfolio investments to engage an independent valuation firm, the Company considers a number of factors, including, but not limited to, the potential for material fluctuations in valuation results, size, credit quality, and the time lapse since the last valuation of the portfolio investment by an independent valuation firm. The scope of services rendered by the independent valuation firm is at the discretion of the Valuation Committee and subject to approval of the Board, and the Company may engage an independent valuation firm to value all or some of our portfolio investments. In determining the fair value of a portfolio investment in good faith, the Company recognizes these determinations are made using the best available information that is knowable or reasonably knowable. In addition, changes in the market environment, portfolio company performance and other events that may occur over the duration of the investments may cause the gains or losses ultimately realized on these investments to be materially different than the valuations currently assigned. The change in fair value of each individual investment is recorded as an adjustment to the investment's fair value and the change is reflected in unrealized appreciation or depreciation.
The Company records unrealized depreciation on investments when it believes that an investment has decreased in value, including where it believes collection of a debt investment is doubtful or, if under the in-exchange premise, when it believes the value of a debt investment is less than the amortized cost of the investment. Conversely, where appropriate, the Company records unrealized appreciation if it believes that the underlying portfolio company has appreciated in value and, therefore, that its investment has also appreciated in value or, if it believes, under the in-exchange premise, the value of an investment is greater than its amortized cost.
Debt Investments
The Company’s debt investments are substantially considered Level 3 assets under ASC Topic 820 with fair value as
determined in good faith pursuant to the process described above. In making a good faith determination of the value of the Company’s investments, the Company generally starts with the cost basis of the investment, which includes the value attributed to the original issue discount (“OID”), if any, and payment-in-kind (“PIK”) interest or other receivables which have been accrued as earned. The Company then applies the valuation methods as set forth below.
The Company assumes the sale of each debt security in a hypothetical market to a hypothetical market participant where buyers and sellers are willing participants. The hypothetical market does not include scenarios where the underlying security was simply repaid or extinguished, but includes an exit concept. The Company determines the yield at inception for each debt investment. The Company then uses senior secured, leveraged loan yields provided by third party providers to calibrate the change in market yields between inception of the debt investment and the measurement date. Industry specific indices and other relevant market data are used to benchmark and assess market-based movements for reasonableness. As part of determining the fair value, the Company also evaluates the collateral for recoverability of the debt investments. The Company considers each portfolio company’s credit rating, security liens and other characteristics of the investment to adjust the baseline yield to derive a credit adjusted hypothetical yield for each investment as of the measurement date. The anticipated future cash flows from each investment are then discounted at the hypothetical yield to
36

Table of Contents
estimate each investment’s fair value as of the measurement date. The Company’s process includes an analysis of, among other things, the underlying investment performance, the current portfolio company’s financial condition and market changing events that impact valuation, estimated remaining life, current market yield and interest rate spreads of similar securities as of the measurement date.
The Company values debt securities that are traded on a public exchange at the prevailing market price as of the valuation date. The Company values syndicated debt investments, for which sufficient liquidity and market data are available, using broker quotes and bond indices amongst other factors. Debt investments with market quotations are generally considered Level 1 or 2 assets in line with ASC Topic 820. If there is a significant deterioration of the credit quality of a debt investment, the Company may consider other factors to estimate fair value, including the proceeds that would be received in a liquidation analysis.
When originating a debt instrument, the Company generally receives warrants or other equity securities from the borrower. The Company determines the cost basis of the warrants or other equity securities received based upon their respective fair values on the date of receipt in proportion to the total fair value of the debt and warrants or other equity securities received. Any resulting discount on the debt investments from recording warrant or other equity instruments is accreted into interest income over the life of the debt investment.
Equity Securities and Warrants
Securities that are traded in the over-the-counter markets or on a stock exchange will be valued at the prevailing bid price at period end. The Company has a limited amount of equity securities in public companies. In accordance with the 1940 Act, unrestricted publicly traded securities for which market quotations are readily available are valued at the closing market quote on the measurement date.
At each reporting date, privately held warrant and equity securities are valued based on an analysis of various factors including, but not limited to, the portfolio company’s operating performance and financial condition, general market conditions, price to enterprise value or price to equity ratios, discounted cash flow, valuation comparisons to comparable public companies or other industry benchmarks. When an external event occurs, such as a purchase transaction, public offering, or subsequent equity sale, the pricing indicated by that external event is utilized to corroborate the Company’s valuation of the warrant and equity securities. The Company periodically reviews the valuation of its portfolio companies that have not been involved in a qualifying external event to determine if the enterprise value of the portfolio company may have increased or decreased since the last valuation measurement date. Absent a qualifying external event, the Company estimates the fair value of warrants using a Black Scholes OPM. For certain privately held equity securities, the income approach is used, in which the Company converts future amounts (for example, cash flows or earnings) to a net present value. The measurement is based on the value indicated by current market expectations about those future amounts. In following these approaches, the types of factors that the Company may take into account include, as relevant: applicable market yields and multiples, the portfolio company’s capital structure, the nature and realizable value of any collateral, the portfolio company’s ability to make payments, its earnings and discounted cash flows, and enterprise value among other factors.
Investment Funds & Vehicles
The Company applies the practical expedient provided by the ASC Topic 820 relating to investments in certain entities that calculate net asset value (“NAV”) per share (or its equivalent). ASC Topic 820 permits an entity holding investments in certain entities that either are investment companies, or have attributes similar to an investment company, and calculate NAV per share or its equivalent for which the fair value is not readily determinable, to measure the fair value of such investments on the basis of that NAV per share, or its equivalent, without adjustment. Investments which are valued using NAV per share as a practical expedient are not categorized within the fair value hierarchy as per ASC Topic 820.
Derivative Instruments
The Company's derivative instruments include foreign currency forward contracts. The Company recognizes all derivative instruments as assets or liabilities at fair value in its consolidated financial statements. Derivative contracts entered into by the Company are not designated as hedging instruments, and as a result, the Company presents changes in fair value through net change in unrealized appreciation (depreciation) on non-control/non-affiliate investments in the Consolidated Statements of Operations. Realized gains and losses of the derivative instruments are included in net realized gains (losses) on non-control/non-affiliate investments in the Consolidated Statements of Operations. The net cash flows realized on settlement of derivatives are included in realized (gain) loss in the Consolidated Statements of Cash Flows.
Cash, Cash Equivalents, Foreign Cash, and Restricted Cash
Cash and cash equivalents consist solely of funds deposited with financial institutions and short-term liquid investments in money market deposit accounts. Cash and cash equivalents are carried at cost, which approximates fair
37

Table of Contents
value. Foreign cash includes the value of foreign currencies held and translated using the prevailing foreign exchange rates on the reporting date. Restricted cash includes amounts that are held as collateral securing certain of the Company’s financing transactions, including amounts held in a securitization trust by trustees related to its 2031 Asset-Backed Notes (refer to “Note 5 – Debt”).
Foreign Currency Translation
The accounting records of the Company are maintained in U.S. dollars. All assets and liabilities denominated in foreign currencies are translated into U.S. dollars based on the prevailing foreign exchange rate on the reporting date. The Company does not isolate that portion of the results of operations resulting from changes in foreign exchange rates on investments from the fluctuations arising from changes in market prices of securities held. The Company’s investments in foreign securities may involve certain risks, including foreign exchange restrictions, expropriation, taxation or other political, social or economic risks, all of which could affect the market and/or credit risk of the investment. In addition, changes in the relationship of foreign currencies to the U.S. dollar can significantly affect the value of these investments and therefore the earnings of the Company.
Other Assets
Other assets generally consist of prepaid expenses, debt issuance costs related to our Credit Facilities (as defined below) net of accumulated amortization, fixed assets net of accumulated depreciation, deferred revenues and deposits and other assets, including escrow and other investment related receivables.
Escrow Receivables
Escrow receivables are collected in accordance with the terms and conditions of the escrow agreement. Escrow balances are typically distributed over a period greater than one year and may accrue interest during the escrow period. Escrow balances are measured for collectability on at least a quarterly basis and fair value is determined based on the amount of the estimated recoverable balances and the contractual maturity date.
Leases
The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use (“ROU”) assets, and operating lease liability obligations in our Consolidated Statements of Assets and Liabilities. The Company recognizes a ROU asset and an operating lease liability for all leases, with the exception of short-term leases which have a term of 12 months or less. ROU assets represent the right to use an underlying asset for the lease term and operating lease liability obligations represent the obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at lease commencement date based on the present value of lease payments over the lease term. The Company has lease agreements with lease and non-lease components and has separated these components when determining the ROU assets and the related lease liabilities. As most of the Company’s leases do not provide an implicit rate, the Company estimated its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The Company uses the implicit rate when readily determinable. The ROU asset also includes any lease payments made and excludes lease incentives and lease direct costs. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. See “Note 11 – Commitments and Contingencies”.
Investment Income Recognition
The Company’s investment portfolio generates interest, fee, and dividend income. The Company records interest income on an accrual basis, recognizing income as earned in accordance with the contractual terms of the loan agreement, to the extent that such amounts are expected to be collected. The Company’s Structured Debt investments may generate OID related income. "Structured Debt" refers to a debt investment that is structured with an equity, warrant, option, or other right to purchase or convert into common or preferred equity investments. The OID recorded upfront typically represents the value of detachable equity, warrants, or another asset obtained in conjunction with the acquisition of debt securities. The OID value is accreted into interest income over the term of the loan as a yield enhancement following the effective interest method. Additionally, certain debt investments in the Company’s portfolio earn PIK interest. The Company records PIK interest in accordance with the contractual terms of the loan agreement, to the extent that such amounts are expected to be collected. Contractual PIK interest represents contractually deferred interest that is added to the loan balance as principal and is generally due at the end of the loan term.
Additionally, the Company’s loan origination activities generate fee income, which is generally collected in advance and includes loan commitment, facility fees for due diligence and structuring, as well as fees for transaction services and management services rendered by the Company to portfolio companies and other third parties. Loan commitment and facility fees are capitalized and then amortized into income over the contractual life of the loan using the effective interest
38

Table of Contents
method. One-off fees for transaction and management services are generally recognized as income in the period when the services are rendered. The Company may also earn loan exit fees, which are contractual fees that are generally received upon the earlier of maturity or prepayment. The Company accretes loan exit fees into interest income following the effective interest method, recognizing income as earned in accordance with the contractual terms of the loan agreement, to the extent that such amounts are expected to be collected.
From time to time, additional fees may be earned by the Company relating to specific loan modifications, prepayments, or other one-off events. These non-recurring fees are either amortized into fee income over the remaining term of the loan commencing in the quarter for loan modifications, or recognized currently as one-time fee income for items such as prepayment penalties, fees related to select covenant default waiver fees, and acceleration of previously deferred loan fees and OID related to early loan pay-off or material modification of the specific debt outstanding.
Debt investments are placed on non-accrual status when it is probable that principal, interest or fees will not be collected according to contractual terms. When a debt investment is placed on non-accrual status, the Company ceases to recognize interest and fee income until the portfolio company has paid all principal and interest due or demonstrated the ability to repay its current and future contractual obligations to the Company. The Company may determine to continue to accrue interest on a loan where the investment has sufficient collateral value to collect all of the contractual amount due and is in the process of collection. Interest collected on non-accrual investments are generally applied to principal.
Dividend income is recorded on the record date for private portfolio companies or on the ex-dividend date for publicly traded portfolio companies to the extent that such amounts are payable by the portfolio company and are expected to be collected.
Realized Gains or Losses
Realized gains or losses are measured by the difference between the net proceeds from the sale or other realization event and the cost basis of the investment using the specific identification method without regard to unrealized appreciation or depreciation previously recognized, and includes investments charged off during the period, net of recoveries.
Secured Borrowings
The Company follows the guidance in ASC Topic 860, Transfers and Servicing (“ASC Topic 860”), when accounting for participation and other partial loan sales. Certain loan sales do not qualify for sale accounting under ASC Topic 860 because these sales do not meet the definition of a “participating interest”, as defined in the guidance, in order for sale accounting treatment to be allowed. Participations or other partial loan sales which do not meet the definition of a participating interest, or which are not eligible for sale accounting treatment remain as an investment on the consolidated balance sheet as required under U.S. GAAP and the proceeds are recorded as a secured borrowing. Secured borrowings are carried at fair value.
Equity Offering Expenses
The Company’s offering expenses are charged against the proceeds from equity offerings when received as a reduction of capital upon completion of an offering of registered securities.
Debt
The debt of the Company is carried at amortized cost which is comprised of the principal amount borrowed net of any unamortized discount and debt issuance costs. Discounts and issuance costs are accreted to interest expense and loan fees, respectively, using the straight-line method, which closely approximates the effective yield method, over the remaining life of the underlying debt obligations (see “Note 5 – Debt”). Accrued but unpaid interest is included within Accounts payable and accrued liabilities on the Consolidated Statements of Assets and Liabilities. In the event that the debt is extinguished, either partially or in full, before maturity, the Company recognizes the gain or loss in the Consolidated Statements of Operations within net realized gains (losses) as a “Loss on extinguishment of debt”.
Debt Issuance Costs
Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing and are recognized as prepaid expenses and amortized over the life of the related debt instrument using the effective yield method or the straight-line method, which closely approximates the effective yield method. In accordance with ASC Subtopic 835-30, Interest – Imputation of Interest, debt issuance costs are presented as a reduction to the associated liability balance on the Consolidated Statements of Assets and Liabilities, except for debt issuance costs associated with line-of-credit arrangements which are included within Other Assets as permitted under GAAP.
39

Table of Contents
Stock-Based Compensation
The Company has issued and may, from time to time, issue stock options, restricted stock, and other stock-based compensation awards to employees and directors. Management follows the guidance set forth under ASC Topic 718, to account for stock-based compensation awards granted. Under ASC Topic 718, compensation expense associated with stock-based compensation is measured at the grant date based on the fair value of the award and is recognized over the vesting period. Determining the appropriate fair value model and calculating the fair value of stock-based awards at the grant date requires judgment. This includes certain assumptions such as stock price volatility, forfeiture rate, expected outcome probability, and expected option life, as applicable to each award. In accordance with ASC Topic 480, certain stock awards are classified as a liability. The compensation expense associated with these awards is recognized in the same manner as all other stock-based compensation. The award liability is recorded as deferred compensation and included in Accounts payable and accrued liabilities.
Income Taxes
The Company accounts for income taxes in accordance with the provisions of ASC Topic 740 Income Taxes, under which income taxes are provided for amounts currently payable and for amounts deferred based upon the estimated future tax effects of differences between the financial statements and tax basis of assets and liabilities given the provisions of the enacted tax law. Valuation allowances may be used to reduce deferred tax assets to the amount likely to be realized.
Because taxable income as determined in accordance with U.S. federal tax regulations differ from U.S. GAAP, taxable income generally differs from net income for financial reporting purposes due to temporary and permanent differences in the recognition of income and expenses, and generally excludes net unrealized appreciation or depreciation, as such gains or losses are not included in taxable income until they are realized. Permanent differences are reclassified among capital accounts in the financial statements to reflect their appropriate tax character. Permanent differences may also result from the change in the classification of certain items, such as the treatment of short-term gains as ordinary income for tax purposes. Temporary differences arise when certain items of income, expense, gains or losses are recognized at some time in the future for tax or U.S. GAAP purposes.
The Company has elected to be treated as a RIC under Subchapter M Part I of the Code. To qualify as a RIC, the Company is required to meet certain income and asset tests in addition to distributing dividends of an amount generally at least equal to 90% of its investment company taxable income, as defined by the Code and determined without regard to any deduction for distributions paid, to its stockholders. See “Certain United States Federal Income Tax Considerations” included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the SEC on February 13, 2025 for additional information.
As a RIC, the Company is subject to a 4% non-deductible U.S. federal excise tax on certain undistributed income unless the Company makes distributions treated as dividends for U.S. federal income tax purposes in a timely manner to its stockholders in respect of each calendar year of an amount at least equal to the sum of (1) 98% of its ordinary income (taking into account certain deferrals and elections) for each calendar year, (2) 98.2% of its capital gain net income (adjusted for certain ordinary losses) for the 1-year period ending October 31 of each such calendar year and (3) any ordinary income and capital gain net income realized, but not distributed, in preceding calendar years. The Company will not be subject to this excise tax on any amount on which the Company incurred U.S. federal income tax (such as the tax imposed on a RIC’s retained net capital gains).
The amount to be paid out as a distribution is determined by the Board each quarter and is based upon the annual earnings estimated by the management of the Company. To the extent that the Company's earnings fall below the amount of the dividend distributions declared, however, a portion of the total amount of the Company's distributions for the fiscal year may be deemed a return of capital.
Depending on the level of taxable income earned in a taxable year, the Company may choose to carry over taxable income in excess of current taxable year distributions from such taxable income into the next taxable year and incur a 4% excise tax on such taxable income, as required. The maximum amount of excess taxable income that may be carried over for distribution in the next taxable year under the Code is the total amount of distributions paid in the following taxable year, subject to certain declaration and payment guidelines. To the extent the Company chooses to carry over taxable income into the next taxable year, distributions declared and paid by the Company in a taxable year may differ from the Company’s taxable income for that taxable year as such distributions may include the distribution of current taxable year taxable income, the distribution of prior taxable year taxable income carried over into and distributed in the current taxable year, or returns of capital. The Company intends to timely distribute to its stockholders substantially all of its annual taxable income for each year, except that it may retain certain net capital gains for reinvestment and, depending upon the level of taxable income earned in a year, it may choose to carry forward taxable income for distribution in the following year and pay any applicable U.S. federal excise tax.
40

Table of Contents
Earnings Per Share (“EPS”)
Basic EPS is calculated by dividing net earnings applicable to common stockholders by the weighted average number of common shares outstanding. Common shares outstanding includes common stock and restricted stock for which no future service is required as a condition to the delivery of the underlying common stock. Diluted EPS includes the determinants of basic EPS and, in addition, reflects the dilutive effect of the common stock deliverable pursuant to stock options and to restricted stock for which future service is required as a condition to the delivery of the underlying common stock. Diluted EPS is computed using the if-converted method for convertible debt, which reflects the potential dilution that would occur if all of the notes were converted as of the beginning of the reporting period (or the date of issuance, if later). The if-converted method is computed by dividing the net increase (decrease) in net assets resulting from operations (adjusted to reverse any recognized interest expense), by the weighted average number of shares of common stock assuming all potential shares had been converted, and the additional shares of common stock were dilutive. In accordance with ASC 260-10-45-60A, the Company uses the two-class method in the computation of basic EPS and diluted EPS, if applicable.
Comprehensive Income
The Company reports all changes in comprehensive income in the Consolidated Statements of Operations. The Company did not have other comprehensive income for the three months ended March 31, 2025 or 2024. The Company’s comprehensive income is equal to its net increase in net assets resulting from operations.
Distributions
Distributions to common stockholders are approved by the Board on a quarterly basis and the distribution payable is recorded on the ex-dividend date. The Company maintains an “opt out” dividend reinvestment plan that provides for reinvestment of the Company’s distribution on behalf of the Company’s stockholders, unless a stockholder elects to receive cash. As a result, if the Company declares a distribution, cash distributions will be automatically reinvested in additional shares of its common stock unless the stockholder specifically “opts out” of the dividend reinvestment plan and chooses to receive cash distributions.
Segments
The Company has determined that it has a single operating segment in accordance with Topic 280, Segment Reporting (“ASC 280”). Our Chief Executive Officer is the Company’s Chief Operating Decision Maker (“CODM”). While the Company lends to and separately evaluates the performance of each portfolio company in which it invests across various technology-related industries including drug discovery and development, software, consumer & business services, and other healthcare services, the Company and the CODM evaluate and monitor performance of the business on an aggregated basis. Further, each investment is evaluated and managed using similar processes and shared operations support functions such as deal origination, underwriting, documentation, loan and compliance administration in addition to administrative functions of human resources, legal, finance and information technology.
The CODM uses our consolidated net investment income and net increase (decrease) in net assets resulting from operations as reported in the Consolidated Statements of Operations to assess the Company’s performance and when allocating resources. Net Investment Income is comprised of consolidated total investment income (‘segment revenues’) and consolidated total net operating expenses (‘significant segment expenses’), which are considered the key segment measures of profit or loss received by the CODM. The information and operating expense categories included in the Company’s Consolidated Statement of Operations are fully reflective of the significant expense categories and amounts that are regularly provided to the CODM.
41

Table of Contents
3. Fair Value of Financial Instruments
The Company values financial instruments in accordance with ASC 820, using the techniques and approaches outlined in the Company's valuation guidelines, which are approved by the Board. During the periods ended March 31, 2025 and December 31, 2024, there were no changes to the Company’s valuation techniques or approaches as described herein.
Fair value estimates are made at discrete points in time based on relevant information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Investments measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations as of March 31, 2025 and December 31, 2024.
(in thousands)Balance as of
March 31,
2025
Quoted Prices in
Active Markets for
Identical Assets
(Level 1)
Significant
Other Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Description
Cash and cash equivalents
Money Market Fund(1)
$26,000 $26,000 $ $ 
Other assets and liabilities     
Escrow and Other Investment Receivables$1,966 $— $— $1,966 
Accounts Payable and Accrued Liabilities(972)— — (972)
Investments   
Senior Secured Debt$3,674,498 $— $— $3,674,498 
Unsecured Debt64,736 — — 64,736 
Preferred Stock52,662 — — 52,662 
Common Stock(2)
94,088 35,194 — 58,894 
Warrants31,473 — 10,888 20,585 
 $3,917,457 $35,194 $10,888 $3,871,375 
Investment Funds & Vehicles measured at Net Asset Value(3)
6,993    
Total Investments, at fair value$3,924,450    
Derivative Instruments(4)
(301)   
Total Investments including cash and cash equivalents and derivative instruments$3,950,149    
(in thousands)Balance as of
December 31,
2024
Quoted Prices in
Active Markets for
Identical Assets
(Level 1)
Significant
Other Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Description
Cash and cash equivalents     
Money Market Fund(1)
$21,100 $21,100 $ $ 
Other assets and liabilities
Escrow and Other Investment Receivables$152 $— $— $152 
Accounts Payable and Accrued Liabilities(1,012)$— $— (1,012)
Investments   
Senior Secured Debt$3,419,044 $— $— $3,419,044 
Unsecured Debt75,557 — — 75,557 
Preferred Stock53,802 — — 53,802 
Common Stock(2)
74,855 30,262 — 44,593 
Warrants30,500 — 8,677 21,823 
 $3,653,758 $30,262 $8,677 $3,614,819 
Investment Funds & Vehicles measured at Net Asset Value(3)
6,220    
Total Investments, at fair value$3,659,978    
Derivative Instruments(4)
538 
Total Investments including cash and cash equivalents and derivative instruments$3,681,616 
(1)This investment is included in Cash and cash equivalents in the accompanying Consolidated Statements of Assets and Liabilities.
(2)Common stock includes non-voting security in the form of a promissory note with a lien on shares of issuer's common stock.
42

Table of Contents
(3)In accordance with U.S. GAAP, certain investments are measured at fair value using the NAV per share (or its equivalent) as a practical expedient and are not categorized within the fair value hierarchy as per ASC 820. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the accompanying Consolidated Statements of Assets and Liabilities.
(4)Derivative Instruments are carried at fair value and are a Level 2 security within the Company's fair value hierarchy.

The table below presents a reconciliation of changes for all financial assets and liabilities measured at fair value on a recurring basis, excluding accrued interest components, using significant unobservable inputs (Level 3) for the three months ended March 31, 2025 and 2024.
(in thousands)Balance as of
January 1, 2025
Net Realized
Gains (Losses)(1)
Net Change in
Unrealized
Appreciation
(Depreciation)(2)
Purchases(5)
Sales
Repayments(6)
Gross
Transfers
into
Level 3(3)*
Gross
Transfers
out of
Level 3(3)*
Balance as of
March 31, 2025
Investments
Senior Secured Debt$3,419,044 $(48)$(25,181)$428,830 $— $(148,147)$— $ $3,674,498 
Unsecured Debt75,557 — 65 1,336 — — — (12,222)64,736 
Preferred Stock53,802 — (3,953)2,813 — — — — 52,662 
Common Stock44,593 (670)(2,014) (331)— 17,316 — 58,894 
Warrants21,823 (63)(1,527)352  — — — 20,585 
Other Assets and Liabilities             
Escrow and Other Investment Receivables152 56 — 1,814 (56)— — — 1,966 
Accounts Payable and Accrued Liabilities(1,012)— 358 44 (362)— — — (972)
Total$3,613,959 $(725)$(32,252)$435,189 $(749)$(148,147)$17,316 $(12,222)$3,872,369 
(in thousands)Balance as of
January 1, 2024
Net Realized
Gains (Losses)(1)
Net Change in
Unrealized
Appreciation
(Depreciation)(2)
Purchases(5)
Sales
Repayments(6)
Gross
Transfers
into
Level 3(4)*
Gross
Transfers
out of
Level 3(4)*
Balance as of
March 31, 2024
Investments              
Senior Secured Debt$2,987,577 $— $(104)$498,787 $— $(174,035)$— $— $3,312,225 
Unsecured Debt69,722 — 481 542 — — — — 70,745 
Preferred Stock53,038 — (2,326)1,597 — — — — 52,309 
Common Stock41,790 — (1,752)— — — — — 40,038 
Warrants22,088 904 (2,113)1,232 (2,829)— — — 19,282 
Other Assets             
Escrow and Other Investment Receivables10,888 13 7,353 — (13,234)— — — 5,020 
Total$3,185,103 $917 $1,539 $502,158 $(16,063)$(174,035)$ $ $3,499,619 
* The Company recognizes transfers as of the transaction date.
(1)Included in net realized gains (losses) in the accompanying Consolidated Statements of Operations.
(2)Included in net change in unrealized appreciation (depreciation) in the accompanying Consolidated Statements of Operations.
(3)Transfers out of Level 3 during the three months ended March 31, 2025 related to the conversion of the Company's Level 3 debt investments in Hercules Adviser LLC and Carbon Health Technologies, Inc., into common stock Level 3 investments. Transfers into Level 3 during the three months ended March 31, 2025 included the conversion of 23andMe, Inc. Level 1 common stock into Level 3 common stock due to bankruptcy and delisting.
(4)There were no transfers into or out of Level 3 during the three months ended March 31, 2024.
(5)Amounts listed above are inclusive of loan origination fees received at the inception of the loan which are deferred and amortized into fee income as well as the accretion of existing loan discounts and fees during the period. Escrow receivable purchases may include additions due to proceeds held in escrow from the liquidation of Level 3 investments. Amounts are net of purchases assigned to the Adviser Funds.
(6)Amounts listed above include the acceleration and payment of loan discounts and loan fees due to early payoffs or restructures along with regularly scheduled amortization.
The following table presents the net unrealized appreciation (depreciation) recorded for debt, preferred stock, common stock and warrant Level 3 investments relating to assets still held at the reporting date.
43

Table of Contents
(in millions)Three Months Ended March 31,
20252024
Debt investments
$(23.4)$0.4 
Preferred stock
(4.0)(2.3)
Common stock
(2.3)(1.8)
Warrant investments
(1.6)0.7 
The following tables provide quantitative information about the Company’s Level 3 fair value measurements as of March 31, 2025 and December 31, 2024. In addition to the techniques and inputs noted in the tables below, according to the Company’s valuation guidelines, the Company may also use other valuation techniques and methodologies when determining the Company’s fair value measurements. The tables below are not intended to be all-inclusive, but rather provide information on the significant Level 3 inputs as they relate to the Company’s fair value measurements. See the accompanying Consolidated Schedule of Investments for the fair value of the Company’s investments. The methodology for the determination of the fair value of the Company’s investments is discussed in “Note 2 – Summary of Significant Accounting Policies”. The significant unobservable input used in the fair value measurement of the Company’s escrow receivables is the amount recoverable at the contractual maturity date of the escrow receivable.
Investment Type - Level 3
Debt Investments
Fair Value as of
March 31, 2025
(in thousands)
Valuation
Techniques/ Methodologies
Unobservable Input(1)
Range
Weighted
Average(2)
Pharmaceuticals$787,506 Market Comparable CompaniesHypothetical Market Yield
8.78% - 16.34%
12.90%
  Premium/(Discount)
(2.50%) - 3.00%
0.17%
73,719 
Liquidation(3)
Probability weighting of alternative outcomes
10.00% - 90.00%
80.32%
Technology1,281,565 Market Comparable CompaniesHypothetical Market Yield
9.81% - 21.18%
13.21%
  Premium/(Discount)
(1.00%) - 5.00%
0.17%
 27,673 Convertible Note AnalysisProbability weighting of alternative outcomes
1.00% - 70.00%
50.94%
53,584 
Liquidation(3)
Probability weighting of alternative outcomes
10.00% - 72.50%
60.35%
Sustainable and Renewable Technology19,903 Market Comparable CompaniesHypothetical Market Yield
15.78% - 15.78%
15.78%
  Premium/(Discount)
0.50% - 0.50%
0.50%
Medical Devices59,851 Market Comparable CompaniesHypothetical Market Yield
11.81% - 12.77%
12.26%
Premium/(Discount)
0.00% - 0.50%
0.26%
Lower Middle Market585,224 Market Comparable CompaniesHypothetical Market Yield
10.43% - 17.48%
13.63%
  Premium/(Discount)
(0.75%) - 2.25%
0.58%
Debt Investments for which Cost Approximates Fair Value
 516,515 Debt Investments originated within 6 months  
 214,238 
Imminent Payoffs(4)
  
 82,666 Debt Investments Maturing in Less than One Year
36,790 Debt Investments in Wholly-Owned Subsidiaries
 $3,739,234 Total Level 3 Debt Investments
Escrow and Other Investment Receivables1,966 Expected Proceeds
Accounts Payable and Accrued Liabilities(972)
Liquidation(3)
Probability weighting of alternative outcomes
20.00% - 50.00%
39.79%
$3,740,228 Total Level Three Debt Investments and Other Investment Receivables (Payables)
(1)The significant unobservable inputs used in the fair value measurement of the Company’s debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums/(discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation may result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment.
Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries noted above as follows:
Pharmaceuticals, above, is comprised of debt investments in the “Drug Discovery & Development” and “Healthcare Services, Other” industries.
44

Table of Contents
Technology, above, is comprised of debt investments in the “Communications & Networking”, “Information Services”, “Consumer & Business Services”, “Media/Content/Info”, “Space Technologies”, and “Software” industries.
Sustainable and Renewable Technology, above, is comprised of debt investments in the “Sustainable and Renewable Technology” industry.
Medical Devices, above, is comprised of debt investments in the “Medical Devices & Equipment” industry.
Lower Middle Market, above, is comprised of debt investments in the “Healthcare Services – Other”, “Consumer & Business Services”, “Diversified Financial Services”, “Sustainable and Renewable Technology”, and “Software” industries.
(2)The weighted averages are calculated based on the fair market value of each investment.
(3)The significant unobservable input used in the fair value measurement of impaired debt securities and other investment receivables (payables) is the probability weighting of alternative outcomes.
(4)Imminent Payoffs represent debt investments that the Company expects to be fully repaid within the next three months, prior to their scheduled maturity date.
Investment Type - Level 3
Debt Investments
Fair Value as of
December 31, 2024
(in thousands)
Valuation Techniques/ Methodologies
Unobservable Input(1)
Range
Weighted
Average(2)
Pharmaceuticals$947,065 Market Comparable CompaniesHypothetical Market Yield
8.42% - 16.19%
12.03%
  Premium/(Discount)
(2.50%) - 3.00%
0.13%
 55,344 
Liquidation(3)
Probability weighting of alternative outcomes
20.00% - 80.00%
75.53%
Technology1,365,943 Market Comparable CompaniesHypothetical Market Yield
10.21% - 20.58%
13.10%
  Premium/(Discount)
(0.75%) - 4.50%
0.20%
 26,869 Convertible Note AnalysisProbability weighting of alternative outcomes
1.00% - 70.00%
50.66%
 51,004 
Liquidation(3)
Probability weighting of alternative outcomes
22.00% - 78.00%
66.34%
Sustainable and Renewable Technology21,102 Market Comparable CompaniesHypothetical Market Yield
12.41% - 15.44%
15.25%
   Premium/(Discount)
0.25% - 3.50%
0.45%
Medical Devices59,645 Market Comparable CompaniesHypothetical Market Yield
11.79% - 12.75%
12.24%
Premium/(Discount)
0.00% - 0.50%
0.26%
Lower Middle Market636,258 Market Comparable CompaniesHypothetical Market Yield
10.27% - 21.00%
14.12%
   Premium/(Discount)
(0.25%) - 5.00%
1.07%
Debt Investments for which Cost Approximates Fair Value
 242,833 Debt Investments originated within 6 months  
 4,141 
Imminent Payoffs(4)
  
 36,185 Debt Investments Maturing in Less than One Year
48,212 Debt Investments in Wholly-Owned Subsidiaries
 $3,494,601 Total Level 3 Debt Investments
Accounts Payable and Accrued Liabilities(1,012)
Liquidation(3)
Probability weighting of alternative outcomes
20.00% - 50.00%
38.44%
$3,493,589 Total Level Three Debt Investments and Other Investment Receivables (Payables)
(1)The significant unobservable inputs used in the fair value measurement of the Company’s debt securities are hypothetical market yields and premiums/(discounts). The hypothetical market yield is defined as the exit price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The premiums/(discounts) relate to company specific characteristics such as underlying investment performance, security liens, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation may result in a significantly lower (higher) fair value measurement, depending on the materiality of the investment.
Debt investments in the industries noted in the Company’s Consolidated Schedule of Investments are included in the industries noted above as follows:
Pharmaceuticals, above, is comprised of debt investments in the “Drug Discovery & Development” and “Healthcare Services, Other” industries.
Technology, above, is comprised of debt investments in the “Communications & Networking”, “Information Services”, “Consumer & Business Services”, “Media/Content/Info”, and “Software” industries.
Sustainable and Renewable Technology, above, is comprised of debt investments in the “Sustainable and Renewable Technology” industry.
Medical Devices, above, is comprised of debt investments in the “Medical Devices & Equipment” industry.
Lower Middle Market, above, is comprised of debt investments in the “Healthcare Services – Other”, “Consumer & Business Services”, “Diversified Financial Services”, “Sustainable and Renewable Technology”, and “Software” industries.
(2)The weighted averages are calculated based on the fair market value of each investment.
(3)The significant unobservable input used in the fair value measurement of impaired debt securities and other investment receivables (payables) is the probability weighting of alternative outcomes.
45

Table of Contents
(4)Imminent payoffs represent debt investments that the Company expects to be fully repaid within the next three months, prior to their scheduled maturity date.
Investment Type - Level 3 Equity and Warrant InvestmentsFair Value as of
March 31, 2025
(in thousands)
Valuation Techniques/
Methodologies
Unobservable Input(1)
Range
Weighted Average(5)
Equity Investments$48,390 Market Comparable Companies
Revenue Multiple(2)
0.2x - 16.5x
7.0x
  
Tangible Book Value Multiple(2)
1.6x - 1.6x
1.6x
  
Discount for Lack of Marketability(3)
16.31% - 92.53%
33.34%
 7,237 Market Adjusted OPM Backsolve
Market Equity Adjustment(4)
(97.68%) - (0.65%)
(30.32%)
 50,151 Discounted Cash Flow
Discount Rate(7)
11.55% - 32.94%
29.55%
 5,778 
Other(6)
   
Warrant Investments18,779 Market Comparable Companies
Revenue Multiple(2)
0.5x - 12.9x
4.3x
  
Discount for Lack of Marketability(3)
7.36% - 32.40%
24.28%
 1,806 Market Adjusted OPM Backsolve
Market Equity Adjustment(4)
(70.08%) - 54.33%
(3.87%)
Total Level 3 Equity and Warrant Investments$132,141     
(1)The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity securities are revenue and/or earnings multiples (e.g. EBITDA, EBT, ARR), market equity adjustment factors, and discounts for lack of marketability. Significant increases/(decreases) in the inputs in isolation would result in a significantly higher/(lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date. The significant unobservable input used in the fair value measurement of impaired equity securities is the probability weighting of alternative outcomes.
(2)Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments.
(3)Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments.
(4)Represents the range of changes in industry valuations since the portfolio company's last external valuation event.
(5)Weighted averages are calculated based on the fair market value of each investment.
(6)The fair market value of these investments is derived based on recent private market and merger and acquisition transaction prices.
(7)The discount rate used is based on current portfolio yield adjusted for uncertainty of actual performance and timing in capital deployments.
Investment Type - Level 3 Equity and Warrant InvestmentsFair Value as of
December 31, 2024
(in thousands)
Valuation Techniques/
Methodologies
Unobservable Input(1)
Range
Weighted Average(5)
Equity Investments$45,420 Market Comparable Companies
Revenue Multiple(2)
0.4x - 16.8x
9.1x
  
Tangible Book Value Multiple(2)
1.7x - 1.7x
1.7x
  
Discount for Lack of Marketability(3)
17.64% - 92.80%
36.12%
 12,374 Market Adjusted OPM Backsolve
Market Equity Adjustment(4)
(96.57%) - 24.76%
(17.57%)
 34,677 Discounted Cash Flow
Discount Rate(7)
12.17% - 33.34%
30.21%
 5,924 
Other(6)
   
Warrant Investments18,302 Market Comparable Companies
Revenue Multiple(2)
0.8x - 14.1x
4.5x
  
Discount for Lack of Marketability(3)
14.72% - 34.35%
26.76%
 3,521 Market Adjusted OPM Backsolve
Market Equity Adjustment(4)
(56.36%) - 24.76%
1.33%
Total Level 3 Equity and Warrant Investments$120,218     
(1)The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity securities are revenue and/or earnings multiples (e.g. EBITDA, EBT, ARR), market equity adjustment factors, and discounts for lack of marketability. Significant increases/(decreases) in the inputs in isolation would result in a significantly higher/(lower) fair value measurement, depending on the materiality of the investment. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date. The significant unobservable input used in the fair value measurement of impaired equity securities is the probability weighting of alternative outcomes.
(2)Represents amounts used when the Company has determined that market participants would use such multiples when pricing the investments.
46

Table of Contents
(3)Represents amounts used when the Company has determined market participants would take into account these discounts when pricing the investments.
(4)Represents the range of changes in industry valuations since the portfolio company's last external valuation event.
(5)Weighted averages are calculated based on the fair market value of each investment.
(6)The fair market value of these investments is derived based on recent market transactions.
(7)The discount rate used is based on current portfolio yield adjusted for uncertainty of actual performance and timing in capital deployments.
The Company believes that the carrying amounts of its financial instruments, other than investments and debt, which consist of cash and cash equivalents, receivables including escrow receivables, accounts payable and accrued liabilities, approximate the fair values of such items due to the short maturity of such instruments. The debt obligations of the Company are recorded at amortized cost and not at fair value on the Consolidated Statements of Assets and Liabilities. The fair value of the Company’s outstanding debt obligations are based on observable market trading prices or quotations and unobservable market rates as applicable for each instrument.
As of March 31, 2025 and December 31, 2024, the 2033 Notes (as defined in “Note 5 - Debt”) were trading on the New York Stock Exchange (“NYSE”) at $25.23 and $25.17 per unit at par value. The par value at underwriting for the 2033 Notes was $25.00 per unit. Based on market quotations on or around March 31, 2025 and December 31, 2024, the 2031 Asset-Backed Notes (as defined in “Note 5 - Debt”) were quoted for 0.971 and 0.963. Based on market quotations on or around March 31, 2025, the 2028 Convertible Notes (as defined in “Note 5 - Debt”) were quoted for 0.981 per dollar at par value. The fair values of the SBA debentures, June 2025 Notes, June 2025 3-Year Notes, March 2026 A Notes, March 2026 B Notes, September 2026, and January 2027 Notes (each as defined in “Note 5 - Debt”) are calculated based on the net present value of payments over the term of the notes using estimated market rates for similar notes and remaining terms. The fair values of the outstanding debt under the MUFG Bank Facility and the SMBC Facility (each as defined in “Note 5 - Debt”) are equal to their outstanding principal balances as of March 31, 2025 and December 31, 2024.
The following tables provide additional information about the approximate fair value and level in the fair value hierarchy of the Company’s outstanding borrowings as of March 31, 2025 and December 31, 2024:
(in thousands)March 31, 2025
DescriptionCarrying
Value
Approximate
Fair Value
Identical Assets
(Level 1)
Observable Inputs
(Level 2)
Unobservable Inputs
(Level 3)
SBA Debentures$287,049 $268,236 $— $— $268,236 
June 2025 Notes69,960 70,637 — — 70,637 
June 2025 3-Year Notes49,965 50,678 — — 50,678 
March 2026 A Notes49,913 49,012 — — 49,012 
March 2026 B Notes49,905 49,036 — — 49,036 
September 2026 Notes323,566 305,377 — — 305,377 
January 2027 Notes347,598 330,404 — — 330,404 
2028 Convertible Notes278,503 282,109 — 282,109 — 
2031 Asset-Backed Notes116,272 113,433 — 113,433 — 
2033 Notes39,070 40,368 — 40,368 — 
MUFG Bank Facility105,000 105,000 — — 105,000 
SMBC Facility259,822 260,006 — — 260,006 
Total$1,976,623 $1,924,296 $— $435,910 $1,488,386 
47

Table of Contents
(in thousands)December 31, 2024
DescriptionCarrying
Value
Approximate
Fair Value
Identical Assets
(Level 1)
Observable Inputs
(Level 2)
Unobservable Inputs
(Level 3)
SBA Debentures$271,371 $260,436 $— $— $260,436 
February 2025 Notes49,981 50,698 — — 50,698 
June 2025 Notes69,919 69,308 — — 69,308 
June 2025 3-Year Notes49,926 49,713 — — 49,713 
March 2026 A Notes49,889 49,052 — — 49,052 
March 2026 B Notes49,880 49,087 — — 49,087 
September 2026 Notes323,321 302,244 — — 302,244 
January 2027 Notes347,265 327,928 — — 327,928 
2031 Asset-Backed Notes118,769 115,031 — 115,031 — 
2033 Notes39,043 40,272 — 40,272 — 
MUFG Bank Facility116,000 116,000 — — 116,000 
SMBC Facility283,591 283,591 — — 283,591 
Total$1,768,955 $1,713,360 $— $155,303 $1,558,057 
4. Investments
Control and Affiliate Investments
As required by the 1940 Act, the Company classifies its investments by level of control. “Control investments” are defined in the 1940 Act as investments in those companies that the Company is deemed to “control”. Under the 1940 Act, the Company is generally deemed to “control” a company in which it has invested if it owns 25% or more of the voting securities of such company or has greater than 50% representation on its board. “Affiliate investments” are investments in those companies that are “affiliated companies” of the Company, as defined in the 1940 Act, which are not control investments. The Company is deemed to be an “affiliate” of a company in which it has invested if it owns 5% or more, but generally less than 25%, of the voting securities of such company. “Non-control/non-affiliate investments” are investments that are neither control investments nor affiliate investments. For purposes of determining the classification of its investments, the Company has included consideration of any voting securities or board appointment rights held by the Adviser Funds.
The following table summarizes the Company’s realized gains and losses and changes in unrealized appreciation and depreciation on control and affiliate investments for the three months ended March 31, 2025 and 2024.
(in thousands)For the Three Months Ended March 31, 2025
Portfolio Company(1)
TypeFair Value as of March 31, 2025Interest & Dividend Income Fee IncomeNet Change in Unrealized Appreciation (Depreciation) Realized Gain (Loss)
Control Investments
Coronado Aesthetics, LLCControl$47 $ $ $(22)$ 
Gibraltar Acquisition LLC(2)
Control58,900 1,567 39 (941) 
Hercules Adviser LLC(3)
Control45,017 1,900  2,827  
Tectura CorporationControl11,770 170  113  
Total Control Investments$115,734 $3,637 $39 $1,977 $ 
48

Table of Contents
(in thousands)For the Three Months Ended March 31, 2024
Portfolio Company(1)
TypeFair Value as of March 31, 2024Interest & Dividend IncomeFee IncomeNet Change in Unrealized Appreciation (Depreciation)Realized Gain (Loss)
Control Investments
Coronado Aesthetics, LLCControl$283 $ $ $21 $ 
Gibraltar Acquisition, LLC(2)
Control57,931 1,033 36 (4,621) 
Hercules Adviser LLC(3)
Control41,884 1,752  1,171  
Tectura CorporationControl12,117 172  600  
Total Control Investments$112,215 $2,957 $36 $(2,829)$ 
(1)In accordance with Rules 3-09, 4-08(g), and Rule 10-01(b)(1) of Regulation S-X, (“Rule 3-09”, “Rule 4-08(g)”, and “Rule 10-01(b)(1)”, respectively), the Company must determine if its unconsolidated subsidiaries are considered “significant subsidiaries”. As of March 31, 2025 and March 31, 2024, there were no unconsolidated subsidiaries that are considered “significant subsidiaries”.
(2)Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC. The subsidiary has no significant assets or liabilities, other than their equity and debt investments and equity interest in Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC, respectively.
(3)Hercules Adviser LLC is owned by Hercules Capital Management LLC and presented with Hercules Partner Holdings, LLC which are both wholly owned by the Company. Please refer to “Note 1 - Description of Business” for additional disclosure.
Portfolio Composition
The following table shows the fair value of the Company’s portfolio of investments by asset class as of March 31, 2025 and December 31, 2024:
(in thousands)March 31, 2025December 31, 2024
Investments at
Fair Value
Percentage of
Total Portfolio
Investments at
Fair Value
Percentage of
Total Portfolio
Senior Secured Debt$3,674,498 93.6 %$3,419,044 93.4 %
Unsecured Debt64,736 1.7 %75,557 2.1 %
Preferred Stock52,662 1.3 %53,802 1.5 %
Common Stock94,088 2.4 %74,855 2.0 %
Warrants31,473 0.8 %30,500 0.8 %
Investment Funds & Vehicles6,993 0.2 %6,220 0.2 %
Total$3,924,450 100.0 %$3,659,978 100.0 %
A summary of the Company’s investment portfolio, at value, by geographic location as of March 31, 2025 and December 31, 2024 is shown as follows:
(in thousands)March 31, 2025December 31, 2024
Investments at
Fair Value
Percentage of
Total Portfolio
Investments at
Fair Value
Percentage of
Total Portfolio
United States$3,489,550 88.9 %$3,288,737 89.9 %
Netherlands132,889 3.4 %59,157 1.6 %
United Kingdom119,905 3.1 %142,183 3.9 %
Switzerland56,421 1.5 % 0.0 %
Germany49,417 1.3 %49,255 1.3 %
Israel44,321 1.1 %88,066 2.4 %
Canada16,229 0.4 %16,251 0.4 %
Denmark9,111 0.2 %9,284 0.3 %
Ireland4,647 0.1 %4,649 0.1 %
Singapore1,590 0.0 %1,996 0.1 %
Other370 0.0 %400 0.0 %
Total$3,924,450 100.0 %$3,659,978 100.0 %
49

Table of Contents
The following table shows the fair value of the Company’s portfolio by industry sector as of March 31, 2025 and December 31, 2024:
(in thousands)March 31, 2025December 31, 2024
Investments at
Fair Value
Percentage of
Total Portfolio
Investments at
Fair Value
Percentage of
Total Portfolio
Software$1,262,813 32.2 %$1,081,100 29.5 %
Drug Discovery & Development1,119,941 28.5 %1,080,390 29.5 %
Healthcare Services, Other625,556 15.9 %610,184 16.7 %
Consumer & Business Services374,561 9.6 %372,641 10.2 %
Electronics & Computer Hardware167,370 4.3 %162,888 4.5 %
Diversified Financial Services117,366 3.0 %113,491 3.1 %
Medical Devices & Equipment75,238 1.9 %74,962 2.0 %
Space Technologies49,527 1.3 %45,700 1.2 %
Biotechnology Tools34,819 0.9 %35,434 1.0 %
Communications & Networking27,601 0.7 %27,700 0.8 %
Information Services24,923 0.6 %24,356 0.7 %
Sustainable and Renewable Technology22,396 0.6 %27,696 0.8 %
Manufacturing Technology20,653 0.5 %1,162 0.0 %
Consumer & Business Products1,139 0.0 %1,497 0.0 %
Semiconductors425 0.0 %704 0.0 %
Media/Content/Info114 0.0 %63 0.0 %
Drug Delivery8 0.0 %10 0.0 %
Total$3,924,450 100.0 %$3,659,978 100.0 %
No single portfolio investment represents more than 10% of the fair value of the Company’s total investments as of March 31, 2025 or December 31, 2024.
Concentrations of Credit Risk
The Company’s customers are primarily privately held companies and public companies which are active in the “Software”, “Drug Discovery & Development”, “Healthcare Services, Other”, and “Consumer & Business Services” sectors. These sectors are characterized by high margins, high growth rates, consolidation and product and market extension opportunities. Value for companies in these sectors is often vested in intangible assets and intellectual property.
Industry and sector concentrations vary as new loans are recorded and loans are paid off. Investment income, consisting of interest, fees, and recognition of gains on equity and warrant or other equity interests, can fluctuate materially when a loan is paid off or a related warrant or equity interest is sold. Investment income recognized in any given year can be highly concentrated among several portfolio companies.
As of March 31, 2025 and December 31, 2024, the Company’s ten largest portfolio companies represented approximately 30.4% and 31.6% of the total fair value of the Company’s investments in portfolio companies, respectively. As of March 31, 2025 and December 31, 2024, the Company had six and six portfolio companies, respectively, that represented 5% or more of the Company’s net assets. As of March 31, 2025, the Company had four equity investments representing 61.3% of the total fair value of the Company's equity investments, and each represented 5% or more of the total fair value of the Company’s equity investments. As of December 31, 2024, the Company had three equity investments which represented approximately 49.7% of the total fair value of the Company’s equity investments, and each represented 5% or more of the total fair value of the Company’s equity investments.
Investment Collateral
In the majority of cases, the Company collateralizes its investments by obtaining a first priority security interest in a portfolio company’s assets, which may include its intellectual property. In other cases, the Company may obtain a negative
50

Table of Contents
pledge covering a company’s intellectual property. The Company's investments were collateralized as follows as of March 31, 2025 and December 31, 2024:
Percentage of debt investments (at fair value), as of
March 31, 2025December 31, 2024
Senior Secured First Lien
All assets including intellectual property69.0 %67.1 %
All assets with negative pledge on intellectual property13.8 %14.2 %
“Last-out” with security interest in all of the assets8.1 %9.7 %
Total senior secured first lien position90.9 %91.0 %
Second lien7.4 %6.8 %
Unsecured1.7 %2.2 %
Total debt investments at fair value100.0 %100.0 %
Derivative Instruments
The Company enters into forward currency contracts from time to time to help mitigate the impact that an adverse change in foreign exchange rates would have on the value of the Company’s investments denominated in foreign currencies. The following is a summary of the fair value and location of the Company’s derivative instruments in the Consolidated Statements of Assets and Liabilities held as of March 31, 2025 and December 31, 2024:
(in thousands)Fair Value
Derivative InstrumentStatement LocationMarch 31, 2025December 31, 2024
Foreign currency forward contractOther assets$— $538 
Foreign currency forward contractAccounts payable and accrued liabilities301 — 
Total$301 $538 
Net realized and unrealized gains and losses on derivative instruments recorded by the Company during the three months ended March 31, 2025 and 2024 are in the following locations in the Consolidated Statements of Operations:
(in thousands) Three Months Ended March 31,
Derivative InstrumentStatement Location20252024
Foreign currency forward contractNet change in unrealized appreciation (depreciation) - Non-control / Non-affiliate investments$(840)$229 
 Total$(840)$229 
Investment Income
The Company’s investment portfolio generates interest, fee, and dividend income. The composition of the Company’s interest income and fee income is as follows:
(in thousands)Three Months Ended March 31,
 20252024
Contractual interest income$87,817 $90,714 
Exit fee interest income10,228 11,880 
PIK interest income13,473 9,897 
Dividend income2,400 1,600 
Other investment income(1)
1,654 1,688 
Total interest and dividend income$115,572 $115,779 
Recurring fee income$2,680 $2,455 
Fee income - expired commitments317 647 
Accelerated fee income - early repayments942 2,672 
Total fee income$3,939 $5,774 
(1)Other investment income includes OID interest income and interest recorded on other assets.

51

Table of Contents
As of March 31, 2025 and December 31, 2024, unamortized capitalized fee income was recorded as follows:
(in millions)March 31,
2025
December 31,
2024
Offset against debt investment cost$37.2 $36.9 
Deferred obligation contingent on funding or other milestone10.2 9.1 
Total Unamortized Fee Income$47.4 $46.0 
As of March 31, 2025 and December 31, 2024, loan exit fees receivable were recorded as follows:
(in millions)March 31,
2025
December 31,
2024
Included within debt investment cost$41.5 $39.2 
Deferred receivable related to expired commitments2.9 3.0 
Total Exit Fees Receivable$44.4 $42.2 
5. Debt
As of March 31, 2025 and December 31, 2024, the Company had the following available and outstanding debt:
(in thousands)March 31, 2025December 31, 2024
 Total AvailablePrincipal
Outstanding
Carrying Value(1)
Total AvailablePrincipal
Outstanding
Carrying Value(1)
SBA Debentures(2)(4)
$350,000 $295,000 $287,049 $350,000 $279,000 $271,371 
February 2025 Notes   50,000 50,000 49,981 
June 2025 Notes70,000 70,000 69,960 70,000 70,000 69,919 
June 2025 3-Year Notes50,000 50,000 49,965 50,000 50,000 49,926 
March 2026 A Notes50,000 50,000 49,913 50,000 50,000 49,889 
March 2026 B Notes50,000 50,000 49,905 50,000 50,000 49,880 
September 2026 Notes325,000 325,000 323,566 325,000 325,000 323,321 
January 2027 Notes350,000 350,000 347,598 350,000 350,000 347,265 
2028 Convertible Notes287,500 287,500 278,503    
2031 Asset-Backed Notes116,845 116,845 116,272 119,475 119,475 118,769 
2033 Notes40,000 40,000 39,070 40,000 40,000 39,043 
MUFG Bank Facility(2)
400,000 105,000 105,000 400,000 116,000 116,000 
SMBC Facility(2)(3)(5)
475,000 260,006 259,822 475,000 283,790 283,591 
Total$2,564,345 $1,999,351 $1,976,623 $2,329,475 $1,783,265 $1,768,955 
(1)Except for the SMBC Facility and MUFG Bank Facility, all carrying values represent the principal amount outstanding less the remaining unamortized debt issuance costs and unaccreted premium or discount, if any, associated with the debt as of the balance sheet date.
(2)Availability subject to the Company meeting the borrowing base requirements.
(3)“Total Available” includes $175.0 million of available commitment through the letter of credit facility as of March 31, 2025 and December 31, 2024.
(4)As of March 31, 2025 and December 31, 2024, the total available debt under the SBA Debentures was $350.0 million, of which $175.0 million was available to HC IV and $175.0 million was available to SBIC V.
(5)In November 2024, the Company amended its SMBC Facility and converted a portion of the existing revolver facility into a term loan facility in connection therewith. As of March 31, 2025, the term loan portion of the SMBC Facility for total available, outstanding principal, and carrying value was $25.0 million, $25.0 million, and $24.8 million respectively. As of December 31, 2024, the term loan portion of the SMBC Facility for total available, outstanding principal, and carrying value was $25.0 million, $25.0 million, and $24.8 million respectively.
52

Table of Contents
Debt issuance costs, net of accumulated amortization, were as follows as of March 31, 2025 and December 31, 2024:
(in thousands)March 31, 2025December 31, 2024
SBA Debentures$7,951 $7,629 
February 2025 Notes 19 
June 2025 Notes40 81 
June 2025 3-Year Notes35 74 
March 2026 A Notes87 111 
March 2026 B Notes95 120 
September 2026 Notes1,434 1,679 
January 2027 Notes2,402 2,735 
2028 Convertible Notes8,997  
2031 Asset-Backed Notes573 706 
2033 Notes930 957 
MUFG Bank Facility(1)
1,350 1,770 
SMBC Facility(1)(2)
2,823 2,693 
Total$26,717 $18,574 
(1)The MUFG Bank Facility and SMBC Facility are line-of-credit arrangements, the debt issuance costs associated with these instruments are included within Other assets on the Consolidated Statements of Assets and Liabilities in accordance with ASC Subtopic 835-30.
(2)As part of the November 2024 amendment of the SMBC Facility, the existing revolver facility was split into a revolver facility and a term loan facility. As of March 31, 2025, the debt issuance costs, net of accumulated amortization of the revolver facility is $2.6 million and the term loan is $0.2 million. As of December 31, 2024, the debt issuance costs, net of accumulated amortization of the revolver facility is $2.5 million and the term loan is $0.2 million.
For the three months ended March 31, 2025, the components of interest expense, related fees, losses on debt extinguishment and cash paid for interest expense for debt were as follows:
(in thousands)Three Months Ended March 31, 2025
Description
Interest expense(1)
Amortization of debt issuance cost (loan fees)Unused facility and other fees (loan fees)Total interest expense and feesCash paid for interest expense
SBA Debentures$2,499 $227 $ $2,726 $3,971 
February 2025 Notes202 19  221 1,070 
June 2025 Notes754 40  794  
June 2025 3-Year Notes750 39  789  
March 2026 A Notes562 24  586 1,125 
March 2026 B Notes568 26  594 1,138 
September 2026 Notes2,175 203  2,378 4,266 
January 2027 Notes3,079 207  3,286 5,906 
2028 Convertible Notes827 77  904  
2031 Asset-Backed Notes(2)
1,492 80  1,572 1,457 
2033 Notes625 27  652 625 
MUFG Bank Facility2,570 442 560 3,572 2,179 
SMBC Facility3,595 208 219 4,022 3,843 
Total$19,698 $1,619 $779 $22,096 $25,580 
(1)Interest expense includes amortization of OID for the three months ended March 31, 2025, of $42 thousand, $126 thousand, $68 thousand, and $38 thousand related to the September 2026 Notes, January 2027 Notes, 2028 Convertible Notes, and 2031 Asset-Backed Notes, respectively.
(2)During the three months ended March 31, 2025, we have recognized $15 thousand of loss on debt extinguishment for 2031 Asset-Backed Notes.
53

Table of Contents
For the three months ended March 31, 2024, the components of interest expense, related fees, and cash paid for interest expense for debt were as follows:
(in thousands)Three Months Ended March 31, 2024
Description
Interest expense(1)
Amortization of debt issuance cost (loan fees)Unused facility and other fees (loan fees)Total interest expense and feesCash paid for interest expense
SBA Debentures$1,137 $146 $ $1,283 $2,275 
July 2024 Notes1,252 74  1,326 2,504 
February 2025 Notes535 29  564 1,070 
June 2025 Notes754 40  794  
June 2025 3-Year Notes750 39  789  
March 2026 A Notes563 24  587 1,125 
March 2026 B Notes569 26  595 1,138 
September 2026 Notes2,175 203  2,378 4,265 
January 2027 Notes3,079 207  3,286 5,906 
2031 Asset-Backed Notes1,903 100  2,003 1,856 
2033 Notes625 27  652 625 
MUFG Bank Facility1,933 447 609 2,989 1,566 
SMBC Facility2,349 180 246 2,775 1,754 
Total$17,624 $1,542 $855 $20,021 $24,084 
(1)Interest expense includes amortization of OID for the three months ended March 31, 2024 of $42 thousand, $126 thousand, and $47 thousand related to the September 2026 Notes, January 2027 Notes, and 2031 Asset-Backed Notes, respectively.
The overall weighted average interest cost, cost of debt and debt outstanding for the Company for the three months ended March 31, 2025 and 2024 were as follows:
Three Months Ended March 31,
(in thousands)20252024
Weighted average interest cost
4.3 %4.3 %
Weighted average cost of debt(1)
4.9 %4.9 %
Weighted average debt outstanding
$1,815,224 $1,635,890 
(1)Cost of debt includes interest and fees.

As of March 31, 2025 and December 31, 2024, the Company was in compliance with the terms of all borrowing arrangements. There are no sinking fund requirements for any of the Company's debt.
54

Table of Contents
SBA Debentures
The Company held the following SBA debentures outstanding principal balances as of March 31, 2025 and December 31, 2024:
(in thousands)
Issuance/Pooling Date
Maturity Date
Interest Rate(1)
March 31, 2025December 31, 2024
March 26, 2021September 1, 20311.58%$37,500 $37,500 
June 25, 2021September 1, 20311.58%16,200 16,200 
July 28, 2021September 1, 20311.58%5,400 5,400 
August 20, 2021September 1, 20311.58%5,400 5,400 
October 21, 2021March 1, 20323.21%14,000 14,000 
November 1, 2021March 1, 20323.21%21,000 21,000 
November 15, 2021March 1, 20323.21%5,200 5,200 
November 30, 2021March 1, 20323.21%20,800 20,800 
December 20, 2021March 1, 20323.21%10,000 10,000 
December 23, 2021March 1, 20323.21%10,000 10,000 
December 28, 2021March 1, 20323.21%5,000 5,000 
January 14, 2022March 1, 20323.21%4,500 4,500 
January 21, 2022March 1, 20323.21%20,000 20,000 
November 8, 2024March 1, 20355.09%30,000 30,000 
December 6, 2024March 1, 20355.09%33,600 33,600 
December 12, 2024March 1, 20355.09%8,400 8,400 
December 20, 2024March 1, 20355.09%32,000 32,000 
February 5, 2025March 1, 20355.09%6,000  
March 28, 2025(2)
September 1, 20354.89%10,000  
Total SBA Debentures  $295,000 $279,000 
(1)Interest rates are determined initially at issuance and reset to a fixed rate at the debentures pooling date. The rates are inclusive of annual SBA charges.
(2)As of March 31, 2025, $10.0 million of drawn SBA Debentures are scheduled to be pooled on September 25, 2025. The interest rate disclosed is the current effective interim interest rate.
SBICs are subject to a variety of regulations and oversight by the SBA concerning the size and nature of the companies in which they may invest as well as the structures of those investments. The SBA as part of its oversight periodically examines and audits to determine SBICs' compliance with SBA regulations.
HC IV and SBIC V each received their licenses to operate as an SBIC on October 27, 2020 and July 9, 2024, respectively, and each license has a 10 year term. Each license provides the Company access to up to $175.0 million of capital through the SBA debenture program, subject to maintaining certain capital commitments. HC IV has issued the entire $175.0 million in SBIC guaranteed debentures and SBIC V has issued $120.0 million of its SBA guaranteed debentures. SBA debentures bear fixed interest based on the treasury rate plus a spread applicable for the period the debentures are drawn. As of the latest debenture pooling date in March 2025, SBA debentures were issued with an interest rate of approximately 4.89%. The actual rates may vary depending on the timing of drawdown and pooling period.
The Company's SBICs were in compliance with all SBIC terms, including those pertaining to the SBA Debentures as of March 31, 2025 and December 31, 2024. The following table summarizes information related to our SBICs as of March 31, 2025 and December 31, 2024.
March 31, 2025December 31, 2024
DescriptionHC IVSBIC VHC IVSBIC V
Number of investments held35143311 
Fair value of investments (in millions)$376.1$194.7$377.7$155.6 
Percentage of fair value of investments based on the Company's total investment portfolio9.6 %5.0 %10.3 %4.3 %
Tangible assets (in millions)$381.4$197.6$382.9$157.8 
Percentage of tangible assets based on the Company's total assets9.5 %4.9 %10.0 %4.1 %
55

Table of Contents
July 2024 Notes
On July 16, 2019, the Company issued $105.0 million in aggregate principal amount of 4.770% interest-bearing unsecured notes due on July 16, 2024 (the “July 2024 Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering. Interest on the July 2024 Notes was due semiannually. The July 2024 Notes were the general unsecured obligations of the Company that ranked pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.On July 16, 2024, the Company fully repaid the aggregate outstanding $105.0 million principal and $2.5 million of accrued interest pursuant to the terms of the July 2024 Notes.
February 2025 Notes
On February 5, 2020, the Company issued $50.0 million in aggregate principal amount of 4.280% interest-bearing unsecured notes due February 5, 2025 (the “February 2025 Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering. Interest on the February 2025 Notes was due semiannually. The February 2025 Notes were the general unsecured obligations of the Company that ranked pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. On February 5, 2025, the Company fully repaid the aggregate outstanding $50.0 million principal and $1.1 million of accrued interest pursuant to the terms of the February 2025 Notes.
June 2025 Notes
On June 3, 2020, the Company issued $70.0 million in aggregate principal amount of 4.310% interest-bearing unsecured notes due June 3, 2025 (the “June 2025 Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering. Interest on the June 2025 Notes is due semiannually. The June 2025 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.
June 2025 3-Year Notes
On June 23, 2022, the Company issued $50.0 million in aggregate principal amount of 6.000% interest-bearing unsecured notes due June 23, 2025 (the “June 2025 3-Year Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering. Interest on the June 2025 3-Year Notes is due semiannually. The June 2025 3-Year Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.
March 2026 A Notes
On November 4, 2020, the Company issued $50.0 million in aggregate principal amount of 4.500% interest-bearing unsecured notes due March 4, 2026 (the “March 2026 A Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement notes offering. Interest on the March 2026 A Notes is due semiannually. The March 2026 A Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.
March 2026 B Notes
On March 4, 2021, the Company issued $50.0 million in aggregate principal amount of 4.550% interest-bearing unsecured notes due March 4, 2026 (the “March 2026 B Notes”), unless repurchased in accordance with their terms, to qualified institutional investors in a private placement pursuant note offering. Interest on the March 2026 B Notes is due semiannually. The March 2026 B Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.
September 2026 Notes
On September 16, 2021, the Company issued $325.0 million in aggregate principal amount of 2.625% interest-bearing unsecured notes due September 16, 2026 (the “September 2026 Notes”), unless repurchased in accordance with the terms of the Seventh Supplemental Indenture, dated September 16, 2021. Interest on the September 2026 Notes is payable semiannually in arrears on March 16 and September 16 of each year. The September 2026 Notes are general unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.
January 2027 Notes
On January 20, 2022, the Company issued $350.0 million in aggregate principal amount of 3.375% interest-bearing unsecured notes due January 20, 2027 (the “January 2027 Notes”), unless repurchased in accordance with the terms of the Eight Supplemental Indenture, dated January 20, 2022. Interest on the January 2027 Notes is payable semiannually in
56

Table of Contents
arrears on January 20 and July 20 of each year. The January 2027 Notes are general unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. The Company may redeem some or all of the January 2027 Notes at any time, or from time to time, at the redemption price set forth under the terms of the January 2027 Notes Indenture.
2028 Convertible Notes
On March 10, 2025, the Company issued $287.5 million in aggregate principal amount of 4.750% interest-bearing convertible unsecured notes due on September 1, 2028 (the "2028 Convertible Notes"), unless previously converted or caused to repurchase the notes in accordance with their terms by the holders of the 2028 Convertible Notes. The Company may not redeem the 2028 Convertible Notes at its option prior to maturity. Interest on the 2028 Convertible Notes is due semiannually. The 2028 Convertible Notes are unsecured obligations of the Company and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.
Prior to the close of business on the business day immediately preceding March 1, 2028, holders may convert their 2028 Convertible Notes only under certain circumstances set forth in the 2028 Convertible Notes Indenture, dated March 10, 2025, between the Company and U.S. Bank Trust Company, National Association, as trustee. On or after March 1, 2028 until the close of business on the scheduled trading day immediately preceding the maturity date, holders may convert their 2028 Convertible Notes at any time. Upon conversion, the Company will pay or deliver, as the case may be, at its election, cash, shares of its common stock or a combination of cash and shares of its common stock, subject to an irrevocable settlement method election that may be made by the Company. The conversion rate is initially 46.5631 shares of common stock per $1,000 principal amount of 2028 Convertible Notes (equivalent to an initial conversion price of $21.48 per share of common stock). The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, if certain corporate events occur prior to the maturity date, the Company will increase the conversion rate for a holder who elects to convert its 2028 Convertible Notes in connection with such a corporate event in certain circumstances. As of March 31, 2025, the conversion rate was 46.5631 shares of common stock per $1,000 principal amount of 2028 Convertible Notes or conversion price of $21.48 per share of common stock.
2031 Asset-Backed Notes
On June 22, 2022, the Company completed a term debt securitization in connection with which an affiliate of the Company issued $150.0 million in aggregate principal amount of 4.950% interest-bearing asset-backed notes due on July 20, 2031 (the “2031 Asset-Backed Notes”). The 2031 Asset-Backed Notes were issued by Hercules Capital Funding Trust 2022-1 LLC (the “2022 Securitization Issuer”) pursuant to a note purchase agreement, dated as of June 22, 2022, by and among the Company, Hercules Capital Funding 2022-1 LLC, as trust depositor, the 2022 Securitization Issuer, and U.S. Bank Trust Company, N. A., as trustee, and are backed by a pool of senior loans made to certain portfolio companies of the Company and secured by certain assets of those portfolio companies and are to be serviced by the Company. Interest on the 2031 Asset-Backed Notes will be paid, to the extent of funds available.
Under the terms of the 2031 Asset-Backed Notes, the Company is required to maintain a reserve cash balance, funded through proceeds from the sale of the 2031 Asset-Backed Notes and through interest and principal collections from the underlying securitized debt portfolio, which may be used to pay monthly interest and principal payments on the 2031 Asset-Backed Notes. The Company has segregated these funds and classified them as restricted cash. As of March 31, 2025 and December 31, 2024, there was approximately $3.2 million and $3.3 million, respectively, of funds segregated as restricted cash related to the 2031 Asset-Backed Notes. The reinvestment period for 2031 Asset-Backed Notes ended on July 20, 2024, and as a result all principal payments received from portfolio companies will no longer be eligible for reinvestment and will be utilized to pay down the outstanding principal amount. During the three months ended March 31, 2025 and the year ended December 31, 2024, the Company repaid $2.6 million and $30.5 million of principal, respectively, and accelerated recognition of $15 thousand and $0.2 million, respectively, of debt issuance costs associated with extinguishment of the debt. This is disclosed as “Loss on extinguishment of debt” in the Consolidated Statements of Operations.
2033 Notes
On September 24, 2018, the Company issued $40.0 million in aggregate principal amount of 6.250% interest-bearing unsecured notes due October 30, 2033 (the “2033 Notes”), unless repurchased in accordance with the terms of the Sixth Supplemental Indenture to the Base Indenture, dated September 24, 2018. Interest on the 2033 Notes is payable quarterly in arrears on January 30, April 30, July 30, and October 30 of each year. The 2033 Notes trade on the NYSE under the symbol “HCXY.” The 2033 Notes are general unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. The Company may redeem some or all of the 2033 Notes at any time, or from time to time, at the redemption price set forth under the terms of the 2033 Notes indenture after October 30, 2023.
57

Table of Contents
Credit Facilities
As of March 31, 2025 and December 31, 2024, the Company has two available credit facilities, the MUFG Bank Facility and the SMBC Facility (together, the “Credit Facilities”). For the three months ended March 31, 2025 and the year ended December 31, 2024, the weighted average interest rate was 6.32% and 7.63%, respectively, and the average debt outstanding under the Credit Facilities was $390.0 million and $338.0 million, respectively.
MUFG Bank Facility
On January 13, 2023, the Company entered into a third amended credit facility agreement, which amends the agreement dated as of June 10, 2022. The Company, through a special purpose wholly owned subsidiary, Hercules Funding IV LLC (“Hercules Funding IV”), as borrower, entered into the credit facility (the “MUFG Bank Facility”) with MUFG Bank Ltd. as the arranger and administrative agent, and the lenders party to the MUFG Bank Facility from time to time.
Under the MUFG Bank Facility, the lenders have made commitments of $400.0 million, which may be further increased via an accordion feature up to an aggregate $600.0 million, funded by existing or additional lenders and with the agreement of MUFG Bank and subject to other customary conditions. There can be no assurances that additional lenders will join the MUFG Bank Facility to increase available borrowings. Debt under the MUFG Bank Facility generally bears interest at a rate per annum equal to SOFR plus 2.75% for SOFR loans. The MUFG Bank Facility matures on January 13, 2026, plus a twelve-month amortization period, unless sooner terminated in accordance with its terms. The MUFG Bank Facility is secured by all of the assets of Hercules Funding IV. The MUFG Bank Facility requires payment of a non-use fee during the revolving credit availability period.
The MUFG Bank Facility also includes financial and other covenants applicable to the Company and the Company’s subsidiaries, in addition to those applicable to Hercules Funding IV, including covenants relating to certain changes of control of Hercules Funding IV. Among other things, these covenants require the Company to maintain certain financial ratios, including a minimum interest coverage ratio and a minimum tangible net worth with respect to Hercules Funding IV. The MUFG Bank Facility provides for customary events of default, including with respect to payment defaults, breach of representations and covenants, servicer defaults, certain key person provisions, cross default provisions to certain other debt, lien and judgment limitations, and bankruptcy.
SMBC Facility
On November 26, 2024, the Company entered into a fifth amendment (the “Fifth Amendment”) to its revolving credit agreement, which amends the revolving credit agreement, dated as of November 9, 2021, with Sumitomo Mitsui Banking Corporation (the “SMBC Facility”), as administrative agent, and the lenders and issuing banks to the SMBC Facility. As of March 31, 2025, the SMBC Facility provides for borrowings in U.S. dollars and certain agreed upon foreign currencies of up to $300.0 million, from which the Company may access subject to certain conditions. The SMBC Facility contains an accordion feature, in which the Company can increase the credit line up to an aggregate of $500.0 million, funded by existing or additional lenders and with the agreement of SMBC Bank and subject to other customary conditions. Availability under the revolving SMBC Facility will terminate on November 24, 2028, and the outstanding loans under the SMBC Facility will mature on November 26, 2029. Borrowings under the SMBC Facility are subject to compliance with a borrowing base and an aggregate portfolio balance. The Company’s obligations under the SMBC Facility may in the future be guaranteed by certain of the Company’s subsidiaries and primarily secured by a first priority security interest (subject to certain exceptions) in only certain specified property and assets of the Company and the subsidiary guarantors thereunder.
Interest under the revolving portion of the SMBC Facility is determined by the nature and denomination of the borrowing. Interest rates are determined by the appropriate benchmark rate (SOFR, EURIBOR, Prime, CORRA, or TIBOR) as applicable for the type of borrowing plus an applicable margin adjustment which can range from 1.0% to 2.0% per annum subject to certain conditions. In addition to interest, the SMBC Facility is subject to a non-usage fee of 0.375% per annum (based on the immediately preceding period’s average usage) on the unused portion of the commitment under the SMBC Facility during the revolving period. The Company is required to pay letter of credit participation fees and a fronting fee on the average daily amount of any lender’s exposure with respect to any letters of credit issued under the SMBC Facility.
In connection with the Fifth Amendment, $25.0 million of the total available commitment under the revolver facility was converted into a term loan (the “SMBC Term Loan”). The SMBC Term loan is a SOFR based interest-bearing plus 2.0% spread loan and will mature on November 26, 2029, unless repurchased in accordance with the terms of the SMBC Facility. Interest on the SMBC Term Loan is payable monthly, quarterly, or semiannually based on the SOFR tenor. The SMBC Term Loan is general unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company. The Company may redeem some of all of SMBC Facility at any time, or from time to time, at the redemption price set forth under the terms of SMBC Facility Indenture.
58

Table of Contents
On February 5, 2025, the Company entered into the Third Amendment to the SMBC Letter of Credit Facility Agreement (the "SMBC LC Facility"), which amends the SMBC LC Facility with Sumitomo Mitsui Banking Corporation, dated as of January 13, 2023. The SMBC LC Facility provides for a letter of credit facility with a final maturity date ending on February 5, 2028 and a commitment amount of $175.0 million as amended. Further, the SMBC LC Facility includes an accordion provision to increase the commitment up to $400.0 million, subject to certain conditions. The Company’s obligations under the SMBC LC Facility may in the future be guaranteed by certain of the Company’s subsidiaries and is primarily secured by a first priority security interest (subject to certain exceptions) in only certain specified property and assets of the Company and any subsidiary guarantors thereunder.
The SMBC Facility contains customary events of default with customary cure and notice provisions, including, without limitation, nonpayment, misrepresentation of representations and warranties in a material respect, breach of covenant, cross-default and cross-acceleration to other indebtedness and bankruptcy. The SMBC Facility also includes financial and other covenants applicable to the Company and the Company’s subsidiaries, including covenants relating to minimum stockholders' equity, asset coverage ratios, and our status as a RIC.
6. Income Taxes
The determination of taxable income pursuant to U.S. federal income tax regulations differs from U.S. GAAP. As a result, permanent differences are reclassified among capital accounts in the financial statements to reflect their appropriate tax character.
Taxable income and taxable net realized gains (losses) for the three months ended March 31, 2025 and 2024 appears as follows:
(in millions, except per share data)
Three Months Ended March 31,

20252024
Taxable income$73.2 $78.3 
Taxable income per share $0.43 $0.50 
Taxable net realized gains (losses)$3.5 $5.9 
Taxable net realized gains (losses) per share $0.02 $0.04 
Weighted average shares outstanding171.5 157.4 
The aggregate gross unrealized appreciation (depreciation) of the Company’s investment over cost for U.S. federal income tax purposes appears as follows:
(in millions)March 31, 2025December 31, 2024
Aggregate gross unrealized appreciation$110.7 $108.4 
Aggregate gross unrealized depreciation181.0 156.5 
Net unrealized appreciation (depreciation) over cost for U.S. federal income tax purposes (70.3)(48.1)
Aggregate cost of securities for U.S. federal income tax purposes (in billions)4.0 3.7 
For the three months ended March 31, 2025, the Company paid approximately $6.0 million of income tax, including excise tax, and had $1.5 million of accrued, but unpaid tax expense as of March 31, 2025. For the three months ended March 31, 2024, the Company paid approximately $4.9 million of income tax, including excise tax, and had $1.9 million of accrued, but unpaid tax expense as of March 31, 2024.
Additionally, the Company has taxable subsidiaries which hold certain portfolio investments in an effort to limit potential legal liability and/or comply with source-income type requirements contained in the RIC tax provisions of the Code. These taxable subsidiaries are consolidated for U.S. GAAP and the portfolio investments held by the taxable subsidiaries are included in the Company’s consolidated financial statements and are recorded at fair value. These taxable subsidiaries are not consolidated with the Company for income tax purposes and may generate income tax expense, or benefit, and tax assets and liabilities as a result of their ownership of certain portfolio investments. Any income generated by these taxable subsidiaries generally would be subject to tax at normal U.S. federal tax rates based on its taxable income.
In accordance with ASC 740, the Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than-not” to be sustained by the applicable tax authority. Tax benefits of positions not deemed to meet the more-likely-than-not threshold, or uncertain tax positions, would be recorded as a tax expense in the current year. It is the Company’s policy to recognize accrued interest and penalties, if any, related to unrecognized tax benefits as a component of provision for income taxes. Based on an analysis of the Company’s tax position, there are no uncertain tax positions that meet the recognition or measurement criteria. The Company is currently not undergoing any tax examinations. The Company does not anticipate any significant increase or decrease in unrecognized tax benefits for the next twelve months. The 2020 – 2023 federal tax years for the Company remain subject
59

Table of Contents
to examination by the Internal Revenue Service. The 2019 – 2023 state tax years for the Company remain subject to examination by the state taxing authorities.
7. Stockholders’ Equity and Distributions
The Company has issued and outstanding 173,285 thousand and 170,575 thousand shares of common stock as of March 31, 2025 and December 31, 2024, respectively. The Company currently sell shares through its equity distribution agreements (the “2024 Equity Distribution Agreements”) with Citizens JMP Securities LLC and Jefferies LLC (the “Sales Agents”) entered into on December 12, 2024. The 2024 Equity Distribution Agreements provide that the Company may offer and sell up to 30.0 million shares of its common stock from time to time through the Sales Agents. Sales of the Company's common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at the market,” as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), including sales made directly on the NYSE or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices. The 2024 Equity Distribution Agreements replaced the ATM equity distribution agreements between the Company and the Sales Agents executed on May 5, 2023.
The Company issued and sold the following shares of common stock during the three months ended March 31, 2025 and 2024:
(in millions, except per share data)
Three Months Ended March 31,Number of Shares IssuedGross ProceedsUnderwriting Fees/Offering ExpensesNet ProceedsAverage Price/Share
20252.0$40.1 $0.7 $39.4 $19.71 
20243.7$67.3 $0.9 $66.4 $17.83 
The Company generally uses net proceeds from these offerings to make investments, to repurchase or pay down liabilities and for general corporate purposes. As of March 31, 2025, approximately 28.0 million shares remain available for issuance and sale under the 2024 Equity Distribution Agreements.
The Company currently pays quarterly distributions to its stockholders. The following table summarizes the Company’s distributions declared during the three months ended March 31, 2025 and year ended December 31, 2024:
(in thousands, except per share data)
Distribution TypeDeclared DateRecord DatePayment DatePer Share AmountTotal Amount
BaseFebruary 8, 2024February 28, 2024March 6, 2024$0.40 $63,359 
SupplementalFebruary 8, 2024February 28, 2024March 6, 20240.08 12,672 
BaseApril 25, 2024May 14, 2024May 21, 20240.40 64,912 
SupplementalApril 25, 2024May 14, 2024May 21, 20240.08 12,982 
BaseJuly 25, 2024August 13, 2024August 20, 20240.40 64,953 
SupplementalJuly 25, 2024August 13, 2024August 20, 20240.08 12,990 
BaseOctober 24, 2024November 13, 2024November 20, 20240.40 66,980 
SupplementalOctober 24, 2024November 13, 2024November 20, 20240.08 13,396 
Total distributions declared during the year ended December 31, 2024$1.92 $312,244 
BaseFebruary 6, 2025February 26, 2025March 5, 2025$0.40 $69,263 
SupplementalFebruary 6, 2025February 26, 2025March 5, 20250.07 12,121 
Total distributions declared during the three months ended March 31, 2025$0.47 $81,384 
During the three months ended March 31, 2025, for income tax purposes, the distributions paid of $0.47 per share were comprised of ordinary income. As of March 31, 2025, the Company estimates that it has generated undistributed taxable earnings “spillover” of $0.92 per share. The undistributed taxable earnings spillover will be carried forward toward distributions to be paid in accordance with RIC requirements.
The Company has a distribution reinvestment plan, whereby the Company may buy shares of its common stock in the open market or issue new shares in order to satisfy dividend reinvestment requests. When the Company issues new shares in connection with the dividend reinvestment plan, the issue price is equal to the closing price of its common stock on the dividend record date. During the three months ended March 31, 2025 and 2024, the Company issued 121,743 and 99,413 shares, respectively, of common stock to stockholders in connection with the dividend reinvestment plan.
8. Equity Incentive Plans
The Company grants equity-based awards to employees and non-employee directors for the purpose of attracting and retaining the services of its executive officers, key employees, and members of the Board. The Company’s equity-based awards are granted under the 2018 Equity Incentive Plan (the “2018 Plan”) for employees and 2018 Non-Employee
60

Table of Contents
Director Plan (the “Director Plan”) for non-employee directors. The 2018 Plan and the Director Plan were approved by stockholders on June 28, 2018 and unless earlier terminated by the Board, terminate on May 12, 2028. Subject to certain adjustments and permitted reversions of shares, the maximum aggregate number of shares that may be authorized for issuance under awards granted under the 2018 Plan and Director Plan is 9,261,229 shares and 300,000 shares, respectively. In connection with the issuance of shares under the 2018 Plan and Director Plan, the Company has registered, in aggregate, 18.7 million and 300,000 shares of common stock, respectively.
The Company has received exemptive relief from the SEC that permits it to issue restricted stock to non-employee directors under the Director Plan and restricted stock and restricted stock units to certain of its employees, officers, and directors (excluding non-employee directors) under the 2018 Plan. The exemptive order also allows participants in the Director Plan and the 2018 Plan to (i) elect to have the Company withhold shares of its common stock to pay for the exercise price and applicable taxes with respect to an option exercise (“net issuance exercise”) and/or (ii) permit the holders of restricted stock to elect to have the Company withhold shares of its stock to pay the applicable taxes due on restricted stock at the time of vesting. Each individual employee would be able to make a cash payment to satisfy applicable tax withholding at the time of option exercise or vesting on restricted stock.
The Company has granted equity-based awards that have service and performance conditions. Certain of the Company’s equity-based awards are classified as liability awards in accordance with ASC Topic 718, Compensation – Stock Compensation. All of the Company’s equity-based awards require future service, and are expensed over the relevant service period. The Company does not estimate forfeitures, and reverses all unvested costs associated with equity-awards in the period they are forfeited. For the three months ended March 31, 2025 and 2024, the Company recognized $3.6 million and $3.1 million of stock-based compensation expense in the Consolidated Statements of Operations, respectively. As of March 31, 2025 and March 31, 2024, approximately $30.1 million and $26.3 million of total unrecognized compensation costs expected to be recognized over the next 2.7 and 2.6 years, respectively.
Service-Vesting Awards
The Company grants equity-based awards which have service conditions, which generally begin to vest one-third after one year after the date of grant and ratably over the succeeding two years in accordance with the individual award terms. Certain awards have service conditions of longer duration and may begin to vest up to seven years after the date of grant. These equity-based awards which vest upon achievement of service conditions are collectively referred to as the “Service Vesting Awards”. The grant date fair value of Service Vesting Awards granted during the three months ended March 31, 2025 and 2024, were approximately $15.6 million, and $14.2 million, respectively.
The Company has granted restricted stock equity awards in the form of restricted stock awards and restricted stock units. The Company determines the grant date fair values of restricted stock equity awards using the grant date stock close price. The activities for the Company's unvested restricted stock equity awards for each of the three months ended March 31, 2025 and 2024, are summarized below:
Three Months Ended March 31,
20252024
SharesWeighted Average Grant Date
Fair Value per Share
Shares Weighted Average Grant Date
Fair Value per Share
Unvested Shares Beginning of Period2,060,432$12.24 1,880,409$14.52 
Granted780,295$19.96 813,676$17.41 
Vested(389,553)$16.63 (416,661)$14.13 
Forfeited(35,458)$12.96 (18,434)$15.12 
Unvested Shares End of Period2,415,716$14.02 2,258,990$12.93 
In addition to the restricted stock equity-based awards, the Company has also issued stock options to certain employees. The fair value of options granted during the three months ended March 31, 2025 and 2024, was approximately $29,000 and $6,000, respectively. During the three months ended March 31, 2025 and 2024, approximately $36,000, and $32,000 of share-based cost due to stock option grants was expensed, respectively.
Liability Classified Awards
The Company has granted equity-based awards which are subject to both service and performance conditions. These awards are settled either in cash or a fixed dollar value of shares, subject to the terms of each individual award, and therefore classified as liability awards (the “Liability Awards”). As of March 31, 2025, all Liability Awards have vested and have been settled. Generally, if the performance conditions of these types of awards are not met, the total compensation expense related to the Liability Awards may be less than the maximum granted value of the awards. The Company records
61

Table of Contents
Liability Awards as deferred compensation within Accounts Payable and Accrued Liabilities included on the Consolidated Statements of Assets and Liabilities.
Certain Liability Awards are structured similar to the Performance Awards and increase in value with corresponding increases to the Company’s TSR and vest after four years. The Company remeasures the value of these awards each period based on the Company’s TSR achieved to date. Certain other Liability Awards are linked to attainment of investment funding goals. The Company determines the fair value of these Liability Awards based on the expected probability of the performance conditions being met and recognized over the service period. The Company accrues for Liability Awards based on the expected probability that the performance conditions would be met, this assumption is re-evaluated each period, and may be adjusted to reflect changes in this assumption. Generally, the other Liability Awards vest over a three-years service term.
During the three months ended March 31, 2025, no compensation expense related to the Liability Awards was recognized in the Consolidated Statements of Operations and no amounts remain outstanding. During the three months ended March 31, 2025, no Liability Awards vested.
As of March 31, 2024, all Liability Awards were unvested and there was approximately $0.1 million of total unrecognized compensation costs expected to be recognized over a weighted average period of 0.1 years. During the three months ended March 31, 2024, there was approximately $0.4 million of compensation expense related to the Liability Awards recognized in the Consolidated Statements of Operations and $3.0 million accrued within Accounts Payable and Accrued Liabilities in the Consolidated Statements of Assets and Liabilities. During the three months ended March 31, 2024, no Liability Awards vested.
9. Earnings Per Share
Shares used in the computation of the Company’s basic and diluted earnings per share are as follows:
(in thousands, except per share data)Three Months Ended March 31,
 20252024
Numerator
Net increase (decrease) in net assets resulting from operations$50,337 $90,964 
Less: Total distributions declared(81,384)(76,031)
Total Earnings (loss), net of total distributions(31,047)14,933 
Earnings (loss), net of distributions attributable to common shares(31,048)14,776 
Add: Distributions declared attributable to common shares80,616 75,230 
Numerator for basic change in net assets per common share49,568 90,006 
Add: Income impact of assumed conversion of 2028 Convertible Notes904
Numerator for diluted change in net assets per common share$50,472 $90,006 
Denominator
Basic weighted average common shares outstanding171,494157,445
Incremental shares from assumed conversion of 2028 Convertible Notes3,272
Common shares issuable617475
Weighted average common shares outstanding assuming dilution175,383157,920
Change in net assets per common share:
Basic$0.29 $0.57 
Diluted$0.29 $0.57 
In the table above, unvested share-based payment awards that have non-forfeitable rights to distributions or distribution equivalents are treated as participating securities for calculating earnings per share. Unvested common stock options and restricted stock units are also considered for the purpose of calculating diluted earnings per share.
The issuance of the 2028 Convertible Notes is considered part of the if-converted method for calculation of diluted earnings per share. In applying the if-converted method, conversion is not assumed for purposes of computing diluted earnings per share if the effect would be anti-dilutive. For the three months ended March 31, 2025, there was no anti-dilution when applying the if-converted method for the 2028 Convertible Notes.
62

Table of Contents
The calculation of change in net assets resulting from operations per common share assuming dilution, excludes all anti-dilutive shares. For the three months ended March 31, 2025 and 2024, the number of anti-dilutive shares, as calculated based on the weighted average closing price of the Company’s common stock for the periods, are as follows:
Three Months Ended March 31,
Anti-dilutive Securities20252024
Unvested common stock options1,9742,004
Unvested restricted stock awards23895
As of March 31, 2025 and December 31, 2024, the Company was authorized to issue 300.0 million shares of common stock with a par value of $0.001. Each share of common stock entitles the holder to one vote.
10. Financial Highlights
Following is a schedule of financial highlights for the three months ended March 31, 2025 and 2024:
(in thousands, except per share data and ratios)Three Months Ended March 31,
 20252024
Per share data: (1)
Net asset value at beginning of period$11.66 $11.43 
Net investment income0.45 0.50 
Net realized gain (loss)(0.01)0.05 
Net unrealized appreciation (depreciation)(0.15)0.02 
Total from investment operations0.29 0.57 
Net increase (decrease) in net assets from capital share transactions(1)
0.04 0.09 
Distributions of net investment income(6)
(0.47)(0.48)
Stock-based compensation expense included in net investment income and other movements(2)
0.03 0.02 
Net asset value at end of period$11.55 $11.63 
Ratios and supplemental data:    
Per share market value at end of period$19.21 $18.45 
Total return(3)
(2.03 %)13.57 %
Shares outstanding at end of period173,285 162,230 
Weighted average number of common shares outstanding171,494 157,445 
Net assets at end of period$2,000,630 $1,885,938 
Ratio of total expense to average net assets(4)
8.33 %9.32 %
Ratio of net investment income before investment gains and losses to average net assets(4)
15.35 %17.40 %
Portfolio turnover rate(5)
3.40 %4.83 %
Weighted average debt outstanding$1,815,224 $1,635,890 
Weighted average debt per common share$10.58 $10.39 
(1)All per share activity is calculated based on the weighted average shares outstanding for the relevant period, except net increase (decrease) in net assets from capital share transactions, which is based on the common shares outstanding as of the relevant balance sheet date.
(2)Adjusts for the impact of stock-based compensation expense, which is a non-cash expense and has no net impact to NAV. Pursuant to ASC Topic 718, the expense is offset by a corresponding increase in paid-in capital. Additionally, adjusts for other items attributed to the difference between certain per share data based on the weighted-average basic shares outstanding and those calculated using the shares outstanding as of a period end or transaction date.
(3)The total return for the three months ended March 31, 2025 and 2024 equals to the change in the ending market value over the beginning of the period price per share plus distributions paid per share during the period, divided by the beginning price assuming the distribution is reinvested on the date of the distribution. As such, the total return is not annualized. The total return does not reflect any sales load that must be paid by investors.
(4)The ratios are calculated based on weighted average net assets for the relevant period and are annualized.
(5)The portfolio turnover rate for the three months ended March 31, 2025 and 2024 equals to the lesser of investment portfolio purchases or sales during the period, divided by the average investment portfolio value during the period. As such, portfolio turnover rate is not annualized.
(6)Includes distributions on unvested restricted stock awards.
11. Commitments and Contingencies
The Company’s commitments and contingencies consist primarily of unfunded commitments to extend credit in the form of loans to the Company’s portfolio companies. As of March 31, 2025, a portion of these unfunded contractual commitments are dependent upon the portfolio company reaching certain milestones before the debt commitment becomes available. Furthermore, the Company’s credit agreements with its portfolio companies generally contain customary lending provisions which allow the Company relief from funding obligations for previously made unfunded commitments in instances where the underlying portfolio company experiences materially adverse events that affect the financial condition
63

Table of Contents
or business outlook for the portfolio company. Since a portion of these commitments may expire without being drawn, unfunded contractual commitments do not necessarily represent future cash requirements. As such, the Company’s disclosure of unfunded contractual commitments includes only those which are available at the request of the portfolio company and unencumbered by future or unachieved milestones.
As of March 31, 2025 and December 31, 2024, the Company had approximately $455.7 million and $448.5 million, respectively, of available unfunded commitments, including undrawn revolving facilities, which were available at the request of the portfolio company and unencumbered by future or unachieved milestones. In order to draw a portion of the Company's available unfunded commitments, a portfolio company must submit to the Company a formal funding request that complies with the applicable advance notice and other operational requirements. The amounts disclosed exclude unfunded commitments (i) for which, with respect to a portfolio company's agreement, a milestone was achieved after the last day on which the portfolio company could have requested a drawdown funding to be completed within the reporting period; and (ii) related to the portion of portfolio company investments assigned to or directly committed by the Adviser Funds as described in “Note -12 Related Party Transactions”. The fair value of the Company’s unfunded commitments is considered to be immaterial as the yield determined at the time of underwriting is expected to be materially consistent with the yield upon funding, given that interest rates are generally pegged to market indices and given the existence of milestones, conditions and/or obligations embedded in the borrowing agreements.
64

Table of Contents
As of March 31, 2025 and December 31, 2024, the Company’s unfunded contractual commitments available at the request of the portfolio company, including undrawn revolving facilities, and unencumbered by milestones were as follows:
(in thousands)
Unfunded Commitments (1) as of
Portfolio CompanyMarch 31, 2025December 31, 2024
Debt Investments:
Earnix, Inc.$41,250 $41,250 
Arcus Biosciences, Inc.37,500 37,500 
Thumbtack, Inc.30,000 30,000 
Harness, Inc.26,950 11,550 
Armis, Inc.25,000 25,000 
Disc Medicine, Inc.22,500 22,500 
Pindrop Security, Inc.19,375 19,375 
Coronet Cyber Security Ltd.17,000 17,000 
Marathon Health, LLC16,550 24,250 
Locus Robotics Corp.16,250 16,250 
Akero Therapeutics, Inc.15,000 15,000 
Dragos, Inc.13,000 13,000 
Aryaka Networks, Inc.12,500 12,500 
GoEuro Travel GmbH12,468 26,250 
WellBe Senior Medical, LLC12,000 12,000 
Semperis Technologies Inc.11,250  
Alector, Inc.10,500 10,500 
DocPlanner9,538  
CoreView USA, Inc.9,000 10,000 
iSpot.tv, Inc.8,250  
Suzy, Inc.8,000 8,000 
PayIt, LLC8,000 8,000 
Heron Therapeutics, Inc.8,000 8,000 
Curana Health Holdings, LLC7,500 7,500 
SmartSheet Inc.4,840  
Ennoble Care LLC4,500  
Babel Street4,367 4,367 
AlphaSense, Inc.4,000 4,000 
Reveleer4,000  
Allvue Systems, LLC3,590 3,590 
Behavox Limited3,500  
LogRhythm, Inc.3,143 3,143 
Zappi, Inc.2,571 2,571 
Dashlane, Inc.2,500 5,000 
Loftware, Inc.2,277 2,277 
Streamline Healthcare Solutions2,200 2,200 
New Relic, Inc.2,176 2,176 
Sumo Logic, Inc.2,000 2,000 
LogicSource1,209 1,209 
TaxCalc1,166 1,166 
LinenMaster, LLC1,000 1,000 
Alchemer LLC890  
Main Street Rural, Inc.874 874 
Fortified Health Security840 840 
65

Table of Contents
(in thousands)
Unfunded Commitments (1) as of
Portfolio CompanyMarch 31, 2025December 31, 2024
Debt Investments:
Dispatch Technologies, Inc.$813 $563 
Omeda Holdings, LLC750 731 
Dronedeploy, Inc.625 625 
ShadowDragon, LLC333 333 
Zimperium, Inc.282 196 
Strive Health Holdings, LLC 8,299 
Viridian Therapeutics, Inc. 8,000 
ATAI Life Sciences N.V. 7,000 
Saama Technologies, LLC 3,875 
Ceros, Inc. 1,707 
3GTMS, LLC 886 
Flight Schedule Pro, LLC 646 
Total Unfunded Debt Commitments:451,827 444,699 
Investment Funds & Vehicles:(2)
  
Forbion Growth Opportunities Fund I C.V.1,757 1,757 
Forbion Growth Opportunities Fund II C.V.2,072 2,072 
Total Unfunded Commitments in Investment Funds & Vehicles:3,829 3,829 
Total Unfunded Commitments$455,656 $448,528 
(1)For debt investments, amounts represent unfunded commitments, including undrawn revolving facilities, which are available at the request of the portfolio company. Amount excludes unfunded commitments which are unavailable due to the borrower having not met certain milestones. These amounts also exclude $136.0 million and $139.7 million of unfunded commitments as of March 31, 2025 and December 31, 2024, respectively, to portfolio companies related to loans assigned to or directly committed by the Adviser Funds as described in “Note -12 Related Party Transactions”.
(2)For investment funds and vehicles, the amount represents uncalled capital commitments in private equity funds.
The following table provides additional information on the Company’s unencumbered unfunded commitments regarding milestones, expirations and type:
(in thousands)
Unfunded Commitments
March 31, 2025December 31, 2024
Expiring during:
2025$244,624 $251,941 
2026156,839 147,840 
202710,020 10,553 
20287,179 6,040 
202924,149 24,149 
20304,176 4,176 
20314,840  
Total Unfunded Debt Commitments451,827 444,699 
Unfunded Commitments in Investment Funds & Vehicles:  
Expiring during:  
20301,757 1,757 
20322,072 2,072 
Total Unfunded Commitments in Investment Funds & Vehicles3,829 3,829 
Total Unfunded Commitments$455,656 $448,528 
66

Table of Contents
The following tables provide the Company’s contractual obligations as of March 31, 2025 and December 31, 2024:
As of March 31, 2025:Payments due by period (in thousands)
Contractual Obligations(1)
TotalLess than 1 year1 - 3 years3 - 5 yearsAfter 5 years
Debt(2)(3)
$1,999,351 $220,000 $780,000 $547,506 $451,845 
Lease and License Obligations(4)
23,400 3,287 6,710 5,618 7,785 
Total$2,022,751 $223,287 $786,710 $553,124 $459,630 
 
As of December 31, 2024:Payments due by period (in thousands)
Contractual Obligations(1)
TotalLess than 1 year1 - 3 years3 - 5 yearsAfter 5 years
Debt(5)(3)
$1,783,265 $170,000 $891,000 $283,790 $438,475 
Lease and License Obligations(4)
23,976 3,246 6,640 5,589 8,501 
Total$1,807,241 $173,246 $897,640 $289,379 $446,976 
(1)Excludes commitments to extend credit to the Company’s portfolio companies and uncalled capital commitments in investment funds.
(2)Includes $295.0 million in principal outstanding under the SBA Debentures, $70.0 million of the June 2025 Notes, $50.0 million of the June 2025 3-Year Notes, $50.0 million of the March 2026 A Notes, $50.0 million of the March 2026 B Notes, $116.8 million of the 2031 Asset-Backed Notes, $40.0 million of the 2033 Notes, $325.0 million of the September 2026 Notes, $350.0 million of the January 2027 Notes and $287.5 million of the 2028 Convertible Notes as of March 31, 2025. There was also $260.0 million outstanding under the SMBC Facility and $105.0 million outstanding under the MUFG Bank Facility as of March 31, 2025.
(3)Amounts represent future principal repayments and not the carrying value of each liability. See “Note 5 – Debt”.
(4)Leases and license obligations includes contractual amounts related to short-term leases.
(5)Includes $279.0 million in principal outstanding under the SBA Debentures, $50.0 million of the February 2025 Notes, $70.0 million of the June 2025 Notes, $50.0 million of the June 2025 3-Year Notes, $50.0 million of the March 2026 A Notes, $50.0 million of the March 2026 B Notes, $119.5 million of the 2031 Asset-Backed Notes, $40.0 million of the 2033 Notes, $325.0 million of the September 2026 Notes and $350.0 million of the January 2027 Notes as of December 31, 2024. There was also $283.8 million outstanding under the SMBC Facility and $116.0 million outstanding under the MUFG Bank Facility as of December 31, 2024.
Certain premises are leased or licensed under agreements which expire at various dates through July 2034. During the three months ended March 31, 2025 and 2024, total rent expense, including short-term leases, amounted to approximately $0.8 million and $1.0 million in each period, respectively. The Company recognizes an operating lease liability and a ROU asset for all leases, with the exception of short-term leases. The lease payments on short-term leases are recognized as rent expense on a straight-line basis. The discount rate applied to measure each ROU asset and lease liability is based on the Company’s incremental weighted average cost of debt. The Company considers the general economic environment and its credit rating and factors in various financing and asset specific adjustments to ensure the discount rate applied is appropriate to the intended use of the underlying lease. While some of the leases contained options to extend and terminate, it is not reasonably certain that either option will be utilized and therefore, only the payments in the initial term of the leases were included in the lease liability and ROU asset.
The following table sets forth information related to the measurement of the Company’s operating lease liabilities and supplemental cash flow information related to operating leases for the three months ended March 31, 2025 and 2024:
(in thousands)Three Months Ended March 31,
20252024
Total operating lease cost$774 $533 
Cash paid for amounts included in the measurement of lease liabilities595 122 
 As of March 31, 2025As of December 31, 2024
Weighted-average remaining lease term (in years)7.567.81
Weighted-average discount rate6.84 %6.85 %
67

Table of Contents
The following table shows future minimum lease payments under the Company’s operating leases and a reconciliation to the operating lease liability as of March 31, 2025:
(in thousands)As of March 31, 2025
2025$2,493 
20263,179 
20273,452 
20282,766 
Thereafter11,324 
Total lease payments23,214 
Less: imputed interest & other items(6,003)
Total operating lease liability$17,211 
The Company may, from time to time, be involved in litigation arising out of its operations in the normal course of business or otherwise. Furthermore, third parties may try to seek to impose liability on the Company in connection with the activities of its portfolio companies. While the outcome of any current legal proceedings cannot at this time be predicted with certainty, the Company does not expect any current matters will materially affect the Company’s financial condition or results of operations; however, there can be no assurance whether any pending legal proceedings will have a material adverse effect on the Company’s financial condition or results of operations in any future reporting period.
12. Related Party Transactions
As disclosed in “Note 1 - Description of Business”, the Adviser Subsidiary is the Company's wholly owned registered investment adviser business, comprised of the collectively held and presented entities Hercules Adviser LLC, Hercules Capital Management, LLC, and Hercules Partner Holdings, LLC entities. The Adviser Subsidiary is accounted for as a portfolio investment of the Company held at fair value. The Adviser Subsidiary has entered into investment management agreements with its privately offered Adviser Funds, and it receives management fees based on the assets under management of the Adviser Funds. In addition, the general partner interests (the “GP Interests”) held by Hercules Partner Holdings, LLC may receive incentive fees based on the performance of the Adviser Funds. Both the Adviser Subsidiary and Hercules Partner Holdings, LLC are owned by Hercules Capital Management LLC. The following table summarized the total income from the Adviser Subsidiary for the three months ended March 31, 2025 and 2024:
(in millions)
Three Months Ended March 31,
20252024
Interest Income$ $0.2 
Dividend Income1.91.6
Refer to “Note 4 – Investments” for additional information related to income, gains and losses recognized related to the Company’s investment.
The Company has a shared services agreement (“Sharing Agreement”) with the Adviser Subsidiary, through which the Adviser Subsidiary has access to the Company's human capital resources (including administrative functions) and other resources and infrastructure (including office space and technology). Under the terms of the Sharing Agreement, the Company allocates the related expenses of shared services to the Adviser Subsidiary based on direct time spent, investment activity, and proportion of assets under management depending on the nature of the expense. The Company’s total expenses for the three months ended March 31, 2025 and 2024, are net of expenses allocated to the Adviser Subsidiary of $3.3 million and $2.9 million, respectively. As of March 31, 2025 and December 31, 2024, there was approximately $0.6 million and less than $0.1 million receivable, respectively, from the Adviser Subsidiary.
In addition, the Company may from time-to-time make investments alongside the Adviser Funds or assign a portion of investments to the Adviser Funds in accordance with the Company’s allocation policy. The assigned investment activities for the three months ended March 31, 2025 and 2024, are summarized below:
(in millions)Three Months Ended March 31,
20252024
Investment commitments assigned to or directly committed by the Adviser Funds
$235.8 $181.1 
Investment fundings assigned to, directly originated or funded by the Adviser Funds
124.1 113.4 
Amounts received by the Company from the Adviser Funds relating to assigned investments
  
68

Table of Contents
13. Subsequent Events
Dividend Distribution Declaration
On April 23, 2025, the Board declared a cash distribution of $0.40 per share to be paid on May 20, 2025 to stockholders of record as of May 13, 2025. In addition to the cash distribution, and as part of the supplemental cash distribution of $0.28 per share to be paid in four quarterly distributions of $0.07 per share, the Board declared a supplemental cash distribution of $0.07 per share to be paid on May 20, 2025 to stockholders of record as of May 13, 2025. Including the $0.07 per share supplemental cash distributions paid to stockholders of record as of March 5, 2025, the Board has declared a total of $0.14 per share of the $0.28 per share of supplemental cash distribution declared on February 6, 2025.
Equity Offering
As of April 29, 2025, through its ATM program, the Company sold 2.2 million shares of common stock for $41.5 million of net proceeds.
69

Table of Contents
ITEM 2.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
FORWARD-LOOKING STATEMENTS
The matters discussed in this Quarterly Report, as well as in future oral and written statements by management of Hercules Capital, Inc., that are forward-looking statements are based on current management expectations that involve substantial risks and uncertainties, including those discussed under “Item 1A. Risk Factors”, which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements. Forward-looking statements relate to future events or our future financial performance. We generally identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. Important assumptions include our ability to originate new investments, achieve certain margins and levels of profitability, the availability of additional capital, and the ability to maintain certain debt to asset ratios. In light of these and other uncertainties, the inclusion of a projection or forward-looking statement in this report should not be regarded as a representation by us that our plans or objectives will be achieved. The forward-looking statements contained in this report include statements as to:
our current and future management structure;
our future operating results;
our business prospects and the prospects of our prospective portfolio companies;
the impact of investments that we expect to make;
our informal relationships with third parties including in the venture capital industry;
the expected market for venture capital investments and our addressable market;
the dependence of our future success on the general economy and its impact on the industries in which we invest;
our ability to access debt markets and equity markets;
the occurrence and impact of macro-economic developments (for example, global pandemics, natural disasters, terrorism, international conflicts and war) on us and our portfolio companies;
the ability of our portfolio companies to achieve their objectives;
our expected financings and investments;
our regulatory structure and tax status as a RIC;
our ability to operate as a BDC and our subsidiaries ability to operate as SBICs;
the impact of information technology system failures, data security breaches, data privacy compliance, network disruptions, and cybersecurity attacks;
the adequacy of our cash resources and working capital;
the timing of cash flows, if any, from the operations of our portfolio companies;
the timing, form and amount of any distributions;
the impact of fluctuations in interest rates on our business;
the valuation of any investments in portfolio companies, particularly those having no liquid trading market; and
our ability to recover unrealized depreciation on investments.
You should not place undue reliance on these forward-looking statements. The forward-looking statements made in this Quarterly Report relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statement to reflect events or circumstances occurring after the date of this Quarterly Report.
Use of Non-GAAP Measures
We present our financial condition and results of operations in the way we believe will be most meaningful and representative of our business results. Some of the measurements we use are “Non-GAAP financial measures” under SEC rules and regulations. GAAP is the acronym for “generally accepted accounting principles” in the United States. The Non-GAAP financial measures we present may not be comparable to similarly-named measures reported by other companies.
Overview
We are a leading specialty finance company with a focus on providing financing solutions to high-growth and innovative venture capital-backed and institutional-backed companies in a variety of technology and life sciences
70

Table of Contents
industries. Our primary business objectives are to increase our net income, net investment income, and net asset value through our investments. We principally invest in debt securities and, to a lesser extent, warrant and equity securities, with a particular emphasis on Structured Debt. We aim to achieve our business objectives by maximizing our portfolio total return through generation of current income from our debt investments and capital appreciation from our warrant and equity investments. We expect that our investments will generally range from $25.0 million to $100.0 million, although we may make investments in amounts above or below this range. Through generation of current income from our debt investments and capital appreciation from our warrant and equity investments, we aim to maximize our portfolio total return.
Since inception through March 31, 2025, we have originated more than $22.0 billion in commitments in over 680 companies. We, through the Adviser Subsidiary, may also agree to manage certain other funds that invest in debt, equity or provide other financing or services to companies in a variety of industries for which we, through the Adviser Subsidiary may earn management or other fees for our services. As of March 31, 2025, we, including through our Adviser Subsidiary, actively manage approximately $5.0 billion of assets.
We are structured as an internally managed, non-diversified, closed-end investment company that has elected to be regulated as a BDC under the 1940 Act. As a BDC, we are required to comply with certain regulatory requirements. For instance, we generally have to invest at least 70% of our total assets in “qualifying assets,” which includes securities of private U.S. companies, cash, cash equivalents, and high-quality debt investments that mature in one year or less. Consistent with requirements under the 1940 Act, we invest primarily in United States based companies and to a lesser extent in foreign companies. We source our investments through our principal office located in San Mateo, CA, as well as through our additional offices in Boston, MA, New York, NY, San Diego, CA, Denver, CO, and London, United Kingdom.
We have elected to be treated for tax purposes as a RIC under the Code and operate in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC, among other requirements, we must maintain certain income, asset, and distribution requirements. As a RIC, we generally will not be subject to U.S. federal income tax on the income that we distribute (or are deemed to distribute) to our stockholders provided that we maintain our RIC status for a given year. See “Certain United States Federal Income Tax Considerations” included in our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 13, 2025 for additional information.
Portfolio and Investment Activity
The total fair value of our investment portfolio as of March 31, 2025 and December 31, 2024 was as follows:
(in millions)Fair Value
March 31, 2025
December 31, 2024
Debt$3,739.2 $3,494.6 
Equity146.8 128.7 
Warrants31.5 30.5 
Investment Funds & Vehicles7.0 6.2 
Total Investment Portfolio$3,924.5 $3,660.0 
Our investments in portfolio companies take a variety of forms, including unfunded contractual commitments and funded investments. Not all debt commitments represent future cash requirements. Unfunded contractual commitments depend upon a portfolio company reaching certain milestones before the debt commitment is available to the portfolio company, which is expected to affect our funding levels. These commitments are subject to the same underwriting and ongoing portfolio maintenance as the on-balance sheet financial instruments that we hold. Debt commitments generally fund over the year following the underwriting of such debt commitment. From time to time, unfunded contractual commitments may expire without being drawn and thus do not represent future cash requirements.
Prior to entering into a contractual commitment, we generally issue a non-binding term sheet to a prospective portfolio company. Non-binding term sheets are subject to completion of our due diligence and final investment committee approval process, as well as the negotiation of definitive documentation with the prospective portfolio companies. These non-binding term sheets generally convert to contractual commitments in approximately 90 days from signing and some portion may be assigned or allocated to or directly originated by the Adviser Funds prior to or after closing. Not all non-binding term sheets are expected to close and do not necessarily represent future cash requirements.
71

Table of Contents
Our portfolio activity for the three months ended March 31, 2025 and 2024 was comprised of the following:
(in millions)
March 31, 2025
March 31, 2024
Investment Commitments(1)
Investment Commitments Originated by Hercules Capital and the Adviser Funds$1,019.4 $956.0 
Less: Commitments assigned to or directly committed by the Adviser Funds
(235.8)(181.1)
Net Total Investment Commitments$783.6 $774.9 
Gross Debt Commitments Originated by Hercules Capital and the Adviser Funds
New portfolio company$775.2 $865.0 
Existing portfolio company236.987.5
Sub-total1,012.1 952.5 
Less: Debt commitments assigned to or directly committed by the Adviser Funds
(233.6)(180.1)
Net Total Debt Commitments$778.5 $772.4 
Investment Fundings(2)
Gross Debt Fundings by Hercules Capital and the Adviser Funds
New portfolio company$337.0 $500.0 
Existing portfolio company194.8101.7
Sub-total531.8 601.7 
Less: Debt fundings assigned to or directly funded by the Adviser Funds
(121.9)(112.4)
Net Total Debt Fundings$409.9 $489.3 
Equity Investments and Investment Funds and Vehicles Fundings by Hercules Capital and the Adviser Funds
New portfolio company$— $— 
Existing portfolio company7.33.5
Sub-total$7.3 $3.5 
Less: Equity fundings assigned to or directly funded by the Adviser Funds
(2.2)(1.0)
Net Total Equity and Investment Funds and Vehicle Fundings$5.1 $2.5 
Total Unfunded Contractual Commitment(3)
$455.7 $483.4 
Non-Binding Term Sheets
New portfolio company$428.3 $100.0 
Existing portfolio company78.5 — 
Total$506.8 $100.0 
(1)Includes restructured loans and renewals in addition to new commitments.
(2)Funded amounts include borrowings on revolving facilities.
(3)Amount represents unfunded commitments, including undrawn revolving facilities, which are available at the request of the portfolio company. Amount excludes unfunded commitments which are unavailable due to the borrower having not met certain milestones. This excludes $136.0 million and $156.0 million of unfunded commitments as of March 31, 2025 and March 31, 2024, respectively, to portfolio companies related to loans assigned to or directly committed by the Adviser Funds.
We receive principal payments on our debt investment portfolio based on scheduled amortization of the outstanding balances. In addition, we receive principal repayments for some of our loans prior to their scheduled maturity date. The frequency or volume of these early principal repayments may fluctuate significantly from period to period. During the three months ended March 31, 2025, we received approximately $144.5 million in aggregate principal repayments. Approximately $12.7 million of the aggregate principal repayments related to scheduled principal payments and approximately $131.8 million were early principal repayments related to 17 portfolio companies.
72

Table of Contents
Total portfolio investment activity (inclusive of unearned income and excluding activity related to taxes payable and escrow receivables) as of and for the three months ended March 31, 2025 and 2024 was as follows:
(in millions)March 31, 2025
March 31, 2024
Beginning Portfolio
$3,660.0 $3,248.0 
New fundings and restructures539.1 605.2 
Fundings assigned to or directly funded by the Adviser Funds
(124.1)(113.4)
Warrants not related to current period fundings— 0.4 
Principal repayments received on investments(12.7)(13.1)
Early payoffs(131.8)(161.1)
Proceeds from sale of equity and warrant investments(0.3)(12.0)
Accretion of loan discounts and paid-in-kind interest24.4 18.2 
Net acceleration of loan discounts and loan fees due to early payoffs or restructures(3.6)0.1 
New loan fees(3.9)(5.0)
Gain (loss) on investments due to sales or write offs(0.9)8.3 
Net change in unrealized appreciation (depreciation)(21.7)(3.9)
Ending Portfolio
$3,924.5 $3,571.7 
Additionally, we may hold investments in debt, warrant, or equity positions of portfolio companies that have filed a registration statement with the SEC in contemplation of a potential initial public offering. There can be no assurance that companies that have yet to complete their initial public offerings will do so in a timely manner or at all.
The following table presents certain additional selected information regarding our debt investment portfolio as of March 31, 2025 and March 31, 2024. This includes information on index rate floors which we have in place on all of our floating rate debt investments.
March 31, 2025
March 31, 2024
Number of portfolio companies with debt outstanding119127
Percentage of debt bearing a floating rate98.0 %97.3 %
Percentage of debt bearing a fixed rate2.0 %2.7 %
Weighted average core yield on debt investments(1)(3)
12.6 %14.0 %
Weighted average effective yield on debt investments(2)(3)
13.0 %14.9 %
Prime rate at the end of the period7.50 %8.50 %
Percentage of Prime rate linked debt investments79.0 %73.1 %
Weighted average floor rate bearing a Prime rate
7.1 %6.1 %
Percentage of SOFR, SONIA and BSBY rate linked debt investments
19.0 %24.2 %
Weighted average floor rate bearing a SOFR, SONIA or BSBY rate
1.0 %1.1 %
(1)The core yield is a Non-GAAP financial measure. The core yield on our debt investments excludes the effects of fee and income accelerations attributed to early payoffs, restructuring, loan modifications, other one-time events, and includes income from expired commitments. Please refer to the “Portfolio Yield” section below for further discussion of this measure.
(2)The effective yield on our debt investments includes the effects of fee and income accelerations attributed to early payoffs, restructuring, loan modifications, and other one-time events. The effective yield is derived by dividing total investment income from debt investments by the weighted average earning investment portfolio assets outstanding during the year, excluding non-interest earning assets such as warrants and equity investments. Please refer to the “Portfolio Yield” section below for further discussion of this measure.
(3)The core and effective yields represent the weighted average yields for the three-month periods ended March 31, 2025 and 2024. Please refer to the “Portfolio Yield” section below for further discussion of these measures.
Macroeconomic Market Developments
The capital markets are subject to fluctuations caused by various external factors such as changes in the inflationary environment, interest rate movements, concerns over slowing economic growth and possible global recession, changes to U.S. tariff and import/export regulations, uncertainty and disruption caused by geopolitical events, including the conflicts in Ukraine, Russia, and the Middle East, among other factors. These macroeconomic developments are outside our control and could require us to adjust our plan of operations, and impact our financial position, results of operations or cash flows in the future. We monitor macroeconomic market developments and their related impact to our business, including impacts to our portfolio companies, employees, due diligence and underwriting processes, and the broader financial markets.
Our investment portfolio continues to be focused on industries and sectors that are generally expected to be more resilient to U.S. and global economic cycles. This includes being partially insulated from declining interest rates as all of our floating rate debt investments, which represent 98.0% and 97.4% of our debt portfolio as of March 31, 2025 and December 31, 2024, respectively, are subject to interest rate floors. While our portfolio is not immune to the impact of
73

Table of Contents
macroeconomic events, we believe we and our portfolio are well positioned to manage the current environment. Given the unpredictability and fluidity of the macroeconomic market, neither our management nor our Board is able to predict the full impact of the macroeconomic events on our business, future results of operations, financial position, or cash flows. For additional information, see Part I - Item 1A. Risk Factors included in our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 13, 2025.
Income from Portfolio
We primarily generate revenue in the form of interest income, from our investments in debt securities, and fee income, which is primarily comprised of commitment and facility fees. Interest income is recognized in accordance with the contractual terms of the loan agreement to the extent that such amounts are expected to be collected. Fees generated in connection with our debt investments are recognized over the life of the loan or, in some cases, recognized as earned. In addition, we generate income from dividends on either direct equity investments or equity interests obtained in connection with originating loans, such as options, warrants or conversion rights. We also generate revenue in the form of capital gains, if any, on warrants or other equity securities that we acquire from our portfolio companies.
As of March 31, 2025, our debt investments generally have a term of between two and five years and typically bear interest at a rate ranging from approximately 7.5% to approximately 14.5%. In addition to the cash yields received on our debt investments, in some instances, our debt investments may also include any of the following: exit fees, balloon payment fees, commitment fees, success fees, PIK provisions or prepayment fees which may be required to be included in income prior to receipt.
Interest on debt securities is generally payable monthly, with amortization of principal typically occurring over the term of the investment. In addition, our loans may include an interest-only period ranging from three to eighteen months or longer. In limited instances in which we choose to defer amortization of the loan for a period of time from the date of the initial investment, the principal amount of the debt securities and any accrued but unpaid interest become due at the maturity date.
Loan origination and commitment fees are generally received in full at the inception of a loan, are deferred and amortized into fee income as an enhancement to the related loan’s yield over the contractual life of the loan. We recognize nonrecurring fees amortized over the remaining term of the loan commencing in the quarter relating to specific loan modifications. As of March 31, 2025 and December 31, 2024, unamortized capitalized fee income was recorded as follows:
(in millions)
March 31, 2025
December 31, 2024
Offset against debt investment cost$37.2 $36.9 
Deferred obligation contingent on funding or other milestone10.2 9.1 
Total Unamortized Fee Income$47.4 $46.0 
Loan exit fees to be paid at the termination of the loan are accreted into interest income over the contractual life of the loan. As of March 31, 2025 and December 31, 2024, loan exit fees receivable were recorded as follows:
(in millions)
March 31, 2025
December 31, 2024
Included within debt investment cost$41.5 $39.2 
Deferred receivable related to expired commitments2.9 3.0 
Total Exit Fees Receivable$44.4 $42.2 
Additionally, we have debt investments in our portfolio that earn PIK interest. The PIK interest, computed at the contractual rate specified in each loan agreement, is recorded as interest income and added to the principal balance of the loan on specified capitalization dates. To maintain our status as a RIC, the non-cash PIK income must be distributed to stockholders with other sources of income in the form of dividend distributions even though we have not yet collected any cash from the borrower. Amounts necessary to pay these distributions may come from available cash or the liquidation of certain investments. During the three months ended March 31, 2025 and 2024, we recorded approximately $13.5 million and $9.9 million of PIK income, respectively.
Portfolio Yield
We report our financial results on a GAAP basis. We monitor the performance of our total investment portfolio and total debt portfolio using both GAAP and Non-GAAP financial measures. In particular, we evaluate performance through monitoring the portfolio yields as we consider them to be effective indicators, for both management and stockholders, of
74

Table of Contents
the financial performance of our total investment portfolio and total debt portfolio. The key metrics that we monitor with respect to yields are as described below:
“Total Yield” - The total yield is derived by dividing GAAP basis “Total investment income” by the weighted average GAAP basis value of investment portfolio assets outstanding during the year, including non-interest earning assets such as warrants and equity investments at amortized cost.
“Effective Yield” on total debt investments - The effective yield is derived by dividing GAAP basis “Total investment income” from debt investments(1) by the weighted average GAAP basis value of debt investment portfolio assets at amortized cost outstanding during the year.
“Core Yield” on total debt investments – The core yield is a Non-GAAP financial measure. The core yield is derived by dividing “Core investment income” from debt investments by the weighted average GAAP basis value of debt investment portfolio assets at amortized cost outstanding during the year. “Core investment income” adjusts GAAP basis “Total investment income” from debt investments(1) to exclude fee and other income accelerations attributed to early payoffs, deal restructuring, loan modifications, and other one-time income events, but includes income from expired commitments.
Three Months Ended March 31,
2025 2024
Total Yield12.6 % 14.3 %
Effective Yield(1)
13.0 % 14.9 %
Core Yield (Non-GAAP)(1)
12.6 % 14.0 %
(1)Yield calculated using Total investment income excluding bank interest, dividend income, and investment income from other assets for the three months ended March 31, 2025 and 2024.
We believe that these measures are useful for our stockholders as it provides further insight into the yield of our portfolio to allow a more meaningful comparison with our competitors. As noted above, Core Yield, a Non-GAAP financial measure, is derived by dividing Core investment income, as defined above, by the weighted average GAAP basis value of debt investment portfolio assets at amortized cost outstanding. The reconciliation to calculate “Core investment income” from GAAP basis “Total investment income” are as follows:
(in thousands)Three Months Ended March 31,
20252024
GAAP Basis:
Total investment income
$119,511 $121,553 
Less: fee and income accelerations attributed to early payoffs, restructuring, loan modifications, and other one-time events except income from expired commitments(4,009)(7,325)
Non-GAAP Basis:
Core investment income
$115,502 $114,228 
Less: bank interest income, dividend income, and other investment income from other assets(2,945)(2,387)
Core investment income from debt portfolio$112,557 $111,841 
We believe the Core Yield is useful for our investors as it provides the yield at which our debt investments are originated and eliminates one-off items that can fluctuate significantly from period to period, thereby allowing for a more meaningful comparison over time.
Although the Core Yield, a Non-GAAP financial measure, is intended to enhance our stockholders’ understanding of our performance, the Core Yield should not be considered in isolation from or as an alternative to the GAAP financial metrics presented. The aforementioned Non-GAAP financial measure may not be comparable to similar Non-GAAP financial measures used by other companies.
Another financial measure that we monitor is the total return for our investors, which was approximately (2.0)% and 13.6% during the three months ended March 31, 2025 and 2024, respectively. The total return equals the change in the ending market value over the beginning of the period price per share plus distributions paid per share during the period, divided by the beginning price assuming the distribution is reinvested on the date of the distribution. The total return does not reflect any sales load that may be paid by investors. See “Note 10 – Financial Highlights” included in the notes to our consolidated financial statements appearing elsewhere in this report.

75

Table of Contents
Portfolio Composition
Our portfolio companies are primarily privately held companies which are active in sectors characterized by high margins, high growth rates, consolidation, and product and market extension opportunities and, to a lesser extent, public companies active in those sectors.
The following table presents the fair value of the Company’s portfolio by industry sector as of March 31, 2025 and December 31, 2024:
March 31, 2025December 31, 2024
(in thousands)Investments at
Fair Value
Percentage of
Total Portfolio
Investments at
Fair Value
Percentage of
Total Portfolio
Software$1,262,813 32.2 %$1,081,100 29.5 %
Drug Discovery & Development1,119,941 28.5 %1,080,390 29.5 %
Healthcare Services, Other625,556 15.9 %610,184 16.7 %
Consumer & Business Services374,561 9.6 %372,641 10.2 %
All other industries(1)
541,579 13.8 %515,663 14.1 %
Total$3,924,450 100.0 %$3,659,978 100.0 %
(1)See “Note 4 – Investments” for complete list of industry sectors and corresponding amounts of investments at fair value as a percentage of the total portfolio. As of March 31, 2025, the fair value as a percentage of total portfolio does not exceed 5.0% for any individual industry sector other than “Software", “Drug Discovery & Development”, “Healthcare Services, Other”, and “Consumer & Business Services”.
Industry and sector concentrations vary as new loans are recorded and loans are paid off. Investment income, consisting of interest, fees, and recognition of gains on equity and warrants or other equity interests, can fluctuate materially when a loan is paid off or a warrant or equity interest is sold. Investment income recognized in any given year can be highly concentrated in several portfolio companies.
For the three months ended March 31, 2025 and the year ended December 31, 2024, our ten largest portfolio companies represented approximately 30.4% and 31.6%, respectively, of the total fair value of our investments in portfolio companies, respectively. As of March 31, 2025 and December 31, 2024, we had six and six investments, respectively, that represented 5% or more of our net assets, respectively. As of March 31, 2025 and December 31, 2024, we had four and three equity investments, respectively, that represented 5% or more of the total fair value of our equity investments. These equity investments represented approximately 61.3% and 49.7% of the total fair value of our equity investments as of March 31, 2025 and December 31, 2024, respectively.
As of March 31, 2025 and December 31, 2024, approximately 98.0% and 97.4%, respectively, of the debt investment portfolio was priced at floating interest rates or floating interest rates with a Prime, SOFR, or SONIA-based interest rate floor, respectively. Changes in interest rates, including Prime, SOFR, or SONIA rates, may affect the interest income and the value of our investment portfolio for portfolio investments with floating rates.
Our investments in Structured Debt generally have detachable equity enhancement features in the form of warrants or other equity securities designed to provide us with an opportunity for capital appreciation. These features are treated as OID and are accreted into interest income over the term of the loan as a yield enhancement. Our warrant coverage generally ranges from 3% to 20% of the principal amount invested in a portfolio company, with a strike price generally equal to the most recent equity financing round. As of March 31, 2025, we held warrants in 98 portfolio companies, with a fair value of approximately $31.5 million. The fair value of our warrant portfolio increased by approximately $1.0 million, as compared to a fair value of $30.5 million as of December 31, 2024, primarily related to the increase in fair value of the portfolio companies.
Our existing warrant holdings would require us to invest approximately $59.9 million to exercise such warrants as of March 31, 2025. Warrants may appreciate or depreciate in value depending largely upon the underlying portfolio company’s performance and overall market conditions. As attractive investment opportunities arise, we may exercise certain of our warrants to purchase stock, and could ultimately monetize our investments. Of the warrants that we have monetized since inception, we have realized multiples in the range of approximately 1.02x to 42.71x based on the historical rate of return on our investments. We may also experience losses from our warrant portfolio in the event that warrants are terminated or expire unexercised.
76

Table of Contents
Portfolio Grading
We use an investment grading system, which grades each debt investment on a scale of 1 to 5 to characterize and monitor our expected level of risk on the debt investments in our portfolio with 1 being the highest quality. The following table shows the distribution of our outstanding debt investments on the 1 to 5 investment grading scale at fair value as of March 31, 2025 and December 31, 2024, respectively:
(in thousands)
March 31, 2025
December 31, 2024
Investment GradingNumber of
Companies
Debt Investments
at Fair Value
Percentage of
Total Portfolio
Number of
Companies
Debt Investments
at Fair Value
Percentage of
Total Portfolio
120$727,098 19.4 %19$654,489 18.7 %
2491,560,078 41.7 %531,649,906 47.2 %
3431,266,687 33.9 %391,012,603 29.0 %
44152,692 4.1 %6159,372 4.6 %
5332,679 0.9 %118,231 0.5 %
119$3,739,234 100.0 %118$3,494,601 100.0 %
As of March 31, 2025 and December 31, 2024, our debt investments had a weighted average investment grading of 2.31 and 2.26 on a cost basis, respectively. Changes in a portfolio company's investment grading may be a result of changes in portfolio company's performance and/or timing of expected liquidity events. For instance, we may downgrade a portfolio company if it is not meeting our financing criteria or is underperforming relative to its respective business plan. We may also downgrade a portfolio company as it approaches a point in time when it will require additional equity capital to continue operations. Conversely, we may upgrade a portfolio company's investment grading when it is exceeding our financial performance expectations and/or is expected to mature/repay in full due to a liquidity event. The overall downgrade of the portfolio's weighted average investment grading is reflective of the impact of the current macroeconomic environment.
If macroeconomic events evolve and cause disruption in the capital markets and to businesses, we monitor and work with the management teams and stakeholders of our portfolio companies to navigate any significant market, operational, and economic challenges created by these events. This includes remaining proactive in our assessments of credit performance to manage potential risks across our investment portfolio.
Performing and Non-accrual Investments
The following table shows the amortized cost of our performing and non-accrual investments as of March 31, 2025 and December 31, 2024:
(in millions)March 31, 2025December 31, 2024
 Amortized Cost
Percentage of Total Portfolio at Amortized Cost
Amortized Cost
Percentage of Total Portfolio at Amortized Cost
Performing$3,923 98.2 %$3,648 98.3 %
Non-accrual72 1.8 %61 1.7 %
Total Investments$3,995 100.0 %$3,709 100.0 %
Debt investments are placed on non-accrual status when it is probable that principal, interest, or fees will not be collected according to contractual terms. When a debt investment is placed on non-accrual status, we cease to recognize interest and fee income until the portfolio company has paid all principal and interest due or demonstrated the ability to repay our current and future contractual obligations. We may choose not to apply the non-accrual status to a loan where the investment has sufficient collateral value to collect all of the contractual amount due and is in the process of collection. Interest collected on non-accrual investments are generally applied to principal.
77

Table of Contents
Results of Operations
Our condensed consolidated operating results for the three months ended March 31, 2025 and 2024, were as follows:
(in thousands, except per share data)
Three Months Ended March 31,
2025
2024
Total investment income$119,511 $121,553 
Total expenses42,053 42,391 
Net investment income77,458 79,162 
Net realized gain (loss):(1,556)8,168 
Net change in unrealized appreciation (depreciation):(25,565)3,634 
Net increase (decrease) in net assets resulting from operations$50,337 $90,964 
Net investment income before gains and losses per common share:
Basic$0.45 $0.50 
Change in net assets resulting from operations per common share:
Basic$0.29 $0.57 
Diluted$0.29 $0.57 
Our operating results can vary substantially from period to period due to various factors, including changes in the level of investments held, changes in our investment yields, recognition of realized gains and losses, and changes in net unrealized appreciation and depreciation, among other factors. As a result, comparison of the net increase (decrease) in net assets resulting from operations may not be meaningful.
Investment Income
Total investment income for the three months ended March 31, 2025 was approximately $119.5 million as compared to approximately $121.6 million for the three months ended March 31, 2024. Investment income is primarily composed of interest income earned on our debt investments, fee income from commitments, facilities, and other loan related fees and dividend income.
Interest and Dividend Income
The following table summarizes the components of interest and dividend income for the three months ended March 31, 2025 and 2024:
(in thousands)Three Months Ended March 31,
2025
2024
Contractual interest income$87,817 $90,714 
Exit fee interest income10,228 11,880 
PIK interest income13,473 9,897 
Dividend income
2,400 1,600 
Other investment income(1)
1,654 1,688 
Total interest and dividend income$115,572 $115,779 
(1)Other investment income includes OID interest income and interest recorded on other assets.
Interest and dividend income for the three months ended March 31, 2025 totaled approximately $115.6 million as compared to approximately $115.8 million for the three months ended March 31, 2024. The decrease in interest and dividend income for the three months ended March 31, 2025 as compared to the period ended March 31, 2024 is primarily attributable to a decrease in Core Yield due to declining benchmark rates in 2024. This was partially offset by an increase in the weighted average principal outstanding and dividend income distributions primarily from the Adviser Subsidiary.
78

Table of Contents
Interest income is comprised of recurring interest income from the contractual servicing of loans and non-recurring interest income that is related to the acceleration of income due to early loan repayments and other one-time events during the period.
The following table summarizes recurring and non-recurring interest income and dividend income for the three months ended March 31, 2025 and 2024:
(in thousands)Three Months Ended March 31,
2025
2024
Recurring interest income$110,105 $109,526 
Non-recurring interest income3,067 4,653 
Dividend income2,400 1,600 
Total interest and dividend income
$115,572 $115,779 
A portion of interest income is earned in the form of PIK interest. The following table shows the PIK-related activity for the three months ended March 31, 2025 and 2024, at cost:
(in thousands)
Three Months Ended March 31,
2025
2024
Beginning PIK interest receivable balance$67,656 38,030 
PIK interest income during the period13,473 9,897 
PIK capitalized as principal or converted to equity or other assets
(1,407)— 
Payments received from PIK loans(991)(2,879)
Ending PIK interest receivable balance$78,731 45,048 
The increase in PIK interest income during the three months ended March 31, 2025 as compared to the three months ended March 31, 2024 is due to an increase in the weighted average principal outstanding for debt investments which earn PIK interest. Payments on PIK loans are normally received only in the event of payoffs. The PIK receivable for March 31, 2025 and March 31, 2024 was approximately 2% and 1% of total debt investments, respectively.
Fee Income
Fee income is comprised of recurring fee income from commitment, facility, and loan related fees, fee income due to expired commitments, and acceleration of fee income due to early loan repayments during the period. The following table summarizes the components of fee income for the three months ended March 31, 2025 and 2024:
(in thousands)
Three Months Ended March 31,
2025
2024
Recurring fee income$2,680 $2,455 
Fee income - expired commitments317 647 
Accelerated fee income - early repayments942 2,672 
Total fee income$3,939 $5,774 
The fee income for the three months ended March 31, 2025 totaled approximately $3.9 million as compared to approximately $5.8 million for the three months ended March 31, 2024. The decrease in fee income for the three months ended March 31, 2025 as compared to the three months ended March 31, 2024 is primarily due to lower acceleration of fee income from early repayments and lower fee income from expired commitments. This is partially offset by higher weighted average principal outstanding.
Operating Expenses
Our operating expenses are comprised of interest and fees on our debt borrowings, general and administrative expenses, taxes, and employee compensation and benefits. During the three months ended March 31, 2025 and 2024, our net operating expenses totaled approximately $42.1 million and $42.4 million, respectively.
Interest and Fees on our Debt
Interest and fees on our debt totaled approximately $22.1 million and $20.0 million for the three months ended March 31, 2025 and 2024, respectively. Interest and fee expense during the three months period ended March 31, 2025 as compared to the three months ended March 31, 2024, increased due to higher weighted average debt outstanding.
Our weighted average cost of debt was approximately 4.9% and 4.9% for the three months ended March 31, 2025 and 2024, respectively. The weighted average cost of debt includes interest and fees on our debt, but excludes the impact of fee accelerations due to the extinguishment of debt, as applicable.
79

Table of Contents
General and Administrative Expenses and Tax Expenses
General and administrative expenses include legal fees, consulting fees, accounting fees, printer fees, insurance premiums, rent, expenses associated with the workout of underperforming investments, and various other expenses. Our general and administrative expenses decreased to $4.8 million from $5.1 million for the three months ended March 31, 2025 and 2024, respectively. The decrease in general and administrative expenses for the three months ended March 31, 2025 is primarily attributable to a decrease in costs of office and professional fees and expenses. Tax expenses were $0.9 million and $0.7 million during the three months ended March 31, 2025 and 2024, respectively. Our tax expenses primarily relate to excise tax accruals.
Employee Compensation
Employee compensation and benefits totaled approximately $13.9 million and $16.3 million, for the three months ended March 31, 2025 and 2024, respectively. The movement between the three months ended March 31, 2025 and 2024 was primarily due to fluctuations in variable compensation.
Employee stock-based compensation totaled approximately $3.6 million and $3.1 million, for the three months ended March 31, 2025 and 2024, respectively. The movement between the three months ended March 31, 2025 and 2024 was primarily attributable to an increase in the grant date fair value of the Service-Vesting Awards.
Expenses allocated to the Adviser Subsidiary
The Sharing Agreement provides the Adviser Subsidiary access to our human capital resources, including deal professionals, finance, and administrative functions, as well as other resources including infrastructure assets such as office space and technology. Under the terms of the Sharing Agreement, we allocate the related expenses of shared services to the Adviser Subsidiary. Our total net operating expenses for the three months ended March 31, 2025 and 2024, are net of expenses allocated to the Adviser Subsidiary of $3.3 million and $2.9 million, respectively. The increase in expenses allocated to the Adviser Subsidiary for the three months ended March 31, 2025 compared to 2024 is due to an increase in time spent on the Adviser Funds by senior management. As of March 31, 2025 and December 31, 2024, there was approximately $0.6 million and less than $0.1 million due from the Adviser Subsidiary, respectively.
Net Realized Gains and Losses and Net Change in Unrealized Appreciation and Depreciation
Realized gains or losses on investments are measured by the difference between the net proceeds from the repayment or sale and the cost basis of an investment without regard to unrealized appreciation or depreciation previously recognized, and includes investments written off during the period, net of recoveries. Realized loss on debt extinguishment relates to additional fees, costs, and accelerated recognition of remaining debt issuance costs, which are recognized in the event our debt is extinguished before its stated maturity. The net change in unrealized appreciation or depreciation on investments primarily reflects the change in portfolio investment values during the reporting period, including the reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized.
A summary of net realized gains and losses for the three months ended March 31, 2025 and 2024 is as follows:
(in thousands)
Three Months Ended March 31,
2025
2024
Realized gains$57 $9,191 
Realized losses(934)(942)
Realized foreign exchange gains (losses)(664)(81)
Realized loss on debt extinguishment(15)— 
Net realized gains (losses)$(1,556)$8,168 
During the three months ended March 31, 2025, we recognized a net realized loss of $1.6 million. The net realized losses were generated from gross realized losses of $0.9 million from the write-off of equity and warrant investments in 3GTMS, LLC, Fresh Tracks Therapeutics, Inc. and others. Additionally, we realized $0.7 million of foreign exchange losses primarily from our investments in foreign denominated debt investments.
During the three months ended March 31, 2024, we recognized a net realized gain of $8.2 million. The net realized gains (losses) were generated from gross realized gains of $9.2 million primarily from the sale of our equity and warrant positions in Palantir Technologies and DoorDash, Inc., and sale proceeds from the completed acquisition of Delphix Corp. Our gains were offset by gross realized losses of $0.9 million from the write-off of equity and warrant investments in Proterra, Inc., The Faction Group LLC, and ADMA Biologics, Inc., which had no value after the respective portfolio companies were acquired.
80

Table of Contents
The net change in unrealized appreciation and depreciation of our investments is derived from the changes in fair value of each investment determined in good faith by our Valuation Committee and approved by the Board. The following table summarizes the change in net unrealized appreciation or depreciation of investments for the three months ended March 31, 2025 and 2024:
Three Months Ended March 31,
(in thousands)
2025
2024
Gross unrealized appreciation on portfolio investments$30,237 $34,267 
Gross unrealized depreciation on portfolio investments(55,842)(30,320)
Reversal of prior period net changes in unrealized appreciation (depreciation) upon a realization event(1,213)(7,469)
Net change in unrealized appreciation (depreciation) on portfolio investments(26,818)(3,522)
Other net changes in unrealized appreciation (depreciation)(1)
1,253 7,156 
Total net change in unrealized appreciation (depreciation) on investments
$(25,565)$3,634 
(1)Includes the net change in unrealized appreciation (depreciation) related to derivative instruments and other assets and liabilities.

During the three months ended March 31, 2025 and 2024, we recorded approximately $25.6 million of net unrealized depreciation and $3.6 million of net unrealized appreciation, respectively, on our investments. The movement in unrealized appreciation to depreciation was primarily related to depreciation of our debt investments during the three months ended March 31, 2025 due to an increase in impairments and discount rates.
The following table summarizes the key drivers of change in net unrealized appreciation (depreciation) of investments for the three months ended March 31, 2025 and 2024:
For the Three Months Ended March 31, 2025
(in thousands)
Debt
Equity, Warrants
and
Investment Funds(1)
Total
Investment valuation appreciation (depreciation)$(28,263)$2,658 $(25,605)
Reversal of prior period net changes in unrealized appreciation (depreciation) upon a realization event(1,729)516 (1,213)
Other net changes in unrealized appreciation (depreciation)4,876 (3,623)1,253 
Net change in unrealized appreciation (depreciation)$(25,116)$(449)$(25,565)
For the Three Months Ended
March 31, 2024
(in thousands)Debt
Equity, Warrants
and
Investment Funds(1)
Total
Investment valuation appreciation (depreciation)$668 $3,279 $3,947 
Reversal of prior period net changes in unrealized appreciation (depreciation) upon a realization event25 (7,494)(7,469)
Other net changes in unrealized appreciation (depreciation)(316)7,472 7,156 
Net change in unrealized appreciation (depreciation)$377 $3,257 $3,634 
(1)Includes the net change in unrealized appreciation (depreciation) related to derivative instruments and other assets and liabilities.
Income and Excise Taxes
We account for income taxes in accordance with the provisions of ASC Topic 740, Income Taxes, under which income taxes are provided for amounts currently payable and for amounts deferred based upon the estimated future tax effects of differences between the financial statements and tax basis of assets and liabilities given the provisions of the enacted tax law. Valuation allowances may be used to reduce deferred tax assets to the amount likely to be realized. We intend to timely distribute to our stockholders substantially all of our annual taxable income for each year, except that we may retain certain net capital gains for reinvestment and, depending upon the level of taxable income earned in a year, we may choose to carry forward taxable income for distribution in the following year and pay any applicable U.S. federal excise tax.
Because federal income tax regulations differ from U.S. GAAP, distributions in accordance with tax regulations may differ from net investment income and realized gains recognized for financial reporting purposes. Differences may be permanent or temporary. Permanent differences are reclassified among capital accounts in the financial statements to
81

Table of Contents
reflect their appropriate tax character. Permanent differences may also result from the classification of certain items, such as the treatment of short-term gains as ordinary income for tax purposes. Temporary differences arise when certain items of income, expense, gain or loss are recognized at some time in the future.
The Adviser Subsidiary
The Adviser Subsidiary has entered into investment management agreements (the “IMAs”) with the Adviser Funds. Pursuant to the IMAs, the Adviser Subsidiary provides investment advisory and management services to the Adviser Funds in exchange for an asset-based fee. In addition, Hercules Capital Management LLC through its control of the general partner interests of each of the Adviser Funds may receive incentive fees based on the performance of the Adviser Funds. The Adviser Funds are privately offered investment funds exempt from registration under the 1940 Act that invest in debt and equity investments in venture or institutionally backed technology related and life sciences companies.
(in thousands)
As of
Assets Under Management *
March 31, 2025
December 31, 2024
Growth %
by the Company
$3,978,771 $3,776,399 5.4 %
by the Adviser Funds
1,028,549 987,314 4.2 %
Total$5,007,320 $4,763,713 5.1 %
*     Assets under management includes investments, at fair value, cash and cash equivalents, foreign cash and restricted cash.
The Adviser Subsidiary’s contribution to our net investment income is primarily derived from dividend income declared by the Adviser Subsidiary and interest income earned on loans to the Adviser Subsidiary. For the three months ended March 31, 2025 and 2024, $1.9 million and $1.6 million, respectively, of dividends were declared by the Adviser Subsidiary.
Financial Condition, Liquidity, Capital Resources and Obligations
Our liquidity and capital resources are derived from our debt borrowings and cash flows from operations, including investment sales and repayments, and income earned. Our primary use of funds from operations includes investments in portfolio companies and payments of fees and other operating expenses we incur. We have used, and expect to continue to use, our debt and the proceeds from the turnover of our portfolio and from public and private offerings of securities to finance our investment objectives. We may also raise additional equity or debt capital through registered offerings off a shelf registration, At-the-Market (“ATM”) offerings, and private offerings of securities, by securitizing a portion of our investments, or by borrowing from the SBA through our SBIC subsidiaries. This “Financial Condition, Liquidity, Capital Resources and Obligations” section should be read in conjunction with the “Macroeconomic Market Developments” section above.
During the three months ended March 31, 2025, we principally funded our operations from (i) cash receipts from interest, dividend, and fee income from our investment portfolio, (ii) cash proceeds from the realization of portfolio investments through the repayments of debt investments and the sale of debt and equity investments, (iii) debt borrowings on our Credit Facilities and 2028 Convertible Notes, and (iv) equity offerings.
During the three months ended March 31, 2025, our operating activities used $222.2 million of cash and cash equivalents, compared to $240.9 million used during the three months ended March 31, 2024. The $18.7 million increase in cash used in operating activities was primarily due to a $76.8 million increase in net purchases of investments offset by a $29.6 million decrease in principal, fee repayments, and proceeds from the sale of debt investments.
During the three months ended March 31, 2025, our investing activities used approximately $8 thousand of cash, compared to $292 thousand used during the three months ended March 31, 2024. The $284 thousand decrease in cash used in investing activities was due to a decrease in purchases of capital equipment.
During the three months ended March 31, 2025, our financing activities provided $160.1 million of cash, compared to $185.5 million provided during the three months ended March 31, 2024. The $25.4 million decrease in cash flows from financing activities was primarily due to a $27.0 million decrease in equity issued and a $4.6 million increase in dividend distributions, offset by an increase in net borrowing activity of $12.4 million. During the three months ended March 31, 2025, we distributed dividends of $78.9 million compared to $74.3 million during the three months ended March 31, 2024. We also reduced the usage of our ATM program, which provided (net of offering costs) approximately $39.4 million and down from $66.4 million, during the three months ended March 31, 2025 and 2024, respectively.
As of March 31, 2025, our net assets totaled $2.0 billion, with a NAV per share of $11.55. We intend to continue to operate in order to generate cash flows from operations, including income earned from investments in our portfolio companies. Our primary use of funds will be investments in portfolio companies and cash distributions to holders of our common stock.
82

Table of Contents
Available liquidity and capital resources as of March 31, 2025
As of March 31, 2025, we had $615.6 million in available liquidity, including $51.2 million in cash, cash equivalents and foreign cash, and available borrowing capacity of approximately $39.4 million (net of $0.6 million of outstanding letter of credits) under the SMBC Facility, $175.0 million under our SMBC letter of credit facility, $295.0 million under the MUFG Bank Facility, and $55.00 million of SBA debentures, subject to certain conditions. Additional liquidity is available through accordion provisions within the terms of our Credit Facilities, through which the available borrowing capacity can be increased by an aggregate $400.0 million, subject to certain conditions. Further, the SMBC letter of credit facility may also be increased by an additional $225.0 million (up to $400.0 million), subject to certain conditions. Total amounts outstanding as of March 31, 2025, were $365.0 million outstanding under our Credit Facilities, which are floating interest rate obligations, and the remaining $1,634.3 million of term debt outstanding, which are all fixed interest rate debt obligations.
Not considered above, as of March 31, 2025, we held $3.2 million of cash classified as restricted cash. Our restricted cash relates to amounts that are held as collateral securing certain of our financing transactions, including collections of interest and principal payments on assets that are securitized related to the 2031 Asset-Backed Notes. Based on current characteristics of the securitized debt investment portfolios, the restricted funds may be used to pay monthly interest and principal on the securitized debt with any excess distributed to us or available for our general operations. Refer to “Note 5 – Debt” included in the notes to our consolidated financial statements appearing elsewhere in this report for additional discussion of our debt obligations.
The 1940 Act permits BDCs to incur borrowings, issue debt securities, or issue preferred stock unless immediately after the borrowings or issuance the ratio of total assets (less total liabilities other than indebtedness) to total indebtedness plus preferred stock is less than 200% (or 150% if certain requirements are met). On September 4, 2018 and December 6, 2018, our Board, including a “required majority” (as such term is defined in Section 57(o) of the 1940 Act) and our stockholders, respectively, approved the application to us of the 150% minimum asset coverage ratio set forth in Section 61(a)(2) of the 1940 Act. As of March 31, 2025, our asset coverage ratio under our regulatory requirements as a BDC was 216.6% excluding our SBA debentures. We received an exemptive order from the SEC that allows us to exclude all SBA leverage as senior securities from our asset coverage ratio. As a result of the SEC exemptive order, our ratio of total assets on a consolidated basis to outstanding indebtedness may be less than 150%, which while providing increased investment flexibility, also may increase our exposure to risks associated with leverage. Total asset coverage when including our SBA debentures as senior securities was 199.8% as of March 31, 2025.
The 1940 Act prohibits us from selling shares of our common stock at a price below the current NAV per share of such stock, with certain exceptions. One such exception is prior stockholder approval of issuances below NAV provided that our Board makes certain determinations. On August 15, 2024, we obtained authorization from our stockholders to issue common stock at a price below our then-current NAV per share for a twelve-month period expiring on August 15, 2025. For a further discussion, refer to Part I, Item 1A “Risk Factors- Risks Related to our Securities - Stockholders may incur dilution if we sell shares of our common stock in one or more offerings at prices below the then current NAV per share of our common stock or issue securities to subscribe to, convert to or purchase shares of our common stock” included in our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 13, 2025 for additional information.
As detailed above, our diverse and well-structured balance sheet is designed to provide a long-term focused and sustainable investment platform. Currently, we believe we have ample liquidity to support our near-term capital requirements. As the impact of the macro-economic events, potential global recession, acts of terrorism, war, geopolitical events, and the related disruption to markets and business continues to impact the economy, we will continue to evaluate our overall liquidity position and take proactive steps to maintain the appropriate liquidity position based upon the current circumstances.
Equity Offerings
We may from time-to-time issue and sell shares of our common stock through public or ATM offerings. We currently sell shares through the 2024 Equity Distribution Agreements with Citizens JMP Securities LLC and Jefferies LLC, as Sales Agents, entered into on December 12, 2024. The 2024 Equity Distribution Agreements provide that we may offer and sell up to 30.0 million shares of our common stock from time to time through the Sales Agents. Sales of our common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at the market,” as defined in Rule 415 under the Securities Act, including sales made directly on the NYSE or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices. The 2024 Equity Distribution Agreements replaced the ATM equity distribution agreements between us, and the Sales Agents executed on May 5, 2023. Additionally, on August 7, 2023 we sold 6.5 million shares of our common stock through an upsized public offering, pursuant to an underwriting agreement entered with Morgan Stanley & Co. LLC, UBS
83

Table of Contents
Securities, and Wells Fargo Securities, LLC as joint book-running managers. We generally use net proceeds from these offerings to make investments, to repurchase or pay down liabilities and for general corporate purposes. As of March 31, 2025, approximately 28.0 million shares remain available for issuance and sale under the 2024 Equity Distribution Agreements.
During the three months ended March 31, 2025, we issued and sold 2.0 million shares of our common stock receiving total accumulated net proceeds of $39.4 million. This is a decrease from the approximately $66.4 million of accumulated net proceeds received from the issuance and sale of 3.7 million shares during the three months ended March 31, 2024.
Stock Repurchase
We may from time to time seek to retire or repurchase our common stock through cash purchases, as well as retire, cancel or purchase our outstanding debt through cash purchases and/or exchanges, in open market purchases, privately negotiated transactions or otherwise. Such repurchases or exchanges, if any, will depend on prevailing market conditions, our liquidity requirements, contractual and regulatory restrictions and other factors. The amounts involved may be material. We had no common stock repurchases during the three months ended March 31, 2025 and 2024.
Commitments and Obligations
Our significant cash requirements generally relate to our debt obligations. As of March 31, 2025, we had $1,999.3 million of debt outstanding, $220.0 million due within the next year, $780.0 million due within 1 to 3 years, and $999.3 million due beyond 3 years.
In addition to our debt obligations, in the normal course of business, we are party to financial instruments with off-balance sheet risk. These consist primarily of unfunded contractual commitments to extend credit, in the form of loans, to our portfolio companies. Unfunded contractual commitments to provide funds to portfolio companies are not reflected on our balance sheet.
Our unfunded contractual commitments may be significant from time to time. A portion of these unfunded contractual commitments are dependent upon the portfolio company reaching certain milestones before the debt commitment becomes available. Furthermore, our credit agreements contain customary lending provisions which allow us relief from funding obligations for previously made unfunded commitments in instances where the underlying company experiences materially adverse events that affect the financial condition or business outlook for the company. These commitments will be subject to the same underwriting and ongoing portfolio maintenance as are the on-balance sheet financial instruments that we hold. Since these commitments may expire without being drawn upon, the total commitment amount does not necessarily represent future cash requirements. As such, our disclosure of unfunded contractual commitments includes only those which are available at the request of the portfolio company and unencumbered by milestones. Refer to “Note 11 – Commitments and Contingencies” included in the notes to our consolidated financial statements appearing elsewhere in this report for additional discussion of our unfunded commitments.
As of March 31, 2025, we had approximately $455.7 million of available unfunded commitments, including undrawn revolving facilities, which were available at the request of the portfolio company and unencumbered by future or unachieved milestones, as well as uncalled capital commitments to make investments in private equity funds. In order to draw a portion of the Company's available unfunded commitments, a portfolio company must submit to the Company a formal funding request that complies with the applicable advance notice and other operational requirements. The available unfunded commitments excludes unfunded commitments (i) for which, with respect to a portfolio company's agreement, a milestone was achieved after the last day on which the portfolio company could have requested a drawdown funding to be completed within the reporting period; and (ii) $136.0 million of unfunded commitments which represent the portion of portfolio company commitments assigned to or directly committed by the Adviser Funds.
Additionally, we had approximately $506.8 million of non-binding term sheets outstanding to six new companies and one existing company, which generally convert to contractual commitments within approximately 90 days of signing. Non-binding outstanding term sheets are subject to completion of our due diligence and final investment committee approval process, as well as the negotiation of definitive documentation with the prospective portfolio companies. Not all non-binding term sheets are expected to close and do not necessarily represent future cash requirements.
The fair value of our unfunded commitments is considered to be immaterial as the yield determined at the time of underwriting is expected to be materially consistent with the yield upon funding, given that interest rates are generally pegged to market indices and given the existence of milestones, conditions and/or obligations embedded in the borrowing agreements.
84

Table of Contents
Critical Accounting Policies and Estimates
The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and revenues and expenses during the period reported. On an ongoing basis, our management evaluates its estimates and assumptions, which are based on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in our estimates and assumptions could materially impact our results of operations and financial condition.
For a description of our critical accounting policies, refer to “Note 2 – Summary of Significant Accounting Policies” included in the notes to our consolidated financial statements appearing elsewhere in this Quarterly Report. We consider the most significant accounting policies to be those related to our Valuation of Investments, Fair Valuation Measurements, Income Recognition, and Income Taxes. The Valuation of Investments is our most significant critical estimate. The most significant input to this estimate is the yield interest rate, which includes the hypothetical market yield plus premium or discount adjustment, used in determining the fair value of our debt investments. The following table shows the approximate increase (decrease) to the fair value of our debt investments from hypothetical change to the yield interest rates used for each valuation, assuming no other changes:
(in thousands)
Change in unrealized
appreciation (depreciation)
Basis Point Change
(100)$49,137 
(50)$25,323 
50$(26,391)
100$(52,841)
For a further discussion and disclosure of key inputs and considerations related to this estimate, refer to “Note 3 – Fair Value of Financial Instruments” included in the notes to our consolidated financial statements appearing elsewhere in this report.
85

Table of Contents
ITEM 3.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are subject to financial market risks, including changes in interest rates. Interest rate risk is defined as the sensitivity of our current and future earnings to interest rate volatility, variability of spread relationships, the difference in re-pricing intervals between our assets and liabilities and the effect that interest rates may have on our cash flows. Changes in interest rates may affect both our cost of funding and our interest income from portfolio investments, cash and cash equivalents and idle fund investments. Our investment income will be affected by changes in various interest rates, including Prime, SOFR, and SONIA rates, to the extent our debt investments include variable interest rates. As of March 31, 2025, approximately 98.0% of the loans in our portfolio had variable rates based on floating Prime, SOFR, or SONIA rates with a floor. The majority of our loans are linked to the Prime rate and comprise 79.0% of the loan portfolio as of March 31, 2025. Our debt borrowings under the Credit Facilities bear interest at a floating rate, all other outstanding debt borrowings bear interest at a fixed rate. Changes in interest rates can also affect, among other things, our ability to acquire and originate loans and securities and the value of our investment portfolio.
Based on our Consolidated Statements of Assets and Liabilities as of March 31, 2025, the following table shows the approximate annualized increase (decrease) in components of net assets resulting from operations of hypothetical base rate changes in interest rates, assuming no changes in our investments and debt:
(in thousands)
Interest
Income
Interest
Expense
Net
Income
EPS
Basis Point Change
(200)$(30,321)$(7,799)$(22,522)$(0.13)
(100)$(18,244)$(3,900)$(14,344)$(0.08)
(75)$(14,204)$(2,925)$(11,279)$(0.07)
(50)$(10,044)$(1,950)$(8,094)$(0.05)
(25)$(4,983)$(975)$(4,008)$(0.02)
25$5,345 $975 $4,370 $0.03 
50$11,170 $1,950 $9,220 $0.05 
75$17,812 $2,925 $14,887 $0.09 
From time-to-time, we may hedge against interest rate fluctuations and foreign currency by using standard hedging instruments such as futures, options, and forward contracts. While hedging activities may insulate us against changes in interest rates and foreign currency, they may also limit our ability to participate in the benefits of lower interest rates with respect to our borrowed funds and higher interest rates with respect to our portfolio of investments. During the three months ended March 31, 2025, we have entered into a foreign currency forward contract to limit our foreign currency exposure with respect to the British Pound. For additional information refer to “Note 4 – Investments”, included in the notes to our consolidated financial statements appearing elsewhere in this report.
Although we believe that the foregoing analysis is indicative of our sensitivity to interest rate changes, it does not adjust for potential changes in the credit market, credit quality, size and composition of the assets in our portfolio. It also does not adjust for other business developments, including our debt borrowings and use of our Credit Facilities that could affect the net increase in net assets resulting from operations, or net income. It also does not assume any repayments from our portfolio companies. Accordingly, no assurances can be given that actual results would not differ materially from the statement above.
Because we currently borrow, and plan to borrow in the future, money to make investments, our net investment income is dependent upon the difference between the rate at which we borrow funds and the rate at which we invest the funds borrowed. Accordingly, there can be no assurance that a significant change in market interest rates will not have a material adverse effect on our net investment income. In periods of rising interest rates, our cost of funds would increase, which could reduce our net investment income if there is not a corresponding increase in interest income generated by variable rate assets in our investment portfolio. For additional information regarding the interest rate associated with each of our debt borrowings, refer to Item 2 - “Financial Condition, Liquidity and Capital Resources” in this report and “Note 5 – Debt” included in the notes to our consolidated financial statements appearing elsewhere in this report.
86

Table of Contents
ITEM 4.    CONTROLS AND PROCEDURES
Disclosure Controls and Procedures
The Company’s chief executive and chief financial officers, under the supervision and with the participation of the Company’s management, conducted an evaluation of the Company’s disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d- 15(e) under the Exchange Act. As of the end of the period covered by this quarterly report on Form 10-Q, the Company’s chief executive and chief financial officers have concluded that the Company’s disclosure controls and procedures were effective to ensure that information required to be disclosed by the Company in reports that the Company files or submits under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that information required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including the Company’s chief executive and chief financial officers, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act that occurred during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
87

Table of Contents
PART II: OTHER INFORMATION
ITEM 1.    LEGAL PROCEEDINGS
We may, from time to time, be involved in litigation arising out of our operations in the normal course of business or otherwise. Furthermore, third parties may try to seek to impose liability on us in connection with the activities of our portfolio companies. While the outcome of any current legal proceedings cannot at this time be predicted with certainty, we do not expect any current matters will materially affect our financial condition or results of operations; however, there can be no assurance whether any pending legal proceedings will have a material adverse effect on our financial condition or results of operations in any future reporting period.
ITEM 1A.    RISK FACTORS
In addition to the risks discussed below, important risk factors that could cause results or events to differ from current expectations are described in Part I, Item 1A “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 13, 2025.
Our financial results could be negatively affected if a significant portfolio investment fails to perform as expected.
Our total investment in companies may be significant individually or in the aggregate. As a result, if a significant investment in one or more companies fails to perform as expected, our financial results could be more negatively affected, and the magnitude of the loss could be more significant than if we had made smaller investments in more companies. The following table shows the fair value of the totals of investments held in portfolio companies as of March 31, 2025 that represent greater than 5% of our net assets:     
(in thousands)March 31, 2025
Fair Value
Percentage of Net Assets
Phathom Pharmaceuticals, Inc.$175,348 8.8 %
Marathon Health, LLC173,880 8.7 %
Axsome Therapeutics, Inc.170,727 8.5 %
Shield AI, Inc.117,312 5.9 %
Tipalti Solutions Ltd.116,736 5.8 %
SeatGeek, Inc.109,744 5.5 %
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders.
Marathon Health, LLC is a provider of employer-sponsored healthcare platform intended to provide convenient and unhurried patient-centered care services.
Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system disorders for which there are limited treatment options.
Shield AI, Inc. is an aerospace and defense technology company that designs and builds AI-powered, autonomous Unmanned Aerial Vehicles (UAVs) for national defense operations and military organizations.
Tipalti Solutions Ltd. is a provider of an end-to-end accounts payable automation software platform for mid-market businesses and enterprises.
SeatGeek, Inc. is a mobile-focused ticket platform that enables users to buy and sell tickets for live sports, concerts and theater events.
Our financial results could be materially adversely affected if these portfolio companies or any of our other significant portfolio companies encounter financial difficulty and fail to repay their obligations or to perform as expected.

88

Table of Contents
ITEM 2.    UNREGISTERED SALES OF EQUITY SECURITIES, USE OF PROCEEDS, AND ISSUER PURCHASES OF EQUITY SECURITIES
Dividend Reinvestment Plan
During the three months ended March 31, 2025, we issued 121,743 shares of common stock to stockholders in connection with the dividend reinvestment plan. These issuances were not subject to the registration requirements of the Securities Act. The aggregate value of the shares of our common stock issued under our dividend reinvestment plan was approximately $2.5 million.
ITEM 3.    DEFAULTS UPON SENIOR SECURITIES
None
ITEM 4.    MINE SAFETY DISCLOSURES
Not Applicable
ITEM 5.    OTHER INFORMATION
Rule 10b5-1 Trading Plans
During the first quarter ended March 31, 2025, no directors or executive officers adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities to satisfy the affirmative defense conditions of Exchange Act Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement.”

89

Table of Contents
ITEM 6.    EXHIBITS
Exhibit
Number
Description
3(a)
3(b)
3(c)
3(d)
3(e)
3(f)
3(g)
4(a)
4(b)
10(a)
31.1*
31.2*
32.1*
32.2*
101.INS*Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH*Inline XBRL Taxonomy Extension Schema Document.
101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104
The cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, has been formatted in Inline XBRL
_____________________________________
*Filed herewith.
(1)Previously filed as part of Pre-Effective Amendment No. 1, as filed on May 17, 2005 (File No. 333-122950) to the Registration Statement on Form N-2 of the Company.
(2)Previously filed as part of the Current Report on Form 8-K of the Company, as filed on March 9, 2007.
(3)Previously filed as part of the Current Report on Form 8-K of the Company, as filed on April 11, 2011.
(4)Previously filed as part of the Registration Statement on Form N-2 of the Company, as filed on April 20, 2015 (File No. 333-203511).
(5)Previously filed as part of the Current Report on Form 8-K of the Company, as filed on March 20, 2020.
(6)Previously filed as part of the Quarterly Report on Form 10-Q of the Company, as filed on October 30, 2024.
(7)Previously filed as part of the Current Report on Form 8-K of the Company, as filed on March 10, 2025.
(8)Previously filed as part of the Current Report on Form 8-K of the Company, as filed on February 5, 2025.
(9)Previously filed as part of the Current Report on Form 8-K of the Company, as filed on February 25, 2016.
90

Table of Contents
Schedule 12 – 14
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES
For the Three Months Ended March 31, 2025 (unaudited)
(in thousands)
Portfolio Company
Investment(1)
Amount of Interest, Dividends, and Fees Credited to Income(2)
Realized Gain (Loss)Fair Value as of
December 31, 2024
Gross Additions(3)
Gross Reductions(4)
Net Change in Unrealized Appreciation/ (Depreciation) Fair Value as of March 31, 2025
Control Investments
Majority Owned Control Investments
Coronado Aesthetics, LLC(8)
Preferred Stock$ $ $69 $ $ $(22)$47 
 Common Stock       
Gibraltar Acquisition LLC(5)
Unsecured Debt1,606  36,212 578   36,790 
 Member Units  23,051   (941)22,110 
Hercules Adviser LLC(6)
Unsecured Debt1,900  12,000  (12,000)  
 Member Units  30,190 12,000  2,827 45,017 
Total Majority Owned Control Investments $3,506 $ $101,522 $12,578 $(12,000)$1,864 $103,964 
Other Control Investments
Tectura Corporation(7)
Senior Debt$170 $ $8,027 $ $ $5 $8,032 
 Preferred Stock  3,623   113 3,736 
 Common Stock  7   (5)2 
Total Other Control Investments $170 $ $11,657 $ $ $113 $11,770 
Total Control Investments$3,676 $ $113,179 $12,578 $(12,000)$1,977 $115,734 
(1)Stock and warrants are generally non-income producing and restricted.
(2)Represents the total amount of interest, fees, or dividends credited to income for the period an investment was an affiliate or control investment.
(3)Gross additions include increases in the cost basis of investments resulting from new portfolio investments, paid-in-kind interest or dividends, the amortization of discounts and closing fees and the exchange of one or more existing securities for one or more new securities.
(4)Gross reductions include decreases in the cost basis of investments resulting from principal repayments or sales and the exchange of one or more existing securities for one or more new securities. Gross reductions also include previously recognized depreciation on investments that become control or affiliate investments during the period.
(5)As of March 31, 2018, the Company's investment in Gibraltar Acquisition LLC became classified as a control investment as a result of obtaining a controlling financial interest. Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC. The subsidiary has no significant assets or liabilities, other than their equity and debt investments and equity interest in Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC, respectively.
(6)Hercules Adviser LLC is owned by Hercules Capital Management LLC and presented with Hercules Partner Holdings, LLC which are both wholly owned by the Company. Please refer to “Note 1 - Description of Business” for additional disclosure.
(7)As of March 31, 2017, the Company's investment in Tectura Corporation became classified as a control investment as of result of obtaining more than 50% representation on the portfolio company's board. In May 2018, the Company purchased common shares, thereby obtaining greater than 25% of voting securities of Tectura as of June 30, 2018.
(8)As of December 31, 2021, the Company's investment in Coronado Aesthetics, LLC became classified as a control investment as a result of obtaining more than 25% of the voting securities of the portfolio company.
91

Table of Contents
Schedule 12 – 14
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES
For the Three Months Ended March 31, 2024 (unaudited)
(in thousands)
Portfolio Company
Investment(1)
Amount of Interest, Dividends and Fees Credited to Income(2)
Realized Gain (Loss)Fair Value as of
December 31, 2023
Gross Additions(3)
Gross Reductions(4)
Net Change in Unrealized Appreciation/ (Depreciation)Fair Value as of March 31, 2024
Control Investments
Majority Owned Control Investments
Coronado Aesthetics, LLC(8)
Preferred Stock$ $ $260 $ $ $22 $282 
 Common Stock  2   (1)1 
Gibraltar Acquisition, LLC(5)
Unsecured Debt1,069  34,478 40   34,518 
 Member Units  28,034   (4,621)23,413 
Hercules Adviser LLC(6)
Unsecured Debt1,752  12,000    12,000 
 Member Units  28,713   1,171 29,884 
Total Majority Owned Control Investments $2,821 $ $103,487 $40 $ $(3,429)$100,098 
Other Control Investments
Tectura Corporation(7)
Senior Debt$172 $ $8,250 $ $ $ $8,250 
 Preferred Stock  3,263   593 3,856 
 Common Stock  4   7 11 
Total Other Control Investments $172 $ $11,517 $ $ $600 $12,117 
Total Control Investments$2,993 $ $115,004 $40 $ $(2,829)$112,215 
(1)Stock and warrants are generally non-income producing and restricted.
(2)Represents the total amount of interest, fees, or dividends credited to income for the period an investment was an affiliate or control investment.
(3)Gross additions include increases in the cost basis of investments resulting from new portfolio investments, paid-in-kind interest or dividends, the amortization of discounts and closing fees and the exchange of one or more existing securities for one or more new securities.
(4)Gross reductions include decreases in the cost basis of investments resulting from principal repayments or sales and the exchange of one or more existing securities for one or more new securities. Gross reductions also include previously recognized depreciation on investments that become control or affiliate investments during the period.
(5)As of March 31, 2018, the Company's investment in Gibraltar Acquisition LLC became classified as a control investment as a result of obtaining a controlling financial interest. Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC. The subsidiary has no significant assets or liabilities, other than their equity and debt investments and equity interest in Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC, respectively.
(6)Hercules Adviser LLC is owned by Hercules Capital Management LLC and presented with Hercules Partner Holdings, LLC which are both wholly owned by the Company. Please refer to “Note 1 - Description of Business” for additional disclosure.
(7)As of March 31, 2017, the Company's investment in Tectura Corporation became classified as a control investment as of result of obtaining more than 50% representation on the portfolio company's board. In May 2018, the Company purchased common shares, thereby obtaining greater than 25% of voting securities of Tectura as of June 30, 2018.
(8)As of December 31, 2021, the Company's investment in Coronado Aesthetics, LLC became classified as a control investment as a result of obtaining more than 25% of the voting securities of the portfolio company.
92

Table of Contents
Schedule 12 – 14
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES
As of March 31, 2025 (unaudited)
(in thousands)
Portfolio CompanyIndustry
Type of Investment(1)
Maturity DateInterest Rate and FloorPrincipal or SharesCost
Value(2)
Control Investments   
Majority Owned Control Investments   
Coronado Aesthetics, LLCMedical Devices & EquipmentPreferred Series A Equity  5,000,000$250 $47 
 Medical Devices & EquipmentCommon Stock  180,000  
Total Coronado Aesthetics, LLC $250 $47 
Gibraltar Acquisition LLC(3)
Diversified Financial ServicesUnsecured DebtSeptember 2026
FIXED 3.45%, PIK Interest 8.05%
$27,104 26,899 26,899 
 Diversified Financial ServicesUnsecured DebtSeptember 2026
FIXED 11.95%
$10,000 9,891 9,891 
Diversified Financial ServicesMember Units1 34,006 22,110 
Total Gibraltar Acquisition, LLC $70,796 $58,900 
Hercules Adviser LLC(4)
Diversified Financial ServicesMember Units  112,035 45,017 
Total Hercules Adviser LLC $12,035 $45,017 
Total Majority Owned Control Investments (5.20%)*
 $83,081 $103,964 
Other Control Investments   
Tectura CorporationConsumer & Business ServicesSenior Secured DebtJanuary 2027
FIXED 8.25%
$8,250 $8,250 $8,032 
 Consumer & Business ServicesCommon Stock414,994,863 900 2 
 Consumer & Business ServicesPreferred Series BB Equity  1,000,000 7 
 Consumer & Business ServicesPreferred Series C Equity  3,235,29813,263 3,729 
Total Tectura Corporation $22,413 $11,770 
Total Other Control Investments (0.58%)*
 $22,413 $11,770 
Total Control Investments (5.78%)*
 $105,494 $115,734 
*Value as a percent of net assets
(1)Stock and warrants are generally non-income producing and restricted.
(2)All of the Company’s control and affiliate investments are Level 3 investments valued using significant unobservable inputs.
(3)Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC. The subsidiary has no significant assets or liabilities, other than their equity and debt investments and equity interest in Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC, respectively.
(4)Hercules Adviser LLC is owned by Hercules Capital Management LLC and presented with Hercules Partner Holdings, LLC which are both wholly owned by the Company. Please refer to “Note 1 - Description of Business” for additional disclosure.

93

Table of Contents
Schedule 12 – 14
HERCULES CAPITAL, INC.
CONSOLIDATED SCHEDULE OF INVESTMENTS IN AND ADVANCES TO AFFILIATES
As of and for the year ended December 31, 2024
(in thousands)
Portfolio CompanyIndustry
Type of Investment(1)
Maturity DateInterest Rate and FloorPrincipal or SharesCost
Value(2)
Control Investments   
Majority Owned Control Investments   
Coronado Aesthetics, LLCMedical Devices & EquipmentPreferred Series A Equity  5,000,000$250 $69 
 Medical Devices & EquipmentCommon Stock  180,000  
Total Coronado Aesthetics, LLC $250 $69 
Gibraltar Acquisition LLC (3)
Diversified Financial ServicesUnsecured DebtSeptember 2026
FIXED 3.45%, PIK Interest 8.05%
$26,569 26,337 26,337 
 Diversified Financial ServicesUnsecured DebtSeptember 2026
FIXED 11.95%
$10,000 9,875 9,875 
 Diversified Financial ServicesMember Units  134,006 23,051 
Total Gibraltar Acquisition, LLC $70,218 $59,263 
Hercules Adviser LLC(4)
Diversified Financial ServicesUnsecured DebtJune 2025
FIXED 5.00%
$12,000 12,000 12,000 
 Diversified Financial ServicesMember Units  135 30,190 
Total Hercules Adviser LLC $12,035 $42,190 
Total Majority Owned Control Investments (5.10%)*
$82,503 $101,522 
Other Control Investments   
Tectura CorporationConsumer & Business ServicesSenior Secured DebtJanuary 2027
FIXED 8.25%
$8,250 $8,250 $8,027 
 Consumer & Business ServicesCommon Stock414,994,863 900 7 
 Consumer & Business ServicesPreferred Series BB Equity  1,000,000 17 
 Consumer & Business ServicesPreferred Series C Equity  3,235,29813,263 3,606 
Total Tectura Corporation $22,413 $11,657 
Total Other Control Investments (0.59%)*
$22,413 $11,657 
Total Control Investments (5.69%)*
 $104,916 $113,179 
*Value as a percent of net assets
(1)Stock and warrants are generally non-income producing and restricted.
(2)All of the Company’s control and affiliate investments are Level 3 investments valued using significant unobservable inputs.
(3)Gibraltar Acquisition LLC is a wholly-owned subsidiary, which is the holding company for their wholly-owned affiliated portfolio companies, Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC. The subsidiary has no significant assets or liabilities, other than their equity and debt investments and equity interest in Gibraltar Business Capital, LLC and Gibraltar Equipment Finance, LLC, respectively.
(4)Hercules Adviser LLC is owned by Hercules Capital Management LLC and presented with Hercules Partner Holdings, LLC which are both wholly owned by the Company. Please refer to “Note 1 - Description of Business” for additional disclosure.
94

Table of Contents
SIGNATURES
Pursuant to the requirements of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 HERCULES CAPITAL, INC. (Registrant)
  
Dated: May 1, 2025
/S/ SCOTT BLUESTEIN
Scott Bluestein
President, Chief Executive Officer, and
Chief Investment Officer
 
Dated: May 1, 2025
/S/ SETH H. MEYER
Seth H. Meyer
Chief Financial Officer, and
Chief Accounting Officer
95